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The delivery of drugs and bioactive molecules using pharmaceutical particulates and membranes
are of great significance for various applications such as the treatment of secondary infections, cancer
treatment, skin regeneration, orthopedic applications and others. Several techniques can be utilized for
the preparation of the particulates and membranes, which include, but are not limited to, lyophilization,
microemulsification, nano-spray-drying, nano-electro-spinning, slip casting and 3D printing. The
particulates and membranes possess great prospects to improve the existing strategies and develop
new ones for sustained and controlled drug delivery. Therefore, the development of this subject as an
area of research has been rapid in the last two decades, and their applications are now very broad.
However, these depend on the properties of the designed particulates and membranes.
In addressing these points, this Special Issue (SI) of the journal Pharmaceutics seeks to highlight
the recent trends and innovative developments in the pharmaceutical particulates and membranes for
the delivery of drug and bioactive molecules.
We received in total twenty submissions for the SI, all of which went through a rigorous peer
review process. Eight papers were declined at the peer review stage, and, the remaining twelve papers
have now been published, all as open access papers as per the policy of the journal. The published
papers are also being compiled as an edited e-book, to be published by MDPI. We introduce the
published twelve papers briefly in this guest editorial.
To begin with, we collaborated with other experts in the field of pharmaceutical particulates and
membranes to review the current state of inorganic nanoparticulates and nanomembranes based on
their design, and the key factors for adjusting their morphology and size for their possible medical
applications, especially as drug carrier materials (Mabrouk et al. [1]). A very good example of these
points can be seen in the paper by Kumar et al. [2] who have developed a prolonged release device for
site-specific delivery of a neuroprotective agent (nicotine). The device has been formulated as a novel
reinforced crosslinked composite polymeric system with the potential for intrastriatal implantation
for Parkinson’s disease interventions. These have been developed in the form of membranes with
minimal rates of matrix degradation and retarding nicotine release. This has led to the zero-order
release for 50 days following exposure to simulated cerebrospinal fluid (CSF).
Mora-Espíet et al. [3] have investigated the effects of specific targeting of microparticles on their
internalization by cells under fluidic conditions. For this purpose, two isogenic breast epithelial cell lines,
one overexpressing the human epidermal growth factor receptor 2 (HER2) oncogene (D492HER2) and
highly tumorigenic, and the other expressing HER2 at much lower levels and nontumorigenic (D492)
were cultured in the presence of polystyrene microparticles of 1 μm in diameter, biofunctionalized with
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either a specific anti-HER2 antibody or a nonspecific secondary antibody. The authors have come to
conclude that the biofunctionalization of microparticles with a specific targeting molecule remarkably
increases their internalization by cells in fluidic culture conditions (simulating the blood stream).
Huang et al. [4] have reported a modified coaxial electrospraying technique, which explored
how to create ibuprofen-loaded hydroxypropyl methylcellulose nanoparticles for accelerating the
drug dissolution rate. During this process, it was shown that a key parameter, i.e., the spreading
angle of atomization could provide a linkage among the working process, the property of generated
nanoparticles and their functional performance. They confirmed that the nanoparticle diameter
(prepared based on a modified technique) has a profound influence on the drug release performance. It
is envisaged that the clear process–property–performance relationship should be useful for optimizing
the electrospraying process, and, in turn, for achieving the medicated nanoparticles with desired
functional performances. Shah et al. [5] designed and optimized a nano-emulsion-based system to
improve therapeutic efficacy of moxifloxacin in ophthalmic delivery. Their findings suggest that
optimized nanoemulsion can enhance the therapeutic effect of moxifloxacin and, therefore, it can
be used as a safe and effective delivery vehicle for ophthalmic therapy. In addition, Wan et al. [6]
developed a novel sustained release pellet of loxoprofen sodium (LXP) by coating a dissolution-rate
controlling sublayer containing hydroxypropyl methyl cellulose (HPMC) and citric acid, and a second
diffusion-rate controlling layer containing aqueous dispersion of ethyl cellulose (ADEC) on the surface
of a LXP conventional pellet in order to compare its performance in vivo with an immediate release
tablet (Loxinon®). Their results identified both the citric acid (CA) and ADEC as the dissolution-
and diffusion-rate controlling materials significantly decreasing the drug release rate. The optimal
formulation for a pH-independent drug release in media has been suggested as at a pH above 4.5 and
at slightly slow release in acid medium. The pharmacokinetic studies have revealed that a more stable
and prolonged plasma drug concentration profile of the optimal pellets has been achieved, with a
relative bioavaibility of 87.16% compared with the conventional tablets.
Iglesias et al. [7] have reported the synthesis and characterization of magnetic nanoparticles of two
distinct origins, one inorganic (MNPs) and the other biomimetic (BMNPs). The authors have declared
that the BMNPs are better suited to be loaded with drug molecules positively charged at neutral pH
(notably, doxorubicin for instance) and released at the acidic tumor environment. In turn, MNPs may
provide their transport capabilities under a magnetic field. However, in this study the authors have
used a mixture of both kinds of particles at two different concentrations, trying to derive the best from
each of them. Also, they have studied which mixture performs better from different points of view,
considering factors such as stability and magnetic hyperthermia response, while keeping suitable
drug transport capabilities. The authors have recommended this as a close to ideal drug vehicle with
enhanced hyperthermia response. Savin et al. [8] have discussed the antitumoral potential of three
gel formulations loaded with carbon dots prepared from N-hydroxyphthalimide (CD-NHF) on two
types of skin melanoma cell lines as well as two types of breast cancer cell lines in 2D (cultured cells in
normal plastic plates) and 3D (Matrigel) models. Antitumoral gels based on sodium alginate (AS),
carboxymethyl cellulose (CMC), and the carbomer Ultrez 10 (CARB) loaded with CD-NHF. The in vitro
results for the tested CD-NHF-loaded gel formulations have revealed that the new composites can
affect the number, size, and cellular organization of spheroids and impact individual tumor cell ability
to proliferate and aggregate in spheroids.
Guadarrama-Acevedo et al. [9] have prepared a novel biodegradable wound dressing by means
of alginate membrane and polycaprolactone nanoparticles loaded with curcumin for potential use in
wound healing. The membrane has exhibited a diverse range of functional characteristics required to
perform as a substitute for synthetic skin, such as a high capacity for swelling and adherence to the
skin, evidence of pores to regulate the loss of transepidermal water, transparency for monitoring the
wound, and drug-controlled release by the incorporation of nanoparticles. The incorporation of the
nanocarriers aids the drug in permeating into different skin layers, solving the solubility problems
of curcumin. The paper by Rancan et al. [10] is related to the production of PVP nanofibrous mats
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and foils loaded with a poorly soluble antibiotic, ciprofloxacin, for the treatment of topical wound
infections. The research has revealed that nanofiber mats reach the highest amount of delivered drug
concentration after 6 h, whereas foils maintain a maximum drug concentration over a 24 h period. The
treatment has had no effect on the overall skin metabolic activity, but influenced the wound healing
process. Importantly, a complete eradication of wound infections with P. aeruginosa (108 CFU) could
be achieved.
Lian et al. [11] introduced red blood cell membrane-camouflaged ATO-loaded sodium alginate
nanoparticles (RBCM-SA-ATO-NPs, RSANs) to relieve the toxicity of ATO while maintaining its
efficacy. The average particle size of RSANs has been found to be 163.2 nm with a complete shell-core
bilayer structure, and the average encapsulation efficiency is 14.3%. Compared with SANs, RAW 264.7
macrophages reduced the phagocytosis of RSANs by 51%, and the in vitro cumulative release rate of
RSANs is 95% at 84 h, which have revealed a prominent sustained release. Furthermore, it has been
demonstrated that RSANs have lower cytotoxicity when compared to normal 293 cells and exhibited
antitumor effects on both NB4 cells and 7721 cells. In vivo studies have further showed that ATO can
cause mild lesions of main organs while RSANs can reduce the toxicity and improve the antitumor
effects. Thus, the developed RSANs system has provided a promising alternative for ATO treatment
safely and effectively.
Finally, this SI has included the paper by Adeleke et al. [12] that has formulated and evaluated a
reconstitutable dry suspension (RDS) containing isoniazid, a first-line antitubercular agent used in the
treatment and prevention of TB infection in both children and adults. These formulations have been
prepared by direct dispersion emulsification of an aqueous-lipid particulate interphase coupled with
lyophilization and dry milling. The dug release behavior has been characterized with an initial burst
up to 5 min followed by a cumulative release of 67.88% ± 1.88% (pH 1.2), 60.18% ± 3.33% (pH 6.8), and
49.36% ± 2.83% (pH 7.4) over 2 h. An extended release at pH 7.4 and 100% drug liberation have been
achieved within 300 min. RDS has been dispersible and stable in the dried and reconstituted states
over 4 months and 11 days respectively, under common storage conditions.
As evident, the SI and the forthcoming e-book demonstrate a range of articles with different
research concerns. We hope that both the authors of the papers and ourselves as guest editors have
been able to motivate future research in the field of pharmaceutical particulates and membranes for
delivering drug and bioactive molecules.
Finally, we would like to acknowledge the contributions made by the authors of each paper
irrespective of whether their submissions have been accepted for publication or not, as these have
determined the success of this SI and the forthcoming e-book. We also acknowledge the Editorial
Office of the Journal Pharmaceutics for their continued interest and support in bringing out the SI and
the edited e-book.
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Abstract: Pharmaceutical particulates and membranes possess promising prospects for delivering
drugs and bioactive molecules with the potential to improve drug delivery strategies like sustained
and controlled release. For example, inorganic-based nanoparticles such as silica-, titanium-, zirconia-,
calcium-, and carbon-based nanomaterials with dimensions smaller than 100 nm have been extensively
developed for biomedical applications. Furthermore, inorganic nanoparticles possess magnetic, optical,
and electrical properties, which make them suitable for various therapeutic applications including
targeting, diagnosis, and drug delivery. Their properties may also be tuned by controlling different
parameters, e.g., particle size, shape, surface functionalization, and interactions among them. In a
similar fashion, membranes have several functions which are useful in sensing, sorting, imaging,
separating, and releasing bioactive or drug molecules. Engineered membranes have been developed
for their usage in controlled drug delivery devices. The latest advancement in the technology
is therefore made possible to regulate the physico-chemical properties of the membrane pores,
which enables the control of drug delivery. The current review aims to highlight the role of both
pharmaceutical particulates and membranes over the last fifteen years based on their preparation
method, size, shape, surface functionalization, and drug delivery potential.
Keywords: pharmaceutical particulates; membranes; drug delivery systems; bio-imaging;
bioactive molecules
1. Introduction
Nanotechnology has emerged as one of the most versatile and powerful technologies in the
development of drug delivery techniques. Nanomaterials include particulates which have at least one
dimension of 100 nm or less. Scale differences and modification to the material surfaces result in different
physico-chemical properties of the materials which make them suitable for biomedical applications
such as drug delivery, disease diagnosis, and therapy. Currently, there are many applications of
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 294; doi:10.3390/pharmaceutics11060294
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nanotechnology in general and nanoparticle (NP)-based drug delivery specifically. Similarly, membrane
technologies that focus on both nanoporous membrane preparation and applications have developed
significantly. In this context, a membrane involves a porous system which is made up of either inorganic,
organic, or a combination of both inorganic and organic materials. The utilization of membranes to
convey medications/bioactives is opening up new treatment preferences of interest, e.g., enhancing the
solubility of bioactives shielding an active ingredient from corruption, enhancing the bioavailability
of medication, lowering lethal impacts, offering suitable structures for all courses of administration,
permitting advancement and offering fitting structures for courses of drug administration, and
permitting fast formulation improvement. These points are discussed further below.
1.1. Why Nanoparticles?
There are many different types of NPs that have promising biomedical applications, e.g., polymeric
NPs, polyethylene glycol (PEG)-ylation modified particles, micelles, liposomes, dendrimers, and
nanosized inorganic materials [1]. Organic NPs vary in their activity in different biological systems
including penetration depths in tissues and their toxicity and targeting efficiency [2]. Inorganic NPs
regularly display novel physical properties as their size is close to nanometer scale measurements.
For instance, the extraordinary physical and chemical properties of these NPs may prompt future
applications in drug delivery and biomedical imaging. Plenty of sophisticated and different applications,
including diagnosis and therapy and flow investigation, are related to configuration of the high
surface-to-volume proportions of NPs as a potential system for these strategies. Structures such as
core/shell NPs can show improved properties and increased usefulness due to their changed chemical
distinction and nanostructured parts. This article therefore features an assortment of structures
and properties that can be acknowledged in materials dependent on inorganic NPs and focuses on
discussing major inquiries brought up in controlling these properties.
Typical characteristics of inorganic nanomaterials, such as ease of fabrication, modification and
functionalization, simple preparation methods, resistance to microbial attacks, high stability and
suitable size for cells (plasma membrane below 100 nm), a low toxicity profile, biocompatibility, and
having a hydrophilic nature, make them suitable as drug carriers [3]. Moreover, these NPs can be
biodegradable, non-toxic, non-immunogenic responsive, have a high loading capacity, and have the
capacity for controlled drug release. These characteristics are desired for biomedical applications
in addition to properties such as magnetism. However, in practice, it is not easy to fabricate ideal
NPs which have all the desired properties [4,5] and some NPs are indeed not suitable for biomedical
applications. To improve their biocompatibility, protective coatings which can be non-toxic, such as
natural polymers (carbohydratesand peptides) or synthetic polymers (e.g., PEG, polyvinyl alcohol
(PVA), and polyglycolic acid (PGA), etc.) can be used. Figure 1 shows a cut-out model of an inorganic
NP functionalized with biomolecules for biomedical applications [6].
Figure 1. A model design of an inorganic nanoparticle (NP) functionalized with biomolecules for
biomedical applications [6]. Reproduced with copyright permission from Springer Nature, 2010.
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1.2. Why a Nanoporous Membrane?
Membranes have several biological functions which are useful in sensing, sorting, imaging,
separating, and releasing bioactive/drug molecules. Engineered nanoporous and microporous
membranes have been developed for their usage in drug delivery. The latest advancement in technology
is therefore possible for use in regulating the physico-chemical properties of membrane pores, which
make them attractive for controlling drug delivery rates. In addition, different types of materials
are used for the fabrication of membranes and their properties and surface modification in order
to improve the functions of the membranes, providing different invitro and in vivo applications of
therapeutic delivery. In spite of the extensive work carried out for preparation, characterization, and
biological evaluation of membranes, there are still a number of challenges which need to be overcome
to develop biological membranes.
Membranes are used to control the rate of delivery of drugs to the body as well as drug permeation
from the reservoir to attain the required rate of drug delivery. Therefore, drug delivery is controlled by
both passive diffusion and biodegradation mechanisms. Membranes can carry one or more bioactive
agents and have been developed into different classes of carriers. These different carriers can be
carbon-based nanomaterials, polymeric membranes, and inorganic membranes, where the bulk
properties of the membrane are governed by its building blocks, i.e., the NPs. Keeping this in mind,
the current review aims to highlight the role of both pharmaceutical NPs and membranes during the
last fifteen years based on their preparation method, size, shape, surface functionalization, and drug
delivery potential. The following classification gives an overview structure of the article (Figure 2).
Figure 2. Structural overview of the article.
2. Drug Delivery System
Since the emergence of controlled drug delivery systems (DDS) in early the 1970s, these systems
have attracted increasing attention. DDS are aimed at delivering drugs using pre-defined doses and
drug delivery rates. Moreover, the area of drug delivery is an expanding domain focused on targeting
genes or drug formulations to a group of diseased cells or tissues. The objective of this technique is to
carry an appropriate amount of drug to the target sites (such as diseased tissues and tumors, etc.) while
limiting undesirable reactions of the drugs within healthy tissues [7]. The propensity of the carrier
material to cure cancer has been influenced by various parameters that relate to the carrier material, e.g.,
the immune response to the carrier material and uncontrollable drug behavior [8]. The morphology
of NPs also performs a significant role in drug loading and release and achieving the maximum cell
viability and minimum cell morbidity [9]. In order to illustrate how NPs have been used as DDS, we
provide a number of key examples below.
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2.1. Calcium Phosphate NPs
Calcium phosphate (CaP) is a common NP used in biological systems and medical applications,
especially within those related to diagnosis and treatment. In particular, CaP NPs are extensively
used in imaging, bone/tooth repair, and DNA delivery in cell biology [10,11]. The widespread uses of
CaP NPs are due to their presence as a natural component in the body, as CaP is well enhanced and
easily absorbed in the circulatory system [12]. Hence, previous studies have shown that CaP NPs can
be used as a drug carrier. Kester et al. [13] have assessed the ability of CaP NPs to be encapsulating
hydrophobic antineoplastic chemotherapeutics. Furthermore, these NPs have shown their ability to
encapsulate both fluorophores and chemotherapeutics. These NPs have a diameter of 20–30 nm and pH
sensitivity, as well as little degree of disparity. In addition, these NPs have been observed to be steady
in physiological solution for a time duration at a surrounding temperature of 37◦C. Bastakoti et al. [14]
have claimed that colloidal NPs smaller than 100 nm filled with fluorescent pigments and anticancer
drugs have resulted in the successful enhancement of robust biocompatible nanocomposites carriers
for simultaneous release of drug molecules and imaging agents.
Shinto et al. [15] have utilized hydroxyapatite porous ceramic blocks (a CaP-based material) NPs
in order to formulate nanocarriers for sustained delivery of antibiotics. Firstly, the cylindrical cavities
in the hydroxyapatite blocks were loaded with the antibiotic and they were further implanted in the
bone defect sites. The results revealed that a higher concentration of the antibiotic was released after
seven days of implant. Then, there was a gradual decrease in the concentration after 12 weeks. Overall,
the release of antibiotics with an efficiency of 70% was obtained.
Zhao et al. [16] have investigated the drug delivery ability of anticancer drug docetaxel-loaded
lipid-calcium phosphate hybrid NPs, where the NPs showed a high drug loading capacity and
biocompatibility. The NPs used in this study had a diameter of 72 nm. Mukesh et al. [17] have
also proposed the use of CaP NPs as a carrier for the anticancer drug methotrexate; the size of
the NPs in their case was 262 nm, with an encapsulation efficiency of 58%.They showed a low
release rate of methotrexate at physiological pH and the authors observed that over 90% release was
obtained in 3 to 4 h at endosomal pH. Liang et al. [18] have examined the in vitro delivery of the
anticancer drug doxorubicin (DOX) hydrochloride from CaP hybrid NPs with particle sizes smaller
than 50nm. Heparin/CaCO3/CaP NPs were loaded with this anticancer drug. It was observed that
the unloaded hybrid NPs showed high biocompatibility while the anticancer loaded NPs exhibited a
strong cell inhibitory effect. These examples suggest a clear potential for CaP NP use in biomedical
applications. CaP NPs have demonstrated successful delivery of drugs and bioactive molecules alone
or in combination with polymers, owing to their biocompatibility. However, more research efforts
should be focused in the future on investigating CaP NP degradation products in vivo and their effects
on the vital organs.
2.1.1. Magnetic Mesoporous CaP NPs
Magnetic mesoporous CaP NPs with high water solubility and a diameter of 41 nm
have been fabricated by Rout et al. [19]. These CaP NPs were composed of platinum
pharmacophorecis-diaquadiamine platinum, folic acid, and rhodamine isothiocyanate, in order
to use them against human cervical carcinoma cells. It was observed that the targeting of these cancer
cells and delivery of cisplatin could be achieved by utilizing magnetic CaP NPs, as confirmed by cell
apoptosis that was followed by cell death. However, no information was reported about their clearance
from the body on both bases of animal models and clinical trials.
2.1.2. Porous Silica CaP NPs
El-Ghannam et al. [8] have used porous silica CaP NP as a carrier for 5-fluorouracil, which
is considered very cytotoxic for 4T1 mammary tumor cells. The invitro study demonstrated that
the NPs loaded with the anticancer drug possessed characteristics of burst release (the maximum
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release rate) in the first 24 h, and, following this, a sustained release, which was observed for the
next 32 days. Meihuaet al. [20] have reported the preparation of mesoporous silica NPs coated with a
CaP-hyaluronic acid hybrid. The core shell was further coated with another hyaluronic acid layer in
order to target CD44 over-expressed cancer cells. The authors proved that the anticancer release in
an acidic subcellular environment could be controlled using their NPs. These studies exhibited the
superiority of core shell nano-systems over normal nanomaterials in the delivering of anticancer in a
sustained manner.
2.2. Carbon-Based Nanomaterials
Other types of nanomaterials that may be utilized in therapeutic delivery, and especially
for anticancer therapy, are carbon-based nanomaterials, including carbon nanotubes (CNTs),
graphene oxides (GOs), and nano-diamonds (NDs), as discussed below.
2.2.1. Carbon Nanotubes
When carbon atom nanostructures are arranged in a tube-like hollow cylindrical shape, they may
be called carbon nanotubes (CNTs) [21]. These are divided into three categories: single-walled carbon
nanotubes (SWNTs), double-walled carbon nanotubes (DWNTs), and multi-walled carbon nanotubes
(MWNTs). Their diameters may range between several angstroms and tens of nanometers while their
lengths may reach half a meter [22,23].
One of the biggest benefits of carbon nanomaterials in biomedical applications is their ability to
be a drug carrier. Pastorin et al. [24] have reported that, as an anticancer drug, methotrexate linked
via a covalent bond to carbon nanotubes with fluorescein isothiocyante (FITC) was more effectively
internalized through folate receptors into cells in comparison to the free drug. CNTs have also been
designed to be tumor targetable through functionalization to be used as drug carriers. Moreover, SWNTs
have also been used as drug carriers in their water-soluble PEG-ylated form. They have demonstrated a
loading capacity for the anticancer drug DOX [25]. MWNTs have been examined as a drug carrier, and
in particular oxidized MWNTs have been PEG-ylated for anticancer drug specific delivery to the brain
for the treatment of glioma. Other polymers have also been utilized as functionalizing agents for CNTs
for drug delivery applications, as has been reported previously [26]. MWNTs have been functionalized
with a polyethylenimine (PEI) composite, which has shown impressive biocompatibility. Furthermore,
these composites were designed to be accompanied by FITC and prostate stem cell antigen (PSCA)
monoclonal antibody (mAb). Finally, a CNT-PEI (FITC)-mAb composite has been obtained which
showed impressive biocompatibility with a cancer-cell-targeted delivery system [27].
Cellular uptake of CNTs has been explained by Bhatt et al. [28]. They have suggested mechanisms
for CNT cell-internalization via two pathways, namely, dependent and independent endocytosis
pathways, where the endocytosis-independent pathway is divided into two types: receptor-mediated
endocytosis and non-receptor-mediatedendocytosis (see Figure 3). CNTs with their available types
either functionalized or not have demonstrated great success in the delivery of bioactive molecules,
especially anticancer agents, and the targeting of tumor cells.This has encouraged scientists to explore
their applicability within most common diseases other than cancer. Nevertheless, CNTs have not been
explored widely, owing to their difficult and expensive preparation methods.
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Figure 3. Receptor-mediated endocytosis of CNTs. (1) Association of ligand conjugated drug-loaded
CNTs with receptor; (2) endosomal internalization of conjugates, (3) drug release, and (4,5) receptor
regeneration [28]. Reproduced with copyright permission from Elsevier, 2016.
2.2.2. Graphene Oxide
Another carbon-based nanomaterial for use in biomedical applications is graphene oxide.
Nano-graphene oxide complexes, especially metal nanocomposites (nanogold and nanosilver), have
been found to be a good choice of material to treat cancer. Due to their greater drug entrapment
capability and photothermal and synergizing effects, it is worth highlighting them for their targeted
treatment of cancer based on their chemo-thermal behavior.
Chauhan et al. [29] selected gold NPs (AuNPs) as the composite metal and folic acid (FA) as the
graphene oxide surface functionalization moiety for active tumor targeting of the model anticancer
drug DOX (see Figure 4). Yang et al. [30] have examined the uptake of graphene oxide which has
been functionalized with PEG, noting that it has good solubility and biocompatibility. In addition
to this, PEG-ylated graphene oxide, which accumulates in tumors and has low retention in the
reticuloendothelial system, has also been reported [30].
Figure 4. Tumor-localized DOX delivery with simultaneous photothermal ablation [29]. Reproduced
with copyright permission from Elsevier, 2017. Legend: FA, folic acid; GO, graphic oxide; AuNPs,
gold NPs.
Moreover, Huang et al. [31] have reported that the magnetic functionalized graphene oxide
composite may be used as a nanocarrier for the delivery of anticancer drugs. Magnetic graphene oxide
was produced by the authors by chemical co-precipitation of Fe3O4 magnetic NPs on graphene oxide
nano-platelets. Furthermore, magnetic graphene oxide was modified by chitosan and mPEG-NHS
through covalent bonds to synthesize mGOC-PEG. Irinotecan (CPT-11) or DOX was loaded to
mGOC-PEG. Another experiment has been reported by Barahuie et al. [32] in which graphene oxide
was synthesized in order to explore its potential use as a nanocarrier for an active anticancer agent,
chlorogenic acid (CA).
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DOX-loaded PEG-ylated nanographene oxide (NGO) preparation has been reported by
Zhang et al. [33] where this combination caused destruction of a tumor without recurrence. Qin et al. [34]
have used FA-conjugated NGO-PVP as a carrier for DOX, where folate receptors of cancer cells possessed
great affinity to bind with folic acid. The FA-NGO-PVP was delivered within the cytoplasm of folate
receptor positive human cervical cancer cells (HeLa). The minimal cellular uptake for the nanocarrier
was an indication of the adhering of the FA-NGO-PVP composites to the folate receptors on the surface
of the A549 cells. Thus, the nanocarrier was shown to have photo-thermal sensitivity and could be used
as an anticancer carrier for chemo-photothermal therapy. Furthermore, camptothecin (CPT) and DOX
were involved in the sulfonated NGO sheets, where folic acid was attached to carboxyl groups of the
sulfonate NGO sheets to deliver DOX. The cytotoxicity of FA-NGO/CPT/DOX to MCF7 human breast
cancer cells has been highlighted elsewhere [35]. Zhao et al. [36] have also prepared pH-responsive
chitosan/ graphene oxide nanohybrids to be used for the delivery of DOX anticancer.
Liu et al. [37] have functionalized NGOs with PEG, using these to deliver the SN38 anticancer
drug for colon cancer. Masoudipoura et al. [38] have reported a nanographene oxide conjugated with
dopamine (DA-nGO) and laden with the anticancer drug methotrexate (MTX) to be supplied to positive
human breast adenocarcinoma though adhering to DA receptors. GOs have demonstrated better
characteristics when compared to CNTs, owing to their greater drug encapsulation ability. However,
their use in biomedical applications is still limited because of their complicated synthesis and lower
production yield, which makes them uneconomical.
2.2.3. Nano-Diamond
Nano-diamond is considered to be another type of carbon-based nanomaterial and is rarely
used in cancer treatment. ND is considered an allotrope of carbon with an average particle size
between 4 to 6 nm and which in aggregation could be recorded as having particle sizes of 100 to 200 nm.
The surface of each ND possesses functional groups which allow for a different series of active molecules
to be conjugated to it, including anticancer drugs [39,40]. The appearance of functional groups on ND
surfaces works in the form of a covalent bond between the ND and other material, such as a polymer,
which improves the solubility of the ND powder in various solvents [39]. NDs have an excellent
biocompatibility, meaning they can be used in chemotherapy. For example, the biocompatibility of
a fluorescent ND powder with a particle size of 100 nm has been confirmed for kidney cells by
Yu et al. [41].
Some trials which have reported the utilization of ND in biomedical applications are summarized
below. Carboxylated NDs have been utilized to improve the solubility in aqueous media of some
anticancer drugs. Purvalanol A and 4-hydroxytamoxifan, known to be effective drugs for breast and
liver cancers, have been conjugated with NDs [42]. Moreover, efficient drug loading capacity has been
confirmed for NDs with negative charge which are accompanied by both NaCl and cationic DOX ions
to achieve better treatment for HT-29 colorectal cancer via a more efficient method, in comparison to
other carbon-based materials [43].
Upal et al. [44] have studied, using invitro testing, modified and surface-unmodified (–NH2 and
–COOH) ND for its ability to carry the anti-HIV-1 drug efavirenz and its cytotoxicity. It was found
that there was a highly significant drug loading capacity for the unmodified ND conjugated drug
formulation in comparison to the surface-modified ND, which had a very low toxic effect. NDs have
shown few successful trials on an in vitro basis but animal studies need to be carried out in the near
future to figure out their effect on the vital organs and their clearance mechanism. However, NDs suffer
from the same restrictions as carbon-based materials, as mentioned above.
2.3. Mesoporous Silica Nanoparticles (MSNPs)
One common types of NP which is used as a drug delivery carrier is the solid mesoporous silica
nanoparticle. Mesoporous NPs are particles in which the core of the particle is solid in nature while the
shell or the particle’s surface is porous in nature. Alternatively, the particle itself is porous in nature.
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MSNPs are inorganic particles comprising of a honeycomb-like porous structure with empty channels
(pores) of nanosized dimensions [45]. There are two types of mesoporous silica according to their
particle size: mesoporous silica microspheres and mesoporous silica nanospheres. Although the use of
mesoporous silica microspheres is important in numerous non-biological applications, they are not
appropriate for use in many biomedical applications. However, the average particle diameter of a
typical MSNP is ~100 nm with pore volumes ~0.9 cm3/g, pore volume surface areas ~900 m2/g, and
pore sizes ~2 nm [46]. A hexagonal crystal structure has been recorded for MSNP porous channels
(Figure 5).
Slowing et al. [47] have studied the implications of surface functionalization of MCM-41-Type
MSNPs on the mechanism and efficiency of endocytosis different charge profiles on HeLa. The study
concluded that the ability of MSNPs to escape endosomal entrapment was influenced by surface
functionalities as this is considered to be a key factor in the designing of compounds that are effective
for intracellular delivery.
Figure 5. TEM images of mesoporous silica nanoparticle (MSNP) material recorded from the direction
(a) parallel or (b) perpendicular to the long axis of the meso-channels [45]. Reproduced with copyright
permission from Elsevier, 2008.
2.4. Gold Nanoparticles (GNPs)
Gold nanoparticles are considered excellent carriers for anticancer drug delivery because of their
many unique features, such as their tunability in surface characteristics and particle size, their inertness,
and their biocompatibility. Sabu et al. [48] have demonstrated that gold NPs can be loaded with
anticancer agents. Paclitaxel (an anticancer drug) has been conjugated covalently by Gibson et al. [49]
to gold NPs of size 2 nm, and the system has been found suitable to be used as a self-therapeutic. Dhar
et al. [50] have conjugated gold NPs with DNA (producing DNA-AuNPs) to be employed as carriers
of platinum compounds for the treatment of cancer. Cellular internalization of the tethered platinum
was more effective than free cisplatin in killing cancer cells.
Brown et al. [51] have reported that oxaliplatin in its active form conjugated with gold NPs has
possessed an effective killing ability with regard to cancer cells compared to pure gold NPs. It has also
been proven that BSA-capped gold NPs can effectively be used as a nanocarrier for anticancer drug
MTX and has been considered to be an anticancer for MCF-7 breast cancer cells when compared to
non-capped NPs, as earlier declared by Yu-Hung et al. [52]. Furthermore, core/shell gold NPs have
been fabricated and evaluated in order to be used as carriers for dual treatment where a radiosensitizer
was presented by GNPs and the anticancer drug (DOX) [53].
Manivasagan et al. [54] have demonstrated a new method for the production of gold NPs to be used
as a drug carrier or to be useful in photo-acoustic imaging (PAI). In particular, they have synthesized
multifunctional doxorubicin-loaded fucoidan-capped gold NPs (DOX-Fu AuNPs). Dhamecha et al. [55]
have also reported that GNPs work as an effective drug carrier for targeting DOX to fibrosarcoma
cancer cells. They have been observed to subsequently reduce DOX-associated cardiac toxicity and
myelo-suppression. DOX was seen to be absorbed onto GNPs with a high drug loading capacity, and
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industrial scalability of the process was demonstrated in their research [55]. Scientists working with
GNPs face very challenging issues related to their removal from the human body along with their
accumulation in the liver and kidney.
2.5. Other NPs Used as Drug Delivery Carriers
Some other inorganic materials (Table 1) have been used as drug delivery systems, and include
functional multilayer fluorescent nonporous silica SNPs with an external shell, e.g., those containing
primary amino groups [56]. AL-Ajmi et al. [57] have also prepared crystalline ZnO NPs using organic
precursor techniques. These ZnO NPs were used as a drug carrier to deliver 5-Fluorouracil (5 Fu).
Table 1. Inorganic nanocarriers for drug delivery.
Inorganic Carrier Drug Loaded Purpose References






Breast, lung, bladder, stomach, and
ovarian cancer, and leukaemia. [18]
Porous silica CaP 5-fluorouracil Mammary tumors [8,20]
NGO SN38 Colon cancer [31–36]







Leukaemia, breast cancer, gastric cancer,
head and neck cancer, Hodgkin’s
lymphoma, liver cancer, kidney cancer,
ovarian cancer, small cell lung cancer,
soft tissue sarcoma, thyroid cancer,
bladder cancer, uterine sarcoma.
[53–55]
NDs-NaCl HT-29 colorectal cancer cells. [43]
Gold NPs Paclitaxel Breast, lung, and pancreatic cancer. [49]
3. Inorganic NPs for Hard Tissue Regeneration
The ideal nanostructured composite presented in the human is bone, which is considered the
typical model of a hierarchical microstructure [58]. Nonstoichiometric nanocrystalline hydroxyapatite
(HAP), (Ca10(PO4)6(OH)2), which is 20–40 nm in length, is the major inorganic component of bone,
and Type-I collagen, which is ~300 nm in length, is its major organic counterpart. It has been revealed
that HAP nanocrystals cover bone collagen molecules to form nanocomposites fibers. HAP C-axes are
generally aligned along the collagen molecules in these nanocomposites [59].
Recently, the synthesis of nanomaterials for bone repair has been explored based on the simulation
of various bone properties. One significant characteristic of materials used for bone regeneration is
their mechanical property, and this property is possessed by different nanomaterials [60,61]. The other
approach is to carry out surface modification at the nano-level, as this can provide an improved
matrix for osteoblasts to grow and function (Figure 6) [62]. Several types of materials are suitable as
biocompatible materials for bone healing with applications possible for metallic oxides (aluminium
oxide, zirconium dioxide, and titanium dioxide), the CaPs family (hydroxyapatite, tricalcium phosphate
(TCP), and calcium tetraphosphate) and glass ceramics (bioglass and ceravital) [63].
In addition, nano-scaffolds have superior properties in comparison to micro-scaffolds, owing to
their higher porous microstructures that can mimic a real extracellular matrix (ECM), their porosity, and
their other physical properties. This in turn improves their osteoblast adherence and viability [60,64,65].
Moreover, NPs enable the delivery of drugs and growth factors to promote healing and functional
recovery. Modifying the surface of these biocompatible materials at the nano-scale for bone healing
purposes has also been studied [66].
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Figure 6. NPs used to repair a bone fracture: in cases of bone fracture, nanomaterials have been
implanted into the target area (adapted from [62]).
3.1. Carbon Nanotubes
Owing to the impressive mechanical characteristics of carbon nanotubes, the idea of reinforcing
brittle ceramic such as HAP using CNTs for the treatment of bone disease and fractures has been
considered in the last three decades. Zhang and Kwok [67] have investigated the bone healing ability
of HAP-TiO2-CNT NPs. They noted the formation of an apatite layer on the surfaces of monolithic
HAP and HAP-CNT and HAP-TiO2-CNT NP coatings after 4 weeks of soaking in Hanks’ solution.
In addition, no remarkable effect was recorded on the formation of the apatite layer on the surfaces of
TiO2 and CNT when added to HAP. Furthermore, it has been reported that the addition of CNTs to
HAP has improved the mechanical properties of the final composite as recorded by nano-indentation
technique. These results revealed that the higher the addition of CNTs the greater the mechanical
properties which were achieved compared to pure HAP [68].
A different application for the CNTs that has been reported aside from their being used as
reinforcing material during bone regeneration is as a biosensor for bone regeneration [69]. Using NPs
as a delivery system for bio-active molecules from bone healing, for example, both genes and proteins
can be delivered to enhance propagation of osteoblasts, angiogenesis, and a reservoir for the necessary
calcium salts [69]. Furthermore, one study has been conducted using multi-walled carbon nanotubes
(MWCNTs) impregnated into HAP and the dip coating of a nanocomposite onto a titanium alloy
(Ti-6Al-4V) plate to enhance the surface roughness of the implant. The authors noted that the mechanical
properties of the HAP coating were enhanced and the surface roughness was reduced upon the addition
of low concentrations of MWCNTs in comparison with pure HAP. Moreover, normal cell attachment
and the growth process were confirmed by cell studies [70].
Other studies have discussed the cytotoxicity of titanium alloy implants coated with
plasma-sprayed CNT-reinforced HAP embedded in rodents’ bones, and it has been observed that there
is no adverse effect or cytotoxicity associated with the addition of CNTs to bone tissues [71]. Balani and
Agarwal have also confirmed the non-toxicity of a HAP-CNT coating on Ti-6Al-4V implants and have
observed the ultimate growth of human osteoblast cells near the CNT regions [72].
CNT-based 3D networks have been found to be suitable for cell growth as a biomatrix scaffold [73].
In [73] a 3D network was produced by exerting chemically-induced capillary forces in order to
manipulate the vertically aligned CNT array and the authors found that those networks seemed to be
suitable for cell growth as a scaffold (Figure 7).
14
Pharmaceutics 2019, 11, 294
Figure 7. Scanning electron micrographs of L929 mouse fibroblasts growing on a multi-walled carbon
nanotube (MWCNT)-based network [73]. Reproduced with copyright permission from the American
Chemical Society, 2004.
Another scaffold based on MWCNTs has been reported by Abarrategi et al. [74]. Here, the MWCNTs
were functionalized by chitosan (MWNT/CHI) and these nanocomposites were affirmed to be a scaffold
for tissue engineering. In addition, this study showed that the MWNT/CHI scaffolds implanted
subcutaneously accompanied by recombinant human bone morphogenetic protein-2 (rhBMP-2) for
3 weeks had increased the growth of C2C12 cell lines. Afterwards, the MWNT/CHI scaffold composite
was replaced by cells and bone regeneration was observed. In this study the authors confirmed the
suitability of the MWNT/CHI scaffolds for utilization in bone reconstruction. Apart from hard (bone)
tissue regeneration, CNTs have also been utilized for soft tissue regeneration (nerve) in order to assess
cells behavior [75]. For this purpose, Keefer et al. [76] designed a neural network made of tungsten
and stainless-steel wires and the electrode’s wires were coated with CNTs by electrochemical methods.
3.2. Titanium Dioxide (TiO2)
Titanium dioxide or titania (TiO2) has been used as a bioactive coating and there has been
consideration given to using TiO2 within the coating as reinforcement as a technique for improving the
mechanical reliability of HAP. Also, it has been proven that TiO2 has the ability to induce osteoblast
cell adhesion and growth [77,78]. It has been determined that the smaller the titanium grain size the
greater the osteoblast adhesion. This may be because of the higher surface area attributed to the TiO2
nanoparticles. Various techniques have been used to improve the TiO2-HAP nanocomposite coatings
for biomedical applications in order to enhance the strengths of coating and adhesion, reducing a loss
of implants because of potential failure at the metal-coating interfaces and achieving an increase in
biological response [79,80].
Kuwabara et al. [80] tested the bone formation ability on TiO2-HAP nanocomposite coatings
with a thickness of 100 nm. They cultured the osteoblast cells, which were derived from rat bone
marrow, on the surface of coatings with different electrical charges and found that the HAP- and
TiO2-coated surfaces demonstrated a higher influence with regard to adhering to and propagation
of cellsin comparison to pure HAP or pure TiO2-coated surfaces. Ahmed et al. [81] revealed that the
proliferation of mesenchymal stem cells (MSCs) was enhanced after using a Se/Ti nanocomposite.
Furthermore, another study has unveiled a new composite which was generated using HAP/chitosan
bioactive nanocomposites [82].
4. Bio-Imaging
Due to the magnificent properties of metal inorganic NPs, they have been directed to plenty of
biomedical applications, especially in the bio-imaging field. The size of NPs plays an important role in
the bio-imaging process, as NPs are preferred to other small molecules owing to their fast penetration
in biological tissues and their ability to pass through the circulatory system. In addition, NPs exhibit
limited renal excretion and prolonged blood circulation time, which allows repeated passing of NPs
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through tumors’ vessels. Unlike organic NPs, inorganic NPs exhibit inefficient extra vasation inside
tumors, which involves inorganic NPs tending to remain in the vasculatures of tumors without being
in the interstitial spaces. This reduces the marking of nonspecific tumor cells within the imaging
spaces [83–86].
An important approach for improving the imaging process which has been conducted by
researchers has been to load one NP with different contrast agents related to several imaging
techniques for multimodal imaging which attempts to overcome the limitations related to single
imaging techniques [87,88]. Moreover, imaging and treatment can be achieved by the same NP [89,90].
NPs such as semiconductor quantum dots (QDs) have been considered for photoluminescence
and have been widely used in bio-imaging [88–90]. In addition, luminescent UCNPs and SERS
nanoprobes based on gold and silver NPs can be used for bio-imaging [91–93]. Magnetic NPs with
sizes 1–100 nm can display superpara-magnetism meaning they can be widely used as a contrast agent
in magnetic resonance imaging (MRI); iron oxide magnetic NPs coated with dextran can also be used
in MRI [94,95]. Because of the optical properties of single-walled CNTs, such as high optical absorption
and photoluminescence in the near IR region and strong resonance Raman-scattering, single-walled
CNTs are widely utilized for bio-imaging [96].
4.1. Quantum Dots
QDs are NPs composed of semiconductor materials or atoms from groups II-IV or III-V,
includingcds, cdse, cdte, zns, znse, zno, GaAs, InAs, and InP, owing to their unique optical properties.
Each semiconductor material is covered by another semiconductor material, and these have a large
spectral bond-gap which allows for an increase in the photo stability and quantum yield for the
emission process; QD NPs show stability against an aggregation with capping agents [97]. In addition,
these materials have a high molar extinction coefficient and high absorption from UV to near IR [88],
where the changing diameter of NPs can modulate the excitation and emission peaks of QDs, with QDs
showing sharp emission peaks that are considered ideal for multi-color imaging [97–99] (Figure 8).
Cai et al. [98] have reported the in vivo integrin αvβ3 imaging of RGD peptide-conjugated
QDs. Their results revealed that RGD peptides when conjugated with PEG-ylated QDs demonstrate
maximum emission at 705 nm when injected intravenously into mice bearing U87MG tumors.
In addition, the results showed a tumor contrast 20 min after injection and reached a maximum 6 h
from injection. Another in vivo study conducted by Chen et al. [87] attempted to use optical and
polyethylene terephthalate (PET) imaging of VEGFR in vasculature tumors by using QDs, where, they
reported that, the amine-functionalized QDs conjugated with VEGF protein and then were exposed
to radiation to be radio-labelled for VEGFR-targeted NIR fluorescence and PET imaging of tumor
vasculatures. Furthermore, Ostendorpet al. [93] have utilized cyclic Asn-Gly-Arg (cNGR), which was
seen to conjugate with paramagnetic QDs (pQDs) as a tumor nanoprobe, where cNGR targeted (the
aminopeptidase N) CD13 on the endothelium of a tumor and was used for fluorescence/MRI dual
evaluation of tumor activity.
Yong et al. [89] prepared InP-ZnS QDs that were used for in vivo detection of pancreatic cancer
because of the low cytotoxicity exhibited by InP-ZnS. These were considered to be biocompatible
nanoprobes for diagnosis of pancreatic cancer cells. The results showed that in primary and metastatic
pancreatic cells the antigen receptors for anti-claudian 4 were over-expressed and QDs conjugated to
anti-claudian 4; in addition, a polyclonal antibody was conjugated to QDs and no damage to the cells
was observed. However, Cai et al. [98] have explored PET imaging of radio-labelled QD-RGD, which
showed predominant uptake of QDs in the spleen and liver. Another problem related to QDs could be
their presence within the body, where long retention time for accumulation of QDs has been observed.
There is in vivo toxicity related to the presence of II-IV groups inside the body, but there are strategies
to overcome this problem where there is a new generation of QDs that has been developed to reduce
toxicity, including Cd-free QDs. Repeated demands of the product development of QDs and their
related fields should be considered for their side effects and in the long run, substantiated by prototype
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modules and pilot-line fabricating, especially in light of arrangement producers and subsidizing
organizations frequently setting their needs in relation to being dependent on these demands.
Figure 8. A semiconductor quantum and a quantum dot (QD) aqueous solution under UV light
showing bright pink fluorescence. QDs are widely used in fluorescence imaging (adapted from [99]).
4.2. Carbon Nanotubes
As mentioned above, there are two types of CNTs, namely, SWNTs and MWNTs. SWNTs have
strong optical absorption in the visible and NIR regions due to the optical properties of CNTs, such
as resonance. Raman-scattering and photoluminescence in the near IR region make CNTs useful for
biomedical imaging. SWNTs exhibit different optical absorption peaks from the UV region to the near
IR region, which made these NPs suitable for utilization as photo-thermal agents and photo-acoustic
imaging agents [99] (Figure 9).
Liu et al. [100] have reported how in vivo integrin αvβ3 imaging was able to utilize SWNTs
and SWNTs functionalized by PEG-ylated phospholipids to increase water solubility which was
labelled by a 64-Cu radioisotope for micro PET imaging. RGD peptide conjugated 64 Cu radiated
SWNTs to PEG coating (SWNT-PEG 5400-RGD) was injected intravenously into the glioblastoma
U87MG tumor in mice and then monitored by a micro PET. The results demonstrated higher uptake of
SWNT-PRG5400-RGD by the tumor (~13% of dose ID/g) when compared to the tumor uptake of SWNTs
without combination with RGD (4~5%) of injected dose per gram tissue. Moreover, Smith et al. [97]
have used RGD conjugated with PEG-ylated SWNTs as a Raman nanoprobe for in vivo tumor imaging
in mice, where SWNT-RGD was injected intravenously into the mice’s tumors with high integrin αvβ3
expression. Raman microscopy showed strong signals for tumor cells injected with SWNT RGD while
weak signals were recorded for the tumors injected with non-targeted SWNTs. They also utilized
SWNT-RGD as a contrast agent for tumor photoacoustic imaging. PET imaging and Raman imaging
showed strong photoacoustic signals in U87MG tumors. CNTs with their impressive biocompatibility
have demonstrated great success in the imaging field, thus encouraging scientists to explore their
applicability in the diagnosis of most common diseases other than cancer. Nevertheless, CNTs have
not been explored widely owing due to their difficult and expensive preparation methods.
Figure 9. A single-walled carbon nanotube and an aqueous solution of SWNTs functionalized by
PEG-SWNTs with highly optical properties, which are considered excellent platforms for biomedical
imaging [99]. Reproduced with copyright permission from Springer Nature, 2010.
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4.3. Super Paramagnetic Iron Oxides NPs
Superparamagnetic iron oxide (SPIO) NPs have been widely utilized as a contrast agent in
MRI imaging; FeCo alloys have the best magnetic properties but because of oxidation and toxicity
their appearance in biomedical applications has been limited [101]. Iron-based oxide NPs have been
investigated by Won et al. [95], in which coated FeCo nanocrystals with a single layer of graphite
carbon (GC) was used as a contrast agent for MRI. These NPs were PEG-ylated to increase the solubility
of the FeCo/GC NPs. The water-soluble FeCo/GC NPs exhibited higher relaxivities on a per metal
atom basis compared to other materials which utilized MRI as a contrast agent. Afsaneh et al. [102]
have reported on recently developed MRI and PET imaging probes using SPIO NPs as a contrast agent
where iron oxide NPs were coated with various coats, such as poly aspartic acid, PEG, dopamine, and
dextran. The effects of these coats were discussed with regards to the particle size, targeted organ,
final uptake, and time retention in the studied organ.
One of the methods by which magnetic NPs are delivered to the diseased organ is by intravenous
infusion or by means of a blood circulatory system. Another method relies on utilizing magnetic
nanoparticles suspensions for infusion. A steady uniform solution is required to avoid the aggregation
of the NPs. Particle size and surface functionalization are two parameters required for the stability
of the magnetic colloidal suspension. Determination of appropriate magnetic nanoparticles is the
principal significant advancement for bioapplication. For applications in drug delivery, the magnetic
nanoparticles are required to be steady in water at neutral pH, which relies on their size, charge, and
surface functionalization. However, super magnetic materials, for example, cobalt and nickel, are not
utilized in biomedical applications because of their lethal properties and oxidation susceptibility.
4.4. Gold NPs
Gold NPs have been highlighted among contrast agent materials for their bioimaging application.
Monodispersity, stability, and higher attenuation coefficients for X-rays are the impressive properties
which make these NPs suitable for this process. Peng et al. [91] have found that a way to synthesize
dendrimer-stabilized gold NPs is by use of amine-terminated fifth-generation poly(amidoamine)
(PAMAM) dendrimers. These were modified by diatrizoic acid as stabilizers for enhanced CT imaging.
Li et al. [103] prepared Au-coated iron oxide (Fe3O4-Au) nanoroses to be used as a probe for
multi-function as well as aptamer-based targeting, MRI, optical imaging, photo thermal therapy,
and chemotherapy. Zhang et al. [104] prepared PEG with PEI-stabilized gold NPs for blood pool,
lymph node, and tumor CT imaging. Moreover, Yigit et al. [105] synthesized gold NPs conjugated
to 3,3-diethylthiatricarbocyanine iodide (AuNP-DTTC) which is used as a contrast agent for in vivo
MRI and Raman spectroscopy. Here the probe consisted of MRI-active super paramagnetic iron
oxide NPs coupled with AuNP-DTTC. Tailoring the properties of gold NPs and utilizing chemical
techniques has grown extensively in the last two decades, especially in the field of bio-imaging.
Developed tests and probing techniques rely on advances in gold nanoparticles conjugates, new
optically-controlled functional materials, new highly specific color-coded probes of cellular function,
and new optically-based therapeutic methods.
5. Porous Membranes
The second objective of this review is to present an overview of the therapeutic applications of
porous membranes and their key challenges. Porous membranes have been used in numerous
engineering applications such as molecular separation, catalysis, and filtration, etc. [106,107].
Literature shows that porous membranes are frequently regarded as nanoporous structures because
the pore size of such membranes lies between 1 and 100 nm, although several terminologies have
been used to explain these porous membranes and the terms nanoporous and microporous are used
based on pore size [108,109]. In this section, different types of membranes, types of materials, etched
membranes, and the fabrication of micro- and nanoporous membranes are briefly explained (Figure 10).
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In the following sections, the properties, surface modification techniques, biocompatibility, and drug
delivery applications are also discussed. Lastly, we describe the key challenges and future prospects of
these membranes.
Figure 10. Key characteristics of porous membranes.
5.1. Membrane Classifications
Membranes can be classified based on the following characteristics.
5.1.1. Material
Membranes comprise of inorganic, organic, polymeric, and composite materials. Mostly,
the organic/polymeric membranes are made of materials such as polycarbonate (PCL), polyethylene
terephthalate (PET), and polysulfones, etc. (Table 2). These composite materials contain two different
materials and combine apolymer and an inorganic material (e.g., a polymer with a ceramic). They are
developed in particular to improve the stability, permeability, and selectivity [110].
5.1.2. Size, Shape, and Order of Pores
Membranes are classified according to their size, distribution of size, order, and shape. Hence,
membranes pores<2 nm are called microporous, those with pores 2–50 nm mesoporous, and those with
pores>50 nm macroporous. The shape of the pores can be cylindrical, slit-like, conical, or irregular in
shape. The pores should be well arranged in a vertical order instead of in a tortuous network [111].
The porous network for drug delivery depends upon the following properties:
• Optimum pore size with narrow distribution;
• Less flow resistance to allow high flux;
• Sufficient mechanical strength with adequate chemical and thermal stability, and;
• Biocompatibility.
5.1.3. Fabrication Method
There are various methods available for fabricating membranes and they include ion-track etching,
lithography, selective electrochemical leaching, focused ion beam etching, the sol-gel process, and the
phase separation technique [111,112].
Ion-Track Etching
The polymeric membrane plays an essential role in drug delivery. One of the most common
methods applied for formulating polymeric membranes with ordered pores is ion-track technology.
This process is achieved by exposing a thin film of polymer with heavy ions which form ion tracks. The
ion tracks are allowed to form pores via a chemical etching process which selectively attacks the ion
tracks. The pores formed by this process are cylindrical or conical in shape with a diameter from 10 nm
to within the μm range. The limitation of this process is that manufacturing of pores of a diameter less
than within the nanometer range is not possible [113].
19
Pharmaceutics 2019, 11, 294
Micromolding
Another important method used to prepare membranes is micromolding. This technique is similar
tothephase separation method and involves a solution of the polymer being poured into a mold, which
is solidified by the phase separation process. Langley et al. and Ultricht et al. have discusseda porous
structure developed by a phase separation micromolding technique which considers the structural,
physical, and chemical properties of the polymers used [109,110].
Lithography
Micro/nanofabrication technologies have been recently developed as the most interesting
methodology used to produce an ordered array of micro/nanopores on the surfaces of silicon.
Conventional methods have drawbacks such as broad size distribution of pores, poor mechanical
strength, and poor chemical stability. Micro/nanofabrication techniques are widely used to overcome
these problems. One example is the work of Desai et al. in which biocapsules with controlled pores of
about 7 nm were developed. The authors established that these nanoporous membranes allow exchange
of nutrients, waste products, and therapeutic proteins, and that they are biocompatible, providing
immune support to cells. In addition, they used their fabricated membrane for an implantable pancreas
and oral drug delivery formulation [114,115].
Focused Ion Beam Etching
Polymeric membranes with a well-ordered array of pore structures and a size range of about
100 nm with a thickness of 1–5 μm have been able to be prepared. The membranes formed with this
technique are called nanosieves and are also effectively achieved by photolithography. An excellent
example of this method has been prepared by Tong et al. which has included an ordered structure of a
cylindrical membrane of diameter 25 nm [116].
Electrochemical Etching
The most extensively studied membrane-producing electrochemical etching method is the anodic
membrane technique. The membranes fabricated with this technique produce a honeycomb-like
and ordered structure. The pore morphology and size can be controlled through the process of
anodization [117]. The organization of the porous structure depends on the voltage and chemicals used
in the fabrication. These ordered channel assemblies of membranes are obtained by an anodization
process. The most effective technique for preparing well-arranged porous membranes with large
dimensions involves this process. During the anodization procedure, thin ordered structures are
engraved within a larger dimension membrane [118]. Within the small ordered structures biomolecules
are encapsulated, and these membranes are used for diffusion-controlled delivery systems. The drug
molecules are encapsulated inside the micelles as biocapsules and it has been shown that membranes
containing biocapsulesare able to release the drugs in a controlled fashion [119].
5.1.4. Surface Modifications
When membranes come into contact with physiological fluids, three main processes occur which
create problems, namely, biofouling, degradation of the membrane, and immune reactions caused by
the membrane. There are various approaches to addressing these problems, and these are discussed as
follows. If cells, proteins, and other materials accumulate on a membrane surface when the membrane
is in contact with a biological environment, a process is occurring which is called biofouling [106,120].
The second issue is that this also causes tissue encapsulation, which leads to fibroblast proliferation,
collagen synthesis, and proliferation of blood vessels. These processes in turn lead to vascular tissue
capsule formation, which delay the transport of glucose molecules in biological environments due
to steric hindrance [121]. Wound healing occurs via the processes of hemostasis, inflammation, and
formation of scars and repair. During the implantation of the membrane, cells of epithelial connective
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tissue and the basement membrane may be damaged. Firstly, the bruised area is filled with coagulated
blood, and this clotting allows neutrophils. The day after wound injury, the inflammatory cells disturb
the function of the membrane by taking nutrients and releasing proteolytic enzymes and free radicals.
On the third day, there is occurrence of macrophages and granulation tissue in the wounded area,
followed by neovascularization on fifth day. Finally, at the end of the first month, the formation of a
mature scar in the epithelial layer of the tissues is observed. Hence, the biocompatibility depends on
the surface of the implanted membrane, which influences each stage of the process. A thick vascular
fibrous scar formation leads to diffusion of analytes and uptake of nutrients, resulting in reduced
response of the membrane [115,122].
In order to reduce biofouling, several reports have demonstrated the use of coatings and other
methods of surface treatment. For this, the membrane surface is treated with cross-linked polymers of poly
(hydroxyethyl methacrylate) or poly (ethylene glycol). Polymer coatings on the membrane surface result
in electrically neutral, polar, flexible, and swellable membranes in water, and create an interface between
the membrane surface and the physiological environment. Coatings of poly (hydroxyethyl methacrylate)
or poly (ethylene glycol) are considered the most attractive for membranes because water-soluble
drugs diffuse through the water-swollen polymer layer [123–125].Biocompatibility of the implantable
membrane is characterized by inflammatory responses. Surfactants are also called surface-active agents
and have hydrocarbon tails attached to polar head groups. Many membranes used for drug delivery
contain these surfactant molecules as a plasticizing agent. Unexpectedly, these surfactants diffuse out
of the membranes and to the surface, until they get depleted. Accordingly, these agents need calcium
chelating plasticizers which limit the enzyme in the coagulation cascade [126,127]. Keeping in mind the
characteristics of the membrane and the physiological environment, the biocompatibility of the material
should also be addressed. In addition, it is very essential to prove that there is very little or no leaching,
degradation, biofouling, and inflammatory responses. Therefore, selection of the perfect surface coating
is important to figure out problems in a biological environment [128].
5.2. Drug Delivery by Membranes
The use of membranes to deliver drugs/bioactives is opening up new therapeutic advantages like
increasing the solubility of bioactives, protecting bioactive molecules from degradation, providing a
sustained release of the actives, improving drug bioavailability, providing targeted delivery, decreasing
lethal effects, offering an appropriate form for all routes of administration, and allowing for rapid
formulation development. Moreover, they can carry one or more bioactive agents and have been
developed into different classes of carriers. The different carriers can be carbon-based nanomaterials,
polymeric membranes, and inorganic membranes [129].
5.2.1. Polymeric Membranes
Here, the drug formulation is encapsulated in the compartment of a drug reservoir, in
which the surface of the drug-releasing layer is covered by a rate-controlled polymeric membrane.
The drug reservoir could be solid, a solid dispersion, or a drug solution in liquid form (Figure 11).
The encapsulation process for preparing the drug formulation inside the reservoir compartment includes
fabrication by microencapsulation, coating, and molding techniques. The polymeric membrane is
manufactured from a nonporous, microporousor semipermeable membrane (Figure 12) [130].
Figure 11. Polymeric membrane used for drug delivery system.
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Figure 12. Classification of polymeric membranes for drug delivery.
Drug release from the polymeric membrane must be at a constant rate (Q/t) which is well-defined







where, Km/r and Ka/m are the partition coefficient of the drug molecule from the reservoir to the
rate-controlling membrane and from the membrane to the aqueous layer, respectively, Dd and Dm are
the diffusion coefficient of the rate-controlling membrane and the aqueous diffusion layer, respectively,
hm and hd are the thickness of the rate-controlling membrane and the aqueous diffusion layer,
respectively, and CR is the drug concentration in the reservoir compartment. The drug release from
this system is controlled at a preprogramed rate by controlling the partition coefficient, diffusivity
of the drug molecule, the rate-controlling membrane, and the thickness of the membrane. There are
several controlled release polymeric membrane drug delivery systems which have been successfully
marketed and some of the examples of these are outlined below [131].
5.2.2. Transdermal Systems
In this type of system, nitroglycerin and lactose are triturated in silicone fluid which is then
encapsulated in a thin membrane of ellipsoid shape. The reservoir of the drug layer is introduced
in between the metallic plastic laminate (backing sheet) which is impermeable and ethylene-vinyl
acetate copolymer porous membrane which is the rate controlling membrane. This is formulated by
the injection molding process and a thin layer of adhesive (silicone) is again coated on the permeable
drug membrane for the immediate contact of the drug-releasing membrane with the skin’s surface to
be maintained and achieved (Figure 13). Nitroglycerin (0.5 mg/cm2)/day is delivered transdermally for
treating angina [132]. Other examples are Estraderm-controlled delivery of estradiol for 3–4 days to
relieve postmenopausal syndrome and osteoporosis [133], Duragesic-controlled delivery of fentanyl
for 72 h to relieve chronic pain [134] and Androderm-controlled delivery of testosterone(24 h) used as
an additional therapy for patients with testosterone deficiency [135].
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Figure 13. Diagrammatic representation of membrane permeation-controlled system in which the drug
reservoir is sandwiched between the membrane layers and the adhesive layers facing the skin’s surface
(adapted from [134]).
5.2.3. Ocusert
In this type of system, in between two transparent microporous membranes a drug reservoir layer
containing a pilocarpine-alginate complex is fabricated (Figure 14). The porous membrane permits
the tears to permeate into the layer containing the drug. When the microporous membrane comes
into contact with the tear fluid, it will dissolve and constantly deliver the pilocarpine at a rate of 20 to
40 mcg/h for treating glaucoma disease [136].
Figure 14. Ocusert: (1) and (4) show transparent polymer membranes, (2) shows a titanium dioxide
white ring, and (3) shows a pilocarpine core reservoir (adapted from [136]).
5.2.4. Progestasert
In this type of system, a drug reservoir layer is used which consists of BaSO4 and progesterone
dissolved in silicone fluid and encapsulated into a T-shaped device using an ethylene-vinyl acetate
copolymer (nonporous membrane) (Figure 15). This system is particularly designed to continuously
deliver progesterone to the uterus with a dose of 65 μg/day to attain contraception for a year [137].
Another example of this system is the Mirenaplastic T-shaped device(steroid reservoir), which contains
52 mg of levonorgesterol for achieving contraception for 5 years [138].
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Figure 15. Progestasert IUD with structural components shown (adapted from [137]).
5.2.5. Polymer Matrix Diffusion-Controlled Drug Delivery
In this type of pre-programmed delivery system, the drug reservoir is prepared by homogenous
dispersion of the drug in a rate-controlling polymer matrix fabricated by a hydrophilic or hydrophobic
polymer. Secondly, the drug dispersion in the matrix is fabricated by blending the drug particles
with a polymer or highly viscous base polymer followed by the cross-linking of polymer chains.
Next, the drug solids are mixed in a rubbery polymer at an elevated temperature. The resulting
drug-polymer dispersion is then extruded or molded to form a drug delivery device of varying
shapes/sizes (Figure 16). It can also be prepared by dissolving the drug and the polymer in a solvent,
followed by solvent evaporation, or under vacuum conditions [139].
Release of drug molecules from this type of controlled release drug delivery system is controlled
at a pre-programmed rate by controlling the:
• Loading dose;
• Polymer solubility of the drug, and;
• Diffusivity in the polymer matrix.
An example of this polymer matrix diffusion-controlled drug delivery system is given in the
subsection on the Nitro-Dur system.
Figure 16. A polymer matrix diffusion-controlled system.






where, Q/t1/2 is the rate of release of the drug, A is the initial drug loading dose in the polymer matrix,
CR is the drug solubility in the polymer and Dp is the diffusivity of the drug in the polymer matrix.
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5.2.6. Nitro-Dur System
This type of system is fabricated by heating a hydrophilic polymer, glycerol, and polyvinyl alcohol
and then lowering their temperature to develop a polymer gel. Nitrogylcerin and lactose are mixed
and dispersed in the polymer, which is solidified at room temperature to form a medicated disc by
molding technique. This is assembled into a metallic plastic laminate where the transdermal patch is
developed with an adhesive rim. This patch is designed for application to the skin for continuous
release of 0.5 mg/cm2 for angina treatment. Poly (isobutylene) or poly (acrylate) adhesive are the
polymers used in this method and this polymeric adhesive is spread by solvent casting technique
over the area of the drug impermeable membrane (Figure 17) [140]. The marketed formulations
are Frandol tape by Toaeiyo/Yamanouchi in Japan—isosorbide dinitrate [141]; Nitro-Dur II by Key
in the United States—nitroglycerin, which replaces Nitro-Dur, a first generation patch from the
market;Habitrol and Nicotrol—nicotine (smoking cessation) [142]; Minitran—nitroglycerin [143],
Testoderm—testosterone (testosterone replacement therapy) [144], and Climara—estradiol (vasomotor
system treatment associated with menopause) [145].
Figure 17. Nitro-Dur system (adapted from [140]).
5.2.7. Compudose
This is a subdermal implant formulated on the basis of dispersing estradiol crystals in a viscous
silicone elastomer and coating the dispersion over a silicone rod by extrusion technique to form a
cylindrically-shape implant (Figure 18). Compudose is subcutaneously implanted for a duration of
200 to 400 days for the delivery of estradiol [146,147].
Figure 18. Compudose implant.
5.2.8. Polymeric Membrane-Based Drug Delivery Systems as Commercialized Formulations
Polymers form the basis of a significant number of membrane-based drug delivery systems. In fact,
advances in the field of polymer sciences have paved the way for a large number of membrane-based
drug delivery system designs that have considerable flexibility and functions [148–150]. Table 2
summarizes various formulations of drug delivery systems emphasizing the physico-chemical and
mechanical properties of various polymers being used in commercially available membrane drug
delivery systems.
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5.3. Future Challenges
The next generation of inorganic particulates and membrane materials could be intended for flow
regulation, screening of size, and dynamic pore sizing by means of external controls. Another possibility
for fabricating these inorganic particulates and membranes is by the use ofa lab on chip microfluidic
model to be used in medical diagnostics. Surface modification of inorganic particulates and membranes
with organic and inorganic materials is now being explored. Moreover, when the surface of the
inorganic particulates and membranes is modified with grafted polymers, in vitro testing shows
promising results. Surface modification using polymers which undergoes conformational changes
with a response to stimuli such as temperature, pH, and concentration of ions has shown acceptable
results as well. The in vivo tests are necessary to confirm effective delivery and biocompatibility.
Many challenges are there in manufacturing biocompatible inorganic particulates and membranes
for in-vivo drug delivery applications. The key challenge is to fabricate inorganic particulates and
membranes which respond to various stimuli. These inorganic particulates and membrane systems
could therefore be used in micro/nanoscale chips for rate-controlled programmable delivery of drugs.
6. Conclusions
Inorganic nanomaterials have emerged as promising materials in different fields, including drug
delivery, hard tissue regeneration and bio-imaging. Their exceptional properties, such as tunable
stability, functionality, high surface area, and low inherent toxicity, make them the materials of choice
for efficient use in targeting. The development of NPs for the enhancement of suitable biomedical
applications and decreasing the permeability of relapse is still to be achieved. Membrane materials
are essential for biomedical applications such as drug delivery, targeted drug delivery, and other
medical applications. The main properties of these membranes include having an average pore size of
about a few μm to nm or less, with a narrow size distribution and even smaller thickness. In addition,
the membranes also possess high flux, adequate mechanical strength, and chemical stability. It is
also obvious that an interdisciplinary approach is important for developing membranes for diverse
biomedical applications. As discussed in this article, advanced fabrication techniques are necessary to
develop well-ordered, monodisperse, and ultrathin membranes. The market for inorganic NPs and
membrane systems is expected to grow steadily in the future.
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Abstract: This study aimed to develop a prolonged-release device for the potential site-specific
delivery of a neuroprotective agent (nicotine). The device was formulated as a novel reinforced
crosslinked composite polymeric system with the potential for intrastriatal implantation in
Parkinson’s disease interventions. Polymers with biocompatible and bioerodible characteristics
were selected to incorporate nicotine within electrolyte-crosslinked alginate-hydroxyethylcellulose
gelispheres compressed within a release rate-modulating external polymeric matrix, comprising either
hydroxypropylmethylcellulose (HPMC), polyethylene oxide (PEO), or poly(lactic-co-glycolic) acid
(PLGA) to prolong nicotine release. The degradation and erosion studies showed that the produced
device had desirable robustness with the essential attributes for entrapping drug molecules and
retarding their release. Zero-order drug release was observed over 50 days from the device comprising
PLGA as the external matrix. Furthermore, the alginate-nicotine interaction, the effects of crosslinking
on the alginate-hydroxyethycellulose (HEC) blend, and the effects of blending PLGA, HPMC, and
PEO on device performance were mechanistically elucidated using molecular modelling simulations
of the 3D structure of the respective molecular complexes to predict the molecular interactions and
possible geometrical orientation of the polymer morphologies affecting the geometrical preferences.
The compressed polymeric matrices successfully retarded the release of nicotine over several days.
PLGA matrices offered minimal rates of matrix degradation and successfully retarded nicotine release,
leading to the achieved zero-order release for 50 days following exposure to simulated cerebrospinal
fluid (CSF).
Keywords: alginate gelispheres; textural analysis; crosslinked matrices; PLGA discs; prolonged
release; powder flow properties
1. Introduction
Parkinson’s disease (PD), a central nervous system disorder, is associated with difficulties
with respect to movement, typically outlined by the patient’s shuffling gait due to unstable
posture, bradykinesia, tremor, and rigidity. The progressive neuronal loss in PD is prolonged,
requiring clinical neuroprotection and/or disease modification as therapeutic strategies for effectively
reducing PD-related disability. The potential application of nicotine as a neuroprotectant in PD was
demonstrated as far back as 1926 [1]. Nicotine has previously been shown to protect against the
degeneration of nigrostriatal neurons via evoking the release of dopamine from the striatum [2–5].
PD is still an incurable disease. The available therapeutic options only offer symptomatic relief and
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2018, 10, 233; doi:10.3390/pharmaceutics10040233
Pharmaceutics 2018, 10, 233
primarily aim to improve the functionality of the patient with no intervention towards the progression
of the associated neurodegeneration. Additionally, a major challenge is to improve patient compliance
to therapy by reducing the side-effects associated with continuous multiple dosing via the oral route
subsequently leading to erratic plasma drug levels.
Generally, prolonged parenteral zero-order drug delivery systems have the capacity to minimize
dose-related side-effects owing to a constant and sustained drug release profile. This is applicable
specifically to drugs with narrow therapeutic indices, wherein such systems can provide a reduction
in administered dose, avoidance of fluctuations in plasma drug levels, reduced frequency of
administration, and hence the enhancement of patient compliance [6,7]. The use of polymers is
a popular means of achieving controlled drug release due to the simplicity, cost-effectiveness, ease of
manufacturing, versatility, and the ability to deliver compounds with a wide range of solubilities [8].
Hydroxypropylmethylcellulose (HPMC) and polyethylene oxide (PEO) have been used
extensively to formulate controlled-release drug delivery systems. Both polymers are hydrophilic
and undergo simultaneous swelling and erosion when exposed to hydration. Depending on the
solubility of incorporated drugs within monolithic matrices of such polymers, the actives diffuse
out into the bulk medium preceding or following erosion of the polymer [9,10]. The mechanisms
relating to the swelling and hydration of hydrophilic polymeric matrices may include, but are not
limited to, polymeric chain extension, disentanglement, and solvent accommodation to macroscopic
characteristics such as drug release [11,12]. In addition, formulation factors such as the quantity of drug
loading, drug-polymer ratio, drug particle size and molecular mass, polymer viscosity and molecular
weight, and presence of formulation excipients and release modulators significantly affect the drug
release rate from hydro-swelling matrices [13,14]. Poly(lactic-co-glycolic acid) (PLGA), a polyhydroxy
acid polymeric carrier, is capable of delivering drugs as a controlled-release site-specific system and has
the advantage of being moderately aqueous-soluble for controlled drug diffusion [15]. Biocompatibility
studies have indicated that PLGA is biodegradable and considerably well tolerated when implanted
into the CNS [16]. Consequently, no surgical intervention or procedures are required for removal of
implantable devices prepared with PLGA. Fournier and co-workers (2003) established that regardless
of the implantation site, PLGA devices initiate only a moderate and non-specific inflammatory reaction,
mainly due to mechanical insult during the implantation procedure [16].
The purpose of this study was to incorporate nicotine-loaded alginate-hydroxyethycellulose (HEC)
gelispheres into an external polymeric matrix with the aim of modulating drug release to achieve
prolonged zero-order release. The alginate-HEC gelispheres were previously developed by the authors
and were physically crosslinked using divalent ions [17]. HPMC, PEO, and PLGA were selected as
the polymers for formulating the device due to the desirable inherent characteristics of the polymers
for implantation into the CNS. The study was further aimed to elucidate the molecular mechanisms
inherent to the drug-polymer interactions, formation of the gelispheres, and finally the fabrication and
performance of various composite polymeric matrices using static lattice atomistic simulations.
2. Materials and Methods
2.1. Materials
Nicotine was obtained from Sigma-Aldrich, St. Louis, MO, USA. The polymers employed for
gelisphere preparation included sodium alginate (FMC BioPolymer, Drammen, Norway) and HEC
(Hercules Inc., Natrosol® Pharm, Wilmington, DE, USA). The crosslinking reagents employed were
calcium chloride (CaCl2) and barium chloride (BaCl2) (UniLab®, Saarchem (Pty) Ltd., Krugersdorp,
South Africa). PLGA (Resomer® L503, Evonik Nutrition & Care GmbH, Essen, Germany), HPMC
(Methocel™ K4M, Dow Chemical Company, Pittsburg, CA, USA) and PEO (PolyoxTM WSR 303;
Union Carbide, Bound Brook, NJ, USA) were employed as the external matrices.
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2.2. Methods
2.2.1. Formulation of the Reinforced Alginate-HEC Gelispheres
The alginate-HEC gelispheres were formulated employing ionotropic gelation as described
elsewhere by the authors [17]. Briefly, an alginate (2% w/v) and HEC (1% w/v; the reinforcing agent)
dispersion was prepared in double-deionised water and subsequently homogenized. Thereafter,
nicotine (1% w/v) was added to the polymeric dispersion through titration at a rate of 5 mL/min. The
resulting solution was immediately added into the crosslinking solution comprising BaCl2 and CaCl2
(2% w/v). The crosslinked alginate-HEC (ALG-HEC) gelispheres were crosslinked for 30 min and
thereafter washed with deionized water. Formulations were then exposed to 2 M HCl subsequent
to curing in order to precipitate alginic acid in the crosslinked system and retard the hydration and
swelling dynamics of the gelispheres.
2.2.2. Formulation of the Gelisphere-Loaded External Polymeric Matrices
Briefly, 500 mg of a dry polymer mixture comprising either HPMC, PEO, PLGA, or various
binary combinations of the polymers and gelispheres equivalent to 20 mg of entrapped nicotine
(approximately 100 mg gelispheres) were compressed into 10-mm flat-faced discs (Beckman®
Hydraulic Press; Beckman Instruments Inc., Fullerton, CA, USA), applying a compression force
of 8 tons. Table 1 summarizes the compositions of the various formulations investigated.
Table 1. Polymeric compositions of the various external matrix formulations. Friability results
for polymeric matrices expressed as % weight loss after 4 (% WL4) and 20 (% WL20) minutes in
a friabilator at 25 rpm. HPMC: hydroxypropylmethylcellulose; PEO: polyethylene oxide; PLGA:
poly(lactic-co-glycolic) acid.
Formulation Code HPMC (mg) PEO (mg) PLGA (mg) % WL4 % WL20
HPMC 500 - - 0.081 0.307
PEO - 500 - 0.101 0.133
PLGA - - 500 0.000 0.026
HPMC-PEO 250 250 - 0.050 0.107
HPMC-PLGA 250 - 250 0.051 0.064
PEO-PLGA - 250 250 0.038 0.102
HPMC-PEO-PLGA 166 166 166 0.025 0.051
2.2.3. Evaluation of the Flowability and Friability of the Polymeric Material
To evaluate the flowability of the powders the angle of repose (ϕ) method was employed. A conical
funnel was attached to a retort stand with the bottom orifice (diameter 7 mm) at a 10-cm height above
the horizontal surface. Samples of 3 g of powder were placed into the funnel while keeping the orifice
closed. The center-point and a graduated set of axes was marked on a piece of graphical paper and
placed beneath the funnel. The contents of the funnel were allowed to flow through the orifice and the
angle of repose (ϕ) was calculated employing Equation (1):
tanϕ = 2h/D (1)
where h is the powder height at center-point (mm) and D is the diameter of powder bed formed (mm).
Friability analysis evaluated the ability of the compressed gelisphere-loaded matrices to withstand
mechanical damage due to the variation in particle size. The matrix friability was measured using a
Roche® Friabilator (Hoffman la Roche, Basel, Switzerland). Samples were accurately weighed and
placed into the friabilator (N = 3). Rotation times of 4 min and 20 min at 25 rpm were used. Matrices
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were then removed and the surface was lightly dabbed to remove any loose particles and re-weighed.
The mass loss was calculated employing Equation (2).
WLt = (W0 − Wt)/W0 × 100 (2)
where WLt is the mass loss at time t (%), Wt is the mean mass at t; and W0 is the mean mass at time t0.
2.2.4. Determination of the Brinell Hardness Number of the Compressed Polymeric Matrices
The change in physicomechanical properties of the matrices following exposure to simulated
cerebrospinal fluid (CSF) was assessed by measuring the Brinell Hardness Number (BHN). The BHN
is an indication of the force required to indent the surface of the gelisphere-loaded matrices and
represents the surface hardness of the compressed polymeric matrices. A TA.XTplus Texture Analyser
(StableMicrosystems®, Surrey, UK) was used to generate force-distance profiles for matrices exposed
to simulated CSF over predetermined time intervals (pH 7.4; 37 ◦C). The input parameters employed
with a 5-kg load cell were pre-test speed (1.0 mm/s), test speed (0.5 mm/s), post-test speed (1.0 mm/s),





D − (D2 − d2) 12
] (3)
where D is the diameter of the ball probe (3.175 mm), d is the indentation distance (0.25 mm), and F is
the force (N) generated.
2.2.5. Evaluation of Conductivity Changes Following Polymeric Matrix Gelation
An OAKTON TDS TestTM Kit (Model WD-35661-70; OAKTON Instruments, Solon, OH, USA) was
employed to measure the conductivity of the PBS (0.1 M; pH 7.4) solution containing the polymeric
discs at predetermined intervals of time over a period of 30 days. Samples were extracted from the
solutions and diluted 1:10 in double deionized water. The electrode was immersed in the diluted
polymer-PBS solution and conductivity (μSiemens) was read.
2.2.6. Evaluation of the Matrix Erosion upon Hydration
Pre-weighed hydrated discs were removed from simulated CSF at predetermined intervals and
dried under ambient conditions (21 ◦C) for 7 days. The dried discs were re-weighed and the percentage
weight loss (% WL) calculated.
2.2.7. Evaluation of Surface Morphology of the Matrices
Scanning electron microscopy (SEM) was employed to assess the changes in the porosity of the
polymer matrices following hydration. Dried samples of the discs were cross-sectioned and coated
with a thin layer of colloidal graphite. Thereafter they were mounted onto aluminum stubs and coated
with a thin layer of gold–palladium under an electrical potential of 20 keV. Samples were viewed in
the FE-SEM (JEOL JSM-840, Tokyo, Japan) at a magnification of 65 and probe current of 30 nanoamps.
SEM images were processed using MathematicaTM 8.0 (Wolfram Research, Champaign, IL, USA) as
described in the supplementary data. Initially, images were cropped to restrict image content to that of
the scaffold.
2.2.8. Textural Analysis of the Hydrated and Unhydrated Gelisphere-Loaded External
Polymeric Matrices
The Texture Analyzer (TAXT.plus, Stable Micro Systems®, Surrey, UK) was employed to conduct
textural analysis of the gelisphere-loaded polymeric matrices (N = 5). The texture analyzer was fitted
with a 10-mm cylindrical steel probe and a 40-kg load cell was used. Matrix resilience, deformability
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modulus, and fracture energy of the crosslinked gelispheres were assessed according to their G and
M content in both the unhydrated and hydrated states. For the later test, gelispheres were immersed
in 15 mL double deionised water in glass vials and agitated at 50 rpm in a shaker bath (Labline®
Instruments, Melrose Park, IL, USA) maintained at 37 ◦C. Samples (N = 10) were removed and
analyzed for four 24-h intervals and evaluated for the above stated entities. The association of the
monomers, i.e., GG, GM, and MM blocks and their interaction with the crosslinking cations on the
mechanical properties was also examined. Samples with an identical G/M ratio were compared
according to differences in viscosity. The input parameters employed with a 5-kg load cell (50% strain)
were pre-test speed (1.0 mm/s), test speed (0.5 mm/s), post-test speed (1.0 mm/s), and trigger force
(0.5 N). The force-time profile was employed for the determination of matrix resilience. This refers
to the ability of the gelisphere to recover upon application of deforming stress to its original state of
equilibrium. This was calculated as the ratio of the areas under the compression and decompression
curve. A forcedistance profile generated for the gelispheres was employed to obtain the area under the
curve (AUC), which enabled the evaluation of the energy needed to rupture the gelisphere matrix, i.e.,
the fracture energy (Nm) while the gradient to the peak force, known as the deformability modulus
(N/mm), corresponds to the deformability modulus of the gelisphere matrix [18].
2.2.9. In Vitro Drug Release Studies of the Gelisphere-Loaded External Polymeric Matrices
In vitro drug release studies were performed on the nicotine-loaded matrices using simulated
cerebrospinal fluid (CSF). Gelisphere-loaded external polymeric matrices were immersed in 100 mL of
0.1 M phosphate-buffered saline (PBS) (pH 7.4; 37 ◦C) in sealed 150-mL glass jars that were placed in a
shaker bath (Labex, Stuart SBS40 South Africa) and agitated at 50 rpm. At predetermined intervals,
5-mL samples were removed and the samples were analyzed by UV spectroscopy (245 nm; Specord®
40, Analytik Jena UV-VIS, Aargau, Switzerland). To maintain sink conditions; 5 mL of nicotine-free
PBS were replaced into the glass jars.
2.2.10. Static Lattice Atomistic Molecular Structural Simulations
To elucidate the interaction profile of individual molecules within the alginate-drug complex,
alginate-HEC gelisphere matrices, and the external matrices, molecular mechanics computations were
conducted in a vacuum using the HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc.,
Gainesville, FL, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK).
The polymers (PLGA and PEO) were drawn in their syndiotactic stereochemistry as 3D models; the
carbohydrate (alginate) and cellulose derivatives (HEC and HPMC) were built from standard bond
lengths and angles using a sugar builder module; and the structure of nicotine was drawn with natural
bond angles. The structures so-obtained were energetically optimized using a progressive minimization
paradigm employing MM+ and the Amber 3 (Assisted Model Building and Energy Refinements) force
field. The conformer having the lowest energy was used to create the polymer-polymer complexes. A
complex of one molecule with another was assembled by disposing them in a parallel way, and the
same procedure of energy minimization was repeated to generate the final models: alginate-nicotine
(ALG–NCT), ALG–HEC, ALG–HEC–Ca2+, ALG–HEC–Ba2+, PLGA–HPMC, HPMC–PEO, PLGA–PEO,
and PLGA–HPMC–PEO. Full geometry optimization was carried out in vacuum employing the
Polak–Ribiere conjugate gradient algorithm until an RMS gradient of 0.001 kcal/mol was reached. For
molecular mechanics calculations in vacuum, the force fields were utilized with a distance-dependent
dielectric constant scaled by a factor of 1. The 1–4 scale factors were electrostatic = 0.5 and van der
Waals = 0.5 [19].
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3. Results and Discussion
3.1. Flowability and Friability of the Polymeric Matrices
The flowability results indicated that PLGA had the greatest degree of inter-particle interaction
(cohesion). Hence, its high angle of repose (AR) (40.40◦) indicated that it had poor flow properties.
When combined with HPMC, their mutually attractive interaction was indicated by the highest AR of
52.41◦, which implies that the combination had the potential for producing highly dense compressed
discs. PEO on the other hand indicated excellent flow properties, as it demonstrated a lower AR of
13.49◦. This can be explained in terms of the fact that it was predominately composed of spherical
granular particles. These particles had a smaller surface area per particle to interact with each other,
as compared to PLGA and HPMC. Its incorporation with PLGA and HPMC resulted in a significant
decline in AR (11.46◦ and 12.74◦, respectively) and improved overall flowability, and thus it negatively
impacted on the cohesive tendency of the particles, which implied that matrices generated with the
aforementioned combinations would generate less compact matrices. From a manufacturing process
point of view, improved flowability permits easier processing conditions. However, this implies that
additional substances (such as binders) may need to be added to enhance powder compressibility to
generate discs. According to the United States Pharmacopoeia (USP 23), conventional compressed
tablets that incur a loss in weight after 100 revolutions (which is the equivalent of 4 min in the friabilator
at 25 rpm) in a friabilator of less than 0.5–1.0% are considered acceptable. The results indicated that
the discs generated were well within the predetermined limits. PLGA discs were exceedingly well
compressed and underwent negligible loss in weight following 500 revolutions (i.e., 20 min at 25 rpm)
(Table 1). Furthermore, the incorporation of PLGA with HPMC and PEO into the disc resulted in
an enhanced robustness imparted into the matrix, while the addition of PEO has the reverse effect,
indicated by the greater friability.
3.2. Changes in the Brinell Hardness Number (BHN) of Compressed External Polymeric Matrices
Following Hydration
Evaluating changes in the Brinell Hardness Number (BHN) of the discs allowed us to establish
the rate at which water penetrated the surface of the discs and lead to their subsequent hydration and
erosion. The faster this occurred, the more quickly the incorporated gelispheres became exposed to the
surrounding aqueous medium and released the entrapped nicotine. The results demonstrated that the
most significant changes in BHN occurred within the first day of exposure to simulated CSF (Figure 1a).
Discs composed of PEO in particular experienced a significant decline in BHN value within the first
24 h (Figure 1a). Both PEO and HPMC hydrogels imbibed and retained a substantial amount of water
from the surrounding buffer media to become hydrated, and subsequently underwent polymeric
relaxation, generating a gel front on the surface of the disc. Subsequent to the initial 24-h decline, the
discs underwent gelation to the core of their compressed matrices rapidly. Furthermore, the presence
of PEO impeded cohesion between the HPMC and PLGA powder particles consequently generated
matrices that were more prone to degradation upon exposure to hydration and mechanical stress.
Due to the more complex nature of the HPMC polymer in comparison to PEO, it did not undergo
polymeric relaxation as rapidly. Thus, the BHN value for HPMC declined most significantly between
days 1 and 6. PLGA proved to be the exception to this rule. It demonstrated a steady decline in BHN
over the 30 days. The combination of PLGA–HPMC also depicted a gradual, albeit more rapid decline
in BHN, indicating that the presence of PLGA with the HPMC generated sufficient cohesion between
the polymers to restrict the diffusion of water molecules into the compressed polymeric matrix.
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Figure 1. Physical properties of compressed polymeric discs following exposure to simulated CSF over
a period of 30 days: (a) Changes in the Brinell Hardness Number (N/mm2; N = 3; SD < 23.67 N/mm2);
(b) Matrix erosion (%; N = 3; SD < 0.05%); and (c) Changes in conductivity (μSiemens; N = 3;
SD < 16.34 μS).
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3.3. Evaluation of Erosion of Compressed External Polymeric Matrix
In contact with dissolution medium (in this case simulated CSF), hydrophilic polymers such as
PEO and HPMC either swell into a hydro-gel layer or undergo erosion or both. Such swelling behavior
is proportional to the rate of hydration and along with relative mobilities of dissolution medium and
drug it dictates the kinetics as well as mechanism of drug release [20]. As portrayed in the previous
results, PEO discs demonstrated lower gel strength, greater water uptake, and therefore demonstrated
greater matrix erosion as depicted in Figure 1b. HPMC discs on the other hand demonstrated greater
matrix swelling with negligible matrix erosion (Figure 1b). However, from the results it was observed
that the rate of drug release by far superseded the rate of matrix degradation; hence it was concluded
that the rate of drug release in this case was predominately a result of the diffusion of the drug from
the matrices as opposed to matrix degradation.
As mentioned previously, PLGA is a hydrophobic bioerodible polymer. Thus, the mechanics of
polymeric degradation and matrix erosion therefore occur via two main mechanisms, namely bulk
erosion and surface erosion [21]. The degradation of such polymers is based on the conversion of the
macromolecule into its water-soluble monomers via the hydrolytic cleavage of the ester bonds that
constitute the backbone of the polymer. While bulk erosion does occur, a second mechanism which is
surface erosion also takes place concurrently. This refers to the occurrence of hydrolytic breakdown of
the polymer confined to the surface of the polymeric matrix. This was reflected by the steady decline
in its BHN value over time following hydration (Figure 1b). Drug release therefore involved complex
combination of both the drug diffusion from the surface as a result of bulk erosion as explained further
in the manuscript.
3.4. Changes in Conductivity of Compressed External Polymeric Matrices Following Hydration
These results inversely correlated with those observed for matrix erosion i.e., the greater the
matrix erosion, the lower the observed conductivity of the solution. This indicated a greater degree of
interaction between the untangling polymeric chains and the ions in solution. As greater quantities of
the polymer unraveled from the disc, i.e., the matrix eroded, it ionized and interacted with ions in the
surrounding PBS. Hence, we observed a decline in the conductivity of the solution over the 30 days
(Figure 1c). The greatest decline was observed for PEO. This is not surprising as it undergoes the most
rapid rates of matrix degradation. Since the most significant phase of degradation of the PEO discs
occurred within the first 12 days of exposure to simulated CSF, conductivity declined exponentially
until this point, after which equilibrium was attained. HPMC demonstrated a steady, almost linear
decline in conductivity until day 21, after which a significant amount of the matrix had degraded to
interact with surrounding counter-ionic species. As expected, PLGA expressed the least change in
electrical conductivity, since it demonstrated the minimal change in weight (matrix erosion) over time
following hydration.
3.5. Evaluation of Porosity Changes upon Hydration
Scanning electron micrographs of the discs demonstrated the progression of pore formation and
enlargement, formation of a trabeculated network of channels within the structure followed by erosion,
and loss of integrity (Figure 2). PLGA discs demonstrated the most intact matrices in comparison to
other systems. Figure 2a indicates the formation of a porous structure within the matrix at day 21
following exposure to simulated CSF. Larger pores (diameter of approximately 300 μm) were limited
to the periphery of the discs, while the core of the matrix was relatively intact (where pores have a
diameter of approximately 50 μm).
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Figure 2. Scanning electron micrographs (Magnification 65×) of compressed: (a) PLGA,
(b) HPMC–PLGA, and (c) PEO-PLGA discs following exposure to simulated cerebrospinal fluid
(CSF) after 21 days.
This matrix did not expand significantly, nor did it undergo any significant erosion. In contrast
by day 21, HPMC–PLGA discs (Figure 2b) had a significantly more patent network, with pore sizes
in the core of the matrix having comparatively larger diameters. The disc expanded in width and
cross-sectional diameter due to the tendency of HPMC to ‘swell’. PEO–PLGA discs (Figure 2c)
demonstrated a significant degree of erosion within the matrix while simultaneously indicating a
greater degree of swelling and erosion. By day 21, the entire network, including the core of the matrix,
was extremely patent and highly trabeculated. The majority of the matrix appeared to be composed of
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PLGA. A detailed image processing analysis of the PLGA matrix is provided in the supplementary
data (Figure S1).
3.6. In Vitro Drug Release from Nicotine-Loaded Compressed Gelisphere Polymeric Matrices
In vitro drug release studies in simulated CSF indicated that reinforced alginate gelispheres
released 100% of entrapped drug within 50 h through a biphasic first- and zero-order release profile
(Figure 3a). It was observed that reinforced alginate gelispheres incorporated into PLGA discs
demonstrated zero-order release kinetics that were able to provide controlled and prolonged release
for approximately 50 days (Figure 3b). Drug release kinetics indicated a rapid burst in drug release
after day 35, where after a first-order release profile was obtained. An additional 40% of entrapped
nicotine was released between days 35 and 40. In retrospect it was observed that PLGA had the
maximum cohesive tendency between its particles and has the ability to be most compressible. Being a
hydrophobic polymer, its main degradative mechanisms are through the hydrolytic cleavage of its
polymeric backbone. Consequently, these discs underwent minimal matrix degradation.
Figure 3. Drug released (%) from: (a) nicotine-loaded reinforced alginate gelispheres, and (b)
nicotine-loaded reinforced alginate gelispheres compressed into polymeric discs following exposure to
simulated cerebrospinal fluid (CSF) over a period of 50 hours (N = 3; SD < 0.53) and 50 days (N = 3;
SD < 0.59%) respectively.
The rapid release rates observed from PEO and HPMC matrices (Figure 3b) allowed us to
conclude that drug release occurred primarily by Fickian diffusion. The presence of PEO in matrices
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enhanced the rate of drug release from the compressed discs. Its hydrophilic character allowed
rapid disentanglement and degradation of the compressed matrices. Its tendency was therefore
to undergo comparatively rapid bulk erosion when it came in contact with the alkaline hydrating
medium (Figure 3b). HPMC is a hydrogel; hence, it has the capacity to imbibe a significant amount of
water before beginning to degrade. Furthermore, as observed from previous results, its particles were
sufficiently cohesive to generate compact discs that are able to provide zero-order release following
the achievement of an equilibrium hydrated state (discussed under later sections). Between days 3
and 18, a linear drug release profile was observed from HPMC discs (Figure 3b). Prior to this, a burst
release was observed, whereby approximately 33.25% of the entrapped nicotine was released within
the first 24 h. Combining HPMC and PLGA had a unique effect on drug release. While in this case
zero-order release was also observed, they exceeded those observed with the individual polymers. A
burst effect was observed until day 6, by which time 54.31% of the drug had been released (Figure 3b).
Thereafter, drug release followed a linear zero-order release profile until day 32. Release kinetics for all
other combinations exhibited rapid burst rates of drug release and predominately first-order release
(Figure 3b).
3.7. Molecular Mechanics Energy Relationship (MMER) Analysis
Molecular mechanics energy relationship (MMER), analysis, a method for analytico-mathematical
representation of potential energy surfaces, was used to provide information about the contributions
of valence terms, noncovalent Coulombic terms, and noncovalent van der Waals interactions for the
drug-polysaccharide complex, crosslinked polysaccharide morphologies, and the polymer-polymer
composites. The MMER model for the potential/steric energy factors in various molecular complexes
can be written as:
Emolecule/complex = V∑ = Vb + Vθ + Vϕ + Vij + Vhb + Vel (4)
where V∑ is related to total steric energy for an optimized structure, Vb corresponds to bond stretching
contributions, Vθ denotes bond angle contributions, Vϕ represents the torsional contribution from
dihedral angles, Vij incorporates van der Waals interactions due to non-bonded interatomic distances,
Vhb symbolizes hydrogen bond energy function, and Vel stands for electrostatic energy.
3.7.1. Energy Minimizations Involving Drug-Polymer Morphologies
The energy-minimized and geometrically optimized conformation depicting the alginate–nicotine
(ALG–NCT) complex is presented in Figure 4. The component binding energies and intrinsic molecular
attributes are listed in Equations (5)–(7) and Table 2, respectively. It is evident from Figure 4 that NCT
and ALG show close interaction via formation of H-bonds between C–O–C...N–H and C=O...N–H
group of ALG and NCT, respectively. The final energy of the drug–polymer complex was stabilized by
all three non-bonding interactions (van der Waals interactions, H-bonding and electrostatic interactions)
between the constituent molecules ALG and NCT. The surface-to-volume ratio (SVR) of the complex
ALG–NCT (SVR = 0.451) displayed lower SVR than the individual molecules (Table 2) further
confirming the stability of the complex—the lower the SVR, the more stable the structure. However,
the finally globally minimized energy values suggest that the ALG–NCT complex is destabilized by a
binding energy of ~4 kcal/mol (Equations (5)–(7)) due to exceptionally high torsional contribution
arising due to deviations from optimum dihedral angles (Equation (7)). Such interactions may induce
dipoles in the molecular complex due to the torsional strains experienced around dihedral angles.
EALG = −23.369V∑ = 2.148Vb + 26.810Vθ + 23.631Vϕ + 8.649Vij − 4.500Vhb − 80.110Vel (5)
ENCT = 13.283V∑ = 0.388Vb + 3.672Vθ + 6.198Vϕ + 3.023Vij (6)
EALG-NCT2 = 7.204V∑ = 3.403Vb + 34.575Vθ + 54.275Vϕ + 8.182Vij − 5.407Vhb − 87.824Vel (7)
[ΔEBINDING = 4.007 kcal/mol]
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Figure 4. Visualization of geometrical preferences of nicotine in complexation with alginate after
molecular mechanics simulations. Color codes: C (cyan), O (red), N (blue), and H (white).
Table 2. Calculated molecular attributes of the complexes involving alginate (ALG) and nicotine (NCT).
Structure
Molecular Attributes
Surface Area (grid) Volume Surface-To-Volume Ratio
ALG 828.99 1518.13 0.546
NCT2 # 603.16 1088.42 0.554
ALG–NCT2 # 1026.16 2273.41 0.451
ΔRef = Ref(HostGuest) – Ref(Host) – Ref(Guest). # Data represent two molecules of nicotine.
It can be deduced from the above discussion that although nicotine formed a polyelectrolyte
complex in association with alginate, the complex being unstable as it was might have led to release of
nicotine upon hydration of the matrix. The above findings corroborated with the need of strategies
for controlling the release of nicotine from the alginate matrix. We propose that this may be achieved
by three different approaches applied together. Firstly, this may be achieved by inclusion of another
polymer to stabilize the alginate matrix. Secondly, the strengthening of the alginate matrix can be
achieved by crosslinking the hydrogel matrix using divalent ions such as Ca2+ or Ba2+. The third
approach is by incorporating the crosslinked blend hydrogel–matrix in a release rate-modulating
external polymeric matrix.
3.7.2. Mechanistic Elucidation of Crosslinked Polymer Conformations
The general molecular mechanics program was used in this study to compute the energy of the
polymer–saccharide (ALG–HEC) and the cation-polymer-saccharide conformations. The geometrical
conformation of the ALG–HEC after SLAS are shown in Figure 5a and the corresponding energy
attributes are depicted in Equations (5), (8) and (9).
EHEC = 130.862V∑ = 4.017Vb + 80.816Vθ + 35.115Vϕ + 10.28Vij − 0.231Vhb + 0.863Vel (8)
EALG-HEC = −4.459V∑ = 6.685Vb + 44.109Vθ + 77.607Vϕ + 9.085Vij − 4.062Vhb − 137.886Vel (9)
[ΔEBINDING = −111.952 kcal/mol]
EALG-HEC-Ca2+ = −10.907V∑ = 6.666Vb + 44.137Vθ + 77.733Vϕ + 2.794Vij − 4.018Vhb − 138.22Vel (10)
[ΔEBINDING = -118.4 kcal/mol]
EALG-HEC-Ba2+ = −13.641V∑ = 6.700Vb + 44.245Vθ + 77.981Vϕ + 0.116Vij − 4.060Vhb − 138.625Vel (11)
[ΔEBINDING = −121.134 kcal/mol]
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Figure 5. Visualization of geometrical preference of (a) Hydroxyethyl cellulose in complexation
with alginate; (b) oligosaccharide–Ca2+ complex, and (c) oligosaccharide–Ba2+ complex derived after
molecular mechanics simulations. Color codes: C (cyan), O (red), N (blue), Ca (yellow), Ba (brown),
and H (white).
The final minimized energy values for the ALG-HEC complex demonstrated a stabilization of
binding energy by 111.952 kcal/mol and was significantly supported by the van der Waals interactions
due to the presence of ethyl aliphatic groups in the constituent polymers. The interaction led to the
formation of both intermolecular H-bonds between the sugar moieties (Figure 5a). These underlying
weak chemical interactions may not cause a structural change in the polymers but may initiate
aggregation of the aliphatic chains creating dense localized regions not characteristic of the bulk
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polymers. In addition, ALG-induced intramolecular hydrogen bonding in HEC and vice versa may
influence the hydration process of the polymer matrix. This energy stabilization along with the matrix
entanglement may provide a prolonged nicotine release along with reduced burst release as compared
to alginate alone.
We further screened ALG–HEC interactions for two divalent cations (Ca2+ and Ba2+) using SLAS,
wherein the ion probes were placed within the van der Waals surface of the polymeric chains as shown
in Figure 5a,b. The component binding energies listed in Equations (5), (8), (10) and (11) confirmed
that the ALG–HEC–Ba2+ formed a more thermodynamically stable conformer than ALG–HEC–Ca2+.
Interestingly, the polymer chains formed an ordered secondary structure outlined by the presence
of cation binding sites as ordered arrays and within the polysaccharide fragments. These energy
optimizations were supported by the electrostatic forces while the van der Waals interactions and the
torsion angle energies destabilized the cation-crosslinked molecules. The geometrical conformation of
the polymer chains and the steric organization of the cations conformed the role of stereospecificity,
ligand spacing and position of the coordination shell for the cation interaction display (Figure 5).
A close look at Figure 5 revealed that Ba2+ provided significantly close packed 3D architecture as
compared to Ca2+ and hence increased the tendency of the polymer network to form intraglycosidic
hydrogen bonds and an increase in hydration energy. In essence, the torsional strains, cavity formation
contribution and hydration factors together contributed to complexation energies. This behavior of
the Ca2+ and Ba2+ was also in agreement with experimental data in the case of ALG–HEC gelispheres
where the corrugated polysaccharide chains might “offer several oxygen atoms whose stereochemical
arrangement fits into the coordination sphere” of the cations resulting in prolonged release of nicotine
from gelisphere matrices.
3.7.3. 3D Computational Modeling for Polymer–Polymer Complexes
The measured differences in the flowability and friability properties and texture profile of external
matrices were elucidated by randomly disposing PLGA or PEO or PLGA/PEO around HPMC to form
HPMC–PLGA, HPMC–PEO and PLGA/HPMC/PEO.
EHPMC = 49.713V∑ = 2.089Vb + 18.821Vθ + 22.360Vϕ + 6.776Vij − 0.335Vhb (12)
EPLGA = 2.021V∑ = 0.522Vb + 4.905Vθ + 2.575Vϕ − 5.982Vij (13)
EPEO = 29.483V∑ = 0.643Vb + 6.092Vθ + 15.675Vϕ + 7.072Vij (14)
EPLGA-HPMC = 32.098V∑ = 2.366Vb + 21.460Vθ + 26.393Vϕ − 17.375Vij − 0.747Vhb (15)
[ΔEBINDING = −19.636 kcal/mol]
EPLGA-PEO = 11.572V∑ = 1.240Vb + 8.231Vθ + 18.895Vϕ − 16.794Vij (16)
[ΔEBINDING = −19.932 kcal/mol]
EHPMC-PEO = 53.607V∑ = 2.540Vb + 17.290Vθ + 42.725Vϕ − 7.945Vij − 1.003Vhb (17)
[ΔEBINDING = −25.236 kcal/mol]
EPLGA-HPMC-PEO = 40.662V∑ = 3.043Vb + 25.015Vθ + 40.473Vϕ − 26.637Vij − 1.233Vhb (18)
[ΔEBINDING = −40.555 kcal/mol]
It is evident from Equations (12)–(18) that the formation of HPMC–PLGA, PLGA–PEO,
HPMC–PEO and PLGA/HPMC/PEO (in vacuum) were accompanied by energy stabilization of
−19.636 kcal/mol, −19.932 kcal/mol, −25.236 kcal/mol and −40.555 kcal/mol, respectively. Since
all four molecular complexes displayed –ve energy of binding, it can be estimated that the polymers
demonstrated compatibility and stability to form a polymeric blend in a dried state [22].
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The chemical interactions within the polymeric blends were primarily represented by non-bonding
interactions (van der Waals forces) and were accountable for the for mechanical strength and flow
characteristics of the composites. This energy minimization involving HPMC demonstrated extensive
rotations among the monosaccharide residues leading to the formation of a strained architecture
which was eventually relieved by angle adjustments and bond length, resulting in H-bonding
within the PLGA–HPMC and PEO–HPMC composites (Figure 6). As reported earlier in this paper,
PLGA–HPMC–PEO produced highly dense compressed discs due to high angle of repose and
flowability. This could be due to the interactions of aliphatic groups of PLGA/PEO with pendent
groups of HPMC → formation of unfavorable regions → large steric modulations and overcoming of
torsional barriers → large accessible potential energy surface → formation of a polymeric matrix. This
became even more applicable when the matrices were hydrated. Given the high torsional strain within
the HPMC matrices, it may induce degradation of the polymeric matrix in order to acquire energy
stabilization upon hydration. The movement of water molecules inside the torsional strains may in
turn lead to an early release of drug molecules. This corroborates with the experimental results wherein
rapid release rates were observed from PEO and HPMC matrices (Figure 3). This torsional restraint
relaxation during hydration also led to the decrease in BHN values in HPMC and PEO matrices as
compared to PLGA matrices (Figure 1).
Figure 6. Visualization of geometrical preference of (a) PLGA in complexation with HPMC; (b) PEO in
complexation with HPMC; (c) PLGA–HPMC–PEO tripolymeric comples with PEO H-bonded to HPMC;
and (d) PLGA–HPMC–PEO tripolymeric complex with PLGA H-bonded to HPMC after molecular
mechanics simulations. Color codes: C (cyan), O (red), N (blue), and H (white).
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4. Conclusions
The intended drug delivery system that this study sought to develop was one that could provide
sustained zero-order release of nicotine from a crosslinked polyspheric system. This would allow for
the attainment of constant drug levels at the site of action and minimize adverse effects associated
with fluctuating drug levels, as well as optimizing patient therapy and compliance. PLGA matrices
incorporating calcium barium-crosslinked alginate-hydroxyethylcellulose gelispheres offered minimal
rates of matrix degradation and successfully retarded nicotine release, leading to the achieved
zero-order release for 50 days following exposure to simulated CSF. The computational modeling
methods that were used for the prediction of preferred molecular conformations of the drug–polymer
and polymer-polymer complexes using force field minimizations and the modes of interaction
corroborated well the experimental results. The developed drug delivery system displays a great
potential for use in the treatment of Parkinson’s disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/233/s1,
Figure S1: Image processing of micrograph of a PLGA scaffold: (a) BLURimage: blurred SEMimage; (b) CQimage:
colorquantized image of BLURimage; (c) UniHisto: uniform histogram of CQimage; (d) UniHistoSep: separated
uniform histogram of CQimage after image processing; (e) NonUniHisto: non-uniform histogram of SEMimage
before image processing; and (f) NonUniHistoSep: separated non-uniform histogram of SEMimage before image
processing. Note that each color channel is only capable of highlighting most of the pores, but not all.
Author Contributions: Conceptualization, Y.E.C. and V.P.; Methodology, P.K., L.D.d.T. and N.S.; Software, P.K.;
Formal Analysis, P.K. and N.S.; Resources, V.P.; Writing—Original Draft Preparation, P.K.; Writing—Review &
Editing, all authors; Supervision, Y.E.C. and V.P.; Funding Acquisition, V.P.
Funding: This work was funded by the National Research Foundation (NRF) of South Africa.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Moll, H. The treatment of post encephalitic Parkinsonism by nicotine. Br. Med. J. 1926, 1, 1079–1081.
[CrossRef] [PubMed]
2. Quik, M.; Zhang, D.; McGregor, M.; Bordia, T. Alpha7 nicotinic receptors as therapeutic targets for
Parkinson’s disease. Biochem. Pharmacol. 2015, 97, 399–407. [CrossRef] [PubMed]
3. Barreto, G.E.; Iarkov, A.; Moran, V.E. Beneficial effects of nicotine, cotinine and its metabolites as potential
agents for Parkinson’s disease. Front. Aging Neurosci. 2014, 6, 340. [CrossRef] [PubMed]
4. Mouhape, C.; Costa, G.; Ferreira, M.; Abin-Carriquiry, J.A.; Dajas, F.; Prunell, G. Nicotine-induced
neuroprotection in rotenone in vivo and in vitro models of Parkinson’s disease: Evidences for the
involvement of the labile iron pool level as the underlying mechanism. Neurotox. Res. 2018, in press.
[CrossRef] [PubMed]
5. Villafane, G.; Thiriez, C.; Audureau, E.; Straczek, C.; Kerschen, P.; Cormier-Dequaire, F.; Van Der Gucht, A.;
Gurruchaga, J.-M.; Quéré-Carne, M.; Paul, M.; et al. High-dose transdermal nicotine in Parkinson’s disease
patients: A randomized, open-label, blinded-endpoint evaluation phase 2 study. Eur. J. Neurol. 2018, 25,
120–127. [CrossRef] [PubMed]
6. Oliveira, S.S.M.; Oliveira, F.S.; Gaitani, C.M. Microparticles as a strategy for low-molecular-weight heparin
delivery. J. Pharm. Sci. 2011, 100, 1783–1792. [CrossRef] [PubMed]
7. Pahwa, R.; Saini, N.; Kumar, V.; Kohli, K. Chitosan-based gastroretentive floating drug delivery technology:
An updated review. Exp. Opin. Drug Deliv. 2012, 9, 525–539. [CrossRef] [PubMed]
8. Kamaly, N.; Yameen, B.; Wu, J.; Farokhzad, O.C. Degradable controlled-release polymers and polymeric
nanoparticles: Mechanisms of controlling drug release. Chem. Rev. 2016, 116, 2602–2663. [CrossRef]
[PubMed]
9. Hu, A.; Chen, C.; Mantle, M.D.; Wolf, B.; Gladden, L.F.; Rajabi-Siahboomi, A.; Missaghi, S.; Mason, L.;
Melia, C.D. The properties of HPMC:PEO extended release hydrophilic matrices and their response to ionic
environments. Pharm. Res. 2017, 34, 941–956. [CrossRef] [PubMed]
53
Pharmaceutics 2018, 10, 233
10. Zhang, Q.; Fassihi, M.A.; Fassihi, R. Delivery considerations of highly viscous polymeric fluids mimicking
concentrated biopharmaceuticals: Assessment of injectability via measurement of total work done “WT”.
AAPS PharmSciTech 2018, 19, 1520–1528. [CrossRef] [PubMed]
11. Kumar, P.; Bhatia, M. Functionalization of chitosan/methylcellulose interpenetrating polymer network
microspheres for gastroretentive application using central composite design. PDA J. Pharm. Sci. Technol.
2010, 64, 497–506. [PubMed]
12. Colombo, P.; Bettini, R.; Peppas, N.A. Observation of swelling process and diffusion front position during
swelling in hydroxypropyl methyl cellulose (HPMC) matrices containing a soluble drug. J. Control. Release
1999, 61, 83–91. [CrossRef]
13. Jamzad, S.; Tutunji, L.; Fassihi, R. Analysis of macromolecular changes and drug release from hydrophilic
matrix systems. Int. J. Pharm. 2005, 292, 75–85. [CrossRef] [PubMed]
14. Mansour, H.M.; Sohn, M.; Al-Ghananeem, A. Materials for pharmaceutical dosage forms: Molecular
pharmaceutics and controlled release drug delivery aspects. Int. J. Mol. Sci. 2010, 11, 3298–3322. [CrossRef]
[PubMed]
15. Kapoor, D.N.; Bhatia, A.; Kaur, R.; Sharma, R.; Kaur, G.; Dhawan, S. PLGA: A unique polymer for drug
delivery. Ther. Deliv. 2015, 6, 41–58. [CrossRef] [PubMed]
16. Fournier, E.; Passirani, C.; Montero-Menei, C.N.; Benoit, J.P. Biocompatibility of implantable synthetic
polymeric drug carriers: Focus on brain biocompatibility. Biomaterials 2003, 24, 3311–3331. [CrossRef]
17. Choonara, Y.E.; Pillay, V.; Khan, R.A.; Singh, N.; Du Toit, L.C. Mechanistic evaluation of alginate-HEC
gelisphere compacts for controlled intrastriatal nicotine release in Parkinson’s disease. J. Pharm. Sci. 2009, 98,
2059–2072. [CrossRef] [PubMed]
18. Bawa, P.; Pillay, V.; Choonara, Y.E.; du Toit, L.C.; Ndesendo, V.M.K.; Kumar, P. A composite polyelectrolytic
matrix for controlled oral drug delivery. AAPS PharmSciTech 2011, 12, 227–238. [CrossRef] [PubMed]
19. Kumar, P.; Choonara, Y.E.; Pillay, V. In silico analytico-mathematical interpretation of biopolymeric
assemblies: Quantification of energy surfaces and molecular attributes via atomistic simulations.
Bioeng. Transl. Med. 2018, 3, 222–231. [CrossRef] [PubMed]
20. Caccavo, D.; Cascone, S.; Lamberti, G.; Barba, A.A. Controlled drug release from hydrogel-based matrices:
Experiments and modeling. Int. J. Pharm. 2015, 486, 144–152. [CrossRef] [PubMed]
21. Rafiei, P.; Haddadi, A. Pharmacokinetic Consequences of PLGA nanoparticles in docetaxel drug delivery.
Pharm. Nanotechnol. 2017, 5, 3–23. [CrossRef] [PubMed]
22. Kumar, P.; Choonara, Y.E.; Toit, L.C.; Modi, G.; Naidoo, D.; Pillay, V. Novel high-viscosity polyacrylamidated
chitosan for neural tissue engineering: Fabrication of anisotropic neurodurable scaffold via molecular
disposition of persulfate-mediated polymer slicing and complexation. Int. J. Mol. Sci. 2012, 13, 13966–13984.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Cell Internalization in Fluidic Culture Conditions
Is Improved When Microparticles Are Specifically
Targeted to the Human Epidermal Growth Factor
Receptor 2 (HER2)
Inmaculada Mora-Espí 1, Elena Ibáñez 1, Jorge Soriano 1, Carme Nogués 1,
Thorarinn Gudjonsson 2,3 and Leonardo Barrios 1,*
1 Unitat de Biologia Cel·lular, Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de
Biociències, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain;
xapaxin@gmail.com (I.M.-E.); Elena.ibanez@uab.cat (E.I.); jorge.soriano@uab.cat (J.S.);
carme.nogues@uab.cat (C.N.)
2 Biomedical Center, University of Iceland, 101 Reykjavík, Iceland; tgudjons@hi.is
3 Department of Anatomy, Faculty of Medicine, and Department of Laboratory Hematology, University
Hospital, 101 Reykjavik, Iceland
* Correspondence: lleonard.barrios@uab.cat; Tel.: +34-93-581-2776; Fax: +34-93-581-2295
Received: 21 February 2019; Accepted: 8 April 2019; Published: 11 April 2019
Abstract: Purpose: To determine if the specific targeting of microparticles improves their
internalization by cells under fluidic conditions. Methods: Two isogenic breast epithelial cell
lines, one overexpressing the Human Epidermal Growth Factor Receptor 2 (HER2) oncogene
(D492HER2) and highly tumorigenic and the other expressing HER2 at much lower levels and
non-tumorigenic (D492), were cultured in the presence of polystyrene microparticles of 1 μm in
diameter, biofunctionalized with either a specific anti-HER2 antibody or a non-specific secondary
antibody. Mono- and cocultures of both cell lines in static and fluidic conditions were performed,
and the cells with internalized microparticles were scored. Results: Globally, the D492 cell line showed
a higher endocytic capacity than the D492HER2 cell line. Microparticles that were functionalized
with the anti-HER2 antibody were internalized by a higher percentage of cells than microparticles
functionalized with the non-specific secondary antibody. Although internalization was reduced in
fluidic culture conditions in comparison with static conditions, the increase in the internalization
of microparticles biofunctionalized with the anti-HER2 antibody was higher for the cell line
overexpressing HER2. Conclusion: The biofunctionalization of microparticles with a specific targeting
molecule remarkably increases their internalization by cells in fluidic culture conditions (simulating
the blood stream). This result emphasizes the importance of targeting for future in vivo delivery of
drugs and bioactive molecules through microparticles.
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1. Introduction
Drug targeting has the potential to improve the therapeutic efficacy and mitigate the non-specific
effects of many drugs. In the last years, several types of drug delivery vehicles have been developed,
including monoclonal antibodies [1], peptides [2], proteins [3], lipoproteins [4], carbohydrates [5],
and polymeric nanoparticles [6,7]. Compared with the number of studies in which nanoparticles
(NPs) are used [8–12], only a small number of studies involve the use of microparticles (μPs) [13–15].
It has been reported that small sizes and positive charges favor NP intake by cells [14–16], but in
some cases, larger particle sizes could be advantageous for preventing non-specific interactions
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and internalization into normal non-phagocytic cells or for optimal tissue entrapment and transient
retention [17]. Moreover, to target cancer cells, NPs and μPs surfaces can be modified to increase
the interaction with plasma membrane-specific markers like the transferrin receptor [18], the folate
receptor [19], or the human epidermal growth factor receptor 2 (HER2, also known as ERBB2) [20,21].
HER2 is a receptor tyrosine kinase which is overexpressed by some types of cancer cells and is
considered a marker of poor clinical outcome in breast and ovarian cancer [22,23]. Some treatments
directed to this target have already been approved and are clinically used, such as the anti-HER2
monoclonal antibody trastuzumab, alone or in combination with emtansine (T-DM1) [24], and the
HER2 tyrosine kinase activity inhibitor lapatinib.
Traditionally, in vitro studies on drug carriers and drug release have been performed in static
monolayer cell cultures. However, studies in microfluidic environments, mimicking the circulatory
system, are currently gaining interest [12]. Compared with static cultures, microfluidic studies allow
for better predictions about how a drug or a drug carrier running in a circulating flow, will interact
with cells [25–27]. On the other hand, because normal and tumoral cells are intermingled in vivo,
cocultures of normal and tumoral cells can better simulate tissue conditions than monocultures [28,29].
The overall objective of the present study was to evaluate the efficiency of targeting μPs to cells in
physiological-like conditions (fluidic culture conditions). Two isogenic breast epithelial cell lines were
used, one normal (D492) and the other overexpressing HER2 (D492HER2). Moreover, polystyrene μPs
of 1 μm in diameter were biofunctionalized with a specific targeting protein, an anti-HER2 antibody,
or with a non-specific secondary antibody. The specific objectives of the study were to evaluate and
compare the cell internalization of these μPs in different culture conditions: monoculture versus
coculture conditions, and static versus fluidic culture conditions.
2. Material and Methods
2.1. Biofunctionalization of Polystyrene μPs
Carboxylate polystyrene μPs of 1 μm in diameter (Polybead® Carboxylate Microspheres.
Polysciences, Inc., Warrington, PA, USA) were biofunctionalized with two different targeting molecules:
(1) mouse anti-c-ERBB2/c-Neu (Ab-5) clone TA-1 (Millipore, Darmstadt, Germany), herein referred
to as antiH, and (2) goat anti-mouse IgG2a secondary antibody Alexa Fluor® 647 conjugate (Life
Technologies, Carlsbad, CA, USA), herein referred to as secAb. Biofunctionalization was carried out
using the PolyLink Protein Coupling Kit for COOH Microspheres (Polysciences) according to the
manufacturer’s instructions. The size of the μPs before and after biofunctionalization was analyzed
by transmission electronic microscopy (TEM) (JEOL, JEM 2011). Biofunctionalization was evaluated
under a fluorescence inverted microscope (Olympus IX71, Olympus, Hamburg, Germany) and by the
change in the ζ-potential.
Microscopically, biofunctionalization of μPs with secAb (μP-secAb) was evaluated directly on
the basis of their far-red fluorescence emission. On the other hand, μPs biofunctionalized with antiH
(μP-antiH) were incubated for 5 min with chicken anti-mouse IgG (H+L) secondary antibody Alexa
Fluor® 488 conjugate (1:500. Life Technologies) before the evaluation of green fluorescence emission.
Biofunctionalized and non-biofunctionalized μPs were separately resuspended in H14 culture
medium [30] and sonicated for 5 min (Fisherbrand FB15047, Fisher Scientific, Germany) to achieve
a monodispersed sample. Their ζ-potential was then measured with a Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK).
2.2. Cell Lines
Two isogenic breast epithelial cell lines, D492 and D492HER2, were used in the study. D492 is
a non-tumorigenic cell line with stem cell properties that expresses low levels of the HER2
oncogene [30,31]. D492HER2 was generated by overexpressing the HER2 oncogene in D492 and
is highly tumorigenic [32]. Both cell lines constitutively express green fluorescent protein (GFP).
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The cells were cultured in serum-free H14 culture medium [30,31] at 37 ◦C and 5% CO2 (standard
conditions). As explained below, cell culture was performed as follows: mono- or cocultures in static
conditions, and cocultures in fluidic conditions.
2.3. Cell Cultures in Static Conditions
For monoculture experiments, cells were seeded at a density of 60,000 cells/well in 24-well
plates (μ-Plate 24-Well ibiTreat: #1.5 polymer coverslip. ibidi, Martinsried, Germany). For coculture
experiments, 30,000 cells of each cell line (D492 and D492HER2) were seeded together in each well.
In both cases, the cells were maintained for 24 h in standard culture conditions prior to performing
any experiments.
To analyze μP internalization, μPs (μP-antiH or μP-secAb) were sonicated for 5 min, diluted
(1:100), counted with a hemocytometer, and then added at a proportion of 45 μP/cell to the cell cultures
and incubated for further 24 h in standard culture conditions.
2.4. Cell Cultures in Fluidic Conditions
For these experiments, only cocultures were performed. Before seeding, channel slides (μ-Slides
I 0.8 mm ibiTreat, ibidi) were coated with bovine collagen type I (Advanced Biomatrix, San Diego,
CA, USA) to enhance cell adhesion. Then, 1.5 × 105 cells of each cell line (D492 and D492HER2)
were seeded in H14 medium containing 2% penicillin/streptomycin (Biowest, Nuaillé, France) and
incubated in standard culture conditions. After 24 h, the slides were connected to a microfluidic
system consisting of a perfusion set (Perfusion Set Red ID 1.6 mm, ibidi) filled with fresh H14 medium
containing the μPs (μP-secAb or μP-antiH) and a Fluidic Unit connected to an ibidi Pump, controlled by
a pump-control software (ibidi). The microfluidic system was kept at 37 ◦C and 5% CO2. The cultures
were maintained for 24 h under a unidirectional flow rate fixed at 4.32 mL/min with a shear stress of
1.50 dyn/cm2 and a pressure of 7.9 mbar, as recommended by the manufacturer.
2.5. Evaluation of Microparticles Internalization
After being cultured in either static or fluidic conditions, the cells were washed three times with
phosphate buffer saline (PBS) at room temperature (RT), fixed for 15 min with 4% paraformaldehyde
(Sigma-Aldrich, St Louis, MO, USA) in PBS, and washed again with PBS (three times). Next, the fixed
cells were permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 10 min at RT, washed with
PBS (three times), and blocked with 3% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS for
40 min. PBS with 3% BSA was also employed to dilute the antibodies used in this work.
The cells from the monocultures were incubated with Alexa Fluor® 546 Phalloidin (1:40,
Life Technologies) to label actin microfilaments and, in the case of samples with μP-antiH, also with
goat anti-mouse IgG1 secondary antibody Alexa Fluor® 647 conjugate (1:150. Life Technologies) for
1 h at RT to detect μP-antiH.
To distinguish between D492 and D492HER2 in cocultures, the cells were first incubated with
rabbit anti-HER2 monoclonal antibody (1:200, Cell Signaling, Danvers, MA, USA) overnight at 4 ◦C.
Then, the samples were washed three times with PBS and incubated for 2.5 h at RT with Alexa Fluor®
546 Phalloidin to label actin microfilaments to visualize the cell limit and chicken anti-rabbit IgG (H+L)
Alexa Fluor® 405 conjugate secondary antibody (1:150, Life Technologies) to label HER2 in the plasma
membrane; for cells incubated with μP-antiH, goat anti-mouse IgG1 secondary antibody Alexa Fluor®
647 conjugate was also used.
Finally, the cells were washed three times with PBS and maintained at 4 ◦C in PBS until evaluation
under a confocal laser scanning microscope (CLSM. Olympus, Tokyo, Japan). Orthogonal projections
of z-stacks of at least 100 cells for each cell line were evaluated in each replicate. The xyz sequentially
acquired images allowed for assessment of whether the particles were inside the cells or attached to
their surfaces.
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2.6. Statistical Analyses
At least three replicates of each experiment were performed. To compare μP internalization in
each experimental condition and for each cell line, ANOVA with post-hoc Tukey HSD test was used;
p < 0.05 was considered statistically significant.
3. Results
3.1. Microparticles Characterization after Biofunctionalization
Biofunctionalization did not affect the size of μPs, as can be observed in TEM images (Figure 1A).
Moreover, biofunctionalization was confirmed in two ways, microscopically and by analyzing the
ζ-potential. As expected, under fluorescence microscopy, μP-secAb emitted far-red fluorescence,
and μP-antiH emitted green fluorescence after incubation with an Alexa® 488-conjugated secondary
antibody (Figure 1B). Biofunctionalization was also confirmed by changes in the μP surface charge.
Non-biofunctionalized polystyrene carboxylate μPs (μP-COOH) showed a ζ-potential value of
−32.3 mV, whereas μP-secAb and μP-antiH increased their ζ-potential to smaller negative values of
−11.23 mV and −11.5 mV, respectively (Figure 1C).
Figure 1. Characterization of microparticles (μP) biofunctionalization. (A) Transmission electronic
microscopy (TEM) images of microparticles before (COOH) and after biofunctionalization (μP-secAb
and μP-antiH). (B) Images of microparticles biofunctionalized with a secondary antibody (μP-secAb)
or an anti-HER2 antibody (μP-antiH) in bright-field (upper panels) and fluorescence (lower panels)
microscopy. (C) Zeta potential before (COOH) and after biofunctionalization (μP-secAb and μP-antiH).
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3.2. Microparticles Internalization by Cells
The internalization of μPs by cells was evaluated through the orthogonal images captured by
a CLSM in both static and fluidic culture conditions (examples in Figures 2 and 3, respectively).
Staining of actin filaments was useful to visualize the cell perimeter and, together with the
orthogonal projections, allowed us to clearly distinguish between internalized and non-internalized
μPs. From these images, the number of cells with at least one internalized μP was scored.
Figure 2. Immunofluorescence analysis by confocal laser scanning microscope (CLSM) of cells cultured
in static conditions. Confocal images of D492 and D492HER2 cells cocultured in static conditions and
incubated with microparticles biofunctionalized with a non-specific secondary antibody (μP-secAb) or
a specific anti-HER2 antibody (μP-antiH). Cells, constitutively expressing green fluorescent protein
(GFP, green), were incubated with Alexa Fluor® 546 Phalloidin (red) to label actin microfilaments
and Alexa Fluor® 405 conjugate secondary antibody (blue) to label HER2 in the plasma membrane.
The arrows point to some examples of μPs located inside the cells.
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Figure 3. Immunofluorescence analysis by CLSM of cells cultured in fluidic conditions. Confocal
images of D492 and D492HER2 cells cocultured in fluidic conditions and incubated with microparticles
biofunctionalized with a non-specific secondary antibody (μP-secAb) or a specific anti-HER2 antibody
(μP-antiH). The cells, constitutively expressing GFP (green), were incubated with Alexa Fluor® 546
Phalloidin (red) to label actin microfilaments and Alexa Fluor® 405 conjugate secondary antibody
(blue) to label HER2 in the plasma membrane. The arrows point to some examples of μPs located
inside the cells.
As can be seen in Figure 4, in all conditions, the percentage of D492 cells with internalized
microparticles was always higher than that of D492HER2 cells, indicating that D492 cells have
an inherent superior capacity to internalize microparticles. Regarding the importance of specific
biofunctionalization in μPs recognition and intake by the cells, the internalization related to non-specific
binding due to the intrinsic cell endocytic capacity, was represented by the percentage of cells
with internalized μPs biofunctionalized with the non-specific antibody (μPs-secAb). In contrast,
the internalization related to the specific recognition of μPs by the cells was represented by the
increase in the percentage of cells with internalized μPs when these were specifically functionalized
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(μP-antiH) to recognize a cell membrane receptor (HER2). For both cell lines, the biofunctionalization
with a specific targeting antibody (antiH) resulted in higher internalization percentages than the
biofunctionalization with a non-specific targeting antibody (secAb). The differences between static
monoculture and coculture conditions were not significant. As expected, fluidic culture conditions
globally decreased internalization, but again internalization was higher for microparticles which were
specifically biofunctionalized (μP-antiH) than for those that were biofunctionalized with a non-specific
antibody (μP-secAb). The increase in the percentage of cells with internalized μP-antiH was also
higher for cells with HER2 overexpression (D492HER2) than for cells without HER2 overexpression
(D492) (Figure 4). Remarkably, the increase in the percentage of cells with internalized μP-antiH with
regard to μP-secAb internalization was higher in fluidic conditions than in static conditions, especially
in D492HER2 cells (164% versus 77–99% in D492HER2 cells, and 100% versus 22–35% in D492 cells).
 
Figure 4. Microparticles internalization by monocultured or cocultured D492 and D492HER2 cells in
static and fluidic conditions. Percentages of cells with internalized microparticles biofunctionalized
with a non-specific secondary antibody (μP-secAb) or a specific anti-HER2 antibody (μP-antiH).
Statistically significant differences are indicated with different letters on top of the bars. An increase of
μPs internalization, as a percentage, is indicated in blue together with blue arrows.
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4. Discussion
Polystyrene μPs were successfully biofunctionalized with an anti-HER2 antibody or with a
secondary antibody, as demonstrated by the detection of fluorescence under a microscope and by
changes in their ζ-potential. The reduction in μPs electronegativity could help in their interaction with
the plasma membrane, which contains negatively charged saccharides. In fact, it has been described
that positively or slightly negatively charged particle surfaces favor cell intake [14,33–35].
The cell lines used in this study are isogenic breast epithelial cell lines. D492 was established
by isolating suprabasal cells from a reduction mammoplasty and subsequently immortalizing them
using the E6 and E7 oncogenes from the human papilloma virus [30,31]. D492 has stem cell properties
evaluated by the ability to generate luminal and myoepithelial cells and, in 3D culture, to form
branching ductal–alveolar-like structures. D492HER2 was generated by overexpressing the HER2
oncogene in D492 [32]. Interestingly, D492 showed higher percentages of μPs internalization than
D492HER2. A possible explanation could be the differences in phenotype between these cells.
D492HER2 cells undergo an epithelial to mesenchymal transition (EMT) and express mesenchymal
markers, which could reduce their ability to internalize μPs [31,32]. Higher rates of μP internalization
have also been described in MCF10A breast epithelial normal cells than in SKBR3 breast epithelial
tumoral cells, which also overexpress HER2 [14].
The molecules used to bio-functionalize the μPs also influenced the internalization rates. For both
cell lines, the percentage of cells with internalized μP-antiH was higher than that of cells with
internalized μP-secAb. This result was expected, since we hypothesized that a specific recognition
between the cells and the μPs, such as that afforded by antiH biofunctionalization, could result in an
increase in μP internalization. Also as expected, the increase in the percentages of μPs internalization
obtained with antiH biofunctionalization was higher for D492HER2 cells, which overexpress HER2,
than for D492 cells, which express HER2 at much lower levels [32]. These results clearly indicate
that when μPs are biofunctionalized with molecules that specifically interact with plasma membrane
receptors, their internalization can be improved, and the level of improvement is related to the number
of receptors that are present on the cell surface.
Finally, in relation to the culture conditions, our results indicate that the percentage of cells with
internalized μPs clearly decreased in fluidic conditions compared with static conditions. This was
probably because the establishment of prior transient contacts between the plasma membrane and
the μPs may be more difficult in fluidic conditions or in high shear stress conditions [36,37]. One can
hypothesize that in the case of dynamic cultures, specific targeting may be helpful to improve the
internalization rates, as it may facilitate the frequency and strength of μPs-cell contacts. Our results
agree with this hypothesis because, for both cell lines, the increase of μPs-antiH internalization was
higher in fluidic than in static cocultures when compared with μPs-secAb internalization, which opens
the door to scale-up studies.
The present results, together with previous research, emphasize the relevance of cell type, specific
targeting, and culture conditions such as mono- or cocultures and static or fluidic, to the potential
application of NPs and μPs for drug delivery to cancer cells.
5. Conclusions
The present study indicates that, for all culture conditions, μPs biofunctionalized with anti-HER2
antibodies were more efficiently internalized by cells expressing HER2 than μPs biofunctionalized
with a non-specific antibody. Moreover, in fluidic culture conditions (simulating the blood stream),
the specificity of targeting was still more useful for μP internalization, because the increase in
internalization was higher for cells overexpressing HER2. Overall, the results presented emphasize
the importance of targeting not only for directing μPs to the appropriate cells but also for achieving
reasonable internalization rates, thereby opening the door to the use of microparticles as carriers for
drug delivery.
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Abstract: In pharmaceutical nanotechnology, the intentional manipulation of working processes to
fabricate nanoproducts with suitable properties for achieving the desired functional performances
is highly sought after. The following paper aims to detail how a modified coaxial electrospraying
has been developed to create ibuprofen-loaded hydroxypropyl methylcellulose nanoparticles for
improving the drug dissolution rate. During the working processes, a key parameter, i.e., the spreading
angle of atomization region (θ, ◦), could provide a linkage among the working process, the property
of generated nanoparticles and their functional performance. Compared with the applied voltage
(V, kV; D = 2713 − 82V with RθV2 = 0.9623), θ could provide a better correlation with the diameter
of resultant nanoparticles (D, nm; D = 1096 − 5θ with RDθ2 = 0.9905), suggesting a usefulness
of accurately predicting the nanoparticle diameter. The drug released from the electrosprayed
nanoparticles involved both erosion and diffusion mechanisms. A univariate quadratic equation
between the time of releasing 95% of the loaded drug (t, min) and D (t = 38.7 + 0.097D − 4.838 × 105D2
with a R2 value of 0.9976) suggests that the nanoparticle diameter has a profound influence on the
drug release performance. The clear process-property-performance relationship should be useful for
optimizing the electrospraying process, and in turn for achieving the desired medicated nanoparticles.
Keywords: coaxial electrospraying; polymeric nanoparticles; spreading angle;
process-property-performance relationship
1. Introduction
Today, nanomaterials play one of the most important roles in the research and development
of modern pharmaceutics [1–3]. New material processing procedures [4–8], combined with
different kinds of raw materials [9–13] and novel innovative strategies for constructing functional
products [14–18], are frequently introduced into this application field for providing efficacious drug
delivery and enhancing the therapeutic effects of active pharmaceutical ingredients (APIs). Among
them, electrohydrodynamic atomization (EHDA) is a popular technique for creating nanoproducts,
which mainly includes electrospraying and electrospinning. These new methods explore electrical
energy to atomize the working fluid for producing solid products at micro or nano scale [19–23].
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 226; doi:10.3390/pharmaceutics11050226
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The past two decades have witnessed the rapid progress of electrosprayed nanoparticles being
utilized as functional products in a wide variety of fields [24–30]. In pharmaceutics, further
developments of medicated electrosprayed nanoparticles include creating complex nanostructures
(just as its counterpart electrospinning [31–36]), production on large scales, potential clinical applications,
and commercial products [37,38]. However, the electro–hydro–dynamic working process is still far
from being understood, due to the overlap of several disciplines such as fluid mechanics, electric
dynamics, and polymer rheology during the extremely fast drying processes of electrospraying [39,40].
Even a purposeful and conscious manipulation of the electrosprayed nanoparticle’s diameter is very
hard to realize.
Shown in Figure 1 is a diagram about the single-fluid electrospraying process and the possible
experimental parameters that can exert significant influences on the diameters of resultant nanoparticles.
An electrospraying apparatus brings together the working fluid and electrostatic energy at the
convergent point, i.e., the nozzle of spraying head. Between the two electrodes consisting of spraying
head and collector, the working fluids are atomized and solidified into particles within several decades
of microseconds. Based on this, all the experimental parameters can be divided into three categories
which are concluded in Figure 1. Correspondingly, the resultant nanoparticles’ diameter (D) can be a
function of working fluid’s property (w), operation conditions (o), and environmental parameters (e),
i.e., D = f (w,o,e).
 
Figure 1. A diagram of the single-fluid electrospraying process and the experimental parameters
exerting influence on the diameter of resultant nanoparticle.
During the past several decades, numerous publications have investigated the influence of
particular parameters on electrosprayed products. These articles disclosed the process-property
relationship for intentionally manipulating the particles’ diameters, morphology, and surface
smoothness [41–43]. However, there are too many parameters that can exert significant influence on
the final products during the electrospraying processes [44,45]. For example, the properties of working
fluid include polymer concentration (C), viscosity (η), surface tension (δ), and also conductivity (σ).
The operational parameters include the applied voltage (V), the fluid flow rate (F), and also the particle
collected distance (L). The environmental conditions include temperature (T), humidity (H), possible
vacuum (U), and sometime with hot air blowing.
Thus, it is difficult to manipulate the diameter of final nanoparticles accurately through particular
experimental parameters. In contrast, the parameters of the electrospraying itself seem to be neglected.
Compared with the experimental parameters that can be controlled directly by researchers, very few
publications have reported uncontrollable parameters in relation to working processes, such as the
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size and angle of a Taylor cone, the length of straight fluid jets, and the spreading angle of the
atomization region.
Based on the above-mentioned knowledge, here for the first time, we have investigated the
influence of spreading an angle of the atomization region on the diameter of resultant nanoparticles.
Meanwhile, the influence of applied voltage on the spreading angle and nanoparticles’ diameters,
and the size of medicated nanoparticle on the drug fast release performance were also studied.
Thus, an example about how to disclose the process-property-performance relationship of medicated
nanoparticles prepared by modified coaxial electrospraying is showed. In the experiments, ibuprofen
(IBU) and hydroxypropyl methylcellulose (HPMC) were selected as the model drug and polymer
matrix, respectively. IBU, a typical nonsteroidal anti-inflammatory drug, is broadly exploited to treat
pain, fever and inflammation. However, its poor water solubility always limits its fast action for
achieving a desired therapeutic effect [46–48]. HPMC is commonly utilized as an excipient in oral
tablet, eye drops, and capsule formations. It can be used both as a delaying agent for controlled release,
as well as an enhancer to improve the soluble rate of a soluble drug [49,50].
2. Materials and Methods
2.1. Materials
IBU was provided by Wuhan Anruike Biological Pharmaceutical Co., Ltd. (Wuhan, China).
HPMC powders (2910 5cps, Mn = 428,000 g/mol, methoxy content = 28.0–30.0%, hydroxypropoxy
content = 7.5–12%) were obtained from Shandong Fine Chemical Co., Ltd. (Jinan, China). Ethanol
and dichloromethane (DCM) were purchased from Shanghai Lingfeng Chemical Testing Co. Ltd.
(Shanghai, China). All other chemicals are analytical reagents, and water was distilled twice before use.
2.2. Modified Coaxial Electrospraying
A solidifiable solution consisting of 7% (w/v) HPMC and 3% (w/v) IBU in a mixture of ethanol
and DCM (1:1, v:v) was prepared and utilized as the core fluid. Pure solvent ethanol was used as the
shell fluid. Four nanoparticles referred to as P1, P2, P3, and P4 were prepared at an applied voltage
of 16, 17, 18, and 19 kV, respectively. For all preparations, the particle-collected distance was fixed at
15 cm. The shell and core fluid flow rates were 0.2 and 0.8 mL/h, respectively. The electrospraying
processes were recorded using a digital camera (PowerShot A640, Tokyo, Japan).
2.3. Morphology of the Prepared Nanoparticles
The surface morphological characterization of the prepared nanoparticles was observed under
scanning electron microscopy (SEM; Quanta FEG450, FEI Corporation, Hillsboro, OR, USA) at 20 kV of
accelerated voltage. Before the observation, the samples were sputter-coated with gold under vacuum.
The images were analyzed by ImageJ software with the measuring of over 100 different nanoparticles
and their diameters presented as mean ± S.D.
2.4. Drug Fast Release Performance
An amount of 20 mg medicated nanoparticles was placed in 50 mL of phosphate buffer solution
(PBS) with a pH value of 7.0. The buffer solutions including samples were incubated in a shaking
bath at 37 ± 0.1 ◦C and an agitation speed of 50 rpm. Each type of sample was repeated 6 times.
At predetermined time intervals, 1 mL of sample solutions were withdrawn and replaced with 1 mL
fresh medium. The amount of IBU released from the nanofibers was measured using a UV-Vis
Spectrophotometer (UV-2102PC, Unico Instrument Co. Ltd., Shanghai, China) by measuring the
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absorbance at 264 nm. The calibration curve was obtained, and all concentrations were evaluated in
percentage as mean ± S.D. using Equation (1).
Accumulative release (%) =
Amount o f drug release
Amount o f initial drug
× 100 (1)
3. Results and Discussion
3.1. Preparations of the Medicated Particles Using the Modified Coaxial Electrospraying
A diagram about the modified coaxial electrospraying process is shown in Figure 2a. Right from
the first publication about coaxial electrospraying [25], all the shell fluids must be solidifiable to
ensure the creation of core-shell nano-/micro-structures. However, this limitation was broken by Yu
and his co-worker. They reported a modified coaxial process, in which fluids without solidifiable
properties using a single-fluid electrospraying process can be introduced into the coaxial process and
was explored as the shell working fluids [43–45]. This new process greatly expanded the capability of
electrospraying as it was deemed capable of generating additional kinds of nanostructures, including
core-shell solid structure, nanocoating and homogeneous particles with a high quality (Figure 2a).
Figure 2. The modified coaxial electrospraying: (a) A diagram about the process, by which many kinds
of nanostructures can be created through the unsolidifiable shell fluids; (b) implementation of the
modified coaxial electrospraying, the upper-left inset shows the home-made concentric spraying head;
(c) the connection of power supply and working fluid with the spraying head.
The organization of electrospraying systems and the implementation of an electrospraying process
are exhibited in Figure 2b. A home-made concentric spraying head was exploited to implement
the modified coaxial electrospraying (the upper-left inset of Figure 2b), which can also be utilized
to conduct coaxial electrospinning [49]. The inner metal capillary has an inner and outer diameter
of 0.3 mm and 0.6 mm, respectively. The orifice of the outer capillary has a diameter of 1.2 mm.
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Two syringe pumps (KDS100 and KDS 200, Cole-Parmer®, Vernon Hills, IL, USA) were employed to
drive the core and shell liquids to the spraying head (Figure 2b). A copper line was directly attached
on the concentric spraying head to convey the electrostatic energy to the working fluids (Figure 2c).
During the EHDA process, the applied voltage is one of the most important parameters that
have significant influence on the final products. As for the working fluids systems, there are often
suitable working ranges for almost all the experimental parameters. In the present systems, when the
applied voltages were changed from 16 kV to 19 kV, all the coaxial electrospraying processes were
run continuously, smoothly and robustly. With an enlarged shooting, the images of Taylor cones are
shown in Figure 3a–d. The estimated spreading angles of three measurements are (42 ± 3)◦, (70 ± 6)◦,
(83 ± 5)◦, and (92 ± 4)◦, for an applied voltage of 16, 17, 18 and 19 kV, respectively. As the voltage
elevated, the spreading angles increased correspondingly. For reference, to achieve the clearest images
these photos were taken under a certain tilted angle, however the camera lens should always keep the
same height as the nozzle of a spraying head.
 
Figure 3. (a–d) The typical changes of spreading angles with the elevation of applied voltages (kV)
from 16, to 17, 18, and 19, respectively (n = 3); (e–h) SEM images of the resultant nanoparticles and
their diameter distributions (e) P1; (f) P2; (g) P3; (h) P4.
The SEM images of the prepared nanoparticles and their diameter distributions are shown in
Figure 3e–h. Nanoparticles P1, P2, P3, and P4 have an estimated diameter of 880 ± 130, 760 ± 110,
680 ± 140, and 630 ± 130 nm, respectively. All the nanoparticles have a round surface with some
satellites. As the applied voltages increased, the diameters decreased correspondingly.
3.2. The Process–Property Relationship and the Related Mechanism
Shown in Figure 4a is the influence of applied voltage on the spreading angle. The trend is clear
that the spreading angle increased as the applied voltage elevated. A linear regression suggests these
two parameters have a relationship of θ = 17V − 229, with a correlation coefficient RθV2 = 0.9623.
The applied voltage is an operational parameter that can be manipulated directly by researchers.
The spreading angle is a process parameter, however it cannot be directly manipulated by certain
operational parameters in relation to the working fluid’s property. Although these two different kinds
of parameters have a positive correlation, the spreading angle should also receive the influence of other
parameters. It should be the normal oscillation of other operational parameters (such as the shell and
core fluids’ flow rates and the ambient conditions) that make the correlation coefficient vary from a
number of one.
Figure 4b demonstrated the influence of applied voltage on the diameter of nanoparticles.
A negative correlation is clear in that the nanoparticles’ diameter decreased as the applied voltage
elevated. A linear regression suggests these two parameters have a relationship of D = 2713 − 82V,
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with a correlation coefficient RDV2 = 0.9624. Diameter is one of the most important parameters of the
medicated nanoparticles. This equation suggests that a certain relationship exists, which can then be
explored for manipulating the size of final products. This strategy has been frequently demonstrated
in literature [15]. However, as seen in the relationship between spreading angle and applied voltage,
the relationship between nanoparticles’ diameter and applied voltage is seemingly influenced by other
parameters. Their normal oscillations would make the manipulation effect of final products’ size using
the applied voltage often unsatisfactory.
Although the applied voltage did not have a strong linear relationship with the spreading angle
and the nanoparticles’ diameter, the spreading angle had a better linear relationship with the size of
nanoparticles, which is shown in Figure 4c. A linear equation can be regressed as D = 1096 − 5θ, with a
correlation coefficient RDθ2 = 0.9905. The highly linear correlation between these two parameters is able
to be anticipated. This is because any changes of almost all experimental parameters (including those
about working fluids’ property, those about operational conditions and those about the environment)
will equally exert their influences on both the atomization processes and the successive solid particles’
properties, represented by the spreading angle and the particles’ diameter.
 
Figure 4. The applied voltage-spreading angle-nanoparticle diameter relationships: (a) The influence
of applied voltage on the spreading angle; (b) the influence of applied voltage on the nanoparticles’
diameter; (c) the accurate relationship between the spreading angle and the nanoparticles’ diameter.
Despite the number of fluids an electrospraying process treats simultaneously, they will typically
experience five steps, as originally demonstrated by single-fluid blending electrospraying. Shown in
Figure 5, the five steps included; the fluid being charged, the formation of the Taylor cone, the convergent
point of straight fluid jet, the atomization region, and the final collection of solid nanoparticles. The key
intermediate steps comprise the three stages during which the working fluids are dried into solid
particles. The third stage, i.e., the atomization region, often determines the solidification effects and
the quality of the final solid products. Although many publications have investigated the formation
of Taylor cones and the initiation of an EHDA process [49], little attention has been payed to the
atomization process and which can be described by the spreading angle (θ).
Figure 5. A diagram about the coaxial electrospraying and the force analysis of a charged droplet.
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During the atomization process, the nascent mono-disperse fluid droplets formed by the Columbic
explosion should be quickly split and shrunk owing to the accumulation of surface charges and the
rapid evaporation of solvents resulting from the huge surface areas. For a certain droplet, the force
analysis is shown in Figure 5. The droplet should have repelling forces from all sides, for example
the vertical direction repelling forces Frv and the horizontal direction repelling forces Frh. Meanwhile,
the droplet should receive the force (FE) between the two electrodes and gravity (G), which pushed the
droplets/nanoparticles from the nozzle of the spraying head to the collector during the solidification
process. When the applied voltages elevated, the droplets should have more charges, and the repelling
forces should be increased correspondingly. Within a fixed collected distance, the increase of horizontal
direction repelling forces Frh should expand the atomization region and increase the spreading angle
automatically. Thus, the larger applied voltage provided, the bigger the spreading angle the atomization
region had. Meanwhile, the increase of applied voltage should promote the Columbic explosion
and the successive splitting of droplets, resulting in nanoparticles with smaller diameters. Both the
spreading angle and the nanoparticles’ diameter are the direct results of the applied voltage and are
similarly influenced by the fluctuations of a series of other parameters. Thus, these two parameters
have a very high correlation.
Additionally, from a standpoint of force analysis, the spreading angle is a combined effect of a
series of forces under the electrical field, giving a hint that it can be a useful tool for accurately predicting
the resultant nanoparticle’s diameter. This discovery is very important because new methods can
now be exploited to accurately predict the size of final products and give researchers more power
in respect to manipulating the electrospraying process. As far as the measurement of spreading
angle is concerned, a High Frequency Camera (HFC) can be utilized to record the working process of
electrospraying and should be able to improve our present work.
3.3. The property-Performance Relationship and the Related Mechanism
Shown in Figure 6a is the drug in vitro release profiles from the four types of medicated HPMC
nanoparticles. Although all of them were able to release over 50% of the contained drug at the first
minute after they were placed into the dissolution media (52.7 ± 5.1%, 61.3 ± 4.7%, 72.1 ± 5.6%,
and 82.4 ± 4.3% for nanoparticles P1, P2, P3, and P4, respectively), a trend soon became clear. The finer
the particles were, the faster the loaded drug was exhausted from the nanoparticles. The times
needed for releasing 95% of a drug were 8.82, 6.88, 4.45 and 3.04 min for nanoparticles P1, P2, P3,
and P4, respectively.
Figure 6. (a) The in vitro dissolution tests of the electrosprayed nanoparticles; (b) a schematic of the
drug erosion mechanism from the medicated nanoparticles.
Improving the release rate and apparent solubility of poorly water-soluble drugs is always one
of the major challenges in the fields of pharmaceutics and medicated nanomaterials. Traditionally,
comminution of the drug powders with hydrophilic polymers such as HPMC is frequently performed
to reduce the drug particle size. However, the drug fast release performance is often limited (such as
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IBU-HPMC xerogel granule [51]) and the preparation process is time-consuming (such as IBU-HPMC
nano-suspension [52]). In comparison, the present IBU-HPMC nanoparticles were able to provide a
better performance about promoting the fast dissolution of IBU and could be generated using a simple
and straightforward one-step process.
HPMC is a soluble and hydrophilic polymer. During the dissolution process, the increase of
diameter has both positive and negative influence on the loaded drug molecules to free into the
dissolution media. Shown as Figure 6b is a diagram about the drug release mechanism. In the
electrosprayed nanoparticles, the drug molecules are homogeneously distributed all over them due to
the extremely fast drying process of electrospraying. When these medicated nanoparticles are placed
into water, they will absorb water to swell gradually. This is a process that the water molecules penetrate
in the solid nanoparticles. Meanwhile, the drug molecules should leave the polymer chains and go into
the penetrated water, and further diffuse outward to the bulk solution due to the concentration gradient.
This is a typical drug diffusion mechanism. As the swelling goes forward, the outer layer HMPC
molecules will free into the bulk solution themselves, together with the contained and penetrated drug
molecules. Thus, the erosion mechanism also happens here.
As the increase of nanoparticles’ diameters, on one hand, the penetration distance of water and
diffusion distance of drug molecules should all increase correspondingly. This is to say the increase of
diameter will prolong the drug release time period due to the diffusion mechanism. On the other hand,
there is a competition between the swelling rate and the dissolution rate of HPMC in the gradually
enlarged particles in water, the larger particles may accelerate the drug release through the easy erosion
of the outer layer of the swollen particles to shorten the drug release time period. Thus, the two factors
co-act on the drug release, and show a univariate quadratic equation relationship between the diameter
of particle with release time apparently, as indicated in Figure 7. To fit the time needed to release 95%
of the loaded drug (t, min) with the nanoparticles’ diameter (D, nm), a relationship between them can
be found, i.e., t = 38.7 + 0.097D − 4.838 × 105D2 (R2 = 0.9976). This univariate quadratic equation
with a R2 value of 0.9976 suggests that the diameter of nanoparticles has a profound influence on the
drug release performance. As hinted by the primary power (0.097D), the increase of diameter will
prolong the drug release time. However, the increase of diameter may also shorten the drug release
time, as suggested by the quadratic term (−4.838 × 105D2). This should have a close relationship with
the property of drug loaded polymer HPMC and also the density of resultant nanoparticles.
Figure 7. The relationship between the size of medicated HPMC nanoparticles and the time for releasing
95% of the loaded drug.
Poorly water-soluble drugs are one of the most difficult and long-existing issues in
pharmaceutics [53–55]. Nanotechnologies have brought new lights on resolving this problem.
However, how to take advantage of these advanced techniques comprises a challenge to the researchers.
The present work shows a fine example to build clear process-property-performance relationship for
73
Pharmaceutics 2019, 11, 226
exploring the modified coaxial electrospraying to create medicated nanoparticles. These nanoparticles
can be further transferred into capsules or tablets for potential oral administration.
4. Conclusions and Perspectives
In the present work, the influences of spreading the angle of the atomization region (θ) during
a modified coaxial electrospraying process on the resultant nanoparticles’ diameter, and in turn on
the drug dissolution rate from the prepared IBU-loaded HPMC nanoparticles were systematically
investigated. With θ as a key parameter, a series of process-property-performance relationships were
found. These relationships include θ = 17V − 229 (RθV2 = 0.9623), D = 2713 − 82V (RDV2 = 0.9624),
D = 1096 − 5θ (RDθ2 = 0.9905), and t = 38.7 + 0.097D − 4.838 × 105D2 (R2 = 0.9976). Compared with the
applied voltage (V), θ could provide a better correlation with the diameter of resultant nanoparticles
(D), suggesting its usefulness for accurately predicting the nanoproducts’ size.
Today, electrospraying, is fast developing from treating a single fluid (mainly creating
homogeneous particles [56,57]), to the treatment of double fluids (such as coaxial and side-by-side
processes for generating core-shell and Janus particles [58–60]), and to the simultaneous treatment
of three or even more working fluids [61,62]. In contrast, it is drawing increasing attention for
producing particles on a larger-scale, just as its peer electrospinning [63,64]. Regardless of the different
development directions of this advanced technique, how to build an accurate relationship between the
experimental conditions and the final products’ quality always poses a big challenge to the researchers.
Here, a proof-of-concept method is shown that the spreading angle, as a process parameter, can be
explored to predict the resultant nanoparticles’ diameters in an accurate manner. Along this way,
many new possibilities can be anticipated. For example, the precise control of the diameters of
core-shell, Janus, and tri-layer nanoparticles and the size of their internal compartments. Particularly
for fabrication of electrosprayed nanoparticles on a large scale, the process parameters (including
those for characterizing Taylor cone and the atomization region) should be useful tools for elaborately
manipulating the nanoproducts’ quality and functional performances.
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Abstract: Nanoemulsion is one of the potential drug delivery strategies used in topical ocular
therapy. The purpose of this study was to design and optimize a nanoemulsion-based system to
improve therapeutic efficacy of moxifloxacin in ophthalmic delivery. Moxifloxacin nanoemulsions
were prepared by testing their solubility in oil, surfactants, and cosurfactants. A pseudoternary
phase diagram was constructed by titration technique and nanoemulsions were obtained with four
component mixtures of Tween 80, Soluphor® P, ethyl oleate and water. An experiment with simplex
lattice design was conducted to assess the influence of formulation parameters in seven nanoemulsion
formulations (MM1–MM7) containing moxifloxacin. Physicochemical characteristics and in vitro
release of MM1–MM7 were examined and optimized formulation (MM3) was further evaluated for
ex vivo permeation, antimicrobial activity, ocular irritation and stability. Drug pharmacokinetics in
rabbit aqueous humor was assessed for MM3 and compared with conventional commercial eye drop
formulation (control). MM3 exhibited complete drug release in 3 h by Higuchi diffusion controlled
mechanism. Corneal steady state flux of MM3 (~32.01 μg/cm2/h) and control (~31.53 μg/cm2/h) were
comparable. Ocular irritation study indicated good tolerance of MM3 and its safety for ophthalmic
use. No significant changes were observed in the physicochemical properties of MM3 when stored in
the refrigerator for 3 months. The greater aqueous humor concentration (Cmax; 555.73 ± 133.34 ng/mL)
and delayed Tmax value (2 h) observed in MM3 suggest a reduced dosing frequency and increased
therapeutic efficacy relative to control. The area under the aqueous humor concentration versus time
curve (AUC0–8 h) of MM3 (1859.76 ± 424.51 ng·h/mL) was ~2 fold higher (p < 0.0005) than the control,
suggesting a significant improvement in aqueous humor bioavailability. Our findings suggest that
optimized nanoemulsion (MM3) enhanced the therapeutic effect of moxifloxacin and can therefore be
used as a safe and effective delivery vehicle for ophthalmic therapy.
Keywords: nanoemulsion; mixture design; aqueous humor; antimicrobial activity
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1. Introduction
The ocular drug delivery system is one of the most attractive and challenging drug delivery
systems for pharmaceutical scientists [1]. Conventional eye drops account for more than 90% of the
available ophthalmic formulations but the efficiency of these products is limited by transient residence
time, low permeability of corneal epithelium, rapid pre-corneal loss and high tear fluid turnover [2].
However, less than 5% of the drugs contained in eye drops penetrates the corneal membrane and
reaches the intraocular tissues; and the remaining dose usually undergoes trans-conjunctival absorption
or trans-nasal absorption or drainage via the nasolacrimal duct. Consequently, extensive research has
been conducted to improve the effectiveness of topical ocular therapy by developing drug delivery
systems which can increase ocular retention, improve trans-corneal drug absorption and reduce
systemic adverse effects while retaining the ease of application and benefit of eye drops. Various drug
delivery strategies such as bioadhesive hydrogels, temperature or pH-sensitive in situ gel forming
systems, collagen shields, colloidal dosage forms like microparticles, microemulsions, nanoparticles,
nanosuspensions, nanoemulsions, liposomes, niosomes, nanomicelles, and dendrimers have been
formulated and evaluated to partially or fully achieve these objectives [3]. Among various delivery
approaches, the colloidal systems received greater attention due to their potential to improve corneal
penetration, greater retention at ocular surface, as well as ease of administration similar to eye drop
solutions [4]. Despite the fact that the colloidal ocular drug delivery systems like liposomes and
niosomes offer certain improvement over conventional liquid dosage forms, the major limitations
which have limited their prospects include their inherent tendency to aggregate, the instability and
leakage of entrapped drug have limited their future prospect [5,6].
Nanoemulsions are thermodynamically stable and optically transparent fine dispersion
(10–200 nm) of multi-component fluids, and frequently consist of an aqueous phase, an oily phase,
a primary surfactant as an emulsifying agent, a cosurfactant generally an alkanol of intermediate
chain length and occasionally an electrolyte [7]. The major benefits of this colloidal dispersion include
enhancement in ocular retention and extended duration, reduced drug protein binding, improved
corneal drug permeation, sustained drug release, reduced systemic adverse effects and ease of use
for the incorporation of both hydrophilic and lipophilic drugs. In addition, nanoemulsions can
interact with the lipid layer of the tear film, can stay in the conjunctival sac for longer times, and
subsequently act as a drug depot [8]. The potential of nanoemulsions as a promising alternative for
conventional eye formulation in treating various ocular diseases of both the anterior and posterior
ocular segments has been described in literature [4]. In this context, moxifloxacin, a fourth-generation
fluoroquinolone antibiotic is commercially available as an ophthalmic solution (0.5% w/v) and is used
for the treatment of bacterial conjunctivitis or other bacterial infections of the eyes. Moxifloxacin acts
by inhibiting the DNA gyrase and topoisomerase IV required for bacterial DNA replication, repair,
and recombination. It was reported that moxifloxacin has enhanced efficacy, safety and tolerance
in comparison to older fluoroquinolone derivatives [9]. However, the conventional therapy of this
drug in ocular therapy is limited by short residence time. Hence, encapsulating moxifloxacin in
droplets that form a nanoemulsion could be an alternative for its ophthalmic use. The objective of
this investigation was to optimize the moxifloxacin-loaded nanoemulsion system, characterize and
compare the in vivo ocular efficacy with the commercial eye drop. A pseudoternary phase diagram
of four component mixtures was constructed by titration technique. Selected nanoemulsions were
characterized for pH, droplets size, polydispersity index, zeta potential, conductivity, viscosity, drug
content, and dilution potential. The optimized nanoemulsion (MM3) was further evaluated for corneal
permeation, antimicrobial effect, ocular irritation and in vivo drug pharmacokinetics in the aqueous
humor of rabbits.
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2. Materials and Methods
2.1. Materials
Moxifloxacin (molecular weight of 437.9 Da) was received as an in-kind gift from Zydus Cadila
Ltd., Ahmedabad, India with a purity of 99.99%. Soluphor® P was generously supplied by BASF,
Ludwigshafen, Germany. Tween 80 was purchased from S.D Fine Chem, Mumbai, India and ethyl
oleate was purchased from Central Drug House Pvt. Ltd., Mumbai, India. All other chemicals used
were of analytical grade.
2.2. Drug Analysis
The amount of moxifloxacin was determined by the high-performance liquid chromatography
(HPLC) method described in the literature [10]. A HPLC system (1525, Waters, Milford, MA, USA)
consisting of a Discovery C18 column (250 mm × 4.6 mm, i.d, 5 μm) was used. Chromatographic
separation was carried out using a mixture of methanol: acetonitrile: water (85:5:10, v/v/v), pH 2.75
adjusted with phosphoric acid was delivered at a flow rate of 1 mL min−1 with an injection volume of
25 μL. The isocratic elution was done at 25 ◦C and monitored using UV detector at 290 nm.
2.3. Development of Pseudoternary Phase Diagram
The pseudoternary phase diagram of four component mixtures of oil (ethyl oleate), surfactant
(Tween 80), cosurfactant (Soluphor P) and water was constructed by titration technique to obtain
concentration ranges that can result in large existence with the nanoemulsion region at room
temperature [11]. A titration technique was employed for the preparation of the pseudoternary
phase diagrams [12]. Briefly, Tween 80 was blended with Soluphor P in a fixed weight ratio of 1:1,
1:1.5, 1:2, 1:2.5, 1:3, 1:4 and 1:5, respectively. Aliquots of each Tween 80 and cosurfactant mixture
(Smix) were then mixed with oil phase at room temperature (25 ◦C). The ratio of oil to Smix was varied
as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 7:3, 2:8 and 1:9. Then, water was added to the above mixture in 5%
increments and checked for formation of emulsion or liquid crystal or gel. The phases were identified
using visual inspection, microscopic inspection, and measurement of droplets size. The resulting
nanoemulsion was tightly sealed and stored at ambient temperature. The points corresponding to
mixture components that resulted in nanoemulsion were noted and marked in a phase diagram region.
The resulted phase diagrams of different surfactant: Cosurfactant ratios were compared and the ratio
that could result in the large existence area of nanoemulsion domain in phase diagram was selected for
further optimization.
2.4. Preparation of Moxifloxacin Nanoemulsion
Moxifloxacin nanoemulsions (o/w) were formulated by appropriate quantity of deionized water,
ethyl oleate, Tween 80 and Soluphor P. Required amount of moxifloxacin (0.5%, w/v) was dissolved in
ethyl oleate. To Smix, an adequate amount of ethyl oleate was added and mixed. Then the mixture
was titrated by gradual addition and mixing of distilled water in order to achieve the equilibrium
immediately. Further, it was thoroughly stirred and vortexed to obtain nanoemulsion. To maintain
sterility of the prepared formulation, benzalkonium chloride (0.005%, w/w) was used as a preservative
and stored in multi-dose containers [13].
2.5. Experimental Design
The objective of modeling the phase diagrams is to quantify the effect of formulation composition
on the droplets size. A successful “mixture design” shows the statistical approach to obtain the
relationship between the droplets size distribution and the amounts of various components. In this
method, the pseudoternary phase diagrams were plotted and several points were selected within the
nanoemulsion region for particle size measurement. The points (black dots) represent the nanoemulsion
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region in Figure 1A. Within the nanoemulsion region, a triangular area was arbitrarily selected and
marked with a red triangle (Figure 1A) which shows different runs of mixture design and the enlarged
version is represented in Figure 1B. Hence, Figure 1B shows the sketch diagram of Run (trial) 1 to Run
7 of mixture design. The constraint that the proportions of different components must sum to 100%
should be satisfied. According to Figure 1B, the points can be chosen such as three vertexes, three
halfway points between vertices and the center point. Each vertex represents a formulation containing
the maximum quantity of one component, with the other two components at a minimum amount.
The halfway point between the two vertices illustrates a formulation incorporating the average of
the minimum and maximum quantity of the two constituents represented by the respective apex.
The centre point shows a formulation containing one third of the individual component. A total of
seven formulations (MM1–MM7) were opted from the nanoemulsion region for further study and
their compositions are summarized in Table 1.
 
Figure 1. Pseudo ternary phase diagram showing nanoemulsion region (A) and distribution for each
of run in a mixture design (B).
Table 1. Formulation composition used for preparing nanoemulsions after applying simplex
lattice design.
Formulations Run
Formulation Components Transformed Proportion
Smix (%) Oil (%) Water (%) Smix Oil Water
MM1 1 52 4 44 1 0 0
MM2 2 36 20 44 0 1 0
MM3 3 36 4 60 0 0 1
MM4 4 44 12 44 0.5 0.5 0
MM5 5 44 4 52 0.5 0 0.5
MM6 6 36 12 52 0 0.5 0.5
MM7 7 41.33 9.33 49.33 0.33 0.33 0.33
MM8 * 8 * 37 18 45 0.063 0.875 0.063
* Check point batch.
2.6. Characterization of Moxifloxacin Nanoemulsions
2.6.1. Drug Content and pH
Drug content in the prepared nanoemulsions (MM1–MM7) was determined using HPLC. The pH
of formulations (MM1–MM7) were measured by a calibrated pH meter (Mettler Toledo MP-220,
Greifensee, Switzerland).
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2.6.2. Transmittance, Conductivity and Dilution Potential
The percentage of the transmittance of nanoemulsions was measured using colorimeter
(Photoelectric Colorimeter 113, Systronics, Ahmedabad, India). Percentage transmission was set
to zero using filter and 100% using transparent cuvette filled with water. Then, different nanoemulsion
samples were kept in the transparent cuvette and percentage transmission was measured. Electrical
conductivity of nanoemulsions was studied using a conductometer to determine the type. Briefly,
an electrode was totally immersed and fixed in the nanoemulsion (20 mL) and the temperature was
raised to 1 ◦C/min steadily. The nanoemulsion was agitated with a stirrer, and the change in the
conductivity was recorded. To determine dilution potential, the nanoemulsion was diluted 10 times
with continuous media and the occurrence of phase separation was noted.
2.6.3. Particle Size Characterization and Zeta Potential
The droplets size, size distribution and polydispersity index of nanoemulsions were analyzed
employing a dynamic light scattering technique using Malvern Zetasizer (Nano ZS90, Malvern
Instruments, Malvern, UK) at 25 ◦C. In brief, a few drops of respective samples were added directly
to a polystyrene disposable cuvette and fixed in the direction of laser light beam. The scattered light
signal was measured with a detector placed at a right angle and the droplets size were determined
based on the physical properties of the scattered light such as the angular distribution, frequency shift,
the polarization and the intensity of the light [14]. For the zeta potential measurement, samples were
diluted with deionized water and the electrophoretic mobility values was determined at 25 ◦C using
the software DTS, version 4.1 (Malvern, England, UK, 2009).
2.6.4. Viscosity
Viscosity of nanoemulsions was measured at different angular velocities at a temperature of 25 ◦C
using the Brookfield synchro-Lectric viscometer (LVDVI prime, Middleborough, MA, USA).
2.7. Transmission Electron Microscopy (TEM)
Structural morphology of nanoemulsion droplets was investigated with TEM (Tecnai 20, Philips,
Holland, OR, USA) operated at 200 kV and of a 0.15 nm efficient in comprehensive resolution. The bright
field imaging technique with high magnification and diffraction modes was used to examine the
morphology and structure of the nanoemulsion globules [15]. TEM imaging was carried out by staining
a drop of the nanoemulsion with phosphotungstic acid solution (2% w/v) and directly placing on the
copper grids, subsequently dried at room temperature (25 ± 2 ◦C).
2.8. In Vitro Release
The drug release studies were performed employing a vertical Franz diffusion cell having an
effective surface area of 1.13 cm2 and simulated tear fluid (pH 7.4) as the dissolution medium [16].
Briefly, 1 mL of nanoemulsion (equivalent to 5 mg of moxifloxacin per ml) or drug solution (control) in
the stimulated tear fluid was taken on a previously soaked cellophane dialyzing membrane (MWCO
12–14 kDa, Spectra/por® Spectrum Laboratories Inc., Rancho Dominguez, Berkeley, CA, USA) that
separates the donor and receptor cell. The entire assembly was kept on a thermostatically controlled
water bath set at 37 ± 0.5 ◦C and receptor medium was stirred at 50 rpm. Aliquots of sample (1 mL)
were drawn at regular time intervals (0.5, 1, 2, 3, 4, 5 and 6 h) and replaced with the same volume of
fresh media. The samples were subsequently diluted and analyzed for moxifloxacin content by HPLC.
The data were analyzed to determine correlation coefficient (r2) and release kinetics using various
mathematical models [17];
a. Zero order model Q = Q0 + kt
b. First order model Q = Q0 × ekt
c. Higuchi model Q = k × t0.5
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d. Hixson-Crowell model Q1/3 = kt + Q01/3
e. Korsmeyer–Peppas model Q = k × tn
f. Weibull model Q = 1 − exp[−(t)b/a]
where Q represents quantity of drug released in time t, Q0 represents value of Q at zero time, k represents
the rate constant, n represents the diffusional exponent, a represents the time constant and b represents
the shape parameter. The correlation coefficient (r2) and the order of release pattern was calculated in
each case.
2.9. Ex Vivo Permeation
The permeation studies were carried out using the Franz diffusion cell with a standard setup
previously used in our earlier study [18]. Briefly, optimized formulation (MM3) or control (commercial
eye drops; Vigamox™) (equivalent to 5 mg of moxifloxacin per mL) was placed in donor compartment
and simulated tear fluid (pH 7.4) in the receptor compartment. Between donor and receptor
compartment, the isolated rabbit cornea membrane was placed. The temperature of the medium was
maintained at 37 ± 0.5 ◦C by the circulation of warm water through the outer jacket. Samples were
withdrawn at predetermined time intervals (up to 6 h) and the same volume of fresh medium was
replaced. The withdrawn samples were diluted and analyzed by HPLC.
2.10. Antimicrobial Efficacy
The antimicrobial efficacy of MM3 was determined by the agar diffusion test employing the
cup plate technique and compared with control (commercial eye drops of moxifloxacin). The sterile
products (MM3 or control) were poured (0.01 mL) into the cups of sterile nutrient agar previously
inoculated with susceptible test organisms (Pseudomonas aeruginosa and Staphylococcus aureus) under
horizontal laminar air flow hood. After allowing diffusion of the solutions for 2 h, the agar plates were
incubated at 37 ◦C for 24 h. The zone of inhibition measured around each cup was compared with
the control. Both positive (with test organisms) and negative controls (without test organisms) were
maintained throughout the study.
2.11. Ocular Irritation
Albino rabbits (2–3 kg) placed in an animal house under observation were given ad libitum access
to water and diet for 24 h. The guidelines of the Institutional Animal Ethics Committee were strictly
followed while performing experiments (IPS/PCEU/PHD10/002). In vivo ocular irritation studies
were performed according to the Draize technique [19]. Single administration of 60 μL was instilled
in the left eye of each rabbit while keeping the untreated eye as the control. The sterile MM3 was
administered twice daily for a period of 21 days (1, 2, 3, 4, 7, 10, 15, 18 and 21 days). The rabbits were
observed periodically for redness, swelling and watering of the eye.
2.12. Pharmacokinetics
In vivo pharmacokinetic studies were carried out in Albino rabbits (2–3 kg). Animals were
separated into two groups of each containing six rabbits. All animal procedures were performed at
the Nirma University following the guidelines (IPS/PCEU/PHD10/002, dated; 23/01/2010, Scientific
Research Ethics Committee, Nirma University). Rabbits were treated with MM3 or control (commercial
eye drops). For the first group, drops (50 μL of 0.5% w/v moxifloxacin) of MM3 was instilled in the
lower cul-de-sac of both eyes of each rabbit [20], and the upper and lower eyelids were gently held
closed for 2 min to maximize drug cornea contact. In a similar manner, both eyes of each rabbit of the
second group were given single topical instillation (50 μL of 0.5% w/v moxifloxacin) of commercial
eye drops. Each rabbit was anaesthetized by intra muscular injection of ketamine (50 mg/kg) and
xylazine (10 mg/kg) [21]. Additionally, lidocaine (2% w/v) was applied at the injection site to provide
local anesthesia. Then eyelash and eye liners/lids were wiped with povidone solution (5% w/v) to
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maintain standard of care to give intra-ocular injection. A 29-gauge insulin syringe needle was used to
collect aqueous humor (0.5, 1, 2, 4 and 8 h) and samples (50 μL) were mixed with acetonitrile, and
stored at −80 ◦C. The mixture was then centrifuged at 3000 rpm for 15 min and the supernatant was
analyzed for drug content using HPLC.
2.13. Stability
Sterile nanoemulsion (MM3; 5 mL) was stored in an amber colored container for a period of three
months in the refrigerator (2–8 ◦C). Stability of MM3 was routinely evaluated by visual inspection of
the samples initially on a daily and later on a weekly basis for pH, phase separation, flocculation or
precipitation [22]. Stability of nanoemulsion was also checked by centrifugation (Remi Centrifuge,
Mumbai, India) by 12,000 rpm for 30 min and then the clarity, phase separation and concentration
of drug were investigated. Droplet size of the nanoemulsion upon storage was also determined to
assess the stability in terms of drastic changes in the mean droplet diameter due to droplet coalescence
or aggregation.
2.14. Data Analysis
A plot of the cumulative amount of moxifloxacin permeated across the cornea was plotted against
time and the slope was measured as flux [23]. The statistical evaluation of the data was analyzed
using one-way analysis of variance (ANOVA) (SPSS 23, SPSS Inc., Chicago, IL, USA). The statistical
differences between values showing p < 0.05 were considered as significant.
3. Results and Discussion
3.1. Pseudoternary Phase Diagram
Preliminary studies were carried out to select ingredients for preparing moxifloxacin nanoemulsion.
Indeed, the selection of the vehicle is extremely important as it provides good solubilizing efficiency of
the drug, which is essential for constituting a nanoemulsion [24]. Hence, the solubility of moxifloxacin
in various oils, surfactants, and cosurfactants was determined by the standard procedures. Based
on the high moxifloxacin solubility, ethyl oleate (oil; solubility ~28.37 mg/mL), Tween 80 (surfactant;
solubility ~10.56 mg/mL) and Soluphor P (cosurfactant; solubility ~7.22 mg/mL) were selected for
nanoemulsion preparation. The utility of the selected vehicles in preparing nanoemulsions is described
in the literature. For instance, ethyl oleate has been used in nanoemulsions due to its lower molecular
size (310.51 g/mol) as related to medium chain triglycerides (~800 g/mol). Furthermore, nanoemulsions
formulated with ethyl oleate have demonstrated enhancement in corneal permeation of drugs [25].
Similarly, Tween 80 (up to 10% w/w) has been used as a surfactant in many commercial ophthalmic
preparations which usually do not cause ocular irritation [26]. Due to the longer hydrocarbon chain
length of Tween 80, it can broaden the area of the nanoemulsion region [27]. In addition, Soluphor P
has demonstrated improved drug penetration across the biological membranes [28].
The pseudoternary phase diagram of the systems consisting of surfactant: Cosurfactant (Tween
80: Soluphor P) mixture (Smix), oil phase and water was illustrated in Figure 1A. The binodal curve
separating two phase and one phase in the pseudoternary phase diagram was indicated by the visual
observation of the sample appearance from turbid to transparent or vice versa. To complete the entire
nanoemulsion domain, in addition to the water titration method, oil and water components were
fixed and surfactant component varied. Similarly, water and Smix components were fixed and the
oil component varied. The nanoemulsion domain obtained by these trials at ratios of 1:1, 1:2 and
2:1 with surfactant (Tween 80) to cosurfactant (Soluphor P) ratio were plotted in the phase diagram
(Figure 1A). The phase behavior study revealed that, when the surfactant to cosurfactant ratio was 1:2,
the maximum quantity of oil can be included in the nanoemulsion system. From the phase diagram,
it was indicated that the change in phase behavior within the nanoemulsion region is mainly due
to the hydrophobic carbon chain length of the oil and the ratio between surfactant and cosurfactant
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mixture used in the formulation. Therefore, it is likely that the hydrocarbon chain length compatibility
among surfactant and oil is an important factor that affects the globule size formation and stability of
nanoemulsion as suggested by Schneider et al. [29].
3.2. Formulation Optimization
The nanoemulsions selected for the optimization were evaluated for parameters like droplets size,
polydispersity index, zeta potential, and conductivity. The droplets size was optimized as a response
in simplex design. The droplets size was in the range of 28.78–81.04 nm. Regression summary output,
full model confirmed that components A (Smix), B (oil), C (water), AB and BC significantly affect the
response (droplets size). Whereas AC has p value >0.05 suggests that it does not significantly affect the
response. Therefore, reduced model was developed eliminating AC term and simplex coefficients were
obtained from regressions summary output using Microsoft Office Excel® 2007. R Square value of
0.999 suggests the suitability of the model and the lower stand error value of 1.9505 suggests minimum
error in the model.
Response was calculated over the simplex space, and a contour diagram is plotted (Figure 2).
It is inferred from the contour plot that particle size is minimum, when the water component is at
higher level (1) and oil and surfactant components are at lower level (0). The optimized formulation of
the nanoemulsion consists of ethyl oleate (4%), Tween 80 (12%), Soluphor P (24%) and water (60%).
Moxifloxacin was included at a concentration of 0.5% w/w in all tested formulations.
Figure 2. Contour plot (A) over the simplex space and response surface graph (B) representing
nanoemulsion particle size (nm).
3.3. Validation of Applied Design
The simplex equation of response, droplets size is derived as follows:
Y = 40.76 A + 81.16 B + 27.72 C − 55.72 AB + 48.71 BC
The result at the extra-design checkpoint is predicted based on the equation to confirm the validity
of the applied design. It was found that the observed value was close to the practically measured value
and hence establishes the effectiveness of the tested mathematical model.
3.4. Characterization of Nanoemulsion
Various physicochemical characteristics of prepared nanoemulsions (MM1–MM7) were
determined and summarized in Table 2. The drug content of nanoemulsions were in the range
of 90–105%. The pH of formulations was ~6–7 and was comparable to commercial ophthalmic
drops (pH 6.8), which is likely to be buffered by the lachrymal fluid and may not induce any ocular
irritation, reflex tears or rapid blinking of the eye. The developed nanoemulsion shows percentage
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transmittance value >90% which proves the transparency of the system and droplets are in the
nanometer dimensions, confirmed by the average value obtained for droplets size (29–81 nm). The
conductivity of nanoemulsions was in the range of 0.08–0.2 mS/cm. No phase separation was observed
when diluted 10 times with continuous media in all prepared nanoemulsions. The polydispersity
index value of 0–0.5 indicates homogenous, uniformly sized, spherical vesicles. As shown in Table 2,
MM1–MM7 have polydispersity indices ranged from 0.24–0.39, which indicate that they were more
uniform and homogenous. According to the classical electrical double layer theory, zeta potential value
above ±30 mV demonstrates moderate repulsion between similar charged particles, thereby decreasing
flocculation or aggregation and potentially stabilizes the dispersion. The observed zeta potential
values of MM1–MM7 (0.28–0.38 mV) were comparable, signify the formulation components have not
influenced the zeta potential in the current experimental conditions. Viscosity is another important
parameter as it can significantly influence the corneal retention time as well as ocular bioavailability
from an ophthalmic product. The prepared nanoemulsions have viscosity range from 3.2–6.5 cP, which
renders it easily pourable during instillation into the eye and is comparable to normal human tear
fluids [30]. Based on the physiochemical properties observed, it seems nanoemulsion MM3 possesses
the smallest droplets size and the lowest viscosity as compared to other nanoemulsions prepared.
Hence, the nanoemulsion MM3 was selected for further investigation.
3.5. TEM
A representative TEM image of prepared moxifloxacin nanoemulsion (MM3) is shown in Figure 3.
It is evident from Figure 3 that the prepared system has droplets in circular shape with uniform size
and can be easily distinguished. The droplets appear darker with bright background and are randomly
dispersed without any agglomeration throughout the field.
 
Figure 3. A representative transmission electron microscopy image of moxifloxacin nanoemulsion
(MM3).
86













































































































































































































































































































































































































































































































































































Pharmaceutics 2019, 11, 230
3.6. In Vitro Release
The release of drug from nanoemulsions is essential for absorption as well as its therapeutic effect.
Figure 4 compares the cumulative percentage of moxifloxacin released at periodic time intervals from
MM1–MM7 and control. It is evident from Figure 4 that the drug release profile showed a similar trend,
increased steadily over time and is more than 90% in 3 h for all formulations. However, the release of
moxifloxacin from control was rapid and complete in 45 min. Amongst all designed o/w nanoemulsion
formulations, MM3 showed complete drug release in 150 min. Overall, the release profiles indicate the
ability of prepared nanoemulsions to provide a steady drug release for 3 h, which in turn can prolong
the therapy. The release mechanism for MM3 was studied using various models and the values are
summarized in Table 3. It is evident from the Table 3 that the release kinetics of moxifloxacin from
MM3 was fitted into the Higuchi model displaying high r2 value (0.9486), least SSR value (613.14) and
F value (87.59). Thus, the release of moxifloxacin from MM3 was due to Higuchi diffusion controlled
mechanism. Further, the n value was less than 0.5 which indicates that drug release in MM3 is mainly
by Fickian diffusion.
 
Figure 4. Comparison of percentage moxifloxacin release from prepared nanoemulsions (MM1–MM7)
and drug solution (control). The data represents average ± SD of six trials.
Table 3. Model fitting for selected nanoemulsion (MM3).
Model Name Multiple R R Square X Variable Slope SSR Fischer Ratio
Zero order 0.9486 0.8999 0.5862 12.7455 1194.4235 170.6319
First order 0.9558 0.9135 −0.0166 2.3706 20804.4358 2972.0623
Higuchi 0.9740 0.9486 8.7765 −10.4853 613.1492 87.5927
Korsmeyer–Peppas 0.9766 0.9538 0.8446 −1.8055 1086.6082 155.2297
Weibull Model 0.9904 0.9810 1.6232 −2.8693 4932.8215 704.6888
Hixson–Crowell 0.9940 0.9880 0.0271 −0.2801 5019.6483 717.0926
3.7. Ex Vivo Permeation
The diffusion of therapeutic molecules into and across the biological membrane is mainly influenced
by the drug’s physicochemical properties, physiological characteristics of the membrane and different
transport routes available for permeation [18]. Figure 5 compares the amount of moxifloxacin
transported across the isolated rabbit cornea membrane from MM3 and control (commercial eye drops).
A typical permeation profile was exhibited by both MM3 and control and the steady state flux values
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were comparable (MM3; 32.01 μg/cm2/h and control; 31.53 μg/cm2/h). The flux value observed here
signifies that the physicochemical characteristics of MM3 are suitable for cornea permeation. The
permeation rate was relatively high in the first hour with control as compared to MM3. This is probably
due to the unique structure of moxifloxacin along with biphasic solubility (both lipophilic and aqueous
solubility) and high lipophilicity which would have assisted its easy permeation through the corneal
membrane [31].
Figure 5. Comparison of moxifloxacin ex vivo permeation across the isolated rabbit cornea membrane
from optimized nanoemulsion (MM3) and control (commercial eye drops). The data represents average
± SD of six trials.
3.8. Antimicrobial Efficacy
It is essential to perform microbiological efficacy studies to demonstrate the activity of the
drug in the nanoemulsion against the commonly susceptible microorganisms [32]. The optimized
formulation (MM3) showed microbicidal activity, when microbiological testing was performed by
the cup plate technique. Visible zones of inhibition were noticed in case of MM3 and control
formulation. The diameter of the zone of inhibitions generated by MM3 against both test organisms
(Pseudomonas aeruginosa and Staphylococcus aureus) were either similar or more than that produced by
commercial ophthalmic drops (Table 4). The broad-spectrum antibacterial activity of moxifloxacin
in the nanoemulsion against the susceptible pathogens was similar to the reference formulation in
terms of antimicrobial efficacy. This clearly indicates that the prepared formulation did not change the
inherent bactericidal effect of the incorporated moxifloxacin.
Table 4. Antimicrobial efficacy of the optimized formulation (MM3).
Concentration (μg/mL)
Zone of Inhibition in (cm)
Control * MM3
Staphylococcus aureus
1 1.63 ± 0.22 1.63 ± 0.26
10 2.44 ± 0.31 2.58 ± 0.18
100 3.52 ± 0.25 3.94 ± 0.24
Pseudomonas aeruginosa
1 1.82 ± 0.34 1.97 ± 0.16
10 2.77 ± 0.23 3.05 ± 0.21
100 4.05 ± 0.25 4.71 ± 0.29
* Control: Commercial eye drops of moxifloxacin.
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3.9. Ocular Irritation
The eye irritation potential of the inducing agent was classified into four grades; practically
non-irritating, score 0–3; slightly irritating, score 4–8; moderately irritating, score 9–12; and severely
irritating (or corrosive), score 13–16 [20]. The eye irritation score was calculated by dividing the
total score for all rabbits by the total number of rabbits tested. The observed eye irritation score in
the control was 0.33 and for MM3 was 0.66, which signifies excellent ocular tolerance. Moreover,
no ocular damage or abnormal clinical signs pertaining to the cornea, iris, or conjunctivae were visible.
In addition, no signs of redness, watering of the eye or swelling were noticed for both MM3 and control.
Overall the results of this study revealed that MM3 is safe for ocular application.
3.10. Pharmacokinetics in the Aqueous Humor
The concentration of the drug permeated into the aqueous humor after administration to the
rabbit eyes was quantified to evaluate the ocular bioavailability of moxifloxacin from MM3 as well
as the control. Different pharmacokinetic properties were analyzed by using a non-compartmental
method [33]. The determined pharmacokinetic parameters are summarized in Table 5. Figure 6
compares the mean moxifloxacin concentration in the aqueous humor following topical installation of
MM3 and control in rabbits. It is evident from Figure 6 that the kinetic profiles are distinct for MM3 and
control. Indeed, moxifloxacin absorption was rapid and available in the aqueous humor after 30 min
in MM3 (113.98 ± 51.45 ng/mL) and control (209.44 ± 64.53 ng/mL), however, the amount of drug was
different. At 1 h, the drug level in the aqueous humor increased to 305.99 ± 94.95 ng/mL and 454.19 ±
126.91 ng/mL in MM3 and control, respectively. The drug absorption in MM3 was further prolonged
and the drug level in the aqueous humor continued to rise to attain the peak drug concentration (Cmax;
555.73 ± 133.34 ng/mL) and the time corresponding to peak concentration (Tmax) was 2 h (which is
1 h in control). Comparing the drug absorption with the ex vivo permeation data, one can easily
corroborate that the delay in absorption of moxifloxacin into the aqueous humor in MM3 is probably
due to its slow permeation rate in the first hour observed in Figure 5. Followed by the rapid absorption,
the drug level declined in both groups. At 4 h, the drug level in aqueous humor was considerably
higher in MM3 (p < 0.0001) as compared to control. At 8 h, the drug level in aqueous humor for MM3
was 35.90 ± 13.01 ng/mL while no moxifloxacin was detected in the control. The mean value of area
under the aqueous humor concentration versus time curve (AUC0–8 h) for MM3 (Table 5) was ~2 fold
higher (p < 0.001), relative to the control, suggesting significant improvement in ocular bioavailability
by MM3 in comparison to the control. The possible reason for the greater observed AUC could be due
to the longer retention of vesicles (MM3) in the ocular surface which in turn prolongs the contact time
of medicament with the eye and thereby improve corneal penetration, when compared to conventional
eye drops, as described in the literature [34].
Table 5. Mean pharmacokinetic parameters of moxifloxacin in aqueous humor following topical
installation of nanoemulsion (MM3) and control in rabbits.
Parameter Nanoemulsion (MM3) Control
Tmax (h) 2 1
Cmax (ng/mL) 555.73 ± 133.34 454.19 ± 126.91
AUC0–8 (ng.h/mL) 1859.76 ± 424.51 * 958.63 ± 206.84
* Significant difference (p < 0.001) observed in moxifloxacin level in nanoemulsion (MM3) group compared to
control. Area under the aqueous humor concentration versus time curve (AUC0–8 h).
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Figure 6. Comparison of mean moxifloxacin concentration in the aqueous humor following topical
installation of optimized nanoemulsion (MM3) and control (commercial eye drops) in rabbits. The data
represents average ± SD of six trials.
3.11. Stability Assessment
Stability studies were conducted to determine the influence of various excipients on drug in MM3
and also to determine physicochemical characteristics of the finished product during storage. After
stability testing, the nanoemulsion was found to be a transparent biphasic solution and exhibited no
coagulation, aggregation or precipitation. No significant change in pH of MM3 was observed during
the stability period. Drug content of MM3 was more than 95% during storage period. There was no
phase separation or creaming on visual observation and it was found stable after cooling centrifugation.
The data observed indicate minimum changes in stability indicating parameters of nanoemulsion
systems like droplets size of MM3 after three months of storage.
4. Conclusions
The nanoemulsion system of moxifloxacin was successfully formulated by developing
pseudoternary phase diagram of different proportions of ethyl oleate, Tween 80, Soluphor P and water.
It is inferred from the contour plot that particle size is minimum when the water component is at a higher
level (1) and oil and surfactant components are at lower level (0). The developed nanoemulsions have
optimum viscosity for instillation in eye. They show transmittance value >95% which proves the
transparency of the system and the droplets are in nanometer dimensions. The optimized nanoemulsion
(MM3) showed adequate antimicrobial effect of the entrapped moxifloxacin and is safe for ocular
application. The moxifloxacin level in the aqueous humor was prolonged by MM3 which is greater
than the minimum concentration necessary for the therapeutic efficacy (i.e., 0.2 μg/mL or >>>MIC90 for
aerobic gram-positive and gram-negative pathogens responsible for causing eye infections), signifying
the importance of nanoemulsion for ocular therapy. In a nutshell, the optimized nanoemulsion
formulation (MM3) could be a promising and viable drug delivery system for effective delivery of
moxifloxacin for treatment of various bacterial eye infections.
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Abstract: This study aimed to develop a novel sustained release pellet of loxoprofen sodium (LXP) by
coating a dissolution-rate controlling sub-layer containing hydroxypropyl methyl cellulose (HPMC)
and citric acid, and a second diffusion-rate controlling layer containing aqueous dispersion of ethyl
cellulose (ADEC) on the surface of a LXP conventional pellet, and to compare its performance in vivo
with an immediate release tablet (Loxinon®). A three-level, three-factor Box-Behnken design and
the response surface model (RSM) were used to investigate and optimize the effects of the citric acid
content in the sub-layer, the sub-layer coating level, and the outer ADEC coating level on the in vitro
release profiles of LXP sustained release pellets. The pharmacokinetic studies of the optimal sustained
release pellets were performed in fasted beagle dogs using an immediate release tablet as a reference.
The results illustrated that both the citric acid (CA) and ADEC as the dissolution- and diffusion-rate
controlling materials significantly decreased the drug release rate. The optimal formulation showed a
pH-independent drug release in media at pH above 4.5 and a slightly slow release in acid medium.
The pharmacokinetic studies revealed that a more stable and prolonged plasma drug concentration
profile of the optimal pellets was achieved, with a relative bioavaibility of 87.16% compared with the
conventional tablets. This article provided a novel concept of two-step control of the release rate of
LXP, which showed a sustained release both in vitro and in vivo.
Keywords: sustained release pellets; double coating layer; loxoprofen; citric acid; pharmacokinetic
studies
1. Introduction
Pellets, as multiple unit preparations, offer a lot of clinical benefits compared with single unit
dosage forms, such as reduced intra- and inter-subject variability on drug plasma, decreased local
irritations, less dose dumping risk, and stable plasma concentrations [1,2]. To prepare sustained release
pellets, film coating is an ideal method. With the development of aqueous-based dispersion systems,
film coating technologies have shifted from organic-based polymeric solutions to aqueous-based
polymeric dispersion systems [3]. As one of the aqueous ethyl cellulose dispersions, Surelease® (ADEC)
could be used alone or combined with other polymers to obtain satisfactory release profiles [4–7].
Additionally, most of these release profiles showed a diffusion-controlled release mechanism, which
meant a predictable release pattern could be achieved by altering the ADEC coating weight gain [8,9].
Loxoprofen sodium (LXP), as a 2-phenylpropinate non-steroidal anti-inflammatory drug
(NSAD), was first introduced by Sankyo Company in Japan. It has been widely used for the
treatment of osteoarthritis, scapulohumeral periarthritis, rheumatoid arthritis, arthritis, toothache,
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 260; doi:10.3390/pharmaceutics11060260
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and post-operation pain [10]. As a pro-drug, LXP is converted to its active metabolite (trans-OH
LXP) in vivo to inhibit the activity of cycloosygenase (COX), which mediates the production of
inflammatory prostaglandins [11]. Due to the short elimination half-life of approximately 65 min [12],
the commercial tablet of LXP has to be administrated three times a day to maintain the therapeutic
concentration in plasma, which might cause high risks of gastrointestinal (GI) lesions and systemic
side effects [13,14]. Several studies have been reported on the preparation of LXP sustained release
dosage forms [15–17]. However, due to its high solubility, most of the preparations, especially for the
matrix-based formulations, showed a burst release (drug release >30%) during the first 2 h [18], which
could cause unexpected GI mucosal injury for patients. Therefore, a sustained release dosage form
with decreased initial release would be necessary.
As a weakly acidic drug, loxoprofen shows good solubility at high pH, while poor solubility
at low pH. Several strategies have been developed to prepare sustained release formulations of the
pH-sensitive drugs [19–22]. Among them, incorporation of pH-modifiers into the preparation was
a common approach in matrix or coating systems. These pH modifiers could significantly modify
the micro-environmental pH (pHM) inside the systems, and result in a decrease or increase of the
drug solubility, leading to a modified drug dissolution rate [22–24]. In addition, their extent and
duration played an important role on the drug release rate [25]. Approaches like using coated
pH-modifier as the starting core [23], blending pH-modifier with drugs into the core with a subsequent
coating [26], or incorporating pH-modifiers into the matrix formulations [20], have been proposed and
studied to achieve the sustained release of pH-sensitive drugs. However, for the maintenance of an
appropriate pHM inside the dosage forms, more than 20% pH-modifiers in the preparations were often
needed [20,23,26], which might cause undesired GI irritations, especially for patients with GI ulcers.
In order to reduce the usage of pH-modifiers and maintain an appropriate pHM in the dosage form,
citric acid (CA) as the pH-modifier was first proposed to be incorporated into the dissolution-rate
controlling layer to decrease the dissolution rate of LXP.
Drug delivery systems (DDS), based on their system design or rate-controlling mechanism, can be
divided into models such as dissolution, diffusion, erosion, osmosis, and swelling [27]. As for the film
coating systems, the diffusion or osmosis mechanisms were often applied to elucidate the drug release
profiles [5,28–30], while the influence of drug dissolution rate was often omitted or just attributed to the
drug diffusion rate [27]. In the most common cases, only one of these mechanisms was applied to control
the drug release rate in DDS, except for the bio-erodible or hydrogel matrix systems, where the drug
release rate was controlled by two or three of these release mechanisms [31,32]. Although theoretical
approaches regarding the dissolution-diffusion mechanism have been extensively reported [33,34],
a combination of the dissolution and diffusion release mechanisms as a rate-controlling strategy was
seldom reported.
In this study, a novel concept of two-step control of the drug release rate is proposed. A schematic
diagram of this hypothesis is illustrated in Figure 1. In this system, the first-step control was to reduce
the dissolution rate of LXP by creating a sub-coating layer containing pH-modifier CA, while the
second-step control was to decrease the diffusion rate of LXP by creating a non-soluble polymeric film.
Furthermore, a three-level, three-factor Box-Behnken experiments design was conducted to optimize
and evaluate the effects of different parameters on the drug release. Additionally, the pharmacokinetic
studies of the optimal formulation were performed in fasted beagles to compare its in vivo performance
with the conventional tablet.
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Figure 1. Schematic diagram of the sustained release pellets.
2. Materials and Methods
2.1. Materials
LXP dihydrate was purchased from Fujian Hui Tian biological Pharmaceutical Co., Ltd. (99.1%
purity, China). Loxonin® tablets were purchased from Daiichi Sankyo Co., Ltd. (Tokyo, Japan).
Ketoprofen was purchased from Sigma (St. Louis, MO, USA). Microcrystalline cellulose SH-101 and corn
starch were supplied by Sunhere Pharmaceutical Co., Ltd. (Huainan, China). Hydroxypropylmethyl
cellulose (Methocel E5LV) and Surelease® E-7-7050 (aqueous ethyl cellulose dispersion) were supplied
by Colorcon Ltd. (Dartford, Kent, UK). Hard gelatin capsules were from Suzhou Capsugel Ltd.
(Suzhou, China). Other chemicals were of reagent grade or higher grades.
2.2. HPLC-Assay for LXP and CA Contents
HPLC methods were used for the determination of LXP and CA. Chromatograph was carried out
on Shimadzu LC-2030 (Shimadzu, Japan), equipped with an autosampler and an SPD-20A UV detector.
The mobile phase used for the determination of LXP consisted of a mixture of methanol-water-acetic
acid-triethylamine (600:400:1:1, v/v). Separation was achieved by applying an Inertsil C18 column
(5 μm, 4.6 × 150 mm, Shimadzu, Japan), and the chromatogram was recorded at 223 nm. The limit of
determination (LOD) and limit of quantitation (LOQ) for LXP were 0.03 and 0.1 μg/mL respectively.
The mobile phase performed for the determination of CA was carried out with one part isopropanol
and 999 parts 0.018 M phosphate buffer, adjusted to pH 2.5 with phosphoric acid. An Inertsil C18
column (5 μm, 4.6 × 150 mm, Shimadzu, Japan) was employed to separate the CA content. The flow
rate was 1 mL/min, and the column temperature was controlled at 40 ◦C with the UV detection at
210 nm. The LOD and LOQ for CA were 0.2 and 0.6 μg/mL respectively. In addition, the calibration
curve over the concentration range of 0.6–60 μg/mL had a regression coefficient of 0.9996.
2.3. Solubility/pH Profiles of LXP
Solubilities of LXP in different pH media were determined by adding excess of LXP to different
buffer solutions: hydrochloric acid solutions (pH 1.2, 2.2), phosphate buffers (pH 3.0, 3.5, 4.0, 4.5 and
6.8). After vibrated at 25 ◦C for 24 h in a constant-temperature shaker (SHZ-82, Guohua Co., Ltd.,
Changzhou, China), 2 mL of the saturated solution was filtered through a membrane filter, and was
diluted to avoid crystallization. Sample was determined by HPLC method.
2.4. Preparation of Drug-Loaded Pellets
The core consisted of loxoprofen sodium (37.1%, w/w), microcrystalline cellulose (41.9%, w/w),
corn starch (19.9%, w/w), and talc (1.1%, w/w). Briefly, the mixture was blended in an ERWEKA mixer
(Type AR YB5, Heusenstamm, Germany) at a speed of 40 rpm for 30 min. Then it was kneaded with
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the ethanol water solution (30%, v/v) in a laboratory kneader (Type LK5, Heusenstamm, Germany) for
10 min. The obtained moist mass was extruded at a speed of 500 rpm through a stainless steel barrel
with a die of 0.8 mm diameter. Then, 300 g of the extrudates were processed in a 23 cm radial cut
plate of spheronizer (JBZ-300, Liaoning New Drug Research Institute, China) at 1000 rpm for 10 min.
The obtained pellets were collected on a Teflon tray and were dried in a hot oven at 60 ◦C for 24 h to
remove the residual water and ethanol. Pellets with fraction size between 800 and 1250 μm were used
for the following procedure.
2.5. Preparation of Sustained-Release Pellets
2.5.1. Preparation of the Dissolution-Rate Controlling Layer
Methocel E5 LV was added to purified water to achieve a hydroxypropylmethyl cellulose
concentration of 4% (w/w). Then the solution was mixed with critic acid, with a concentration range
from 0% to 6% (w/w), and was plasticized with PEG 6000 (0.5%, w/w) for 40 min [9]. Then, talc was
added to the polymer mixture at a concentration of 2.5% (w/w). The aqueous suspension was stirred
during the coating process. Using bottom spray with a Wurster insert, 50 g pellets were coated in
a laboratory-scale fluid bed coater (Hanse, Changzhou, China). The process parameters were as
follows: inlet temperature 50 ◦C, material temperature 40 ◦C, atomization pressure 0.15 MPa, spray
rate 0.8 mL/min, and air flow rate 35 m3/h.
2.5.2. Preparation of the Diffusion-Rate Controlling Layer
ADEC was separately used as the diffusion-rate controlling layer. Mainly, aqueous dispersion
of Surelease® was diluted in purified water to achieve a solid content of 15% (w/w), and was stirred
for 45 min before coating. Then the aqueous dispersion was sprayed on pellets sub-coated with the
dissolution-rate controlling layer in the same equipment. The process parameters for ADEC coating
were as follows: inlet temperature 54 ◦C, material temperature 42 ◦C, atomization pressure 0.18 MPa,
spray rate 1.0 mL/min and air flow rate 40 m3/h. After the coating process, pellets were cured in a hot
oven at 60 ◦C for 16 h.
2.6. Experimental Design
A three-factor, three-level Box-Behnken experiment design was applied to evaluate the effects
of different parameters on drug release rate. Briefly, the design is equal to the three replicated centre
points and the set of points lying at the midpoint of each surface of the three-dimensional cube that
defines the region of interest of each parameter. The three independent variables (X1, X2 or X3) were
the concentration of CA in the sub-coating aqueous dispersion (X1), the sub-coating weight gain
based on the dry uncoated pellet mass (X2), and the ADEC coating weight gain based on the sub
coated pellets mass (X3). Each variable was coded to be in the range of −1, 0, 1, which represented
different variable levels. Levels of the factors and constraints for the in vitro drug release based
on preliminary pharmacokinetic study are listed in Table 1. The design required 15 experimental
formulations. The independent variables of each formulation and their responses are listed in Table 2.
The response surface model generated by the design is given as Equation (1):
Y = a0 + a1×1 + a2X2 + a3X3 + a4X1X2 + a5X2X3 + a6X1X3 + a7X12 + a8X22 + a9X32 (1)
where Y is the response parameter, X1, X2, and X3 are the independent parameters, a0 is the intercept, a1
− a3 are the main effect coefficients, a4 − a9 are coefficients of parameters with interaction or quadratic
effects. Statistical analysis of the model was performed in Design-Expert software (V.8.0.6, Stat-Ease
Inc., Minneapolis, MN, USA). The regression models of Y1, Y2, and Y3 were evaluated in terms of
statistically significant coefficients using analysis of variance (ANOVA) and r2 values. Only coefficients
with p values less than 0.05 were constructed in the models. In addition, response surface plots were
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performed to visualize the effect of parameters and their interactions on the responses. Design space,
which was determined from the common region of successful operating ranges for the responses, was
established following the obtained response surface to clarify the optimal formulation.




X1 = citric acid concentration (%) 1 2 3
X2 = subcoating weight (%) 6 8 10
X3 = ADEC coating weight (%) 10 13 16
Responses Constraints
Y1 = the drug release within 2 h <30%
Y2 = the drug release within 6 h 50–70%
Y3 = the drug release within 12 h >90%
Table 2. Independent variables and observed responses of the Box-Behnken design.
Formulations
Factors (%) Responses (%)
X1 X2 X3 Y1 Y2 Y3
1 2.0 10.0 10.0 21.5 71.2 93.8
2 3.0 10.0 13.0 8.4 46.0 78.5
3 2.0 6.0 16.0 7.4 40.9 68.9
4 2.0 8.0 13.0 17.1 54.8 87.0
5 3.0 6.0 13.0 13.1 53.8 81.0
6 1.0 6.0 13.0 31.4 75.0 91.0
7 1.0 8.0 16.0 21.0 58.0 86.0
8 2.0 8.0 13.0 17.7 59.7 89.0
9 1.0 10.0 13.0 27.8 75.5 92.6
10 3.0 8.0 16.0 13.6 33.1 57.7
11 1.0 8.0 10.0 56.0 88.0 99.0
12 2.0 10.0 16.0 8.6 40.2 68.3
13 3.0 8.0 10.0 20.5 60.2 91.0
14 2.0 6.0 10.0 38.2 81.6 90.0
15 2.0 8.0 13.0 13.9 60.7 89.0
2.7. In Vitro Release of LXP and CA
A dissolution test was carried out at 37 ◦C in 900 mL water, using a dissolution apparatus (78X-6A,
Huanghai medicine inspecting institute, China) with the basket rotation speed of 100 rpm, which
is specified in China Pharmacopoeia. The prepared sustained-release pellets containing 90 mg of
anhydrous LXP were added to the dissolution apparatus. At pre-determined intervals, 5 mL of the
sample was withdrawn and replaced with fresh medium. Then the samples were analyzed by HPLC.
In order to better understand the impact of CA on the drug release rate, simultaneous release
profiles of CA and LXP in formulations with different CA concentrations were conducted. Additionally,
the impact of dissolution media on the release of CA and LXP were investigated by performing the
dissolution tests in the following media: pH 1.0 HCl, pH 4.5 and 6.8 phosphate buffers, and water.
The contents of CA and LXP in the formulations were determined by HPLC.
2.8. Release Mechanism Studies
The in vitro release mechanisms of LXP were analyzed by seven kinetics models. As shown in
Table 3, Qt is the release amount of LXP at time t, Q0 is the initial amount of LXP in the pellets, k0 is
the zero order release constant and k1 is the first order release constant, kH is the Higuchi dissolution
constant, n is exponent constant characterizing different release mechanisms, a is a time scale parameter
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and b is a shape parameter that characterizes the curves of the release profiles. The dissolution data of
LXP were fitted to these models by linear or non-linear least-squares fitting methods. The correlation
coefficients calculated by regression analysis were used to evaluate the goodness of fit for each model.
Table 3. Models for drug release.
Model Name Equation
Zero-order model Qt = k0t
First-order model ln(Q0 − Qt) = −k1t + Q0
Higuchi diffusion model Qt = kHt1/2
Ritger–Peppas model lnQt = n lnt + k
Weibull distribution model log[−ln(1 − Qt)] = b logt − loga
Hixson–Crowell model (1 − Qt)1/3 = 1 − kt
Baker–Lonsdale model 3/2 [ 1 − (1 − Qt)2/3] − Qt = kt
2.9. Morphology Study
Scanning electron microscopy (S-8000; Hitachi High-Technologies Europe, Krefeld, Germany) was
used to evaluate the morphology of the surface and cross-section of coating pellets. Samples were
fitted on the copper sample holder with a double sided adhesive tape, sputter coated with a 10-nm
thick gold layer under argon atmosphere.
2.10. The Pharmacokinetic Studies
2.10.1. Administration Programme
All animal treatments were performed in accordance with the Regulations of the Administration
of Affairs Concerning Experimental Animals and the study protocol was admitted by the Ethics
Committee of China Pharmaceutical University (Approval No. 2018-0315). An open label, randomized,
two-period crossover experiment design with one week wash-out period was used in this study.
Six male beagle dogs (weight 8.7 ± 1.1 kg), fasted but free access to water for 12 h prior to the
experiment, were used in the study. Pellets of the optimal formulation were filled into hard gelatin
capsules. The immediate release tablet (Loxonin®, 60 mg anhydrous LXP) and the capsule of the
optimal formulation (90 mg anhydrous LXP) were administered to beagles in the morning with 100 mL
water. Then, 6 h after dosing, dogs were provided with standard food.
A total of 2 mL of the blood samples were withdrawn before and then 0.5, 1.0, 2.0, 3.0, 4.0, 5.0,
6.0, 8.0, 10.0, and 12.0 h after dosing via cannulated needle from front legs. Plasma was obtained by
centrifuging the blood at 4000 rpm for 15 min, and was kept frozen at −20 ◦C before analysis.
2.10.2. Determination of LXP in Plasma
A stable and selective HPLC method, modified by previous papers [12,35], was applied for the
analysis of LXP in dog plasma. Pretreatment was carried out by adding 50 μL of internal standard
(100 μg/mL ketoprofen in acetonitrile), 50 μL of zinc sulfate solution (10%, w/w) and 750 μL acetonitrile
into 500 μL plasma sample. After vortex-mixing for 1 min, sample was centrifuged at 8000 rmp for 15
min. Then 10 μL of the supernatant was injected into the HPLC system. The separation was performed
on an Inertsil C18-ODS column (5 μm, 4.6 × 150 mm, Shimadzu, Japan) with a guard column (4.6 ×
10 mm, 5 μm particle size, ANPEL Laboratory Technologies Inc, Shanghai, China) at a flow rate of
1 mL/min. Additionally, the mobile phase was a mixture of acetonitrile and 0.05 M monopotassium
phosphate (35:65, v/v), adjusted to pH 3.0 with phosphoric acid. Chromatograms were recorded at
223 nm with a Shimadzu-SPD detector. The linear range of this method was 0.1–20.0 μg/mL with
an r2 value of not less than 0.999. The lower limit of quantification (LLOQ) was 100 ng/mL and the
extraction recoveries of high, middle, and low concentrations of LXP were 102.5 ± 2.0%, 97.1 ± 2.5%
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and 97.1 ± 5.9%, respectively. The R.S.D.s reflecting the intra-day and inter-day precision of LXP were
less than 11.77%.
2.10.3. Bioavailability Study
Non-compartmental pharmacokinetic analysis was applied to calculate parameters such as Tmax,
Cmax, AUC0–t, and AUC0–∞ from the plasma concentration-time curve data using WinNonlin software
(version 1.5, Pharsight Corp. Mountain View, CA, USA). The relative bioavailability of the optimal
formulation to the commercial tablet (reference) was calculated using the following Equation (2):
Relative.bioavaibility =
AUCT0−∞ ×XR
AUCR0−∞ ×XT × 100% (2)
where XR and XT were the administered dose of the reference and test respectively. Results were
presented as means ± standard deviation. A one-way ANOVA (SPSS, version 19) with p < 0.05 as a
level of significance was applied to examine the differences of Cmax and AUC0–∞ between the test
and reference.
3. Results and Discussions
3.1. Impact of CA on Drug Release
Formulations with different concentrations of CA in the sub-layer were developed to evaluate
the effect of pH-modifier on the drug release rate, while the dissolution-controlling layer and ADEC
coating levels were kept at 8% and 11% respectively. The results in Figure 2 illustrated that formulation
without CA showed a fast release of LXP (>80% within 2 h), while the drug release within 2 h was
decreased to 40% at a CA concentration of 1%. Additionally, the release rate continued to decrease
with the increase of CA concentration, which showed 16.37%, 11.34%, and 7.77% of LXP release within
the first 2 h. At the CA concentration of 1%, a completed drug release was finished within 6 h. While
at higher CA concentrations, there were still 21.80% (2.5% CA) and 32.43% (4.0% CA) of the initial
drug amount released after 6 h.
Figure 2. Effect of citric acid concentration on the drug release within different intervals.
As a pH modifier, CA was aimed to modulate the pHM inside the systems. For pH-sensitive
compound, its solubility is more appropriate to be described as the solubility in the diffusion layer
at the surface of the dissolving particles [25]. Therefore, according to the Noyes–Whitney theory,
the dissolution rate of LXP was much more dependent on the solubility in the low pHM beneath the
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diffusion-controlling layer, other than the dissolution media. Theoretically, drug release rate from a
coherent film coating system is controlled by both the coating level and the drug concentration gradient
across the coating film, which obeyed the Fick’s diffusion law. As the film coating level was kept
constant, drug release rate was predominantly controlled by the drug concentration gradient, which
was determined by the dissolution rate of LXP inside the pellets. Therefore, as the drug release was
significantly decreased with the increase of CA concentrations (Figure 2), the first step of developing a
dissolution-rate controlling layer proved to work.
Furthermore, simultaneous release profiles in Figure 3 were constructed to investigate the impact of
dynamic release process of CA on the drug release rate. In formulations with lower CA concentrations,
with the release of CA during the dissolution period, pHM could be changed from 0.4 (the saturated
solution pH of CA) to the approximate equilibrium pH of the dissolution medium [36]. As the solubility
of LXP changed approximately 300 times within this pH range (Supplementary Materials Figure S1),
the drug dissolution rate was significantly dependent on the amount of CA left inside the pellets.
Therefore, matching release profiles of LXP and CA were observed at low concentrations of CA.
Figure 3. The simultaneous release profiles of citric acid and loxoprofen from sustained release pellets
at different concentrations of citric acid (n = 3).
While in formulations with higher CA concentrations, as a sufficient amount of CA remained
inside the pellets at the end of the dissolution period, e.g., 30% or 40% of the initial CA amount left at
the concentration of 4% or 6% respectively, a constant and effective pHM was achieved inside the pellets,
which resulted in no further decrease of the drug release rate (Figure 3). A similar phenomenon was
observed in a matrix tablet containing dipyridamole, due to a constant and effective pHM maintained
by fumaric acid inside the dosage form, no further enhancement of the dipyridamole release was
observed after increasing the fumaric acid concentration to 40% [37]. Therefore, a discrepancy of the
release profiles between CA and LXP was observed in formulations with higher CA concentrations.
3.2. Release Experiments and Statistical Evaluation
3.2.1. Testing of Drug Release
Experimental variables and observed responses of all the 15 formulations were listed in Table 2.
And their drug dissolution profiles were displayed in Figure 4. At a low level of CA concentration,
most of the formulations (Formulation Nos. 6, 9, 11) showed a fast drug release except Formulation
No. 7, which had a high coating level of ADEC. The fast release in Formulation Nos. 6, 9, 11 was
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attributed to an inefficient pHM inside the pellets and the short diffusion pathway of ADEC coating,
which could be identified as the failure of the first- and second-step control. As a prolonged diffusion
pathway was developed in Formulation No. 7, the release rate of LXP was significantly decreased.
While at a low coating level of ADEC, most of the formulations (Formulation Nos. 1, 11, 14) showed a
fast drug release rate, expect Formulation No. 13, which was incorporated with a high concentration
of CA. The fast release in Formulation Nos. 1, 11, 14 could be explained by a failure of the second-step
control, as a short diffusion pathway created by the low coating level of ADEC was unable to retard the
release rate of LXP. However, when 3% of the CA concentration was applied in Formulation No. 13,
the effective control of the drug dissolution-rate could compensate for the failure of the diffusion-rate
control to achieve a sustained release of LXP.
(a) (b) 
(c) 
Figure 4. Dissolution profiles of loxoprofen in formulations prepared by the Box-Behnken design
experiments (a) Formulation Nos. 1–5, (b) Formulation Nos. 6–10, (c) Formulation Nos. 11–15.
3.2.2. Regression Equations
Based on the experiment data, the coefficients and their p-values of the fitted full quadratic
equations calculated by Expert-Design 8.0.6 (Stat-Ease Inc., Minneapolis, MN, USA) are listed in Table 4.
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The final equations consisted of only statistically significant coefficients. It is clear that the citric acid
concentration (X1) and ADEC coating weight gain (X3) showed significant effects on the drug release
rate throughout the dissolution period, while the weight gain of the dissolution-rate controlling layer
(X2) showed only a weak effect during the dissolution period. The impact of X1 on the drug release
rate verified the effectiveness of the first-step control on the drug release rate, which could be explained
by its impact on the pHM, as extensively reported in the literature [36,37]. The effect of X3 on the drug
release rate could be attributed to its control on the drug diffusion rate, which was considered as the
second-step control [38]. Besides, an interaction effect of X1 and X3 was observed on the response of
Y1 and Y3, which might be explained by a speculation that X3 also showed an effect on the release rate
of citric acid. Additionally, it seemed that X3 played a more dominant role on the final drug release,
as high coefficients of the main, interaction, and quadratic effects of X3 were observed in Y3. From
the statistic results in Table 4, we could conclude that both the dissolution-rate and diffusion-rate
controlling steps have significant effects on the drug release rate.








Cofficient p-Value Cofficient p-Value Cofficient p-Value
Constant 16.23 0.000 58.40 0.000 88.33 0.000 *
X1 −10.08 0.001 * −12.91 0.001 * −7.38 0.000 *
X2 −2.98 0.007 * −2.30 0.091 0.29 0.697
X3 −10.70 0.001 * −16.11 0.001 * −11.79 0.000 *
X1*X2 −0.27 0.787 −2.07 0.240 −1.02 0.347
X2*X3 4.47 0.006 * 2.42 0.180 −1.10 0.316
X1*X3 7.03 0.000 * 0.70 0.672 −4.72 0.005 *
X1*X1 6.40 0.001 * 2.78 0.148 0.13 0.902
X2*X2 −2.45 0.058 1.40 0.427 2.69 0.047 *
X3*X3 5.15 0.004 * −1.33 0.451 5.39 0.003 *
Regression
equation
Y1 = 16.23 − 10.08X1 −
2.98X2 − 10.7X3 − 4.47X2X3 +
7.03X1X3 + 6.4X12 + 5.15X32
Y2 = 58.40 − 12.91X1 −
16.11X3
Y3 = 88.33 − 7.38X1 −
11.79X3 − 4.72X1X3 −
2.69X22 − 5.39X32
R-Squared 0.9921 0.9865 0.9891
* p-value < 0.05.
3.2.3. Response Surface Plots
The relationship between the dependent and independent variables was further elucidated using
a 3D response surface plot, which is useful to see the effect of two factors on the response at one time
while the third factor is kept at a constant level. The effects and interactions between concentration of
citric acid (X1), the sub coating weight gain (X2), and ADEC coating weight gain (X3) on the finial drug
release (Y3) are given in Figure 5. The similar impacts of the three factors on the other responses (Y1
and Y2) can be seen in Supplementary Materials Figures S2 and S3. As illustrated in Figure 5a,b, it was
clear to see that X2 showed little effect on Y3 irrespective of the levels of other two factors. This was
attributed to the fact that the dissolution-rate controlling layer is made up of aqueous polymer, which
was dissolved before 12 h.
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Figure 5. Contour plots showing the effects of (a) X1 and X2, (b) X2 and X3, and (c) X1 and X3 on the
response Y3.
The effects of citric acid concentration (X1) and the ADEC coating weight gain (X3) on Y3 are
depicted in Figure 5c. While X3 was kept at low level, the increase of X1 from 1% to 3% showed no
effect on Y3, which kept nearly constant at above 90%. While at a high level of X3, the increase of X1
from 1% to 3% resulted in a significant decrease of Y3 from 85% to 60%. The result indicated that an
interaction effect of the two factors existed on the drug release rate, as mentioned in Section 3.2.2. At a
high level of X3, an effective diffusion barrier was formed on the surface of the pellets [38], which
significantly reduced the diffusion rate of loxoprofen. However, the release rate of loxoprofen was
not solely controlled by the diffusion-controlling layer. For example, a nearly complete release of
loxoprofen (>85%) was observed at a high level of X3 (Figure 5c), when X1 was kept at a low level of
1%. Therefore, the release rate of loxoprofen was a combined result of the two controlling steps. At a
low level of X3, the citric acid was soon released regardless of its concentrations, which resulted in
a quick increase of the pHM and a fast drug release rate. When the concentration of citric acid and
ADEC coating weight gain were kept at high levels, both the drug dissolution and diffusion rate were
reduced, which resulted in a prominent decrease of the drug release rate.
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3.2.4. Design Space and Formulation Parameters Optimization
Design space was defined by the ICH Q8 as the relationship between the process inputs (material
attributes and process parameters) and the critical quality attributes that have been demonstrated
to provide assurance of quality [39]. The wider the design space is, the more robust and flexible the
process is to resist variations [40]. As the response surface models of the output parameters as a
function of selected variables were given, design space of X1, X2, and X3 was determined by applying
constraints on Y1 (<30%), Y2 (50–70%), and Y3 (>90%). The yellow overlap region of ranges for the
three responses in Figure 6a–c show the proposed design space of the citric acid concentration X1
and the ADEC coating weight gain X3 at three different levels of the sub-coating weight gain X2.
As shown in Figure 6a, there was no design space of X1 and X3 at the low level of X2. Additionally,
Figure 6c depicted a narrow design space of X1 and X3 at high level of X2, which would increase the
difficulty of the operation process since an accurate coating load of ADEC must be achieved during the
manufacturing process. While at the medium level of X2 (Figure 6b), the design space was expanded,
which showed a less strict field of ADEC coating level. As the design space depicted the ranges of the
formulation parameters for achieving the desired quality of product, the levels of the three factors for
the optimal formulation must be set within the design space. Considering the robustness and flexibility,
parameters of the optimal formulation were set at the medium level of sub coating weight gain with
the CA concentration and coating level of ADEC at 2.5% and 11.0% respectively. The model predicted
a release profile of 19.87% at 2 h, 64.48% at 6 h, and 91.71% at 12 h. To verify these values, a new batch
of the optimal formulation was prepared. The obtained release data of the optimal formulation were in
close agreement with the predicted values with a maximum percentage error of 11.73% at the initial
release (data not showed).
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(a) (b) 
(c) 
Figure 6. Design space of operating variables of the citric acid (CA) concentration and aqueous
dispersion of ethyl cellulose (ADEC) coating level (a) at the low level of the sub-layer coating weight
gain, (b) at the medium level of the sub-layer coating weight gain, and (c) at the high level of the
sub-layer coating weight gain (yellow zone: design space; grey zone: failure space).
3.3. Simultaneous Release of CA and LXP from the Optimal Formulation in Different Dissolution Media
In order to evaluate the effect of pH on drug release, various media simulating different physiology
pH values were applied. As shown in Figure 7, dissolution tests were performed in pH 1.0 HCl, pH 4.5
and pH 6.8 phosphate buffer solutions and water. Furthermore, the release profiles of CA were also
investigated in these media. As illustrated in Figure 7, drug release profiles were pH-independent at
pH above 4.5, and showed similar release profiles to that of CA.
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Figure 7. Loxoprofen and citric acid released from sustained release pellets in different dissolution
media. (a) pH 1.0 HCl (b) pH 4.5 phosphate buffer (c) pH 6.8 phosphate buffer (d) water (means ± SD,
n = 3).
Although the solubility of LXP was pH-independent in media with pH above 4.5 (Supplementary
Materials Figure S1), it seemed that the dissolution media were not the reason for this pH-independent
release behavior. As the drug showed a completed release within 3 h without the incorporation of CA
inside the pellets (Figure 3, formulation with the CA concentration of 0%), it should exhibit a similar
release for the optimal formulation as the dissolution media were also above 4.5. In the contrast, the
optimal formulation showed sustained release for almost 12 h. It was the pHM created by CA, which
showed similar release profiles at pH above 4.5, that accounted for the pH-independent release profiles
of LXP (Figure 7). As mentioned before, the saturated solution pH of CA was 0.4 [36], which was
much lower than that of the dissolution media except the pH 1.0 HCl. However, with the release of
CA during the dissolution period, the amount of CA left inside the optimal pellets was insufficient to
maintain a constant pHM inside the pellets. The pHM was gradually increased, which resulted in a
consistent enhancement of the drug solubility. In addition, matching sustained release profiles of LXP
and CA were achieved in Figure 7.
While at pH 1.0, it was the dissolution media that showed a major effect on the drug release rate.
With the decrease of CA, the pHM would soon be increased up to above 1.0. However, the dissolution
media that penetrated into the pellets provided a stable pHM inside the pellets, which in turn resulted in
a different release profile to the other three. In conclusion, the dissolution media and the incorporated
CA played a combined effect on the drug release rate. In media with high pH values, the CA showed
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a greater effect on the drug release rate. While in media with low pH values, it was the dissolution
media that dominated the drug release rate.
3.4. Release Mechanism Studies
In order to elucidate the transport mechanism of LXP in the optimal formulation, different
mathematical models were applied to analyze the kinetics of the release data. As shown in Table 5,
the incorporation of CA into the sub-layer resulted in abnormal release kinetics of this ADEC coating
system, as the n value for Ritger–Peppas was 0.7422, which is between 0.45 and 0.89, indicating a
non-Fick diffusion [41]. Additionally, a general empirical equation of Weibull distribution model with
r2 of 0.9944 was more appropriate to describe the release process of the optimal formulation. In the
model, the derived estimate of b value was calculated to be 1.38, which represented a sigmoid shape
curve (b > 1) for the release profile [41]. The initial slow release representing the starting part of the
sigmoid curve was a result of several factors. As reported previously, the permeability of water through
the EC coating is much faster than the permeability of the compound [38], which might contribute to
the initial slow release of LXP. Besides, the decreased dissolution rate created by the initial low pHM
inside the pellets also played an important role on the initial slow release. Furthermore, the hydration
of the hydroxypropyl methyl cellulose (HPMC) inside the pellets during the initial dissolution period
could also inhibit the initial drug release rate. Thereafter, due to the saturation of water inside the
pellets and the disruption of the dissolution-rate controlling layer, the drug release rate was dominated
by the dissolution- and diffusion-rate control, which resulted in a sustained release profile.
Table 5. Models simulated for the drug release profiles of the optimal formulation.
Content Model Equation r2
loxoprofen
Zero-order model Qt = 0.0833t + 0.0238 0.9288
First-order model ln(Q0 − Qt) − lnQ0 = −0.1787t + 0.0814 0.9794
Higuchi diffusion model Qt = 0.3126t1/2 − 0.1496 0.9454
Ritger–Peppas model lnQt = 0.7422 lnt + 2.7562 0.9597
Weibull distribution model log[−ln(1 − Qt)] = 1.3840 logt − 1.0449 0.9944
Hixson–Crowell model (1 − Qt)1/3 = −0.0514t + 1.0167 0.9874
3.5. Scanning Electron Photomicrographs
Figure 8 shows the scanning electron photomicrographs of the optimal pellets. The surface of
pellets were smooth (Figure 8a,b), and no crack could be seen. Besides, layers of the dissolution-rate
controlling layer and the diffusion-rate controlling layer were clearly seen in the cross-section of the
coating pellets (Figure 8c,d). These results indicated that a successful procedure had been developed
for manufacturing the sustained release pellets.
108







Figure 8. SEM photographs of pellets with double coating layers: (a) Surface of sustained release pellets
with 70 magnifications, (b) surface of sustained release pellets with 450 magnifications, (c) cross-section
of sustained release pellets with 70 magnifications, (d) cross-section of sustained release pellets with
350 magnifications.
3.6. Pharmacokinetic Studies
The pharmacokinetic studies of the optimal pellets and the commercial tablets were investigated
on fasted beagles. The profile of mean plasma concentrations of LXP versus time is shown in Figure 9.
The main pharmacokinetic parameters are summarized in Table 6. As shown in Figure 9, the plasma
concentration of the commercial tablet quickly increased and reached the peak concentration of
5.16 μg/mL at 0.5 h after administration. Then it dropped down and was only 0.2 μg/mL at 6 h.
This was attributed to the short half-life (t1/2 = 64.46 min) of LXP [12], which resulted in a quick
elimination of the drug in vivo. The optimal formulation reached the maximum plasma concentration
of 2.40 μg/mL at 5 h after administration, and the drug concentration fell slowly even at 12 h, when the
drug concentration was 0.15 μg/mL, in contrast with the undetectable drug concentration in plasma for
the commercial tablet 8 h after administration.
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Figure 9. Plasma drug concentrations vs. time after oral administration of conventional tablets (60 mg)
and sustained release pellets (90 mg).
Table 6. The pharmacokinetic parameters of loxoprofen after oral administration of the optimal















(90 mg) 2.60 ± 0.23 4.80 ± 0.57 12.77 ± 0.88 13.48 ± 0.94 87.16 ± 0.07
Commercial tablets
(60 mg) 5.16 ± 0.60 0.60 ± 0.22 9.73 ± 0.61 10.31 ± 0.45 -
As a pro-drug, LXP inhibits the activities of cyclooxygenase-1 and -2 (COX-1 and COX-2) by
its active metabolite trans-OH LXP, of which the IC50 values for COX-1 and COX-2 were 0.38 and
0.12 μM, respectively [42]. It has been reported that the concentration of trans-OH LXP, which was the
major metabolite of LXP, was equal to more than half of the LXP concentration detected in plasma [12].
As the LXP concentration range in plasma of the optimal pellets was 0.6–10.0 μM, we can deduce
that the concentration of trans-alcohol LXP after administration of the optimal pellet would be higher
than the IC50 of the trans-OH LXP. Therefore, a therapy concentration of trans-OH LXP in plasma
after administration of the optimal pellets would be maintained for almost 12 h. As the frequency of
dosage of the optimal formulation was reduced to two times a day, the patient’s compliance would
be better improved. It has been reported that the incidence of gastric lesions after administration of
LXP in rats showed a dose-dependent manner. Additionally, the amount of PGE2, which has a strong
protective effect on the GI mucosa, also decreased in a concentration-dependent manner after treatment
of LXP within the concentration range of 1.0 μM to 1.0 M [14,43]. Therefore, the risk of GI lesions
would be significantly decreased, since the initial burst release disappeared in vivo and the Cmax of
LXP was significantly decreased from 20 to 10 μM after administration of the optimal formulation.
Besides, a less fluctuant drug concentration in plasma was achieved for the optimal pellets in Figure 9.
The significant difference (p < 0.05) of AUC0–∞/dose between the test formulation and conventional
tablet might be caused by the limited GI absorption site of LXP, which would need further investigation.
The relative bioavailability of the test formulation was 87.16% compared with the reference, and it
would be improved in patients as a prolonged GI transit time has been reported in humans [44].
4. Conclusions
In conclusion, this article provided a novel concept of two-step control of the release rate of
pH-sensitive drugs. Additionally, the results of the drug in vitro release profiles proved that both
the dissolution-rate controlling step created by the sub-layer containing CA and the diffusion-rate
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controlling step developed by the ADEC coating showed significant effects on the release rate of LXP.
In addition, the amount of the acid modifier in the optimal formulation, which accounted for only
approximately 3% of the total preparation weight, was dramatically decreased compared with other
formulations containing acidic modifiers. The in vivo studies revealed that this novel two-step control
system could achieve a more stable and sustained release plasma concentration of LXP compared with
the immediate release tablet.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/6/260/s1,
Figure S1: pH solubility profiles of loxoprofen at 25 ◦C. Figure S2: Contour plots showing the effects of (A) X1 and
X2, (B) X2 and X3, and (C) X1 and X3 on the response Y1. Figure S3: Contour plots showing the effects of (A) X1
and X2, (B) X2 and X3, and (C) X1 and X3 on the response Y2.
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Abstract: In this work we report on the synthesis and characterization of magnetic nanoparticles of
two distinct origins, one inorganic (MNPs) and the other biomimetic (BMNPs), the latter based on a
process of bacterial synthesis. Each of these two kinds of particles has its own advantages when used
separately with biomedical purposes. Thus, BMNPs present an isoelectric point below neutrality
(around pH 4.4), while MNPs show a zero-zeta potential at pH 7, and appear to be excellent agents for
magnetic hyperthermia. This means that the biomimetic particles are better suited to be loaded with
drug molecules positively charged at neutral pH (notably, doxorubicin, for instance) and releasing it
at the acidic tumor environment. In turn, MNPs may provide their transport capabilities under a
magnetic field. In this study it is proposed to use a mixture of both kinds of particles at two different
concentrations, trying to get the best from each of them. We study which mixture performs better from
different points of view, like stability and magnetic hyperthermia response, while keeping suitable
drug transport capabilities. This composite system is proposed as a close to ideal drug vehicle with
added enhanced hyperthermia response.
Keywords: biomimetic magnetite; drug delivery; magnetic hyperthermia; magnetite; MamC;
nanoparticles stability
1. Introduction
In spite of the certainly wide variety of magnetic nanoparticles (MNPs) with different geometries,
compositions and functionalizations [1–8] that have become available in recent years, and of the number
of applications that have been devised for them [1,9–12], when the goal is to provide a nanocarrier
suitable for targeted chemotherapy, there is still room for progress. On one hand, the methods for
obtaining MNPs need to be more cost- and time-effective, eco-friendly, and scalable. On the other,
the nanoparticles themselves should be improved in terms of maximizing the magnetic moment per
particle and providing novel surface properties while exploring their potential as hyperthermia agents
that would allow them to combine therapies in the near future.
In this context, cancer is one of the fields of application where magnetic nanoparticles certainly
appear as most promising [12–18]. Aside of drug delivery, whereby functionalized magnetic
nanoparticles are loaded with the chosen drug and some targeting molecule, such an antibody,
driven to the site of action, maintained there by continuous magnetic fields and eventually set
for delivery by some external action, magnetic hyperthermia appears as a realistic application of
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 273; doi:10.3390/pharmaceutics11060273
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MNPs [19–27]. For that purpose, MNPs are dispersed at a suitable concentration in an aqueous
solution and located in the target place for action. There, they are subjected to an alternating magnetic
field (with induction of tens mT and frequency of several hundred kHz). Subsequently, the magnetic
nanoparticles increase the temperature of the microenvironment in which they are immersed inducing
apoptosis of the tumor cells, usually more sensitive to temperature increase compared to healthy
cells [28–30].
MNPs are generally produced either by the co-precipitation of iron salts in basic aqueous
media possibly stabilized by biocompatible surfactants/polymers or by the thermal decomposition
of organometallic precursors in high-boiling nonpolar organic solvents at elevated temperatures
(200–360 ◦C), allowing a great control of the size of the MNPs, their monodispersity and uniformity [31].
However, these methods have some drawbacks mainly derived from the high temperatures used,
organic solvents or poor solubility of the nanoparticles in water.
Many of these drawbacks are overcome in biomimetic MNPs (BMNPs). These are produced by
the mediation of magnetosome membrane-associated proteins (MAPs) from magnetotactic bacteria,
and in vitro experiments have been demonstrated to control the size (and thus the magnetic moment
per particle), shape, and surface properties of the nanoparticles [32,33]. BMNPs production can
be scaled up in vitro in eco-friendly, cost-effective magnetite precipitation experiments run at room
temperature and 1 atm total pressure by the simple addition of the recombinant protein. Promising
BMNPs have been obtained by the mediation of MamC protein from Magnetococcus marinus MC-1,
since these BMNPs are (i) superparamagnetic at room and body temperature while they present a
saturation magnetization of 61 emu/g (at 500 Oe and 25 ◦C); (ii) are larger than most commercial MNPs
and/or other biomimetic magnetites, although still single magnetic domain, showing higher blocking
temperature and slower magnetization increase, and thus, larger magnetic moment per particle; (iii)
contain up to 4.5 wt% of MamC, which provides functional groups allowing for functionalization;
and (iv) adopt the isoelectric point of MamC (pHiep 4.4), and are strongly negatively charged
at physiological pH (pH 7.4); this property allows the coupling and release of molecules to be
pH-dependent. Thus, at physiological pHs, they bind to positively charged molecules (such as
doxorubicin, DOXO hereafter) through electrostatic interactions, which are weaker at acidic pHs (such
as those found in tumor microenvironments), allowing the release of the adsorbed molecules, and
(v); they are fully cytocompatible and hemocompatible, but when they are coupled with DOXO they
display dose-dependent cytotoxicity [33].
Recall that single-domain magnetic nanoparticles are characterized by a spin configuration such
that in the absence of an external magnetic field, all spins are oriented parallel to each other and parallel
or antiparallel to a crystallographic direction, called the easy (or anisotropy) axis [34–36], so that each
particle is characterized by a large magnetic moment. Let us imagine for the moment that the particles
are immobile, fixed in a non-magnetic matrix, with their easy axes oriented randomly. At very low
temperature (or at very high frequencies of the external magnetic field, if this is non-stationary), the
transition between the two orientations along the easy axes can only be achieved by the application of
sufficiently large external magnetic field, so that the magnetization-H curve will take the form of a
square hysteresis cycle, according to the Stoner-Wohlfarth model [35,37]. As temperature rises above
0 K, the transition between the two orientations can be thermally activated, and the coercivity tends
to be reduced, eventually making hysteresis negligible. The same effect will be observed when the
field frequency or the particle size is very low, since the coercive field HC is related to the anisotropy
field Hk (in turn related to Keff, the effective magnetic anisotropy constant of the particles, and their
saturation magnetization MS as Hk = 2 Keff /μ0MS) by [35]:
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where kBT is the thermal energy, V is the particle volume (or, in the case of coated particles, the volume
of the magnetizable core), μ0 is the vacuum magnetic permeability, H0 is the field amplitude, f is the
field frequency, and the characteristic time τ0 depends on such quantities as temperature, saturation
magnetization or anisotropy constant. It will be assumed to be a constant in the range of 10−10–10−9 s.
If it is admitted that it suffices with HC being 0.01–0.1Hk to have reversible cycles and absence of
hysteresis, then the combination of H0, f, V, and MS must be such that κ = 0.97–0.75.
An approximate approach to the general solution of the problem, not using models based on
the Stoner-Wohlfarth one is the so-called linear-response theory, where, keeping the assumption of
immobile particles, it is found that the hysteresis cycle has its origin in the Néel-Brown relaxation,
characterized by a relaxation time τN, which is a measure of the time taken by the system to return
to equilibrium after application of a step magnetic field, or half the time needed for spontaneous
inversion of magnetic moment orientation [38–40]. It is given by:






This brings about a delay between magnetization and field, or an imaginary component of the
magnetic susceptibility, and manifests again in a finite area hysteresis cycle, as long as the frequency of
the field remains in the vicinity of 1/τN. This approach is only strictly valid for low applied magnetic
field strength or highly anisotropic particles.
For hyperthermia applications, the particles are typically dispersed in an aqueous solution, and
hence they can rotate under field inversions so that viscous friction is an additional source of phase
delay between magnetization and external field, and hence, an additional relaxation contribution to





where η is the viscosity of the medium, and VH its hydrodynamic volume (including, if any, that of the
coating layer) [19,41,42]. Taking the value of Keff equal to 25 kJ/m3 for magnetite, the Brownian relaxation
times for biomimetic (~35 nm in diameter, reported below) and purely inorganic particles (~28 nm) are,
respectively, 14.4 μs, and 7.4 μs, and orders of magnitude higher in the case of magnetization reversal.
This means that for the particle sizes and frequencies involved, the magnetic moment is frozen in the
particle and the only heating source is friction, according to the linear response model. Considerations
on the validity of the relaxation approach just described can be found in References [43–46]. In the
context of the linear response theory, if the alternating magnetic field has a frequency in the vicinity
of the reciprocal of the mentioned times (f in the order of 70 kHz and 135 kHz, respectively), the
imaginary component, χ”, of the complex magnetic susceptibility is maximum, and this is important,





Another important aspect, not always considered, regards the stability of the particles in the
suspension, compromised not only by the colloidal interactions but also by the magnetic dipolar
ones. Hence the need for properly controlling the stability, as the hyperthermia response degrades for
aggregated systems [22,47] or when the monodomain range is surpassed [36,48].
Experimentally, the quantity of interest is the so-called Specific Absorption Rate (SAR), or heat
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C being the volume heat capacity of the suspension, Vs its volume and dT/dt the rate of temperature
increase [28,39]. Typical SAR values are in the order of tens to hundreds of W/g. In order to perform a
comparison between different materials without the interference of the details of the specific device
used (very often lab-made), a quantity is defined as a measure of the magnetothermal performance of





with typical values in the order of 10−9 Hm2kg−1.
In this work, we explore the possibility of maximizing the hyperthermia effect (the rate of
temperature rise, in fact) by combining the two types of magnetic particles (BMNPs and MNPs),
differing in size and other properties. The goal of the present study is to provide a composition that
could be used in the future as a platform for combining drug delivery and hyperthermia. The former
particles, BMNPs, mediated by MamC have been chosen because of their demonstrated ability to
function as nano-transporters of drugs, being the nanoassembly stable at physiological pH while it
destabilizes releasing the drug under acidic pH values, which naturally occur in the tumor environment.
The second ones, MNPs, have been chosen because of their potential as hyperthermia agents [33]. By
mixing the two systems, we expect to deliver a system that, in the future may prove useful to combine
both treatments, i.e targeted chemotherapy plus targeted hyperthermia by using the same platform.
To the best of our knowledge, the hyperthermia of mixed systems has never been investigated, but
advantages are foreseen regarding the possibility of optimizing the response.
2. Experimental
2.1. BMNPs and MNPs Production
Details of the production process are given in Reference [32], and just a short account will be
provided here. The MamC gene (ABK44766.1, NCBI Database) was first amplified by the polymerase
chain reaction and cloned into pTrcHis-TOPO vector, and expressed in Escherichia coli TOP10 competent
cells, both from Life Technologies, Invitrogen, Grand Island, NY, USA. The cells were grown at 37 ◦C
in Luria-Bertani (LB) broth supplemented with 100 mg/mL of ampiciline. After 5-h contact with
isopropyl-β-d-thiogalactopyranoside (IPTG, Fisher BioReagents, Pittsburgh, PA, USA) the expression
of the recombinant MamC was induced. The cell pellet was resuspended in guanidinium lysis buffer
overnight. The lysate was centrifuged, and the supernatant loaded onto a HiTrap chelating HP column
(GE Healthcare, Chicago, IL, USA) equilibrated with Denaturing Binding Buffer (A). The protein eluate
was obtained with Denaturing Elution Buffer (B), and the final step was isolating the MamC protein by
successive dialyzations with buffers A and B. The isolated protein was stored at 4 ◦C until used in the
biomineralization process (all buffers were purchased from Sigma Aldrich, St. Louis, MO, USA).
The following step was the production of the MNPs and BMNPs (all reagents needed in this process
were purchased from Sigma-Aldrich, Madrid, Spain). Milli-Q water (Millipore, Barcelona, Spain) was
first deoxygenated by boiling it for 1 h and then cooling in an ice bath while bubbling nitrogen. The
water was immediately stored inside an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI,
USA) with a 4% H2 in N2 atmosphere. The following solutions were prepared inside the chamber:
NaHCO3/Na2CO3 (0.15 M/0.15 M), FeCl3 (1 M), Fe(ClO4)2 (0.5 M), and NaOH (5 M). The precipitation of
inorganic magnetite (MNPs) was carried out as described in Reference [49], and consisted in mixing the
prepared solutions to the final concentrations of 3.5 mM/3.5 mM, 5.56 mM, and 2.78 mM, respectively,
at 25 ◦C and 1 atm. NaOH was added to reach a pH of 9. The biomimetic nanoparticles were obtained
by adding the purified MamC protein (at a final concentration of 10 μg/mL) to the solution used for
MNPs. In both cases, the solids were allowed to grow for 30 days, and magnetically decanted and
washed three times with deoxygenated water. The magnetic particles were kept in water inside the
Coy chamber until further use.
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2.2. Nanoparticle Characterization
The morphology and particle size of the synthesized nanocrystals were analyzed by Transmission
Electron Microscopy (TEM Philips Model CM20, Eindhoven, The Netherlands) equipped with an
energy dispersive X-ray spectrometer (EDAX). The size of the particles was measured by using ImageJ
1.47 software, and size distribution curves and ANOVA statistical analyses were determined from
measurements performed on 1000 particles. Averages were considered significantly different if p <
0.05. Powder x-ray diffraction (XRD) analysis was carried out on lyophilized samples with an Xpert
Pro X-ray diffractometer (PANalytical; Almelo, The Netherlands) using Cu Kα radiation, with the scan
range set from 20–60◦ in 2θ (0.01◦/step; 3 s per step). Electrophoretic mobility measurements were
carried out in a Zetameter Nano-ZS (Malvern Instruments, Malvern, UK) at 25 ◦C, in suspensions
with 0.01% w/v solids concentration and constant ionic strength of 5 mM KNO3. For each suspension,
5 measurement runs were taken. Magnetization cycles and zero-field cooled field-cooled (ZFC-FC)
curves were obtained in an MPMS-XL SQUID magnetometer (Quantum Design, San Diego, CA,
USA). The stability of the samples was evaluated optically by measuring the time evolution of the
phase separation line between particles and medium: The samples were photographed at certain
intervals. Afterward, the height and volume of each phase were determined through image processing
and analyzed.
Magnetic hyperthermia experiments were carried out using an AC current generator with a
double four-turn coil made of water-cooled copper tube, 4 mm in inner diameter, with 800 mL/min flow
rate, comparable to other experimental hyperthermia devices [50]. Three frequencies, namely, 197 kHz,
236 kHz, and 280 kHz were selected, with a fixed magnetic field intensity of 18 kA/m, measured at the
center of the coil with a NanoScience Laboratories Ltd. Probe (Staffordshire, UK), with 10 μT resolution.
These were the combinations accessible with our measurement system, but are close to those used by
other authors [45,46,51]. The samples to be evaluated were placed in plastic Eppendorf tubes (1.5 mL
sample volume). Four kinds of dispersed systems were evaluated, namely those based on pure MNPs
or BMNPs, and mixtures containing 25% BMNPs + 75% MNPs (here referred to as 25 B + 75 M), and
60% BMNPs + 40% MNPs (60 B + 40 M). This selection was based on using a combination with a
predominance of inorganic MNPs and another one with a higher fraction of biomimetic particles in
order to estimate the relative contribution of each type of particles.
The SAR and ILP of the dispersions were obtained by measuring the rate of temperature increase
as a function of time [19,52], with an optical fiber thermometer (Optocon AG, Dresden, Germany),
and using Equations (6) and (7). Considering the rather low concentration of MNPs, the corrections
proposed by Gas and Miaskowski [51] in the calculation of the heat capacity of the suspension did not
appear necessary. All samples for hyperthermia were prepared with a solids concentration of 25 mg/mL.
Note that this concentration is higher than usual in hyperthermia applications (more in the range
of 1–10 mg/mL), but it was chosen with the aim of magnifying differences. At such concentrations,
magnetic or colloidal interactions might likely affect hyperthermia, as increased stability seems to
favor the temperature elevation, if the frequency of the magnetic field is selected in accordance with
the size of individual, non-aggregated particles. In fact, in a previous work [22], we found that the
hyperthermia response was improved if the suspensions were more stable, although the SAR of 20 nm
magnetite suspensions was constant up to 2% (v/v) (or about 100 mg/mL) concentration.
3. Results and Discussion
3.1. Particle Characterization
Figure 1B,D show representative TEM pictures of the two kinds of particles. Size histograms are
represented in Figure 1A,C, respectively. The mean (± S.D.) diameters obtained from the histograms
were 35 ± 11 nm for BMNPs and 18 ± 6 nm for the purely inorganic nanoparticles. Insets in the pictures
also show that the shape of both kinds of particles is rather polyhedral, with better homogeneity in the
biomimetic case.
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Figure 1. Diameter histograms (A,C) and TEM pictures (B,D) of biomimetic (BMNPs) and purely
inorganic (MNPs) magnetic nanoparticles. The scale bar in B, D is 200 nm.
Figure 2 shows the XRD patterns of both samples. Note the good crystallinity in the two cases,
and the excellent coincidence with the magnetite reference pattern (JCPDS card No 19-0629), being the
main reflection for magnetite the 311 (d-spacing = 2.530 Å, for Cu Kα radiation, 2θ is 35.44 degrees).
The goethite diffraction lines are also superimposed in the figure, and only a low-angle peak seems
to correspond to this oxide. Using Scherrer’s formula [53], the crystallite size was obtained for both
samples from the half-intensity width of all the lines in the pattern, using specialized Rietveld software
(TOPAS 5.0, Bruker, Hamburg, Germany). Calculated crystallite sizes for MNPs vary between 13.0 and
18.3 nm, while those for BMNPs vary between 13.1 and 22.5 nm. Thus the calculated size from XRD
data for MNPs matches that measured from TEM images. However, this is not the case for BMNPs for
which we get smaller values than those measured with TEM. Recall that the crystallite size calculated
from XRD data is a measure of the size of coherent diffraction domains, which can be smaller than
the particle size if small discontinuities will make the domain lose such a coherency. It is true that
BMNPs could be polycrystals, but this is not what was found by High-Resolution TEM observations
of BMNPs in Reference [54]. No discontinuities in lattice fringes were observed, and therefore, the
polycrystallinity of BMNPs seems to be ruled out, at least for the majority of the BMNPs analyzed.
However, Garcia-Rubia et al. [33] suggested the incorporation of MamC in the outer layers of the
BMNPs crystals, that prevented the removal of the protein, and measured, in fact, that 5% of the total
mass of the BMNPs is MamC. The presence of the protein would, most probably, induce some defects
in the crystal structure, resulting in the loss of coherency in the diffraction. This is why, in BMNPs, the
crystal sizes calculated from XRD are lower than those measured in TEM images.
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Figure 2. The XRD diffraction patterns of purely inorganic (MNPs) and biomimetic magnetic
nanoparticles (BMNPs). The positions and intensities of crystallographically-pure magnetite are
labeled as M, and those of goethite as G.
The magnetization of the two kinds of particles and an example of one of the mixtures (25 B
+ 75 M, in fact the most stable mixture, as will be discussed below) is plotted in Figure 3 for two
temperatures, 5 K and 300 K. The detail in Figure 3 shows that some really low remnant magnetization
(about 20 emu/g at most), and coercivity can be measured at 5 K, with the interesting feature that this
is maximum for the mixed system. This can be ascribed to some degree of aggregation between the
two kinds of particles, as at the pH of the aqueous suspensions in which the mixtures were prepared
they are oppositely charged (detailed below), and electrostatic attraction cannot be ruled out. For
room temperature measurements, the magnetization shows no hysteresis, and the particles behave as
paramagnetic. This is characteristic of superparamagnetism, as mentioned. At room temperature, the
saturation (mass) magnetization reaches 66 emu/g in the case of MNPs and 25 B + 75 M, and 55 emu/g
in the case of BMNPs. Considering the dilution effect of the coating caused by the incorporation of
MamC [33], the corrected value of saturation magnetization is 61 emu/g for BMNPs, and 70 emu/g for
25 B + 75 M.
Zero-field cooling-field cooling (ZFC-FC) curves at 500 Oe (39.8 kA/m) (see Figure 4) show
that the blocking temperature (maximum in the ZFC cooling curve, the lower branch in each case,
corresponding to the rounded appearance of the curve [55]) is 103 K for MNPs, 145 K for BMNPs and
180 K for 25 B + 75 M, and that at temperatures higher than blocking temperature, (including 300
K and above in all cases), these particles will behave as non-magnetic in the absence of an external
magnetic field, confirming the superparamagnetic nature of the two kinds of particles. This prevents
magnetic aggregation, a very favorable feature of the systems investigated.
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Figure 3. Magnetization cycles of MNPs (), BMNPs (), and 25 B + 75 M () at 5 K (top), and 300 K
(bottom). Magnifications of the low-field region are also plotted.
Figure 4. Zero field cooling-field cooling (ZFC-FC) curves at 40 kA/m of MNPs (), BMNPs () and 25
B + 75 M ().
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However, once an external magnetic field is applied, the nanoparticles will respond efficiently.
From these results, it can be inferred that either the bare MNPs and BMNPs, or their mixtures, appear
as ideal candidates for the purpose of hyperthermia, drug delivery or combinations thereof.
3.2. Zeta Potential
For the purpose of drug loading and delivery, the ability of the nanoparticles to be coupled to
molecules forming stable nanoassemblies at physiological pH and to release the drug at the precise time,
as well as the stability, drug-particle or cell membrane-particle interactions, among other properties, are
strongly determined by the surface charge, or, alternatively, by the zeta potential ζ, of the particles when
dispersed. Calculations of the zeta potential were done from the measurements of the electrophoretic
mobility of the particles BMNPs and MNPs by means of O’Brien and White’s general theory [56]. As
one can see in Figure 5, the isoelectric point (pHiep or pH of zero ζ) of MNPs was obtained at pH 7.0,
while for BMNPs it was 4.4. This zeta potential plot reveals significant differences between both types
of nanoparticles. They are positively charged at low pH values and negatively charged at high pH,
but BMNPs change from positive to negative at quite a different pH: This suggests that the MamC
protein is affecting the surface of the particles, and it is probably located mainly at the interface. In
fact, the investigations by Nudelman et al. [57], and other authors [54,58] on the biomineralization
mechanism induced by this protein demonstrate that the particularity of MamC is the template effect
for magnetite nucleation and growth that this protein exerts. The two negatively charged amino acids
Asp70 and Glu66, located in MamC loop, are separated by about 8 Å, and this distance can match
the disposition of iron cations on (100), (110), and (111) faces. Therefore, the crystal could grow in
an orderly manner, first from the Fe cations available in solution and then, since the amount of Fe in
solution is limited, at the expense of the release of the Fe cations adsorbed in other negatively charged
moieties of MamC. Since the process of nucleation is kinetically favored by this template effect, it is
precisely those exposed amino acids that act as nucleation sites. Therefore, the restricted number of
nucleation sites in the presence of MamC compared to the process of homogeneous nucleation from
the bulk solution allows the formation of larger crystals in the former. Moreover, since (100), (110),
and (111) faces show up in the final morphology of the BMNPs [57], it can be concluded that, while
exerting this template effect for the nucleation, the protein prevents the growth of the crystal on these
specific directions.
Figure 5. Zeta potential of purely inorganic MNPs () and biomimetic magnetic nanoparticles
BMNPs ().
The shift of the isoelectric point of the BMNPs relative to that of MNPs make the former adequate
nanocarriers, a fact that is important for the sought application. Since most common drugs for cancer
therapy are positively charged at physiological pH, they could be electrostatically attached to BMNPs
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at such pH values, resulting in a stable nanoassembly. On the contrary, when they eventually reach the
tumor (acidic pH values), the drug releases from the BMNPs, as the charge of the latter at acidic pH
values is nearly zero [33]. That makes the BMNPs better drug nanocarriers compared to MNPs, as
in the former the release of the drug can be controlled by an external factor, as it is a change in the
environmental pH value. This feature is absent in MNPs, as their charge is positive anywhere below
pH 7.
3.3. Stability
Like in many other applications, the use of magnetic nanoparticles in health applications requires
to ensure sufficient stability. Previous results from our laboratory demonstrated that, specifically when
it comes to hyperthermia applications, the stability, either electrostatically or polymerically achieved,
is an essential factor for optimizing the performance of the system [22]. Hence, in this part of the
study, we focus on the possibility of improving hyperthermia by favoring stability. It must be recalled
that superparamagnetic nanoparticles interact attractively through van der Waals interactions and
dipolar magnetic ones (if remanence is not negligible, which is not our case at room temperature,
see Figure 3). Furthermore, the repulsive interactions due to the surface charge will be very low at
physiological pH values in the case of MNPs, and larger in the case of BMNPs (Figure 5). In addition,
steric hindrance could contribute to the stability of the biomimetic nanoparticles through the presence
of surface MamC molecules. In order to confirm this possibility, we evaluated the sedimentation
behavior vs. time of the samples (pure end members and mixtures of BMNPs and MNPs). The time
evolution of the boundary between sedimented volume (height h) and clear supernatant, relative to
the initial height h0, will be used as a simple test of stability. Data are plotted in Figure 6. Surprisingly,
it can be observed that, although the stability of bare MNPs is lower than that of BMNPs, as expected
from the steric and electrostatic repulsions due to the MamC coating, adding BMNPs to the former
at a relative concentration of 25/75 (25 B + 75 M) brings about a measurable increase of stability.
This may be the result of a compromise between the smaller size of MNPs favoring stability and the
addition of the protective coating represented by the BMNPs. As a result, an ideal system with a mixed
composition emerges.
Figure 6. Height of the sedimented volume relative to its initial value as a function of time for MNPs
(), BMNPs (), 60 B + 40 M (), and 25 B + 75 M (). Inset: Short-time detail.
3.4. Performance in Hyperthermia
As a novel field of application of the two kinds of particles and their mixtures, we consider to
what extent they are efficient magnetic hyperthermia agents. Figure 7 shows the time evolution of the
temperature of the suspensions of MNPs, BMNPs and the two mixtures 25 B + 75 M and 60 B + 40 M
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under the influence of an alternating magnetic field at the indicated frequencies and a fixed magnetic
field strength of 18 kA/m. All types of nanoparticles are able to raise the temperature, the fastest
rise occurring for the highest frequency. This effect is particularly visible at longer times. The rate
of temperature increase is maximum (~34 ◦C/min) in mixture 25 B + 75 M and minimum in BMNPs
(~17 ◦C/min) at the highest frequency. It appears that inorganic MNPs are better hyperthermia agents
than BMNPs. This justifies their presence in the mixtures under study. They make it possible to design
a composition of nanoparticles that (i) can be guided to the target by the application of an external
magnetic field; (ii) behave as suitable drug nanocarriers, stable at physiological pH values and from
which the drug release is dependent of an external stimuli, e.g., acidic tumor environment (these are
the BMNPs); (iii) produce a fast increase of the temperature of the system upon the application of an
external magnetic field (these are the MNPs).
Figure 7. Time evolution of the temperature of the MNP suspensions, for different frequencies: 197
kHz (), 236 kHz (), and 280 kHz (). Field strength: H0 = 18 kA/m. Sample volume 0.5 mL; particle
concentration: 25 mg/mL.
In fact, maximum SAR (up to 96.2 W/g) and ILP (1.26 nHm2kg−1) values were obtained for the 25
B + 75 M sample, followed by MNPs, 60 B + 40 M and, finally, BMNPs (Figure 8, Table 1). The lower
heating induced by BMNPs is probably related to the larger size of the particles and to the presence
of MamC attached to their surface, which probably hinders the rotation of the nanoparticles. The
increased SAR and ILP values obtained for the 25 B + 75 M samples is promoted by stability, as single
particles with close-to-spherical symmetry rotate under the action of the field less impeded than in the
case of aggregated particles. In addition, it is likely that the field frequencies used are closer to those of
maximum phase lag between magnetization and field, for the MNPs than for the BMNPs, so the latter
would play here the role of favoring stability.
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(a) (b) 
Figure 8. Frequency dependence of (a) SAR and (b) ILP, for the investigated systems. MNPs (), BMNPs
(), 60 B + 40 M (), and 25 B + 75 M (). Magnetic field strength: 18 kA/m; particle concentration:
25 mg/mL.
Table 1. Summary of Specific Absorption Rate (SAR), Intrinsic Loss Power (ILP) calculations, and
temperature increase after 60 s exposition time, ΔT, for the different samples tested [inorganic Magnetic
Nanoparticles (MNPs) and MamC-medianted Biomimetic Magnetic Nanoparticles (BMNPs)], and the
field frequencies indicated.
System Frequency f [kHz] SAR [W/g] ILP [nHm2kg−1] ΔT [◦C]
MNPs
197 64 ± 5 1.01 ± 0.07 20.2 ± 0.2
230 80 ± 5 1.04 ± 0.06 25.2 ± 0.2
280 87 ± 6 0.96 ± 0.06 28.3 ± 0.2
BMNPs
197 32 ± 3 0.50 ± 0.04 11.6 ± 0.2
230 36 ± 3 0.47 ± 0.04 12.9 ± 0.2
280 47 ± 3 0.52 ± 0.03 16.7 ± 0.2
25 B + 75 M
197 73 ± 3 1.15 ± 0.05 28.5 ± 0.2
230 83 ± 3 1.08 ± 0.04 30.5 ± 0.2
280 96 ± 2 1.26 ± 0.03 34.1 ± 0.2
60 B + 40 M
197 57 ± 4 0.90 ± 0.06 18.1 ± 0.2
230 62 ± 6 0.81 ± 0.07 21.6 ± 0.2
280 75 ± 8 0.82 ± 0.09 27.5 ± 0.2
4. Conclusions
The present study intended to find an appropriate combination of magnetic nanoparticles that
provide suitable targeted hyperthermia, and potentially proper conditions for being loaded with
a positively-charged drug at a neutral pH while releasing it at the acid tumor environment. Both
inorganic (MNPs) and biomimetic (MamC-mediated, BMNPs) nanoparticles have been proven to
be superparamagnetic, having a blocking temperature lower than 300 K, therefore behaving as
paramagnetic at this temperature (thus preventing magnetic agglomeration) but exhibiting a relatively
high saturation magnetization in the presence of an external magnetic field, being thus able to be
magnetically guided to a selected target site. BMNPs have been found to bind different molecules based
on electrostatic interactions, forming stable nano-assemblies at physiological pH, based on the change
in the isoelectric point (iep) of the nanoparticles induced by MamC (iep = 4.4). In contrast, MNPs are
not as good candidates for that purpose, since their pHiep is around 7. The adsorption of a positively
charged drug as doxorubicin on BMNPs would be favored at neutral pH, and at the same time its release
would also be enhanced as the system acidifies (like in tumor microenvironments) approaching the iep
of the BMNPs. However, while potentially good nanotransporters, BMNPs are not as good agents for
hyperthermia as MNPs. Therefore, the present study offers a composition of nanoparticles, namely,
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25% BMNPs + 75% MNPs that, while having the maximum hyperthermia response, likely related to
improved stability of the sample, is also suitable as a drug nanocarrier designed to deliver the drug in
response to changes in the environmental pH. Therefore, the combination of inorganic and biomimetic
nanoparticles potentially allows combined targeted chemotherapy and targeted hyperthermia.
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Abstract: In the present study, the antitumoral potential of three gel formulations loaded with carbon
dots prepared from N-hydroxyphthalimide (CD-NHF) was examined and the influence of the gels
on two types of skin melanoma cell lines and two types of breast cancer cell lines in 2D (cultured
cells in normal plastic plates) and 3D (Matrigel) models was investigated. Antitumoral gels based on
sodium alginate (AS), carboxymethyl cellulose (CMC), and the carbomer Ultrez 10 (CARB) loaded
with CD-NHF were developed according to an adapted method reported by Hellerbach. Viscoelastic
properties of CD-NHF-loaded gels were analyzed by rheological analysis. Also, for both CD-NHF
and CD-NHF-loaded gels, the fluorescence properties were analyzed. Cell proliferation, apoptosis,
and mitochondrial activity were analyzed according to basic methods used to evaluate modulatory
activities of putative anticancer agents, which include reference cancer cell line culture assays in both
classic 2D and 3D cultures. Using the rheological measurements, the mechanical properties of gel
formulations were analyzed; all samples presented gel-like rheological characteristics. The presence
of CD-NHF within the gels induces a slight decrease of the dynamic moduli, indicating a flexible gel
structure. The fluorescence investigations showed that for the gel-loaded CD-NHF, the most intense
emission peak was located at 370 nm (upon excitation at 330 nm). 3D cell cultures displayed visibly
larger structure of tumor cells with less active phenotype appearance. The in vitro results for tested
CD-NHF-loaded gel formulations revealed that the new composites are able to affect the number,
size, and cellular organization of spheroids and impact individual tumor cell ability to proliferate and
aggregate in spheroids.
Keywords: composite; N-hydroxyphthalimide; carbon dots; polymer gels; antitumoral activity
1. Introduction
Statistically, it has been reported that approximately 8 million people die from different types of
cancer each year in the world; including breast, lung, liver, skin, and brain cancers, etc. So far, the main
therapeutic methods for cancer treatment remain surgery and chemotherapy; however, researchers
have made enormous efforts in the last years to develop new compounds that are better tolerated
by patients during cancer therapy. In order to attack cancer cells and to reduce the same effect in
the healthy cells, new treatments methods have been investigated. Among them, transdermal drug
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 303; doi:10.3390/pharmaceutics11070303
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delivery systems appear as a promising alternative strategy to carry antineoplastic agents due to certain
several advantages such as increased drug solubility, better bioavailability, high stability, controlled
drug release, prolonged half-life, selective organ or tissue distribution, and reduction of the total
required dose [1]. Enhanced topical delivery of the active principle to the target site, including those
for cancer therapy, can be achieved by noninvasive drug delivery systems which can ensure sustained
therapy with a single application, thus avoiding first-pass hepatic metabolism, gastric degradation,
or frequent dosing and also the inconvenience of parenterals [2].
Carbon dots (CD) are a new star of the carbon nanomaterials family; their unique properties
mean they are attractive materials for a wide range of applications such as bioimaging, biosensing,
drug delivery, optoelectronics, photovoltaics, and photocatalysis [3,4]. Therefore, more and more
researchers are paying significant interest to the synthesis, properties, and applications of these
carbon nanostructured materials. However, the investigations toward drug delivery for biomedical
applications are still at their beginning [5], along with their putative antitumoral properties. Precursors
used to synthesize carbon dots determine their properties, creating a new opportunity for finding
new anticancer molecules for certain types of cancer (personalized cancer therapy) [6]. Gels based
on natural and/or synthetic polymers represent a good pathway for biomedical applications, due
to their hydrophilic properties and their biocompatibility. Physical gels are usually prepared by
mixing a polymer and a solvent, with or without thermal treatment, resulting a homogeneous
material with remarkable mechanical properties related to the aggregation process of the polymer
chains [7]. So far, different types of natural or synthetic polymers have been used to prepare
polymer–drug conjugates, produced mainly by physical entrapment of the biologically active principle
into macromolecular hydrogels, micro/nanoparticles, or liposomes in therapeutic approaches for the
treatment of various cancers.
Polysaccharides are renewable resources found in all living organisms, which have been widely
used in different important fields such as the biomedical, pharmaceutical, and food industries and
tenvironmental remediation. Their unique properties, such as biocompatibility, biodegradability,
nontoxicity, hydrophilicity, stability, and structural variability, allow a high capacity for carrying
biological information, making them suitable as a promising natural biomaterial [8]. In recent years,
the scientific community has used polysaccharides in a broad range of biomedical applications, such as
drug delivery systems for the treatment of inflammation, cell–cell recognition, immune responses,
metastasis (tumor cells are spreading from primary tumor to secondary organs e.g., from breast to
lungs), and in tissue engineering in scaffolds and wound dressings [9]. Sodium alginate (AS) is
a natural polysaccharide, extracted from brown seaweed, used in various biomedical applications
such as drug delivery, tissue engineering, and wound healing, due to the attractive properties such
as biocompatibility, low toxicity, ease of manipulation, and mild gelation [10]. Another attractive
polysaccharide is carboxymethylcellulose (CMC) in its sodium salt form. CMC is the major cellulose
ether, also known as cellulose gum, formed from carboxymethyl ether groups. CMC’s valuable
properties, such as its hydrophilic nature, capacity to form gels at high concentration, and thixotropy,
make it suitable for biomedical applications such as drug delivery and tissue engineering [11]. From the
synthetic polymers category, carbomers (CARB) are a high-molecular-weight crosslinked polymer of
acrylic acid, which are playing an important role in many commercial products such as gels, creams,
and lotions, providing viscosity, stabilization, and suspension properties [12].
In this article, we focus on the embedding of N-hydroxyphthalimide carbon dots (CD-NHF) in
different continuous matrices formed of natural (alginate or carboxymethyl cellulose) or synthetic
(CARB) polymers. Due to the recently proven antitumoral activity of NHF [13], CD-NHF were
developed and the composite was proven also to induce breast cancer cell apoptosis at doses that
only marginally affect normal cell counterparts. The reason for embedding CD-NHF is on one hand,
to reduce the aggregation tendency of CD which can affect the treatment efficacy, and on the other
hand, to be protected by a polymer environment against chemical modification, which can also
affect their properties. The fluorescence analysis demonstrates the CD-NHF presence within the gel.
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Appropriate gel properties were investigated from a rheological point of view considering different
polymer concentrations; the optimum formulation has been used as the matrix for CD-NHF and further
biological investigations.
Cancer is a disease that causes cells to change and grow in an uncontrolled manner. Many—if not
all—of the tumor aggressivity behaviors are caused by key molecular defects in multiple biochemical
pathways controlling cell survival, proliferation, differentiation, and integration in histological tisular
structures and immune interactions. Apoptosis is a cell suicide program that plays an important
role in tissue homeostasis by eliminating unnecessary cells [14,15]. The deregulation of the apoptotic
pathway results in variety of diseases and has been shown to be involved in cancer cell resistance
to conventional anticancer therapy [16]. There are two critical pathways of apoptosis—the extrinsic
pathway (death receptor-mediated pathway) and the intrinsic pathway (mitochondria-mediated
pathway)—and caspases are fundamental players in both pathways [17]. Mitochondria are vital
organelles for energy production and intracellular Ca2+ homeostasis and they are involved in a variety
of cellular processes, including differentiation, proliferation, and apoptosis. It has been shown that
abnormal mitochondrial dynamics have an important role in tumorigenesis. Also, the increased
anaerobic glycolysis activity in neoplastic cells was the result of a dysfunction of the mitochondrial
activity [18].
We consider that CD-NHF incorporation in gels could be a convenient way to manipulate its
local availability (and effects) and its persistence. While the actual mechanism of action is still
incompletely understood for many emerging nanoformulations, interactions with extracellular matrix
components are plausible objectives in many drug designs. The incorporation of CD-NHF in both
gel varieties utilized in our assay was thought to be promising for possible targeted applications in
certain malignancies (perhaps including basocellular and spinocellular skin carcinomas). The effect of
gels with CD-NHF in 4T1 (mouse mammary breast cancer), MDA-MB-231 (human mammary breast
cancer), HDMVECn (primary dermal microvascular endothelial cells), Balb/c-5064 (mouse dermal
microvascular endothelial cells), A375 (human malignant melanoma), and B16F10 (mouse malignant
melanoma) cells in 2D (cultured cells in normal plastic plates) and 3D (Matrigel) models was evaluated
by assessing cell viability, mitochondrial activity, and apoptosis.
2. Materials and Methods
2.1. Materials
The following materials were used for the experiments: the carbomer Ultrez 10 was provided
by Antibiotice SA Iasi (Iasi, Romania); N-hydroxyphthalimide, medium-viscosity sodium alginate
(extracted from Macrocytis pyrifera), and glycerin (99.9%) were purchased from Sigma-Aldrich
(St. Louis, MO, USA); medium-viscosity carboxymethyl cellulose from Fluka (Buchs, Switzerland);
and reagent-grade ethanol (EtOH) and Milli-Q ultrapure distilled water from Merck Chemicals
(Darmstadt, Germany). The chemical reagents used in this study were of analytical-grade purity
and were used without further purification. MDA-MB-231 cells were purchased from the American
Type Culture Collection, Rockville (ATCC), VA, USA; 4T1 cells were from the American Type Culture
Collection, Rockville, MD, USA; bovine serum was purchased from Sigma-Aldrich; HDMVECn
(primary dermal microvascular endothelial cells) were from ATCC; Balb/c-5064 (mouse dermal
microvascular endothelial cells) were from Cell Biologics (Chicago, IL, USA); and Matrigel Matrix
from BD Biosciences (356234), Bedford, MA, USA. For biological tests, the Live and Dead Cell Assay
(Abcam ab115347), CellTiter-Blue® Cell Viability Assay (Promega, (Madison, WI, USA), MitoTracker™
Red (Molecular Probe, Eugene, OR, USA), Matrigel (Corning, Bedford, MA, USA ), and Caspase-3/7
Assay (Promega, Madison, WI, USA ) were used according to the manufacturer’s recommendations.
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2.2. Methods
2.2.1. Preparation of Gel Formulations Based on CARB, AS, and CMC
Antitumoral gels based on CARB, AS, and CMC, respectively, and loaded with CD-NHF were
prepared according to the method reported by Hellerbach et al. [19] with slight modification. CD-NHF
were prepared according to a protocol reported by Stan et al. [4]. Prior to gel embedment, the carbon dots
were prepared through pyrolytic processing of an NHF precursor using an experimental setup presented
in Figure S1. Briefly, in a typical synthesis procedure, 0.1 g of NHF is thermally processed in carefully
controlled conditions (temperature of the main sequence of the pyrolytic process is 253 ◦C within 30 min),
leading to a typical configuration of the carbon dots consisting of a carbonaceous core with a surface
highly decorated by various functional groups. The slightly different processing parameters compared
with the previously reported preparation path are due to the different experimental setup, which in
this work, was reconfigured and extended in order to increase both the reproducibility of the carbon
dots’ preparation path and the resultant per batch quantities. The resultant reaction mass is primarily
dispersed in high-purity water kept cooled at 4–5 ◦C. In the next stages, the suspension is centrifuged
at 10,000 rpm for 15 min and the supernatant is collected and freeze-dried, with a fine powder of carbon
dots being obtained. A series of gel formulations were prepared by mixing different quantities of
CARB, AS, or CMC (Table 1) in a solution mixture consisting of 10 mL distilled water and 3 mL ethanol
in glass vessels at room temperature. In order to achieve a uniform gel formulation, a T 18 digital
ULTRA-TURRAX disperser by IKA was used (10 min, 10,000 rpm). The gelling agent’s concentration
ranged from 3.8 to 5.8% (Table 1). In order to prepare the gel formulations containing CD-NHF (CARB-F4,
AS-F6, or CMC-F6, respectively), the CD-NHF (3.84 mg/mL) was added into the water–ethanol solution
and dispersed by sonication for 1 min at room temperature using a sonication bath (Bandelin Sonorex,
Berlin, Germany), followed by adding CARB, AS, or CMC. The obtained gel formulations and CD-NHF
gel (Figure S3) were stored at 4◦ C in a refrigerator. The basic molecular formulas for the polymers
and CD-NHF used in order to obtain the gel formulations with and without CD-NHF are: sodium
alginate (AS)—(C6H8O6)n, carboxymethyl cellulose (CMC)—[C6H7O2(OH)2OCH2COONa]n, Ultrez
10 carbomer (CARB)—(C3H4O2)n, and N-hydroxyphthalimide (NHF)—C8H5NO3.
Table 1. Polymeric composition of various CARB, AS, and CMC gel formulations. CARB: carbomer
Ultrez 10; AS: sodium alginate; CMC: carboxymethyl cellulose; GLY: glycerin.
Sample
Code







CARB-F1 3.8 - - -
10 3
-
CARB-F2 4.6 - - - -
CARB-F3 5.8 - - - -
CARB-F4 4.6 - - - 0.050
AS-F1 4.6 4.6 - - -
AS-F2 4.6 4.6 - 9.2 -
AS-F3 3.5 4.6 - 8.1 -
AS-F4 2.3 4.6 - 6.9 -
AS-F5 1.2 4.6 - 5.8 -
AS-F6 4.6 4.6 - 5.8 0.050
CMC-F1 2.9 - 2.9 - -
CMC-F2 2.9 - 2.9 5.8 -
CMC-F3 3.6 - 2.9 6.5 -
CMC-F4 4.3 - 2.9 7.2 -
CMC-F5 5.8 - 2.9 8.7 -
CMC-F6 3.6 - 2.9 6.5 0.050
2.2.2. Characterization of the Prepared NHF Carbon Dots
The morpho-structural characteristics of the prepared NHF carbon dots were essentially similar to
those previously reported [4]. In brief, the XPS survey and high-resolution O1s, N1s, and C1s spectra
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revealed the presence of the defect-rich graphitic core highly decorated with various terminal functional
groups, while the recorded FT-IR spectra revealed the modifications/reconfigurations occurring through
thermal processing of the NHF precursor and confirmed by XPS results which were revealing the
presence of various functional groups attached to the graphitic core, which are essentially responsible
for both optical and antitumoral properties of this type of carbon dots. In Figure S2 are presented the
recorded spectra of the NHF precursor and resultant carbon dots, and several specific vibrations of
various groups are detailed. Interesting details regarding the morphology of the prepared carbon
dots were highlighted by the HR-TEM investigation. Figure 1 presents the recorded micrographs of
two samples obtained by depositing a highly diluted chloroform-dispersed carbon dot solution on
300-mesh carbon-plated copper grids. Both images suggest a cluster organization of smaller entities,
which presumably are individual carbon dots. While their aspect could suggest individual carbon
dots, it is also possible to be attributed to even smaller clusters, as can be seen in Figure 1b.
  
Figure 1. Recorded HR-TEM images of the carbon dots prepared from N-hydroxyphthalimide
(CD-NHF): (a) CD-NHF with an average size of the clusters in 100–300 nm range and (b) CD-NHF
with an average size of the smaller entities in 2–4 nm range
2.2.3. Rheological Studies
Viscoelastic properties of all gel formulations were evaluated in triplicate by using an Anton
Paar Physica MCR 501 (Graz, Austria) rheometer. The modular rheometer is equipped with an
electronically commutated synchronous motor (ECMotor, Graz, Austria), allowing rheological
testing in controlled stress (CS) and controlled strain (CR) modes. Also, the instrument allows
the individual creation of complex real-time tests containing a large number of different intervals
under CS or CR control, both in rotational and oscillatory modes. The rheometer is provided with an
H-PTD200 system for the temperature control. A parallel-plate geometry specially designed for gels
(with serrated plates to avoid slippage) with a diameter of 50 mm was chosen as the measuring system.
The freshly prepared, well-homogenized gel formulations were introduced into the measuring cell
and analyzed. The rheometer has an intelligent configuration system for automatic identification and
configuration—“Tool Master”—which performs automatic transfer of the parameters of the measuring
system (constructive characteristics, operating constants, geometry) and temperature control to the
Rheoplus program. The chip integrated into the geometry contains all data connected to that and
transfers them automatically to the program.
2.2.4. Fluorescence Analysis
The fluorescence analysis of CD-NHF and CD-NHF-loaded gel formulations were recorded on a
Horiba Fluoromax 4P (Fluor Essence Version 35.1.20) provided with the Quanta-ϕ integration sphere.
Also, a visual testing of photoluminescence properties was performed using a Philips UVA TL4WBLB
lamp (München, Germany) with the emission maximum located in the 370–390 nm range and a 50 mW,
440 nm laser diode.
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2.2.5. Cell Culture
MDA-MB-231 cells were cultured in F-12K medium supplemented with 100 U/mL of penicillin and
100 μg/mL of streptomycin and 5% bovine serum; 4T1 cells were cultured in RPMI-1640 supplemented
with 100 U/mL of penicillin and 100μg/mL of streptomycin and 10% bovine serum; HDMVECn (primary
dermal microvascular endothelial cells) and Balb/c-5064 (mouse dermal microvascular endothelial
cells) were cultured in Vascular Cell Basal Medium supplemented with Microvascular Endothelial
Cell Growth Kit-BBE ATCC® PCS-110-040; A375 (human malignant melanoma) and B16F10 (mouse
malignant melanoma) were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with
100 U/mL of penicillin and 100 μg/mL of streptomycin and 10% bovine serum.
2.2.6. Cell Proliferation and Apoptosis Activity
For cell viability estimation, we used the CellTiter-Blue® Cell Viability Assay (Promega). Cells
were seeded into a 96-well flat-bottomed tissue culture plate at a density of 2000 cells/well and allowed
to adhere to the plate by incubating at 37 ◦C under 5% CO2 overnight. Following cell attachment,
the cells were incubated with the tested CD-NHF at 5% concentrations (50 μg/mL) for 72 h. For all
in vitro experiments, we used the 5% CD-NHF concentration, based on our preliminary results. Control
cells were treated with phosphate-buffered saline (PBS), which was equivalent to the amount of PBS
used as vehicle. After each of the 72 h treatment time periods, 50 μL of cell viability solution was added
to each well and the plate was reincubated for 4 h before fluorescence recording using a multiplate
microplate reader (FilterMax F5, Sunnyvale, CA, USA). Apoptosis was assessed using the Caspase-3/7
Assay (Promega) according to the manufacturer’s indications.
2.2.7. Mitochondrial Activity
For mitochondrial assay, MitoTracker™ Red (Molecular Probe, Eugene, OR, USA) cells were
incubated for 72 h with CD-NHF and then subjected to 1 μg/mL MitoTracker and incubated for
30 min before the fluorescence of the resultant solutions was determined at 590 nm using a multiplate
microplate reader.
2.2.8. 3D Matrigel Assays
The 3D Matrigel assays were conducted with 1000 cells seeded in Ibidi plates between 2 layers
of Matrigel (BD Matrigel Matrix, Growth Factor Reduced (BD Biosciences)) and cultured for 14 days
before microscopy analysis (TissueGnostic rig, Vienna, Austria, Europe). Twelve hours post-seeding,
3D embedded cells began to be treated with gels (CARB-F2, CMC-F3, AS-F5) alone and with gels
containing 5% (50 μg/mL) CD-NHF (CARB-F4, CMC-F6, AS-F6) for 72 h. After 72 h, the treatments
were removed and replaced with normal 3D Matrigel medium (medium corresponding to every cell
type supplemented with 2% fetal bovine serum (FBS) and 1% Matrigel). The Live and Dead Cell
Assay (Abcam) was used according to the manufacturer’s instructions. Nuclei were counterstained
with NucBlue Live Ready Probes Reagent (Thermo Fisher Scientific, Eugene, OR, USA). Fluorescence
pictures were acquired at 20×magnification using a Zeiss Axio Observer Z1 Fluorescence Microscope
from TissueGnostics rig. Single focal plane images were acquired using Tissue FAXS 4.2 software.
The TissueQuest 6.0 software was used for total area segmentation analysis and to quantify the area
and sum intensity of fluorescence signal for each spheroid (Figures S4 and S5).
2.2.9. Statistical Analysis
GraphPad Prism was used for statistical analysis using tests stated in the figure legends. Grouped
analyses were performed by t-test. Significance was established when p < 0.05.
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3. Results and Discussion
3.1. Preparation of Gel Formulations
Previous studies concerning the preparation of physical gels based on natural or synthetic
polymers, namely carbomers, sodium alginate, and carboxymethyl cellulose, have pointed out that
these materials are nontoxic and nonhazardous and easily synthesized. We aimed to prepare different
topical CD-NHF-loaded gel formulations based on polymers with antitumoral activity. Herein, physical
gel formulations based on CARB, AS, and CMC were synthesized according to a slightly modified
version of the method reported by Hellerbach et al. [19]. This method offers some advantages compared
with other methods reported, such as being simple, rapid, and consistent; performed in the absence of
crosslinkers (hence, we eliminated the possibility of toxic chemical contamination commonly associated
with methods which use covalent crosslinkers); and the product is a homogeneous soft material formed
at room temperature.
Different concentrations of CARB, AS, or CMC were tailored and their effects were observed.
First, simple gels were prepared and analyzed before loading with CD-NHF. The gel formulations
with or without CD-NHF obtained were stable, odorless, transparent, and highly viscous. Of them,
the best formulations presenting a suitable consistency and the best viscoelastic properties, respectively,
were considered for further study and loading with CD-NHF, namely samples CARB-F2, AS-F5,
and CMC-F3. The carbon-dot-loaded gel samples were denoted as CARB-F4, AS-F6, and CMC-F6.
3.2. Rheology Studies
The viscoelastic nature of polymer gels plays an important role in their adhesion properties;
a very important characteristic considering different biomedical applications. Gels based on
natural or synthetic polymers exhibit an excellent adhesion property due to both the elastic and
viscoelastic properties.
Using the rheological measurements, the mechanical properties of the best formulations were
analyzed. All analyzed samples presented rheological characteristics of a gel. The obtained results
showed that viscosity was directly dependent on the polymeric content of the formulations. During
the rheological measurements, both dynamic moduli were constant. As can be observed from Figure 2,
the storage modulus (G’) exhibited higher values than the loss modulus (G”)) over the entire strain
range of 0.01 to 100%, indicating the gel-like behavior (Figure 2). The results obtained by rheological
analysis confirmed that CARB-F2, AS-F5, and CMC-F3 samples were optimized and further considered
for loading with CD-NHF, due to the gel equilibrium modulus. The presence of CD-NHF (for samples
CARB-F4, AS-F6, and CMC-F6) in the gel structure has a significant influence over both dynamic
moduli. In the case of the AS-F6 sample, the CD-NHF addition induced a slight increase of the dynamic
moduli, indicating stiffness of the gel structure, whereas in CARB-F4 and CMC-F6 gels, the effect
of CD-NHF addition was exactly the opposite, leading to a slight decrease of the dynamic moduli,
indicating a flexible gel structure. Also, the amplitude sweep allows determination of the limits of
the linear viscoelastic range for the prepared gels. These values are not affected by the presence of
CD-NHF (Table 2).
Table 2. The limits of the linear viscoelastic range (γLVE) for the tested gel formulations.
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Figure 2. Amplitude sweep for simple gels (CARB-F2, AS-F5, and CMC-F3) and gels with CD-NHF
(CARB-F4, AS-F6, and CMC-F6). G’: storage modulus; G”: loss modulus.
All tested gels showed a solid-like behavior, as the storage modulus (G’) was always larger than
the loss modulus (G”). As one can observe from Figure 2, the CARB and CMC gel formulations have a
more flexible structure than the AS gel, confirmed by storage modulus (G’) values (G’CARB (620 Pa) >
G’CMC (540 Pa) > G’AS (437 Pa)). Frequency sweep tests allow observation of the elastic response of
gels. The presence of the hydrogen bonding is evidenced by the frequency dependence of the moduli
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Figure 3. Frequency sweep for simple gels (CARB-F2, AS-F5, and CMC-F3) and gels with CD-NHF
(CARB-F4, AS-F6, and CMC-F6).
3.3. Fluorescence Analysis
In order to confirm the presence of CD-NHF in the gel matrices, the formulations were further
evaluated through fluorescence analysis. Fluorescence spectra exhibit the maximum emission (λem) at
424 nm when using an excitation wavelength (λex) of 370 nm for CD-NHF (Figure 4 and Table S1).
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Also, Figure 4 illustrates the emission profile of CD-NHF-loaded gels (CARB-F4, AS-F6, and CMC-F6)
at three different excitation wavelengths ranging from 370 to 410 nm. Moreover, the recorded results
(Table S1) revealed that at 370 nm, in the case of CARB, the blue-light emission was not significantly
affected by the CARB matrix. The observed difference between CD-NHF blue-light emission and
CARB matrix was only 1.5% (Table S1). When AS and CMC were used as a matrix for the entrapment
of CD-NHF, an 11% decrease of the blue-light emission was observed, compared to the case of the
CARB matrix and CD-NHF. Herein, we can conclude that in this case, the polymer matrix clearly plays
an important role for the modification of CD-NHF optical properties.
 









         Excitation (nm)
 370 nm - CD-NHF
 370 nm - CARB-F4
 370 nm - AS-F6
 370 nm - CMC-F6
 390 nm - CD-NHF
 390 nm - CARB-F4
 390 nm - AS-F6
 390 nm - CMC-F6
 410 nm - CD-NHF
 410 nm - CARB-F4
 410 nm - AS-F6









Figure 4. Emission spectra of CD-NHF suspended in H2O: CARB-F4, AS-F6, and CMC-F6 samples.
3.4. In Vitro Studies
Analysis of the cytostatic or cytolytic or growing pattern modulatory activities may be done with
end point assays or live cell imaging techniques. 3D cultures create a better similarity between the
cultured cells and the living organism. The basic methods to evaluate modulatory activities of putative
anticancer agents include reference cancer cell line cultures assays in both classic 2D and 3D cultures.
Viability of HDMVECn cells (primary dermal microvascular endothelial cells) in 2D culture
treated with simple gel formulations (CARB-F2, AS-F5, and CMC-F3) and gel formulations containing
CD-NHF (conc. 5%; CARB-F4, AS-F6, and CMC-F6) was not affected by CARB-F4 and CMC-F6,
whereas, interestingly, AS-F6 had a significant effect (Figure 5).
 
Figure 5. Viability of normal dermal cells (Primary Dermal Endothelial Cells (PDMC)) for gel
formulations without and with CD-NHF (N = 15 wells/column from two independent experiments).
Ctr (Control).
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Proliferation activity of melanoma cell lines (2D system) was not affected the by the presence of
CARB-F2, CMC-F3, or AS-F5 formulations (Figure 6a), respectively, while cell viability was affected in
a gradual manner in cells treated with CARB-F4, CMC-F6, and AS-F6 formulations (Figure 6b,c).
Figure 6. Murine and human melanoma cell viability for gel formulations without (a) and with
(b,c) CD-NHF (conc. 5%). N = 15 wells/column from two independent experiments; viability of
treated groups is expressed relative to the control group. (a) Skin cancer; (b) murine melanoma
(B16F10); (c) human melanoma (A375); (d) scoring of significance effect, where +++ (***) p = 0.0003,
++ (**) p = 0.01, + (*) p = 0.04, and — = no effect.
In the 3D Matrigel assay, the human melanoma cells form visible and consistently larger colonies
compared with the same cells treated with CD-NHF-loaded gel formulations (conc. 5%) (Figure 7 and
Figure S4).
By comparing the left column (Matrigel) with the median (simple gel formulations), it can be
observed that spheroids are less compact, with decreased cellular uniformity and a tendency to
dissociate. In the median column, we find that CMC and AS gel formulations are more unfavorable for
maintaining a homogeneity of metabolic activity (the green shade in the L/D kit reflecting live cell
population) and induce (or amplify) the dissociation tendency of cells from differentiated proliferation
aggregates. The differences found in the analysis of 3D spheroids can be caused by the fact that the
different types of gel formulations used either provide different stability conditions for extracellular
molecules that favor maintaining a differentiated cellular phenotype, or employ different receptors
for adhesion to cell membranes favorable to maintaining both differentiation and inhibition of the
cellular dissemination tendency [20,21]. Comparing the median column (single gel formulations) with
that on the right (gel formulations supplemented with 5% CD-NHF), we find that exposure to CD
was unfavorable to cell proliferation, with global cell counts being significantly impaired and the
quantitative weight of cells in invasion reduced. We specify that the shade of the green marker is
proportional (L/D kit) to the level of cell metabolic activity. Smaller color intensities can be determined
by both a decreased number of cells and more restricted metabolic activity in CD-NHF exposure. Also,
the morphological aspect of spheroids under the influence of gel formulations containing CD-NHF is
presented in Figure 8.
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Figure 7. (a) 3D Matrigel assay for human melanoma cell cultures in standard conditions (left) and
in the presence of added CD-NHF-free gel (middle) versus 5% CD-NHF-loaded gel (right). N = 3D
Matrigel cultures per type of gel with or without CD-NHF; 20×microscope objective. (b) Sum intensity
of fluorescence signal; (c) area of spheroids expressed in μm2.
Figure 8. The morphological aspect of spheroids under the influence of gel formulations. N = 3D
Matrigel cultures per type of gel with or without CD-NHF; 20×magnification.
Also tested was the viability potential of two different breast cancer cell lines, namely 4T1 (mouse
breast cancer) and MDA-MB-231 (human breast adenocarcinoma), in 2D and 3D culture models.
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The viability of the breast cancer cell lines 4T1 (mouse breast cancer) and MDA-MB-231 (human
breast adenocarcinoma) in the 2D culture system treated with CARB-F4 was affected (Figure 9a).
Mitochondrial activity was affected upon CARB-F4 treatment (Figure 9b). In the 3D Matrigel assay,
the malignant cells form visible and consistently larger colonies compared with same cells treated with
CARB-F4 (Figure 9c). Moreover, the apoptotic foci in 3D cultures treated with gels containing CD-NHF
were significantly higher (Figure 9c; white squares in boxes 2 and 4). The apoptotic pattern in the whole
spheroid body is also distorted: while in native culturing, inner cells (typically associated with hypoxic
conditions inside large spheroids) in spheroids began the apoptotic program, at 5% CD-NHF in exposed
spheroids, this form of cell death is initiated in all spheroid compartments. 3D cell cultures displayed
visibly larger structure of cancer cells with reduced active phenotype appearance. This suggests that
treatment with the CARB-F4 formulation could also either induce cell senescence or cell dormancy—a
topic that deserves further clarification. Together, these data suggest that CD-NHF-loaded gels affect
the number, size, and cellular organization of spheroids and impacts individual cancer cell ability to
proliferate and aggregate in spheroids.
 
Figure 9. The effects of gels with 5% CD-NHF in 2D and 3D culture. (a) Viability of MDA-MB-231
(human breast adenocarcinoma 33.3%) and 4T1 (mouse mammary breast cancer 44.87%) cell lines
treated with gels containing 5% CD-NHF (N = 8 wells/column from two independent experiments);
(b) mitochondrial activity in MDA-MB-231 (human breast adenocarcinoma 2%) and 4T1 (mouse
mammary breast cancer 49.2%) treated with gels containing 5% CD-NHF (N = 8 wells/column from two
independent experiments); (c) apoptosis evidence in MDA-MB-231 by immunofluorescence microscopy
and 3D Matrigel culture treated with gels containing 5% CD-NHF (N = 6; 3 Matrigel culture controls
and 3 Matrigel cultures treated with 5% NHF). (c1,c3) represent NucBlue nuclei staining; (c2,c4) reflect
apoptosis. Picture magnification 5×; where *** p < 0.0005, ***** p < 0.000005, ****** p < 0.0000005.
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4. Conclusions
This paper reported the development via a physical method of three topical gel formulations
loaded with CD-NHF, which were evaluated from the point of view of the modulatory activities of
putative anticancer agents. The obtained results indicate that CD-NHF-loaded gels matrices present
complex and interesting cell modulatory activities which are relevant for cancer control in potential
clinical applications. The mechanical properties of gels were investigated, concluding that the presence
of CD-NHF in the gels induced a slight decrease of the dynamic moduli, indicating a more flexible
gel structure. The fluorescence analysis confirmed the presence of the embedded CD-NHF in all gel
formulations. Also, worth noting is the potential antitumoral activity of the gel formulations loaded
with CD-NHF. The most important finding is that the CD-NHF-loaded gel formulations are able to
affect the number, size, and cellular organization of spheroids, while also having a significant impact
on the individual tumor cell’s ability to proliferate and aggregate in spheroids.
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A375 human malignant melanoma
AS sodium alginate
B16F10 mouse malignant melanoma cells
Balb/c-5064 mouse dermal microvascular endothelial cells
CARB Ultrez 10 carbomer
CD carbon dots
CD-NHF N-hydroxyphthalimide carbon dots
Conc. concentration
CMC carboxymethyl cellulose
CR controlled strain mode
CS controlled stress mode
FBS fetal bovine serum
GLY glycerin
HDMVECn primary dermal microvascular endothelial cells
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Abstract: Non-biodegradable materials with a low swelling capacity and which are opaque and
occlusive are the main problems associated with the clinical performance of some commercially
available wound dressings. In this work, a novel biodegradable wound dressing was developed
by means of alginate membrane and polycaprolactone nanoparticles loaded with curcumin for
potential use in wound healing. Curcumin was employed as a model drug due to its important
properties in wound healing, including antimicrobial, antifungal, and anti-inflammatory effects.
To determine the potential use of wound dressing, in vitro, ex vivo, and in vivo studies were carried
out. The novel membrane exhibited the diverse functional characteristics required to perform as a
substitute for synthetic skin, such as a high capacity for swelling and adherence to the skin, evidence
of pores to regulate the loss of transepidermal water, transparency for monitoring the wound, and
drug-controlled release by the incorporation of nanoparticles. The incorporation of the nanocarriers
aids the drug in permeating into different skin layers, solving the solubility problems of curcumin.
The clinical application of this system would cover extensive areas of mixed first- and second-degree
wounds, without the need for removal, thus decreasing the patient’s discomfort and the risk of
altering the formation of the new epithelium.
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 389; doi:10.3390/pharmaceutics11080389
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Keywords: wound dressing; polymeric membrane; nanoparticles; curcumin; alginate; pluronic F68;
drug skin permeation; Franz cells; tape stripping
1. Introduction
Human skin exerts a pivotal function as a protection barrier against diverse exogenous noxious
factors; however, it is exposed and undergoes diverse types of injuries, including burns, ulcers, trauma,
lacerations, and acute or chronic wounds, which may compromise its integrity [1].
In this regard, when skin is damaged, a specialized and highly regulated dynamic process
immediately takes place: wound healing [2]. The main goal of wound healing is to restore tissue
integrity and to achieve homeostasis; however, this process may be complicated by distinct intrinsic
and extrinsic factors [2]. Thus, in order to accelerate wound healing, a variety of wound dressings
have been designed.
Irrespective of the type of wound, the main function of dressings is to aid in the repair of the
wound through the reduction of pain and inflammation, to protect the damaged tissue from pathogenic
agents, and to enhance cell differentiation and proliferation [3]. Although there several types of
dressings which are commercially available, many of these present some drawbacks, such as an
inefficient absorption of exudates, poor protection against infections by microbes, the lack of ability to
maintain humidity, and the triggering of allergic effects [4]. In addition, several dressings may adhere
to the wound and require constant changes, which may interfere with the granulation process and
delay the healing course.
Therefore, in recent years, there has been increasing interest in asymmetric membranes as an
alternative for designing wound dressings [5]. These types of membranes possess multiple advantages,
such as structural similarity with the skin, an ability to absorb exudates due to their porous structure,
and improved cell adhesion and proliferation [6,7]. Different polymers have been employed for their
development, including chitosan, hyaluronic acid, collagen, poly vinyl alcohol (PVA), polycaprolactone
(PCL), and alginate [8]. In particular, alginate is a biopolymer extracted from seaweed and has shown
several unique properties, such as biodegradability, good hydrophilicity, and good biocompatibility [4].
Alginate has exhibited potential for improving wound healing due to its hemostatic properties;
moreover, it may reduce microbial infections, enhance the absorption of exudates, and decrease allergic
reactions [9]. These features render alginate an interesting option for wound dressings. In addition,
alginate membranes possess the advantage that they may be functionalized with bioactive compounds
that enhance their healing properties.
In this regard, curcumin is a natural compound that possesses a plethora of biological activities,
including antimicrobial, antifungal, anti-inflammatory, and antioxidant effects [10–12]. In addition,
curcumin improves wound healing, enhances epithelial regeneration, and increases the proliferation
of fibroblasts [13,14]. Thus, curcumin could be a suitable pharmacological agent for the elaboration
of wound dressings. However, curcumin exhibits low bioavailability and is unstable in neutral and
alkaline aqueous solutions, as well as in hydrophilic topical preparations [12,15]. These drawbacks
could be overcome by a nanoparticle formulation that permits the controlled and gradual release of
the compound.
Therefore, the objective of this study was to design and develop a novel wound dressing comprising
an alginate membrane and PCL nanoparticles loaded with curcumin and stabilized with Pluronic®
F-68 (CNp) for possible application in wound healing. The wound dressing was physicochemically
characterized, and in vivo and ex vivo permeation assays were performed.
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2. Materials and Methods
2.1. Materials
For CNp fabrication, we used PCL (Mn 80,000 g/mol), Pluronic® F-68, and trehalose dihydrate,
which were purchased from Sigma-Aldrich® (Merck KGaA, Darmstadt, Germany), whereas methanol,
ethyl acetate, and curcumin were supplied by Spectrum® (Spectrum Laboratory Products, CA,
USA). For membrane elaboration and characterization, we employed sodium alginate [(SA) (300–700
cps 1.0%, RV, 20 rpm, 25 ◦C], glycerol (Gly), propylene glycol (Prop), and Tween 80, which were
purchased from Droguería Cosmopolita (Mexico City, Mexico). PVA, Pluronic® F-127, acetone, and
phosphate buffered saline (PBS) solution were supplied by Sigma-Aldrich® (Merck KGaA, Darmstadt,
Germany). Kollidon® 30 [Polyvinylpyrrolidone k 30; (PVP k30)] was obtained from BASF (USA).
Ethyl acetate was acquired from Distribuidora Química Alvi (State of Mexico, Mexico). Methanol was
purchased from Fermont (Nuevo León, Mexico). All other chemicals and reagents were of at least
analytical-grade quality.
2.2. Preparation of PCL Nanoparticles Loaded with Curcumin (CNp)
CNp were prepared by the emulsification–diffusion method, as previously described by
Quintanar-Guerrero, et al. [16]. Briefly, the organic saturated phase and aqueous saturated phase were
obtained by the saturation of an ethyl acetate and distilled water mixture at a 1:1 ratio. After that, 2%
(w/v) solution of PCL was prepared by dissolving 400 mg of PCL in 20 mL of the organic saturated phase;
once PCL was dissolved, 100 mg of curcumin was added. At the same time, 5% (w/v) of Pluronic® F-68
solution was prepared using an aqueous saturated phase as solvent. In order to obtain an emulsion,
both solutions were mixed at a 1:2 ratio with a high-speed homogenizer (Ultra Turrax T18; IKA®) at
14,000 rpm for 10 min at room temperature. Then, 160 mL of water was added to the emulsion to
generate polymer aggregation, and the system was maintained under the same conditions for 10 min.
The organic solvent was evaporated by a rotary vacuum (Heidolph®, Schwabach, Germany), and
the nanoparticle suspension obtained was centrifuged at 15,557 g for 30 min at 25 ◦C. Finally, the
pellet was dissolved in distilled water. In order to assess the thermal stability and the properties of
the nanoparticles, CNp were frozen and lyophilized at −49 ◦C, 0.05 mBar for 24 h, employing 5% w/v
trehalose dihydrate as a cryoprotectant.
2.3. Physicochemical Characterization of CNp
2.3.1. Particle Size and Zeta Potential Assessment
The particle size and distribution (polydispersity index, PDI) of the CNp were evaluated by
dynamic light scattering. On the other hand, to determine the Zeta potential of CNp, laser Doppler
velocimetry was employed. CNp dispersions were assessed five times at 25 ◦C in a Zetasizer (Malvern
Instrument ZS90; Malvern, UK).
2.3.2. Atomic Force Microscopy (AFM)
CNp size and geometry were analyzed by atomic force microscopy (AFM) with a scanning probe
microscope (JSPM-4210, JEOL®, Tokyo, Japan). In brief, the CNp dispersion was obtained after
centrifugation, and the pellet resuspension was diluted to 1:100 with distilled water. A drop was
placed on a coverslip, allowing it to dry at room temperature. The coverslip with the drop was held in
place with carbon tape, and room-temperature conditions were utilized to assess the samples.
2.3.3. Drug Loading and Entrapment Efficiency of CNp
To calculate entrapment efficiency (EE) and drug loading (DL), the CNp dispersion was centrifuged
at 15,557 g for 40 min; then, the sediment was resuspended in ethyl acetate and the absorbance was
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measured by UV–Vis spectrophotometry at 420 nm (DLAB®, SP-UV1000, Beijing, China). The amount
of curcumin was obtained by interpolation in a calibration curve (R2 coefficient = 0.99985).









where CN = the amount of curcumin in nanoparticles, IC = the initial amount of curcumin, and N =
the number of nanoparticles.
2.4. Preparation of Polymer Gels and Membranes
Four membrane formulations based on SA (M1, M2, M3, and M4) (See Table 1) were prepared
using the solvent casting method as published by Karki et al. [17]. First, SA and the polymer were
dissolved separately in injectable water by stirring at 35 ◦C. After dissolution, they were mixed with
each other by mechanical stirring. Then, the plasticizer (or a plasticizer mixture) was added by stirring
at room temperature until a homogeneous gel was obtained. In order to eliminate bubbles from the gel,
it was centrifuged at 636 g for 20 min at room temperature (BIOBASE, BKC-TH18II, Shandong, China).
Table 1. Formulation of alginate membranes with different polymers as plasticizers. PVA: poly vinyl
alcohol; PVP: polyvinylpyrrolidone; CNp: polycaprolactone (PCL) nanoparticles loaded with curcumin.
Formulation Code SA (% w/v)
Polymer Plasticizer
PVA (%w/v) PVP (%w/v) Gly (%w/v) Prop (%v/v)
4 2 —- 10 —-
M2 4 2 —- 10 12
M3 4 —- 2 10 —-
M4 4 —- 2 10 12
CNp-M4 4 —- 2 10 12
In order to obtain the membranes, 10 g of each gel, prepared with the previously mentioned
methodology, was poured into a Teflon cast 12 cm in diameter and left to dry into an oven (OAKTON
Stable Temp, IL, USA) at 75.0 ± 0.5 ◦C for 3 h.
2.4.1. Preparation of Nanoparticle-Coated Alginate Membranes (CNp-M4)
The methodology described previously was followed to prepare our nanoparticle-coated alginate
membrane (CNp-M4), but the vehicle utilized was a dispersion of CNp to obtain 0.01% w/v of curcumin
instead of injectable water. In order to prepare the membranes, the gel obtained was poured into a
Teflon cast and left to dry in an oven at 40.0 ± 0.5 ◦C for 4 h.
2.5. Physicochemical Characterization of Membranes
2.5.1. Swelling Test
Samples of M1, M2, M3, M4, and CNp-M4 membranes were cut to a size of 1 × 1 cm and weighed
on pre-weighed aluminum trays. The samples were divided into five blocks, corresponding to different
times as follows: 5, 10, 20, 30, and 60 min. The membranes on the trays were placed on a flat surface,
and 750 μL of PBS 1X pH 7.4 was added to each sample.
Once the established time had elapsed, the trays were turned vertically for 2 min on absorbent
paper, allowing the draining and absorbption of the excess of PBS. After that time, the membranes
in the trays were weighed again [18]. The assessment was performed in triplicate for each of the
different times.
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where Ms and Md are the weight of the swollen membrane and dried membrane, respectively.
2.5.2. Mechanical Test
Tensile strength (TS) and the elongation at a break (%E) of M1, M2, M3, M4, and CNp-M4 were
determined using a Sintech 12 testing machine (MTS, USA), which was equipped with a 100-N load
cell at a crosshead speed of 2.4 mm s−1. Three samples of each formulation were cut into a dumbbell
shape with a width of 10 mm and an effective length of 40 mm between the clamps at the beginning
of the measurement. The thickness of each sample was measured using a Vernier at five different
points before testing, and the average of these was employed for TS calculation. The load (Lb) and
displacement (mm) of each film were recorded during the stretching. TS and %E were calculated by









where TS is reported in MPa, F is the maximum load (N) required to break the film, and A is the initial
cross-sectional area in mm2. In Equation (5), D is the displacement of the film elongation at the rupture
and L is the initial length.
2.5.3. Thermogravimetric Analysis (TGA)
The thermal stability of the membranes (M4, CNp-M4), CNp, and curcumin was evaluated through
TGA, employing a Hi-Res TGA 2950 Thermogravimetric Analyzer (Modulated TA Instruments, New
Castle, DE, USA). In brief, 5 mg of each sample was analyzed starting at room temperature and
increasing to 500 ◦C at a heating rate of 10 ◦C/min under a nitrogen atmosphere.
2.5.4. Differential Scanning Calorimetry (DSC)
The thermal properties of the membranes (M4, CNp-M4), CNp, and curcumin were determined
with the DSC 2910 (Modulated TA Instruments, DE, USA). Lyophilized samples were placed in
hermetic aluminum cells and evaluated starting at room temperature and increasing to 250 ◦C at a
heating rate of 10 ◦C/min under a nitrogen atmosphere.
2.5.5. pH Values
The pH values of M1, M2, M3, M4, and CNp-M4 polymer gels was measured through a pH meter.
The samples were put into contact with the electrode until a constant value was obtained. The pH
meter was previously calibrated against standard solutions to ensure the highest level of accuracy.
2.5.6. Structure and Morphology of M4 and CNp-M4 Membranes
In order to analyze the structure and morphology of the membranes, samples were cut in a circular
shape 1 cm in diameter and in a longitudinal section and were analyzed using a scanning electron
microscope (Jeol-JCM 6000, MA, USA) at 100× and 220×magnification; then, photographs were taken
in four different fields.
The pore diameter and membrane width were measured using a software package (ImageJ, MD,
USA), and the average was calculated. Pore number was counted field-by-field, and the average
was determined.
148
Pharmaceutics 2019, 11, 389
In order to evaluate the transparency of M4 and CNp-M4 membranes, samples were cut into a
circular shape 3 cm in diameter and these were placed over an image (before swelling); then, they were
observed and photographed. Afterward, 1 mL of PBS 1X was added to the samples, and after 20 min
(swelling process), photographs were taken of the samples.
2.5.7. In Vitro Release Study of Drug Dispersion, CNp and CNp-M4 Membrane
To evaluate the curcumin release profile from the CNp and CNp-M4 membrane, the direct
dispersion method was applied. For the drug and CNp dispersion, a certain amount of curcumin
(and the equivalent in nanoparticles) was dissolved into PBS solution (pH 7.4, Pluronic® F-127 2%
w/v), divided into sets of three tubes each, and placed in a shaker incubator, maintaining this at 37 ◦C.
For the CNp-M4 membrane, disks 1 cm in diameter were placed in tubes with the PBS solution under
the conditions previously described. At the defined times of 0, 0.25, 0.5, 1, 2, 4, 6, 24, and 48 h, one set
of tubes was removed from shaking and centrifuged at 18,514 g for 30 min. The curcumin released in
the supernatant was quantified by UV-Vis spectrophotometry at 420 nm.
The results of the release tests of CNp and CNp-M4 membrane were analyzed by mathematical
models such as zero-order, first-order, the Higuchi model, and the Korsmeyer–Peppas model to predict
the drug release mechanism.
2.6. Permeation Assays
2.6.1. Ex Vivo Permeation Assay
Porcine skin was obtained from the back of pig ears within 12 h after slaughter. The pig ears were
cut into circular sections 3 cm in diameter. The excess of fat was removed with surgical scissors, and
the samples were washed with saline solution. The samples were divided into three groups: drug
dispersion with 0.01% w/v of curcumin (2 mL; n = 3), CNp dispersion with 0.01% w/v of curcumin
(2 mL; n = 3), and CNp-M4 membranes (3 cm in diameter; n = 3).
The experiments were conducted in 12 independent Franz cells with a diffusion area of 7.07 cm2.
The freshly excised skin was placed into Franz cells, and the stratum corneum remained in contact with
the donor compartment, with the dermis facing the receptor compartment. This was filled with 30 mL of
0.1 M PBS solution (pH 7.4) with 2.5% of Tween 80 and maintained under constant stirring at 400 rpm.
Franz cells were immersed in a water bath at a constant temperature of 37.0 ± 0.5 ◦C. At
predetermined times (1, 2, 3, 4, 5, 6, 7, 8, 22, 24, 26, 28, and 30 h), 1000 μL of medium was removed
from the receptor compartment and replaced with 1000 μL of fresh receptor medium.
At the end of the test, the skin samples were carefully removed from the Franz cells to conduct the
tape-stripping test, following the in vivo permeation assay methodology (described in Section 2.6.2).
All tapes were placed in a flask with 40 mL of acetone and mechanically stirred for 15 h. Subsequently,
each skin sample was fragmented into small pieces using surgical scissors. The curcumin was extracted
with 25 mL of ethyl acetate:methanol at a ratio of 9:1. The extract was centrifuged at 10,174 g for 10 min.
All samples were analyzed by UV-visible spectrophotometry at a wavelength of 420 nm.
2.6.2. In Vivo Permeation Assay
To evaluate the in vivo permeation of the CNp-M4 membrane through the stratum corneum, the
tape-stripping technique was employed. Four healthy Mexican males aged 22–36 years were recruited
as volunteers. The individuals had neither a history of skin disorders nor had used cosmetic products
on their forearms 24 h prior to the test. Written informed consent was obtained from each volunteer
before each study.
Four sites (3 × 3 cm) were demarcated: two on the right forearm and two on the left forearm.
Before administering the treatment, the sites were cleaned with cotton impregnated with water.
Three treatments were administered to each volunteer. The CNp dispersion with 0.01% of curcumin
(2 mL) and the drug dispersion at the same concentration were contained within a glass cylinder on
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the left forearm. The CNp-M4 membrane (3 cm in diameter) was put on the right forearm, and 1.75 mL
of distilled water was added onto the surface of the membrane. The last site on the right forearm was
used for the blank. The treatments were in contact with the skin for 6 h [20]. Once the time had elapsed,
the membrane was removed with steel nippers. The skin was subjected to 15 successive tape strips
(Scotch® 3M®), previously cut into 3 × 3 cm squares. In each case, the site was pressed uniformly
by sliding a spatula over the surface of the tape five times; then, it was removed by pulling it with
steel nippers from the lower right to the upper left end. The blank site was subjected to the same
procedure. Each tape was immersed in 15 mL of acetone in a different amber glass bottle with a lid.
All of the bottles were placed under mechanical agitation for 15 h; subsequently, the samples were
filtered to remove the glue particles. The quantification of curcumin was performed by UV–visible
spectrophotometry at a wavelength of 420 nm. Each sample was analyzed in triplicate.
3. Results and Discussion
3.1. Physicochemical Characterization of CNp
3.1.1. Particle Size and Zeta Potential Assessment
CNps were obtained, and their mean particle size and PDI were 148.3 ± 1.9 nm and 0.044 ± 0.020,
respectively. These values were expected to improve dermal permeation [21], since nanoparticles
below 500 nm have a larger surface area-to-volume ratio, which ensures direct contact with the stratum
corneum and skin appendages [6,7]. Moreover, the PDI value was below 0.1, which indicates that the
small size measured in the sample is reliable and monodisperse [22].
On the other hand, CNp exhibited a zeta potential value of −7.32 ± 0.03 mV. In this regard,
zeta potential is commonly employed to measure the charge in the nanoparticles and/or electrostatic
repulsion [1], and the literature indicates that nanoparticles are stable in suspension with a zeta potential
above ±30 mV [23]. Despite the CNp zeta potential value not being in this range, it should be considered
that Pluronic® F-68 was added as a stabilizer of nanoparticles, which provides them with stability by
means of a repulsion effect through a steric mechanism [24]. Likewise, CNp possesses a negative charge,
which is related to the carboxylic end group of PCL [25]; thus, negatively charged nanoparticles could
permeate adequately in conjunction with the negative charges existing on the skin [26].
3.1.2. Atomic Force Microscopy (AFM)
The morphology and size of CNp were evaluated by AFM. In agreement with the particle-size
and zeta-potential assessments, the nanoparticles demonstrated a spherical shape and a size of
approximately 200 nm with no agglomeration (Figure 1) [27]. These results support the idea that
the small size of CNp could improve the dermal permeation of curcumin, which would increase its
anti-inflammatory, antimicrobial, and wound-healing activities [6,12].
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Figure 1. Atomic force microscopy (AFM) topography images of the CNp. The size bar is 1 μm.
3.1.3. Drug Loading and Entrapment Efficiency of Nanoparticles
In order to determine the amount of curcumin entrapped inside the CNp, the DL and EE were
determined. The CNp showed DL and EE values of 4.9 ± 0.7% and 96.01 ± 0.95%, respectively. It is
known that the emulsification diffusion method ensures high encapsulation efficiencies (generally
>70%) [28]. On the other hand, DL depends on nanoparticle structure and methodology [29], whereas
both DL and EE depend on the interactions between the drug, the matrix, and the medium [29].
3.2. Physicochemical and Mechanical Characterization of Nanoparticle-Coated Alginate Membranes as
Wound Dressings
3.2.1. Swelling Test
From a practical point of view, the membranes should absorb the exudate from the wound and at
the same time provide a moist environment that promotes healing. For this reason, the percentage of
swelling of five different formulations was determined by weight difference (Figure 2).
Figure 2. Percentage of swelling in alginate membranes as a function of time. Effect on swelling
capacity by the addition of PVA + glycerin (M1), PVA + glycerin + propylene glycol (M2), PVP +
glycerin (M3), PVP + glycerin + propylene glycol (M4), and CNp + PVP + glycerin + propylene glycol
(CNp-M4) (mean ± SE; n = 3). There were significant differences when ANOVA was applied at 5, 20,
30, and 60 min (p < 0.05).
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Figure 2 depicts a difference at a time of 20 min, when propylene glycol is added to the formulation
with PVA (M2) in comparison to M1; however, there is no significant difference between using or not
using propylene glycol in the formulation combined with PVP (M3 and M4, respectively). In order to
determine the differences in the percentage of swelling according to each formulation as a function of
time, an ANOVA was performed. It was demonstrated that both the formulation and the time during
which the membrane was exposed to PBS exerted a statistically significant effect on swelling with a
95% confidence level.
The formulation with the highest swelling value was M1, at 30 min (802.8 ± 76.0%), while the
addition of propylene glycol (M2) decreased the swelling percentage after 10 min. On the other hand,
M2 showed the lowest value in the swelling test before dissolving. The addition of propylene glycol to
the polyvinyl alcohol mixture could increase the intermolecular interactions between both excipients
via hydrogen bonds in the –OH groups, favored by a wide steric disposition, but could decrease the
entry capacity of water molecules and their interaction with alginate by saturation, decreasing the
swelling ability. In the case of the interaction of propylene glycol and PVP, the situation could be the
opposite. The interaction of both excipients is lower, resulting in a lower swelling capacity of the
alginate; i.e., the excipient that determines the majority of the response. This phenomenon is confirmed
with the profile observed for CNp-M4 in relation to M4.
Namely, when water enters the polymer matrix, the chains begin to relax, giving rise to the
opening of the polymer networks. This promotes the penetration of more water; however, in the last
stages of swelling, the diffusion coefficient is diminished because the chains are completely relaxed
and near equilibrium [30].
The membranes began to dissolve after being exposed to PBS for a longer period of time. According
to the composition of the medium, polymers undergo degradation and erosion processes. When a
polymer degrades, the chains are cleaved into oligomers and subsequently monomers. The continuous
loss of monomers will eventually lead to the phenomenon of erosion, which progressively changes
the microstructure of the membrane through the formation of pores [31]. The combination of these
processes could favor the possible application of our M4 and CNp-M4 membranes as wound dressings,
because it would not be necessary to remove them from the application site, avoiding harm through
injury and discomfort to the patient.
Moreover, the level of exudate from a wound (for example, an ulcer) can vary from absent (dry
ulcer) to minimally exuding (<5 mL fluid per 24 h), to moderately exuding (5 to 10 mL fluid per 24 h),
and finally to highly exuding (>10 mL fluid per 24 h) [32]. In this regard, the measurement of the
swelling capacity of a wound dressing developed with alginate could be classified as dressings of low
absorbance (alginate wound dressing that absorbs less than 6 g of liquid per g of dressing, or less than
12 g/100 cm2), and dressings of high absorbency (an alginate wound dressing that absorbs 6 g or more
liquid per g of dressing, or 12 g or more/100 cm2) [33]. With this consideration, CNp-M4 possesses a
value of 17.48 g/100 cm2, corresponding to high absorbency and similar to several commercial products.
3.2.2. Mechanical Test
Wound dressings must be resistant and flexible for ease of handling [17]. Thus, the mechanical
properties of the membranes are depicted in Figure 3. Formulations with PVA (M1 and M2) did not
demonstrate a significant difference in %E with 73.54 ± 0.87% and 74.90 ± 1.67%, respectively. TS was
similar for M1, M2, and M3 samples with 1.32 ± 0.02, 1.34 ± 0.01, and 1.96 ± 0.05 MPa, respectively.
By way of comparison, M1 and M2 membranes exhibited a lower TS and %E than the remaining
formulations, probably due to PVA being a polymer that has been characterized as possessing poor
elasticity, a rigid membrane, and low hydrophilic characteristics [34].
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Figure 3. Effect of plasticizers on the mechanical properties of alginate membranes. Effect on mechanical
properties by the addition of PVA + glycerin (M1), PVA + glycerin + propylene glycol (M2), PVP +
glycerin (M3), PVP + glycerin + propylene glycol (M4), and CNp + PVP + glycerin + propylene glycol
(CNp-M4), respectively. (a) Elongation at break; (b) tensile stress, (mean ± SD; n = 3). * indicates p <
0.05 as statistically significant.
The %E and TS of M3 were 68.63± 6.75% and 1.18± 0.07 MPa, respectively; these values significantly
increased with the addition of propylene glycol (M4), to 120.01± 5.97% and 1.96 ± 0.05 MPa, respectively.
M4 exhibited the highest values in the assay and showed a significant difference with respect to the
remaining formulations without CNp. This may be explained, at least in part, by the properties of
propylene glycol, which is a plasticizer with a small molecular weight that is able to create multiple
H-bonds with PVP and SA chains into a package and, consequently, aid in the formation of cross-linked
networks [35].
Therefore, because of its greater swelling capacity and better mechanical properties, the M4
membrane (a mixture of sodium alginate, PVP, and propylene glycol) was chosen for the incorporation
of CNp.
On the other hand, the mechanical properties of M4 were modified when CNp dispersion was
added to the formulation. The %E of CNp-M4 showed the highest value, with 144.39 ± 14.52%; in
contrast, TS decreased to 1.52 ± 0.16 MPa. This could be due to the addition of CNp dispersion to the
formulation decreasing the number of hydrogen bonds between the polymer molecular chains; as a
result, less strength is necessary to break the membrane [36]. In comparison, CNp-M4 showed the
highest %E, which could be due to the effect of Pluronic® F-68. The latter is a surfactant that decreases
the pore number, providing a membrane with a homogeneous structure; thus, it is more resistant to
changes, rendering higher elasticity properties.
3.2.3. Thermogravimetric Analysis (TGA)
It is important to determine the thermal properties of a substance, because these provide useful
information for their identification and the characterization of materials. In Figure 4, thermograms of
curcumin, CNp, M4, and CNp-M4 membranes are presented. For curcumin, mass loss was observed
at 173 ◦C by TGA (Figure 4a); due to the degradation of turmeric powder, water loss was not observed,
possibly due to its high hydrophobicity [37]. The weight loss of CNp started at approximately 90 ◦C,
corresponding to dehydration, and there was a second plateau from 280 to 350 ◦C, suggesting a better
thermal stability for curcumin when it is inside PCL nanoparticles than when alone. However, CNp
lost more weight in a smaller temperature range.
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Figure 4. Thermal analysis of nanoparticle-coated alginate membrane using (a) thermogravimetric
analysis (TGA) and (b) differential scanning calorimetry (DSC). The thermal properties of the M4
membrane, CNp-M4 membrane, CNp, and curcumin are represented as a, b, c, and d, respectively.
On the other hand, in the M4 membrane, the first mass loss occurred between 90 and 240 ◦C,
whereas for the CNp-M4 sample, weight loss began between 100 and 240 ◦C. This could be due to
the evaporation of water traces, the degradation of propylene glycol, PVP, glycerin (150-220 ◦C), and
turmeric powder [38]. In the case of the CNp-M4 membrane, it presented a slighter weight loss
compared to the M4 membrane. The second mass loss of both samples was between 270 and 425 ◦C; in
this stage, the decomposition of the functional groups of SA polymer chains is presented. Finally, the
last plateau in M4 and CNp-M4 membranes started at 425 ◦C, which corresponds to the degradation
of the SA backbone [19]. In the same manner, the CNp-M4 membrane thermogram revealed a lower
weight-loss temperature compared with that of CNp; this is probably because membrane formulation
is a mixture that contains more substances than CNp. This is similar to the thermal behavior exhibited
by curcumin and CNp.
3.2.4. Differential Scanning Calorimetry (DSC)
DSC is a technique used to determine the quantity of heat either absorbed or released when
substances undergo physical or chemical changes [39]. In Figure 4b, DSC thermograms of curcumin,
CNp, M4 membrane as vehicle, and CNp-M4 membrane are presented. The melting point of curcumin
was found to be 174 ◦C (Table 2), which was expected with regard to the literature [40]. Furthermore,
three thermal events were observed in the CNp: at 63.5; 101, and 212 ◦C. The first thermal event could
correspond to the melting point of PCL (61 ◦C) [41], while events at 101 and 212 ◦C may indicate the
presence of trehalose, which was employed as a cryoprotectant to lyophilize the CNp [42]. Interestingly,
the melting point of curcumin was not detected in the CNp sample; this could be due to the high EE of
curcumin inside PCL nanoparticles as a molecular dispersion.
Table 2. Thermal events of curcumin, CNp, and alginate membranes by DSC.
Sample Tm1 (
◦C) Tm2 (◦C) Tm3 (◦C)
Curcumin 174 —- —-
CNp 63.5 101 212
M4 87 249 —-
CNp-M4 87 233 —-
On the other hand, both M4 and CNp-M4 membranes revealed two thermal events. The first
peak was around 87 ◦C for both formulations, whereas the second peak was around 233 ◦C for the M4
membrane and 249 ◦C for the CNp-M4 membrane. The latter peaks were due to the presence of SA in
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the formulation. A thermal peak prior to 100 ◦C was observed for both samples, possibly due to the
presence of water in the membranes.
3.2.5. pH Determination
The pH values of all the polymer gels were 5.78 ± 0.06, 5.76 ± 0.03, 5.65 ± 0.01, 5.97 ± 0.05 and
5.68 ± 0.03 for M1, M2, M3, M4, and CNp-M4, respectively. All of these values are acceptable because
pH wound dressings must be neither acid nor alkaline in order to avoid skin irritation. Moreover,
membrane pH is important to regulate the wound-healing process. The natural pH of the skin is within
a range of 5–6, depending on the person, while the pH of the chronic wound oscillates in an alkaline
range between pH 7 and 8, which increases susceptibility to wound infection.
3.2.6. Structure and Morphology of M4 and CNp-M4 Membranes
An ideal scaffold is expected to have a suitable microstructure (number of pores and pore size
controlled) in order to transport nutrients, cells, metabolites, gases, and signaling molecules [43]. In this
respect, pores were observed in the top of the membrane structure, which did not span the membrane
(Figure 5a). However, it should be expected that the addition of water to the membranes (for example,
from the wound exudate) promotes the total formation of pores through these. This would allow skin
transpiration and an optimal environment for the wound.
Figure 5. Morphology and porosity of alginate membranes. (a) Micrographs by scanning electronic
microscopy of the alginate membrane surface (A, B, D, and E) and membrane thickness (C and F).
Magnification of 100× for A, D; 220× in B, C, E and F; the scale bar is 100 μm; (b) pore diameter and
membrane thickness of M4 and CNp-M4 membranes, mean ± SE, n = 3. * indicates that p < 0.05 is
statistically significant.
On the other hand, the mean pore numbers in M4 and CNp-M4 membranes found in each
0.199 mm2 were 4 and 2, respectively. The pore diameter in the M4 membrane was 162.25 ± 40.75 μm,
while for CNp-M4 membranes, this was 73.43 ± 11.04 μm (Figure 5b). Moreover, M4 membranes were
significantly thicker and more homogenous in structure than CNp-M4 membranes. These features
could be due to the fact that CNp-M4 membranes have CNp dispersion in their formulation, which
contains Pluronic® F-68, a nonionic surfactant used as a nanoparticle coating that decreases tensile
surface in the polymer gel, thus reducing the number and size of the pores formed in the membranes [43].
Finally, transparency is an expected feature in our alginate membranes used as wound dressings,
in order to observe the possible wound-healing process without removing the dressing. M4 and
CNp-M4 membranes revealed a transparent feature prior to swelling, while CNp-M4 membranes
155
Pharmaceutics 2019, 11, 389
demonstrated a translucent feature during the swelling process (Figure 6). Although the latter was not
completely transparent, it was possible to see through it.
Figure 6. Alginate membranes (M4) before swelling and during the swelling process in PBS medium
(A,B, respectively), and alginate membranes with curcumin nanoparticles (CNp-M4) before swelling
and during the swelling process in PBS medium (C,D, respectively). Scale in centimeters.
3.2.7. In Vitro Release Study of Drug Dispersion, CNp and CNp-M4
To analyze the mechanism of drug release from the nanoparticles (CNp) and from the nanoparticles
inside the membrane (CNp-M4), an in vitro release study was performed via the dispersion method
and is presented in Figure 7. The curcumin release from CNp (red line, circle symbol) showed
a low burst effect at 2 h; this behavior could be related to the presence of the curcumin released
from the nanoparticles, as well as to the curcumin outside the nanoparticle, inside the border-zone
matrix-stabilizer. After that, the release profile exhibited a linear behavior, with nearly 60% of the
curcumin released after 48 h of study. Interestingly, in the release profile for CNp-M4 (blue line,
triangle symbol), the burst effect was not evident, and a faster release than CNp (80% of curcumin
released at 48 h) was found. These behaviors may be due to the interaction among the membrane
excipients, the solvents, and the nanoparticles. To elaborate the CNp-M4 membrane (Section 2.4.1), the
nanoparticles are in contact with water, and the hydrolysis of CNp could be stimulated. In addition,
some excipients, such as glycerin and propylene glycol, are co-solvents that could improve the prior
solubilization of curcumin. As can be observed, the release from both the CNp and CNp-M4 membrane
was considerably slower than the drug dispersion release (black line, square symbol).
In order to investigate the mechanism of curcumin release from CNp and CNp-M4, different
mathematical models were applied (Table 3). The CNp data were fixed with the Higuchi model
(A = 0.0852, B=−0.0459, R2 = 0.9551), according to those previously reported [44]. This model describes
the release of the drug by diffusion from the nanoparticle core into the external solution. On the other
hand, the release from CNp-M4 could be explained with the Korsmeyer–Peppas model, due to the
highest squared-correlation-coefficient value being obtained with this method (A = 0.3119, B = −0.5609,
R2 = 0.9536). This model combines the diffusion and erosion mechanisms of the nanoparticles as the
explanation for drug release.
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Figure 7. Release profile of curcumin from the drug dispersion, CNp and CNp-M4 membrane in PBS
pH 7.4 (0.1 M, Pluronic® F-127 2% w/v) at 37 ◦C. Each point represents the mean ± SE, n = 3.
Table 3. Squared of the correlation coefficient (R2) and coefficients obtained after the linear regression





R2 A B R2 A B
Zero-order Qt = Q0 + K0t 0.842 0.5264 4.7385 0.7358 1.2362 31.432
First-order lnQt = loQ0 + K1t 0.8436 −0.0066 −2.3991 0.8453 −0.0303 −3.1975
Higuchi Qt = KHt1/2 0.9551 0.0852 −0.0459 0.8939 0.1017 0.194
Korsmeyer–Peppas QtQ∞ = KKt
n 0.9037 0.5422 −1.2655 0.9536 0.3119 −0.5609
Qt: amount of drug released in time t; Q0: initial amount of drug in the dosage form; Q∞: total amount of drug
dissolved when the dosage form is exhausted; K0, K1, KH, KK: release rate constants; R2: squared correlation
coefficient. y = ax ± b is an equation obtained after regression: a, slope and b, linear coefficient.
3.3. Curcumin Permeation Assays
3.3.1. Ex Vivo Permeation
An ideal system for potential use in chronic diseases with a slow healing process, such as wounds
or psoriasis, should exhibit sustained drug release in order to allow permeation through the skin [20,45].
In this regard, the alginate membranes developed in our study possess polymeric networks as a
structure, as well as the curcumin encapsulated in PCL nanoparticles dispersed within these networks.
These features will allow the slow release of curcumin.
An ex vivo permeation study was conducted to determine the distribution of the drug and CNp
throughout the stratum corneum, epidermis, and dermis, and to verify whether curcumin can pass
through the skin and reach blood circulation after the administration of CNp-M4 and CNp formulations.
With respect to the aqueous dispersion of curcumin (Figure 8), due to the high lipophilic character
of the drug, a high accumulation was observed in some superficial layers of the stratum corneum
(10.04 ± 1.73 μg/cm2). Interestingly, permeation comprises a considerable amount, even from the
application of a curcumin dispersion in water, which involves solid particle clusters. This means that
the drug particles engage in a dissolution process with the oily components of the stratum corneum,
leading to their brief permeation in the superficial region. Although the values are high, there is a
higher efficiency of permeation with CNp (14.80 ± 1.61 μg/cm2). In the region of the dermis, with a
hydrophilic character, the permeated amount of the drug dispersion decreases considerably due to its
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highly limited solubility in aqueous media (2.40 ± 0.46 μg/cm2); this is nearly one third in relation to the
CNp value (6.99 ± 0.27 μg/cm2). No detection was recorded for the dispersion of the drug that could
completely permeate the skin. According to Figure 8, a significant difference was observed between
CNp dispersion and CNp-M4 membrane treatments, with the highest permeation values observed for
CNp. The CNp-M4 membrane treatment revealed the highest amount of curcumin retained in the
epidermis and dermis—that is, 5.7 μg/cm2 (1.620 ± 0.051% of the total concentration of curcumin)—and
the lowest concentration was found in the stratum corneum (SC), at 0.65 μg/cm2 (0.140 ± 0.006%).
On the other hand, in the CNp dispersion treatment, curcumin was found mostly in the SC; that is,
14.8 μg/cm2 (2.62 ± 0.49%) [26], the highest curcumin value in the entire assay.
Figure 8. Ex vivo permeation of curcumin after 30 h of treatment with drug dispersion, CNp dispersion,
or CNp-M4 membrane. Stratum corneum-bound particles (obtained from 15 tape strips), epidermis +
dermis (surface on which dosed skin was handled after 30 h), and systemic (receptor compartment),
mean ± SE, n = 4; ** indicates p < 0.01 and *** indicates p < 0.001 as statistically significant.
There was also a significant difference in the amount of curcumin that crossed through the skin
(which, in an in vivo model, means reaching the systemic circulation), since the concentration derived
from the CNp-M4 membrane was significantly lower than CNp (0.32% and 2.04% respectively; p-value
= 0.0019).
The aqueous system of CNp dispersion permitted the curcumin to permeate through the dermis and
completely cross the skin. Moreover, CNps have a negative charge; negatively charged nanoparticles
permeate the skin more rapidly than positively charged nanoparticles. The skin is predominately
negatively charged, and the electrostatic interaction of positive particles with the negatively charged
molecules in the skin matrix slows particle diffusion [26]. However, curcumin from CNp-M4 membranes
diffuses more slowly through the skin than that from CNp. These observations may be due to the
fact that, in the CNp dispersion, water was used as the medium. Water affects the absorption rates of
different substances through the stratum corneum, which is in a constant state of partial hydration
under normal conditions. Thus, when immersed in water, dead keratinocytes quickly absorb it,
resulting in the pruning effect of the skin [45]. Furthermore, water in contact with skin creates a flow
gradient toward the skin’s inner layers, since the inside of the stratum corneum is more hydrated than
the surface [46]. On the other hand, the CNp-M4 membrane does not have a liquid medium in the
interface that allows the nanoparticles to flow easily into the deep layers, such as water in the case of
the CNp dispersion. Despite this, for the CNp-M4 membrane, a modulated release is expected because
of the degree of swelling of the membrane in response to the presence of exudate. The swelling would
permit the relaxation of the polymer chains and the release from the CNp. Otherwise, diffusion from a
solid state (CNp-M4) into a semi-solid state (the skin) would be expected. Therefore, the CNp-M4
membrane represents a prolonged release system.
158
Pharmaceutics 2019, 11, 389
In addition, the skin possesses furrows, in which a considerable amount of curcumin is retained,
which could not be extracted with the application of adhesive tapes [47]. This curcumin was quantified
until mechanical disaggregation. This could explain why the epidermis and dermis had the highest
concentration of the drug.
On the other hand, particle size is an important factor in obtaining the desired therapeutic effect,
because nanoparticles with a small size can more easily permeate the physiological barriers; moreover,
due to their greater surface, release of the drug is favored [48]. Thus, it should be expected that CNps,
with their small size (148.3 nm), and the surfactant effect of Pluronic® F-68 can permeate intercellularly
and through hair follicles, favoring accumulation for several hours. In the same way, due to the contact
of nanoparticles with the corneocytes of the skin, as well as the prolonged release thereof, a large
amount of curcumin was found to be retained in the dermis [24,27]. Although after 30 h the majority of
curcumin remained in the stratum corneum when CNp dispersion was applied, the monitoring of the
permeation at longer times could allow the observation of a prolonged release system [49]. Therefore,
the CNp-M4 membrane is proposed as a functional prolonged release system for drug delivery in
chronic diseases; however, it would be necessary to perform a more prolonged test to observe the
diffusion of the drug at a greater proportion.
3.3.2. Permeation Assay in Vivo
In order to evaluate the in vivo skin permeation of curcumin from the CNp-M4 membrane, CNp
dispersion [20], and drug dispersion, a quantification of the curcumin deposited in the stratum corneum
by UV–Vis spectrophotometry was performed. The results are presented in Figure 9, according to the
work of Goto et al. [50].
Figure 9. Cumulative concentration of curcumin quantified in the stratum corneum of healthy
volunteers. Drug extraction from 15 adhesive tapes applied to the treatment site after placing a CNp-M4
membrane, CNp dispersion, or drug dispersion for 6 h (mean ± SE; n = 4).
Higher permeation values were observed for the drug dispersion in water compared to the CNp
and CNp-M4 membrane, at least in the superficial layers of the stratum corneum, where the tape
stripping technique is applied. The higher values of drug permeation could correspond to the high
lipophilicity value of the drug, structural symmetry, and low molecular weight. These values coincide
with Figure 8: greater drug deposition on the stratum corneum surface, a lower proportion in the
dermis due to an inadequate hydrophilic–lipophilic balance, and no recorded quantity that completely
permeates the skin. At 6 h after the application of the drug dispersion, CNp-M4 membrane, and
CNp dispersion, the curcumin measured in the stratum corneum reached 33.08 ± 2.57, 9.82 ± 4.23,
and 18.96 ± 1.25 μg/cm2, respectively [25]. CNp-M4 remained well adhered during the study, even
up to 48 h in other volunteers (data not shown). As can be noted, a greater amount of curcumin was
observed in the stratum corneum when the CNp dispersion treatment was applied, compared with the
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CNp-M4 membrane. This is because, in the CNp-M4 membrane, the nanoparticles must be released
from the polymeric matrix. This result suggests our formulation as a system of prolonged release that
may be useful for long treatments, such as that for a wound (for example, for 7–14 days of application
until closure of the lesion). It is noteworthy that the smallest variation observed in permeation values
with the CNp-M4 treatment reveals a system that allows better gradual control release. Moreover,
these nanoparticles also possess a stabilizer on the outside, Pluronic® F-68, which interacts through
hydrogen bonds with the -OH groups of plasticizers and polymers used in the formulation. Thus,
when the water makes contact with the membrane, the external part of the polymers swells and
promotes the drug—in this case, CNp—to flow outward, permitting its release [51].
With respect to the CNp dispersion, the nanoparticles are free in the medium; thus, they interact
more easily with the stratum corneum. Curcumin is encapsulated and uniformly distributed in the PCL
nanoparticles, forming nanospheres [52]. The release of curcumin from these latter will depend on the
solubility of the drug, the diffusion of curcumin through the matrix of the nanoparticles, thedesorption
of curcumin from PCL, the erosion or degradation of the matrix of the nanoparticles, and on the
combination of the erosion and diffusion processes [23]. It is also known that, under physiological
conditions, a random cleavage of PCL ester bonds occurs, which produces a destabilization of the
polymer matrix of the CNp, inducing the release of curcumin [25].
Finally, many studies have reported an accumulation of nanoparticles in hair follicles and the
pilosebaceous glands in ex vivo skin experiments [49]. In the same manner, it has been reported that
there is better permeation of the drug into the skin, as well as greater absorption in areas with high
hair-follicle density. The hair follicle can become a reservoir of substances comparable to the stratum
corneum [53]. This means that drugs will penetrate better through the skin of a person with greater
amounts of hair follicles. This may explain slight variations in the results obtained, together with
variability among individuals (age, body mass, color, and skin moisturization).
4. Conclusions
In this study, the development of a new wound dressing for possible application in wound healing
was demonstrated. The wound dressing comprises an alginate membrane and PCL nanoparticles
stabilized with Pluronic® F-68 with curcumin inside. This new system was designed with a mixture
of aqueous plasticizers to confer high-strength mechanical properties. The characterization of the
formulation exhibited that it possesses a high absorbency capacity for the removal of possible exudates,
transparency for monitoring the wound bed, the presence of pores with controlled dimensions that
could facilitate the transpiration of the wound as a synthetic skin substitute, and the gradual release of
the drug according to the ex vivo and in vivo studies. In addition, the high adherence of the wound
dressing should be noted even in dry skin, as well as its degradation at later times. Therefore, all of
these advantages reveal our wound dressing as a good option for wound healing without the need for
its removal from the patient.
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Abstract: Topical treatment of wound infections is often a challenge due to limited drug availability
at the site of infection. Topical drug delivery is an attractive option for reducing systemic side
effects, provided that a more selective and sustained local drug delivery is achieved. In this study,
a poorly water-soluble antibiotic, ciprofloxacin, was loaded on polyvinylpyrrolidone (PVP)-based
foils and nanofiber mats using acetic acid as a solubilizer. Drug delivery kinetics, local toxicity,
and antimicrobial activity were tested on an ex vivo wound model based on full-thickness human
skin. Wounds of 5 mm in diameter were created on 1.5 × 1.5 cm skin blocks and treated with the
investigated materials. While nanofiber mats reached the highest amount of delivered drug after 6 h,
foils rapidly achieved a maximum drug concentration and maintained it over 24 h. The treatment
had no effect on the overall skin metabolic activity but influenced the wound healing process, as
observed using histological analysis. Both delivery systems were efficient in preventing the growth
of Pseudomonas aeruginosa biofilms in ex vivo human skin. Interestingly, foils loaded with 500 μg of
ciprofloxacin accomplished the complete eradication of biofilm infections with 1 × 109 bacteria/wound.
We conclude that antimicrobial-loaded resorbable PVP foils and nanofiber mats are promising delivery
systems for the prevention or topical treatment of infected wounds.
Keywords: wound infection; biofilm; pseudomonas aeruginosa; antimicrobial delivery;
polyvinylpyrrolidone; nanofibers
1. Introduction
The number of antibiotic resistant bacteria, as well as the number of immune deficient patients, is
increasing. For this reason, infections of post-operative and chronic wounds are becoming a concern
for many patients and health care providers [1]. Age-related immune deficiency, diabetes mellitus
type 2, venous insufficiency, or immobility are the major conditions leading to chronic wounds [2–4].
Chronic wounds are often associated with microbial biofilms, i.e., organized communities of one or
more microorganism species encased and shielded by extracellular polymeric substances [5,6]. It was
shown that significantly higher concentrations of antibiotics are required to treat biofilm-associated
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2019, 11, 527; doi:10.3390/pharmaceutics11100527
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infections [7,8]. One of the reasons for biofilm drug-resistance is the extracellular polymeric matrix,
which acts as a shield protecting bacteria from the external environment. In addition, the low
concentrations of antibiotics that reach the bacteria in the biofilm favor the formation of persisters, i.e.,
physiologically inactive dormant cells that are less responsive to antibiotics [9]. Thus, for an efficient
treatment of a biofilm-associated infection, a high and sustained concentration of antimicrobial drugs
should be achieved at the site of infection and within the biofilm. This is often not fulfilled by most
of the available antimicrobial formulations because of unfavorable physicochemical properties of
drugs like instability in different biological environments, low solubility, or high molecular weight.
New solubilization strategies and innovative pharmaceutical formulations, like polymer conjugates,
nanocarriers, and membranes, have the potential to improve drug delivery and thus increase their
concentration at the site of infection [10,11].
In this study, we investigated the drug delivery properties of polyvinylpyrrolidone (PVP)-based
foils and nanofiber mats. A ciprofloxacin base was chosen as model drug because of its low
water-solubility, detectability using fluorescence spectroscopy, and quorum sensing inhibiting
properties in Pseudomonas aeruginosa (P. aeruginosa) at concentrations below the minimal inhibitory
concentration (MIC) [12]. It is a broad-spectrum antibiotic that has been approved by the U.S. Food
and Drug Administration (FDA) for the treatment of urinary tract and other infections, including skin
and skin-structure infections. Nevertheless, it has severe side effects, and in 2016, the FDA recognized
the existence of a rare side effect, a potentially permanent syndrome called fluoroquinolone-associated
disability [13]. Because of the low water solubility, ciprofloxacin is formulated into tablets for
oral use as monohydrochloride monohydrate salt. In this form, its absolute bioavailability is of
60% [14]. Alternatively, a ciprofloxacin base has been formulated in oil-based syrups [15] with a better
bioavailability of up to 70% [16]. Formulations for topical use (e.g., ciprofloxacin ophthalmic ointment)
are made by dissolving the drug in mineral oil. However, it was shown that drug crystals can still
form and even cause the blockage of the bottle nozzle [17]. In general, antibiotics are not used for the
topical treatment of chronic wounds because of insufficient drug bioavailability and possible local side
effects. However, topical drug delivery would be an advantage in those cases, like an infected diabetic
foot, where blood circulation is reduced and systemic therapies are often inefficient. In addition, it has
been shown that locally applied antibiotics can reduce the risk of surgical site infections [18]. Finally,
topical therapies reduce systemic toxicity and spare the gut microbiome. Thus, a more efficient topical
drug delivery would improve both the management and prevention of wound infections.
In a previous study, we used a pH modification strategy to solubilize a ciprofloxacin base and
increase the amount loaded on PVP foils and nanofiber mats. Interestingly, the residual acetic acid
bound to PVP conferred a peculiar transparency and elasticity to the foils. These delivery systems
were shown to be safe and to have a good anti-microbial activity in vitro [19]. In this study, we
tested further properties of these materials using a wound infection model based on full-thickness
human ex vivo skin. Different models are available to test the antimicrobial activity of a drug. In vitro
grown biofilms give the possibility to study drug efficacy toward bacteria grown in communities.
Nevertheless, in vitro biofilms are often very different from those found in in vivo infections. In vivo
animal models have diverse advantages, including a tissue scaffold, host immune response, and wound
healing processes. However, besides ethical reasons, animal studies are expensive and results are
not always reproducible in humans. To reduce the number of animal studies, ex vivo models have
been proposed for preliminary studies prior to animal studies. Ex vivo human skin has been used
for several years to test the skin penetration of chemicals and drugs [20]. Yet, in the last few years,
ex vivo porcine or human skin has been used to develop wound infection models [21–27]. Human
full-thickness skin represents not only a three-dimensional scaffold where bacteria can grow, but also
a complex environment with extracellular enzymatic activity, antimicrobial peptides, and several
different cell populations, including immune-active cells. Thus, human skin infection models are
realistic animal-free systems; even if they cannot completely replace in vivo studies, they are useful
tools to screen antimicrobial formulations [26].
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Using this model, we could measure the drug delivery kinetics, monitor eventual toxic effects,
and measure the antimicrobial activity of the tested materials.
2. Materials and Methods
2.1. Preparation of Ciprofloxacin-Loaded PVP Foils and Nanofiber Mats
Transparent films and nanofiber mats were prepared as described by Contardi et al. [15]. Briefly,
films were produced using a solvent casting method starting from aqueous solutions of PVP (3% w/v)
with a molecular weight (MW) of 360,000 g/mol (Sigma-Aldrich, Milan, Italy), monohydrochloride
monohydrate free ciprofloxacin (≥ 98.0% measured by high performance liquid chromatography
(HPLC), Sigma-Aldrich, Milan, Italy) and acetic acid (≥ 99.7%, Sigma-Aldrich, Milan, Italy). Three
different initial quantities of ciprofloxacin (1.2, 30, and 60 mg) were combined with the polymer and
dissolved in acetic acid 30% (v/v) to a final volume of 30 mL to reach different drug concentrations
(2.2, 44, and 88 mmol). The solutions were cast on Petri dishes (diameter 8.75 cm) for 3 days under an
aspirated hood under ambient conditions (16–20 ◦C and 40–50% r.h.). Then, the films were placed
in a vacuum desiccator for 3 more days to complete the removal of excess acetic acid. The nanofiber
mats were fabricated by using a vertical electrospinning set-up. Starting solutions of PVP, acetic
acid (30% v/v), and ciprofloxacin were prepared (final volume 6.2 mL). A higher concentration of the
polymer (25% w/v) was used with respect to the films to allow for the electrospinning process. Three
different concentrations of ciprofloxacin (2.2, 44, and 88 mM) were also prepared for the nanofiber
mats. Syringes with a stainless-steel needle (18 gauge) were filled with the three different solutions and
connected to a syringe pump (NE-1000, New Era Pump Systems, Inc., New York, NY, USA) working at
a constant flow rate (500 μL/h). The needles were clamped to the positive electrode of a high-voltage
power supply generating 26 kV at a distance of 24 cm from an aluminum disk used as a collector
(diameter of 8.75 cm). Only 2 mL of each solution were electrospun in order to obtain the same amount
of ciprofloxacin on both the films and nanofibers.
The morphology of foils and nanofiber mats was analyzed using SEM with a variable pressure
JSM-649 microscope (JEOL, Milan, Italy) equipped with a tungsten thermionic electron source working
in high vacuum mode and an acceleration voltage of 10 kV. The cross-section of the films was obtained
by cutting slices with a UCS ultramicrotome (Leica Microsystems, Wetzlar, Germany) equipped with a
glass knife. The specimens were coated with a 10-nm thick film of gold using the sputter coater 208 HR
(Cressington Scientific Instruments, Watford, U.K.).
2.2. Skin Samples and the Creation of Superficial Wounds
Abdominal skin was obtained after getting informed consent from healthy donors undergoing
plastic surgery. The study was conducted according to the Declaration of Helsinki guidelines and after
approval by the Ethics Committee of the Charité—Universitätsmedizin Berlin (approval EA1/135/06,
renewed on January 2018). Skin explants were used within 2–4 h after surgery. Subcutaneous fat tissue
was partially removed, keeping a layer of approximately 5 mm and skin pieces (1.5 × 1.5 cm) were
stretched and fixed on a Styrofoam block covered with Parafilm (Bemis Company, Neenah, WI, USA)
using needles. The surface of the ex vivo skin (free of injuries or redness) was cleaned with saline
solution (0.9% NaCl). The epidermis was then removed with a ball-shaped milling cutter 6 mm in size
(No. 28725, Proxxon, Föhren, Germany) mounted on a micro motor handpiece (Marathon N7, TPC
Advanced Technology, Inc. Diamond Bar, CA, USA) and rotating at 16,000 rpm. In this way, superficial
wounds of approximately 5 mm in diameter were produced [21].
2.3. Drug Penetration Kinetics
Using a punch biopsy cutter, discs of 8 mm in diameter were cut out from foils, as well as
nanofiber mats containing 44 mmol ciprofloxacin, so that each disc contained approximately 250 μg of
ciprofloxacin. Wounds of 5 mm in diameter were produced on 1.5 × 1.5 cm pieces of skin. The disks
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were applied on the top of the wounds on skin blocs of 1.5 × 1.5 cm that were stretched on a Styrofoam
block, placed in a humid chamber, and incubated at 37 ◦C, 5% CO2, and 100% humidity for different
time points. Thereafter, non-penetrated material was removed with a cotton swab and the treated
wound was removed from the rest of the tissue by means of an 8 mm punch biopsy tool. The tissue
was chopped into small pieces and placed in 2-mL tubes filled with HCl (0.1 N, 1.5 mL) to extract
the ciprofloxacin. The samples were gently mixed on a shaker for 24 h at room temperature. After
centrifugation for 5 min at 300× g, the supernatant was collected and placed in triplicate in a 96-well
plate (100 μL/well). Ciprofloxacin fluorescence (excitation wavelength: 275 nm, emission wavelength:
480 nm) was measured with an EnSpire® Multimode plate reader (Perkin Elmer, Akron, OH, USA).
A standard curve was prepared by dissolving ciprofloxacin in HCl (0.1 N) and preparing dilutions
(0.5–10 μg/mL). The amount of penetrated drug was calculated on the basis of the standard curve.
Results are presented as the means and standard deviations of three independent experiments.
2.4. Metabolic Activity of Skin Cells after the Topical Application of Ciprofloxacin on Ex Vivo Skin Wounds
Wounds were treated with 8 mm discs from PVP-foils loaded with 44 mmol of drug. Wounds
treated with NaCl solution (0.9%, 20 μL) served as negative controls, and wounds treated with
50 μg/cm2 PVP-coated silver nanoparticles (50 nm size, nanoComposix, San Diego, CA, USA) served as
positive controls. Samples and controls were incubated in six-well plates for 20 h in 2 mL RPMI-1640
medium (Gibco, Darmstadt, Germany) without phenol red supplemented with fetal calf serum (FCS)
(10%, Gibco, Darmstadt, Germany), glutamine (2mM, Gibco, Darmstadt, Germany), streptomycin
(100 μg/mL, Gibco, Darmstadt, Germany), and penicillin (100 I.E./mL, Sigma-Aldrich, Hamburg,
Germany). Thereafter, the old medium was replaced with fresh medium added with 500 μL of
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) (Roche Diagnostic,
Berlin, Germany). After 4 h, the medium from each sample and control was collected (3 × 100 μL) and
placed in a 96-well microplate. The optical density at 450 nm was read with the EnSpire® Multimode
plate reader using 650 nm as the reference wavelength. Results are presented as a percentage with
respect to the values from the control wounds. The averages and standard deviations of values from
three independent experiments are reported.
2.5. Histological Analysis of Wound Tissue after the Topical Application of Ciprofloxacin-Loaded Foils
Wounds created on ex vivo skin were treated with ciprofloxacin in solution or loaded on foils
and nanofiber mats (250 μg/wound). Wounds left untreated served as controls. Skin explant cultures
were grown in supplemented RPMI-1640 medium as described in Section 2.4. Every 2 days, the
medium (500 mL) was removed and fresh medium (500 mL) was added. After eight days of incubation,
the skin was plunge frozen in Tissue Freezing Medium (Leica Microsystems, Wetzlar, Germany) and
cryosections were prepared. Hematoxylin and eosin (H&E) staining was performed following the
manufacturer’s manual (Roth, Karlsruhe, Germany) and images were taken using optical microscopy
with an Olympus IX 50 (OLYMPUS, Hamburg, Germany).
2.6. Bacteria Inoculation and Characterization of the PAO1 Wound Infection
An overnight culture of the P. aeruginosa strain PAO1 (ATCC 15692) was diluted with tryptic
soy broth. The suspension (5 μL, 1 × 107 bacteria) was injected with a 10 μL syringe (26 gauge)
with a tapered tip (SGE Analytical Science, Ringwood, VIC, Australia) from the edge of the wound
into the dermis. As a control, sterile saline (5 μL, 0.9% NaCl) was injected in an uninfected control
wound. Wound samples were incubated in a humidified chamber at 37 ◦C for 20 h. Biopsies (8 mm)
were taken and fixed in a solution of formaldehyde (4%) and glutaraldehyde (0.5% in 50 mmol
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) for 48 h at room temperature. Skin
samples were then washed in HEPES (50 mmol), and dehydrated in 30, 50, 70, 90, 95, and 100%
ethanol. Samples were infiltrated first with a LR White/ethanol solution (1:1, 10 min), and then with
pure LR White (2 × 15 min). Successively, samples were transferred to polyallomer centrifuge tubes
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(5 × 20 mm, Beckman Coulter, Inc., Brea, CA, USA) containing LR White with an accelerator (5 μL/mL
monomer). The centrifugation tubes were capped with a gelatin capsule and the samples were left to
polymerize for 1 h on ice, and then at 60 ◦C overnight. Five hundred nanometer sections were cut
using a ultramicrotome (EM UC7, Leica, Wetzlar, Germany), mounted on poly-l-lysine slides, and
incubated for 10 min on an 80 ◦C thermo-plate. Sections were stained for 4 min with Richardson’s stain
(1% Azure II, 1% Methyleneblue, 1% Borax, Sigma-Aldrich, Hamburg, Germany, then washed with
double distilled water (ddH2O), and imaged using a microscope (Axiophot, Carl Zeiss Microscopy
GmbH, Jena, Germany). For analysis with a scanning electron microscope (SEM), after fixation, one of
the sample duplicates was cut with a scalpel in order to reveal the skin profile. The samples were then
dehydrated as described above, critical-point dried, mounted on aluminum stubs, sputter-coated with
a 12-nm layer of gold-palladium, and finally examined with an SEM (ZEISS 1530 Gemini, Carl Zeiss
Microscopy GmbH, Jena Germany) operating at 3 kV using the in-lens electron detector. Images have
been cropped, adjusted for optimal brightness, and contrasted using Photoshop Lightroom (version
6.0, Adobe Systems, San Jose, CA, USA).
2.7. Antimicrobial Activity of Ciprofloxacin-Loaded Foils and Nanofiber Mats
Each tested setting was done in triplicates with a total of at least three runs. Three different dosages
of ciprofloxacin were tested (11, 250, and 500 μg/wound). The treatments with PVP foils and nanofiber
mats started either 1 h or 20 h after bacteria inoculation and lasted for 20 h. Thereafter, an 8 mm punch
biopsy was used to collect the wound tissue, including some of the surrounding intact skin. The tissue
was placed in a 1.5 mL microcentrifuge tube containing saline (0.2 mL) and homogenized for 3 min
with a sterile steel pistil mounted on a digital overhead stirrer at 150 rpm (DSL, VELP Scientifica Srl,
Usmate, MB, Italy). Thereafter, samples were sonicated for 10 min in an ultrasonic bath (BactoSonic1,
Bandelin, Berlin, Germany) at 40 kHz using 200 Weff to detach the bacteria. Volumes of each sample
were transferred to the wells of 96-well microplates and diluted in 1:10 steps (20 μL sample + 180 μL
saline) by using a multichannel pipette. A volume (5 μL) of each well was plated on square tryptic soy
agar plates. After incubation overnight at 37 ◦C, spotting areas with 5 to 50 colony forming units (CFU)
were counted. Mean values of the triplicates were calculated and bacteria number per wound was
calculated considering the used dilutions. In the diagrams, bacteria counts/wound are presented as the
mean and standard deviation of three independent experiments.
2.8. Data Analysis
Data are reported as arithmetic means and standard deviations of at least three experiments.
Calculations, data processing, and graphics were prepared with Excel 2018 (Microsoft, Redmond,
WA, USA).
3. Results and Discussion
3.1. Preparation and Characterization of Drug-Loaded Foils and Nanofiber Mats
Starting from aqueous solutions of PVP, acetic acid, and ciprofloxacin at different concentrations,
transparent films and nanofiber mats were fabricated using the solvent casting and electrospinning
methods, respectively (Figure 1).
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Figure 1. Schematic representation of the methods used for the film and nanofiber mat fabrication, and
pictures of the discs used in the experimental set up. Cipro—ciprofloxacin; PVP—polyvinylpyrrolidone.
The final dry transparent foils had a thickness of 150–180 μm and the absence of crystal
formation was verified using SEM (Figure A1, Appendix A). As recently demonstrated, the obtained
PVP-based foils represent suitable wound dressings due to their flexibility, adhesion, and resorption
properties [19,28]. The nanofiber had an average diameter of 360 ± 80 nm and did not show any defects
or beads (Figure A2, Appendix A).
3.2. Foils and Nanofiber Mats Had Different Drug Delivery Profiles
Foils and nanofiber mats (discs of 8 mm in diameter) were applied on the top of the 5 mm in
diameter wounds created on the 1.5 × 1.5 cm ex vivo skin tissue to provide an applied drug dosage
of approximately 250 μg/wound. The skin explants were incubated in humidified chambers in an
incubator with 100% humidity. This maintained the wetness of the skin blocks, which favored the
dissolution of foils and nanofibers. After different incubation times, the non-penetrated material was
removed, 8 mm biopsies were taken, and extracts were prepared to measure the amount of penetrated
drug (Figure 2).
Figure 2. Time-dependent concentration of ciprofloxacin into wound tissue after the topical application
of ciprofloxacin-loaded foils (a) and nanofibers (b). Ciprofloxacin in wound tissue extracts was
measured by means of a fluorescence microplate reader and drug concentration was calculated from
standard curves. Means and standard deviations from three independent experiments using skin from
three different donors are reported.
Both penetration kinetics could be well-fitted to a second-degree polynomial trend line. Amounts
ranging between 12 and 18 μg of ciprofloxacin/wound were detected for foils, whereas amounts ranging
between 5 and 10 μg/wound were measured for nanofiber discs. Foils delivered high amounts of
ciprofloxacin very quickly (approximately 12 μg after only 2 h), whereas nanofiber mats reached similar
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concentrations later, after 6 h. Interestingly, foils maintained the reached drug concentration in the
wound over 24 h. On the contrary, in samples treated with nanofiber mats, the maximal concentration
was maintained for a shorter time range (6–16 h). The decreased amounts of drug in the wound tissue
observed for nanofiber mats (Figure 2b) were due to drug diffusion to the neighboring tissue (Figure A3,
Appendix B). We suppose that for nanofiber mats, a lower amount of drug penetrated the wound
tissue and that, due to diffusion to the nearby skin tissue, a reduction of local drug concentration in
the wound was measured after 24 h. On the contrary, foils delivered a higher amount of drug to the
wound and could saturate both the wound and the nearby tissue.
In a previous study, the dissolution rate and drug release for both materials was investigated in
a phosphate buffer and on a mice full-thickness wound model [19]. Results showed that nanofibers
dissolved and released the loaded drug very quickly, within the first two hours, whereas foils took
longer. The fast dissolution of nanofibers might result in a high local concentration causing drug
precipitation or crystallization, which in turn can hinder drug penetration. Another important aspect
to be considered is that the investigated PVP-foils contained higher amounts (1.4%) of residual acetic
acid than the nanofiber mats (0.3%) [19], which might also have had an influence on drug solubility
and penetration.
In summary, drug penetration experiments using the ex vivo wound model showed that both
drug delivery systems could deliver the loaded antibiotic to the wound tissue in a controlled manner.
The ability of PVP-foils to maintain a high drug concentration in the wound over 24 h is of significance,
especially for the treatment of biofilm infections, which need high antibiotic concentrations to be
resolved. On the other side, the more controlled delivery profile of the nanofiber mats might be more
useful for the prevention of wound infections.
3.3. Local Toxicity of Ciprofloxacin in Full-Thickness Ex Vivo Skin
The wound model was also used to test the potential cytotoxicity of the drug and investigated
materials after topical application. For these experiments, tissue blocks were cultured in supplemented
RPMI 1640 medium at the air–liquid interface. After 20 h of treatment, tissue viability was tested by
means of an XTT test (Figure 3a).
Many cells in skin explants were still metabolically active and an evident formation of the red
formazan product was observed. PVP foils did not show any toxicity. This was somehow expected with
PVP being a well-tolerated, FDA-approved polymer with many uses, such as a food additive, binder
in tablets, and plasma volume expander [29]. Also, foils prepared from a PVP solution in 30% acetic
acid resulted in having no effect on skin viability due to the fact that only residual amounts of acetic
acid molecules remained within the PVP polymers after solvent evaporation during the preparation
process [19]. Finally, the PVP foils loaded with the three concentrations of ciprofloxacin also resulted in
having no influence on the overall viability of skin cells after 20 h of incubation. Wounds treated with
silver nanoparticles, which release toxic silver ions, served as positive controls. The evident reduction
of formazan formation was indicative of silver toxicity toward wound cells. Thus, even if this test gave
no information about the type of cells being affected by the tested substances, it was a useful method
to detect overall acute toxic effects.
Previous studies have shown that ciprofloxacin has toxic effects on fibroblasts [30] and
keratinocytes [31]. Toxicity was shown to be time- and concentration-dependent. For this reason, we
tested the effect of ciprofloxacin delivered by the investigated foils with regard to re-epithelialization.
After 9 days of incubation in supplemented RPMI-1640 medium, a partial re-epithelialization had
occurred in controls, with the re-growing of a keratinocyte layer on the edges and in the wound bed
(Figure 3b,d,e). Cell nuclei and the collagen network presented a normal morphology in samples
treated with empty PVP foils with residual acetic acid. Only a delayed re-epithelialization was
observed, probably due to oxygen deprivation (data not shown). On the contrary, in wounds treated
with ciprofloxacin, only a thin epithelial layer was observed. Cells’ nuclei appeared small with an
irregular morphology typical of necrotic cells and the collagen matrix was less organized than in the
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controls (Figure 3c,f,g). This effect was visible in all samples treated with ciprofloxacin at different
concentration and was independent of the formulation (data not shown).
In recent years, it has been recognized that fluoroquinolones, despite being well tolerated by a
broad portion of patients, can have rare and very disabling side effects like a tendon rupture and
irreversible nerve damage [13]. There are several hypotheses on the mechanism of toxicity and on the
reason why some persons develop these side effects more than others do. One theory is that there
might be a gene variant responsible for a disrupted quinolone metabolism. Our results show that,
despite ciprofloxacin inducing no changes in whole skin metabolic activity, it negatively influenced
the re-epithelialization of ex vivo wounds. Even if this side effect is tolerable in the case of severe
wound infections, these results stress the importance of a more local and controlled release of drugs
like ciprofloxacin that have narrow therapeutic windows.
Figure 3. Local toxicity of ciprofloxacin delivered using PVP-foils. (a) The XTT assay was run with
a skin biopsy previously treated for 20 h with: 0.9% NaCl (1); PVP foils prepared from solutions in
ddH2O (2); PVP foils prepared from solutions in 30% acetic acid (3); PVP foils loaded with 11 μg (4),
250 μg (5), and 500 μg (6) of ciprofloxacin; and 50 μg of PVP-coated silver nanoparticles (7). Means and
standard deviations from three independent experiments are reported. (b,c) Picture collage of H&E
stained sections after 9 days of tissue culture of (b) an untreated wound and (c) a wound treated with a
PVP foil loaded with 250 μg ciprofloxacin. (d–g) Details from the centre (d,f) and the edges (e,g) of
control (d,e) and treated (f,g) wounds. Arrows show a newly formed epithelial layer.
3.4. Ciprofloxacin-Loaded Foils and Nanofiber Mats Efficiently Reduced P. aeruginosa Infections
Next, we investigated the antimicrobial efficacy of the investigated drug delivery systems using
the ex vivo skin infection model (Figure 4). The PAO1 strain was used, which possesses several
proteolytic enzymes, among those collagenases, and was shown to build biofilm-like infections on
ex vivo skin [21]. Bacteria inoculated in the wounds grew from 1 × 107 to 1 × 109 bacteria per
wound after 20 h of incubation. Macroscopically, the surface of the PAO1-infected wound appeared
shiny and yellowish (Figure 4c). Scanning electron microscopy images of the wound surface showed
bacteria conglomerates typical of a biofilm. These three-dimensional structures are made of bacteria,
extracellular materials, and probably of degraded collagen material (Figure 4d,e). The microscopic
pictures of H&E-stained skin sections (Figure 4f) revealed an approximately 10-μm-thick bacteria
171
Pharmaceutics 2019, 11, 527
film on the surface of the wound, but also groups of bacteria deep in the wound tissue (circles). The
scanning electron microscopic analysis of the wound profile (Figure 4g,h) confirmed the formation of a
bacterial biofilm within the superficial wound tissue, as well as the presence of small agglomerates or
scattered bacteria deep in the wound.
Figure 4. Wound infection model with the P. aeruginosa strain PAO1. (a) A superficial wound of
approximately 5 mm in diameter was produced on skin explants. (b) Bacteria (1 × 107 per wound) were
inoculated and skin explants, which were incubated for 20 h in the previous analysis. (c) Microscopic
appearance of a representative wound 20 h after the PAO1 injection. (d,e) SEM images of the wound
surface at two different magnifications showing the typical morphology of bacterial communities in the
biofilm. (f) Wound section stained with H&E showing a bacteria layer on the surface of the wound and
bacteria agglomerates deep into the tissue (circles). (g,h) SEM images of wound sections at different
magnifications confirming bacterial growth on the surface (g) and deep in the wound tissue (h).
In the ex vivo model, most of bacteria grew on the wound’s surface, despite the fact that they
were inoculated deep in the connective tissue. P. aeruginosa can grow in both aerobic and anaerobic
conditions. However, the less favorable conditions and shortage of oxygen in the deeper wound layers
resulted in a slower proliferation of bacteria. Nevertheless, these small colonies can be the reason for
recurrent infections if not eradicated during a treatment. For this reason, the penetration of adequate
drug concentrations deep in the wound tissue and the eradication of all bacterial colonies is a crucial
factor for a successful therapy.
Pseudomonas aeruginosa has already been cultured on ex vivo skin [24,32–35]. In this study,
we used the ex vivo wound infection model as a three dimensional set up to test the capacity of
ciprofloxacin-loaded PVP drug delivery systems to eradicate bacteria located not only on the surface,
but also deep in the wound’s tissue. The investigated foils and nanofiber mats were loaded with three
different concentrations of ciprofloxacin, corresponding to final doses of 11, 250, and 500 μg per wound.
The treatments were applied on the top of the wounds 1 h or 20 h after bacteria inoculation and kept
for a further 20 h. After 1 h of inoculation, bacteria were still planktonic and thus less resistant to
antibiotics. After 20 h of inoculation, the number of bacteria had increased and bacteria were organized
in a biofilm, which was more difficult to treat. Samples treated 1 h after bacteria inoculation served to
test the drug efficacy toward a moderate infection with approximately 1 × 107 planktonic bacteria,
whereas samples treated 20 h after PAO1 inoculation served to test the efficacy of foils and nanofiber
mats on a severe infection with approximately 1 × 109 bacteria primarily organized into a biofilm. The
experiment terminated after a total of 40 h.
Macroscopically, a thick, yellow biofilm was visible on the surface of untreated wounds, whereas
no bacterial film was visible on the treated samples (Figure 5a).
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Figure 5. Antimicrobial efficacy of PVP foils and nanofiber mats with different ciprofloxacin payloads
applied on wounds infected with planktonic bacteria in a biofilm. (a) Representative pictures of
untreated and treated wounds after 40 h of incubation. (b,c) Bacteria count in tissue extracts of wounds
treated with foils (b) or nanofiber mats (c). (d) Bacteria counts in control wounds treated with plain
PVP foils prepared from solutions in water or 30% acetic acid. Means and standard deviations of
three independent experiments (three donors) run in triplicate are reported. Cipro—ciprofloxacin;
AcCOOH—acetic acid.
Drug crystals were visible on the wound edges, where higher concentrations of the drug were
reached after the foils or nanofibers had dissolved. When applied 1 h after bacterial inoculation, both
foils and nanofiber mats resulted in a complete eradication of the bacterial infection independent from
the amount of drug that was applied. This result shows the potential of these drug delivery materials
for the prevention of wound infections. In particular, nanofibers should be tailored to obtain a more
controlled drug delivery in order to have effective antimicrobial concentrations and limit adverse
side effects.
In contrast, the 20-h-biofilm infection was more difficult to treat. PVP foils had the best performance
(Figure 5b). Foils loaded with 500 μg ciprofloxacin achieved a complete eradication of the bacteria, and
the two lower concentrations resulted in a 3-log reduction of bacteria concentration with respect to the
untreated controls. Nanofiber mats had a lower antimicrobial activity with a maximal 3-log reduction
achieved by the highest concentration. No effect on bacterial growth was measured for plain PVP foils
or foils with residual acetic acid (Figure 5d).
The most striking result was the complete eradication of the biofilm infection achieved with the
500-μg PVP foils. Foils have a higher percentage of residual acetic acid (1.4%) than nanofiber mats
(0.1%) [19]. Because acetic acid also has antimicrobial activity, it might have acted synergistically with
ciprofloxacin. Nevertheless, the superior efficacy of the foils compared to the nanofiber mats correlated
well with the delivery kinetics. Foils delivered higher amounts of the drug and over a longer time than
nanofibers did. Phillips et al. assessed the efficacy of several commercially available treatments in a
porcine ex vivo wound model and found that time-release silver gel and cadexomer iodine dressings
were the most effective in reducing a mature biofilm with a reduction between 5 and 7 logs out of a 7-log
total [24]. Using an in vivo mouse model, Roy et al. found that ciprofloxacin-loaded keratin-based
hydrogels with a sustained drug release profile could reduce the amount of P. aeruginosa in the wound
bed by 99.9% without interfering with the key processes of wound healing [36]. Thus, these and our
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results underline the importance of drug delivery systems with a sustained release profile for the
efficient treatment of P. aeruginosa wound infections.
4. Conclusions
In this study, we used full-thickness ex vivo human skin and a wound infection model to
investigate the efficacy and tolerability of ciprofloxacin-loaded PVP foils and nanofiber mats. The
model allowed us to test the antimicrobial efficacy of these materials and to correlate it to their delivery
properties. Ciprofloxacin was representative of a poorly water-soluble drug to be loaded in PVP-based
drug delivery systems. The use of a solubilizer (acetic acid) increased the loading capacity and drug
delivery properties of nanofibers and foils. This was in turn a crucial point for the accomplishment of
high local drug concentrations that were required for the successful prevention and eradication of the
PAO1 biofilm infections.
This strategy can be used to load PVP-based delivery systems with different types of drugs
or disinfectants, including high molecular weight moieties. Besides their sustained drug release
properties, such matrixes allow for a more precise dosing of the active ingredient in comparison to
ointments or creams. Foils and nanofiber mats are flexible and can be easily applied in less accessible
skin areas, e.g., the lower back or between the toes, which is an advantage, especially for old and
disabled patients. Thus, we conclude that the combination of drug delivery systems and solubilizing
agents is a promising strategy to create attractive new pharmaceutical forms for topical drug delivery
to treat or prevent wound infections.
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Appendix A
Morphological Analysis of Films and Fibers
To verify the absence of crystals in the drug-loaded membranes, SEM analysis was performed.
In Figure A1, representative images of the top-view and cross-section of ciprofloxacin-loaded foils
(88 mmol) are reported.
 
Figure A1. SEM images of the top-view (A) and cross-section (B) of a ciprofloxacin-loaded PVP foils.
Figure A2 shows representative SEM images of the ciprofloxacin-loaded nanofibers (2.2, 44,
and 88 mmol). The diameter of the fibers was determined using ImageJ software. Approximately
100 measurements were taken to obtain the diameter distribution of each type of fiber mat.
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Figure A2. (A–C) Top-view SEM images of the PVP nanofibers loaded with (A) 1.2, (B) 30, and (C) 60
mg of ciprofloxacin respectively.
Appendix B
Drug Diffusion to the Surrounding Skin Tissue
In order to estimate the amount of drug that diffused to the nearby tissue, skin blocks were treated
with ciprofloxacin loaded on PVP-foils or a solution of the drug in water. The wound tissue, as well
as the surrounding tissue, were extracted and analyzed (Figure A3). The kinetics showed that the
drug accumulated first in the wound tissue and diffused successively to the nearby tissue. After
approximately 16 h, similar concentrations were reached in both areas of the ex vivo tissue block.
Figure A3. Penetration of ciprofloxacin into the wound and surrounding tissue after the topical
application of (a) ciprofloxacin-loaded PVP foils (250 μg/wound) and (b) a solution of ciprofloxacin
base in water (13 μg/wound).
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Abstract: Arsenic trioxide (ATO) has a significant effect on the treatment of acute promyelocytic
leukemia (APL) and advanced primary liver cancer, but it still faces severe side effects. Considering
these problems, red blood cell membrane-camouflaged ATO-loaded sodium alginate nanoparticles
(RBCM-SA-ATO-NPs, RSANs) were developed to relieve the toxicity of ATO while maintaining its
efficacy. ATO-loaded sodium alginate nanoparticles (SA-ATO-NPs, SANs) were prepared by the ion
crosslinking method, and then RBCM was extruded onto the surface to obtain RSANs. The average
particle size of RSANs was found to be 163.2 nm with a complete shell-core bilayer structure, and
the average encapsulation efficiency was 14.31%. Compared with SANs, RAW 264.7 macrophages
reduced the phagocytosis of RSANs by 51%, and the in vitro cumulative release rate of RSANs was
95% at 84 h, which revealed a prominent sustained release. Furthermore, it demonstrated that RSANs
had lower cytotoxicity as compared to normal 293 cells and exhibited anti-tumor effects on both NB4
cells and 7721 cells. In vivo studies further showed that ATO could cause mild lesions of main organs
while RSANs could reduce the toxicity and improve the anti-tumor effects. In brief, the developed
RSANs system provides a promising alternative for ATO treatment safely and effectively.
Keywords: red blood cells membrane; arsenic trioxide; sodium alginate nanoparticles; reduce toxicity;
anti-tumor
1. Introduction
Arsenic trioxide (ATO) is the main active ingredient of traditional Chinese medicine (TCM)
Arsenic. In the 1970s, it was first applied to acute promyelocytic leukemia (APL) with significant
efficacy [1] and was approved by the National Medical Products Administration (NMPA) and Food
and Drug Administration (FDA) as a first-line treatment for APL in 1999 and 2000, respectively [2,3].
ATO can induce cell differentiation, inhibit apoptosis, and exert anti-tumor effect [4]. In recent years,
research studies have confirmed the significant growth inhibition and apoptosis induction effect of
ATO in solid tumors, such as liver cancer, breast cancer, stomach cancer, glioma and lung cancer [5–11].
At present, ATO injection has been employed clinically in the treatment of APL and advanced primary
liver cancer. However, the unique physicochemical properties of ATO allow it to be rapidly cleared
from blood, and it requires daily administration during clinical treatment. At the same time, the
uptake of the reticuloendothelial system (RES) makes only a slight amount of ATO reach the tumor
site. Nevertheless, considering the potent toxicity of ATO, increasing the dose of ATO will increase the
systemic toxicity and cause damage to the liver, kidney, heart, and peripheral nerve [12–14].
Based on the size advantage, nanoparticles (NPs) can exude through the tumor vasculature and
effectively delivery the drugs to cells through enhanced permeability and retention (EPR) effects [15].
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Therefore, it is considered to be a kind of formulation with low toxicity and high stability. Different
ATO delivery systems (DDS) have been developed, including magnetic nanoparticles [16], chitosan
nanoparticles [17], microspheres [18], liposomes [19], and mesoporous silica nanoparticles [10,20]. These
formulations can achieve sustained release of ATO, which can reduce the transient plasma concentration
and toxicity of drugs to a certain extent. However, they are still deficient in biocompatibility, and the
safety of these systems needs to be verified [21].
Sodium alginate (SA) is a sort of polyanionic polysaccharide alginic acid salt found in brown
algae that is water-soluble and has the advantages of anti-tumor effect, immune regulation, non-toxic,
biodegradability, and excellent biocompatibility [22,23]. It has been approved by FDA for the
pharmaceutical industry as an excipient [24,25]. For the past few years, NPs prepared from SA as drug
carrier systems have also attracted more attention [26,27]. Red blood cells membrane (RBCM) will
be formed into vesicles (RVs) using extrusion or sonication methods [28]. As a drug carrier, it can be
attached to the surface of NPs to sustain the release of drugs, avoid elimination by the immune system,
increase drug stability, improve biocompatibility and thus prolong drug circulation in vivo [29,30].
Moreover, RBCM coating nanotechnology already has excellent precedents. Che-Ming J et.al [31]
demonstrated the synthesis of an RBCM coated polymeric nanoparticle for long-circulating cargo
delivery, Jinghan Su et al. [32–34] extensively studied the effectiveness of RBCM-camouflaged NPs for
treating metastatic breast cancer. In addition, if the non-toxic SA nanoparticles can be encapsulated by
natural RBCM and combine the superiorities of sustained release and prolonging residence time, the
nano-system can achieve the purpose of maintaining efficacy and reducing toxicity. In addition, this
can provide a new possibility for safe application of ATO.
In this study, RBCM-camouflaged ATO-loaded sodium alginate nanoparticles
(RBCM-SA-ATO-NPs, RSANs) were prepared as shown in Figure 1. ATO-loaded sodium
alginate nanoparticles (SA-ATO-NPs, SANs) were prepared by the ion crosslinking method, followed
by coating of RBCM to obtain RSANs. It was then systematically characterized and evaluated for its
efficacy and toxicity. The results indicated that the system might become a promising delivery system
for the safe, effective, and sustained release of ATO.
Figure 1. Preparation and Characterization of RSANs.
2. Materials and Methods
2.1. Materials
SA (200–500 Pa·s) was purchased from Shanghai Taitan Technology Co., Ltd., Shanghai,
China, anhydrous calcium chloride (CaCl2) was purchased from Shanghai Lingfeng Chemical
Reagent Co., Ltd., Shanghai, China and Polosham 188 (F-188) was purchased from Shaanxi
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Zhengyi Pharmaceutical Accessories Co., Ltd. Carbon support copper mesh (230 mesh) and
phosphotungstic acid were obtained from Beijing Zhongjing Keyi Technology Co., Ltd., Beijing,
China. 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (Dil, cell membrane green
fluorescent probe), Hoechst 33342, 4% paraformaldehyde fix solution, antifade mounting medium and
Cell Counting Kit-8 (CCK-8), were all purchased from Biyuntian Biotechnology Co., Ltd., (sShanghai,
China) 5(6)-aminofluorescein was bought from Nanjing Xinfan Biotechnology Co., Ltd., Nanjing, China.
Polycarbonate film was bought from Whatman Company, City, UK. Dialysis bag (Cut-offmolecular
weight = 3500Da) was obtained from United States for carbonization. Fetal bovine serum (FBS), RPMI
1640 medium, and DMEM medium were ordered from the Shanghai Chenyi Biotechnology Company,
Shanghai, China. Trypsin and penicillin-streptomycin were purchased Yingjie Jieji (Shanghai) Trading
Co., Ltd., Shanghai, China.
2.2. Cells and Animals
RAW264.7 cells (mice macrophages) and HEK-293 cells (normal human embryonic kidney cells)
were bought from the Shanghai Cell Bank of the Chinese Academy of Sciences, Shanghai, China, and
cultured with DMEM complete medium. SMMC-7721 cells (human liver cancer cells) and NB4 cells
(APL cells) were obtained from Shanghai Jihe Biotechnology Co., Ltd., Shanghai, China and cultured
with RPMI 1640 complete medium. Culture of the cells was performed in an incubator kept at 5%
CO2 and 37 ◦C. The male BALB/c nude mice (SCXK 2017-0005) were obtained from Shanghai Slack
Laboratory Animals Co., Ltd., Shanghai, China and kept in the Specific Pathogen Free (SPF) animal
room of School of Pharmacy, Shanghai Jiao Tong University. Guidelines for care and use of laboratory
animals of Shanghai Jiao Tong University were used to perform animal studies and these studies were
duly approved by the animal ethics committee of Shanghai Jiao Tong University (No: A2019046, Date:
5 July 2019).
2.3. Preparation of SANs
SANs were prepared by the ion crosslinking method. In brief, 1.5 mL of 2 mg/mL CaCl2 was
slowly added into 10 mL of 0.3 mg/mL SA (pH = 5) under stirring. After sonication for 5 min at 250 W,
0.1 mL of 10 mg/mL F-188 was added and then stirred for 30 min. To obtain SANs, 0.2 mL of 8 mg/mL
ATO was added and stirred for other 30 min.
2.4. Preparation of RBCM
RBCM was extracted by hypotonic rupture method. In brief, whole blood of SD rats (bought from
Shanghai Jiesijie Experimental Animal Co., Ltd., Shanghai, China) was collected through abdominal
aorta. The blood was centrifuged (2000 rpm, 5 min, 4 ◦C), to obtain red blood cells (RBCs), and then
washed with 1× phosphate buffer saline (1× PBS) for 3 times. To collect RBCM, 900 μL EDTA (0.2 mM)
was added to disrupt the RBCs, followed by centrifugation (13,200 rpm, 10 min, 4 ◦C), and the above
steps were repeated until the supernatant turned colorless. The obtained RBCM was resuspended in
EDTA, and then stored in −80 ◦C refrigerator.
2.5. Preparation of RSANs
The prepared RBCM was sonicated at 250 W for 3 min to obtain RVs, and then sequentially
extruded through polycarbonate films of 800 nm, 400 nm, and 200 nm by LF-50 extruder (Avestin
Inc, agented by Shanghai Narujie Biotechnology Co., LTD, Shanghai, China) for at least 15 times
respectively. The solutions of RVs and SANs were mixed at a ratio of 1:8(v/v). The prepared mixture
was then extruded through polycarbonate films of 400 nm and 200 nm at least ten times, respectively,
to obtain RSANs.
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2.6. Characterization and Stability Test
The particle size and polydispersity index (PDI) of SANs and RSANs were determined by Malvern
Zetasizer (He-Ne, 4.0 Mw, λo = 633 nm, Marvin instruments Ltd., Marvin, United Kingdom. The
stability test was investigated simultaneously. The particle size and PDI of SANs and RSANs were
measured for 15 days consecutively at both 4 ◦C and 37 ◦C.
2.7. Morphological Observation
Transmission electron microscopy (TEM, Thermo Fisher Scientific, Shanghai, China) was
performed to evaluate the morphology of RSANs. 10 μL sample solutions were dropped on
carbon-supported copper, air-dried and then rinses with 10 μL ultrapure water. Drip 10 μL 2%
phosphotungstic acid to stain the samples, and the excess dye was removed with filter paper from the
edge. After baking 30 min under an infrared baking lamp, the morphology was observed by TEM.
2.8. Drug Loading Capacity and In Vitro Release Study
The release study of ATO encapsulated in nanoparticles was performed in 1×PBS (pH 7.4). 2
mL ATO solution (final concentration of 135.6 μg/mL), SANs, and RSANs solution were placed into
dialysis bags, respectively (Mw = 3500). The dialysis bags were fastened at both ends and maintained
under sink conditions at 37 ◦C using 50 mL PBS, then magnetically stirred at 100 rpm. At time point of
3 h, encapsulation efficiency (EE) and drug loading capacity (DL) of the nanoparticles were analyzed
by extracting 1 mL release solution. The optimal DL and EE were investigated by adding different
concentrations of ATO. For the determination of in vitro release, 1 mL release sample was taken at
0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72, and 84 h, and then replaced with 1 mL of fresh PBS. The aliquots were
filtered through 0.22 μm microfiltration membrane and diluted up to 50 times. Inductively coupled
plasma-atomic emission spectroscopy (ICP-AES) was used to detect the concentration of ATO. In
addition, the following formulas were used to calculated DL and EE.
Encapsulation Efficiency (%) = (M1 −M2)/M1 × 100%
Drug Loading Capacity (%) = (M1 −M2)/(M1 −M2 +M3) × 100%
where M1 means the total amount of used ATO, M2 is the amount of ATO in the dialysis solution, and
M3 is the amount of used SA.
2.9. Hemolysis Test
Since it is administered by intravenous injection (iv), it is necessary to ensure that the
nano-preparation will not cause hemolysis or cell aggregation. RBCs from the blood of SD rats
were collected and normal saline was added to obtain a 2% (v/v) RBC suspension. The water, normal
saline, RBC suspension, and RSANs were mixed into 12 tubes according to the ratio shown in Table 1.
Tube 1 (RSANs) replaced with ultrapure water served as a positive control, while tube 2 (RSANs)
replaced with saline as negative control. The results after incubation of 3 h and 24 h at 37 ◦C were
recorded. Meanwhile, the absorbances of supernatant were determined at 3 h and 24 h through an
ultraviolet spectrophotometer at the wavelength of 540 nm, and then the percentage of hemolysis was
calculated according to formula:
Percentage of Hemolysis (%) = (Asample − Atube 2)/(Atube 1 − Atube 2)
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Table 1. Hemolysis test of RSANs.
Tube No. 1 2 3 4 5 6 7 8 9 10 11 12
2% RBC Suspension (mL) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Saline (mL) 0 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6 1.5
Ultrapure Water (mL) 2.5 0 0 0 0 0 0 0 0 0 0 0
Samples (mL) 0 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
2.10. Macrophage Uptake Study
The immune escape ability of nanoparticles was investigated through RAW 264.7 cells. SA was
labeled with 5(6)-aminofluorescein, and SANs and RSANs were prepared with labeled SA. A 12-well
plate (2 × 105 cells per well) was used for 24 h incubation. Serum-free medium was used to starve
cells for 1 h and then replaced by complete medium containing SANs or RSANs (SA concentration
was 50 μg/mL). A complete medium without nanoparticles was used as blank group. The cells
were observed with laser scanning confocal microscope (LSCM) after incubation for 2 h. Before
being photographed, the cells were fixed with 4% paraformaldehyde. The excitation wavelength
of 5(6)-aminofluorescein was 493 nm. Also, three parallel groups were set up to detect the uptake
quantitatively. After incubation with the drugs, each group was first digested with trypsin and then
washed with PBS for 3 times, then resuspended in 500 μL PBS. The detection was performed through
the FITC channel of a flow cytometer.
2.11. In Vitro Cellular Uptake
To investigate the uptake of nano-formulations by tumor cells and the structural integrity of NPs
during this process, the test was implemented on NB4 and 7721 cells. The determination method was
described in Section 2.10. For the qualitative detection, RSANs were prepared with labeled SANs and
RVs (the RVs was labeled with Dil). The density of 7721 cells was 2 × 105 cells per well, and the cells
were cultured for 24 h. The cells were then treated in the same way as Section 2.10. After an incubation
of 2 h, Hoechst 33342 was used to stain the nuclei for 15 min, and then the uptakes were observed with
LSCM. The cells were fixed with 4% paraformaldehyde before being photographed. Since NB4 cells is
a kind of suspension cells, the density of inoculation was doubled to avoid loss during the experiment,
and finally immobilized on a glass slide coated with polylysine. The other steps were the same as the
7721 cells. The excitation wavelengths of 5(6)-aminofluorescein, Dil and Hoechst 33342 were 493 nm,
549 nm, and 405 nm, respectively.
2.12. Cytotoxicity Test
To investigate the toxicity of blank carrier material, the prepared SA nanoparticles (SNs) and
RBCM-SA nanoparticles (RSNs) without ATO were diluted with DMEM complete medium to obtain
SA concentrations of 8, 12, 20, 30, 40, 50, 60 μg/mL respectively. To investigate the toxicity of the
nanoparticles after drug loading, free ATO solution, SANs, and RSANs were diluted to obtain different
concentrations of ATO (1, 2, 4, 6, 8, 10, 12, 20 μg/mL). The above groups were administration groups
(AG). 100 μL 293 cells (5 × 104 cells/mL) were placed into a 96-well culture plate for 24 h. The nutrient
medium was then replaced with 100 μL AG. At 24 h time interval, all the groups were cultured with
100 μL CCK-8 for 2 h. Only DMEM medium was set as a blank group (BG) and only 293 cells were
set as a control group (CG). The optical density (OD) of samples were determined at 450 nm by a
microplate reader and the following formula was used to calculate the cell viability.
Cell viability (%) = (ODAG − ODBG)/(ODCG − ODBG) × 100%
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2.13. In Vitro Efficacy Study
NB4 and 7721 cells were selected to evaluate efficacy. 100 μL NB4 and 7721 cells (5 × 104 cells/mL)
were inoculated in a 96-well culture plate overnight, respectively. Then free ATO solution, SANs, and
RSANs were administered to the cells, respectively. The concentrations of ATO were diluted to 1, 2,
4, 6, 8, 10, 12, 20 μg/mL. After 24 h, 100 μL CCK-8 were administered to evaluate the cell viability.
To further investigate the inhibitory effect, the concentration of the ATO of each group was fixed at
1 μg/mL. The OD was measured after incubation of 4, 8, 12, 24, 36, 48, and 60 h, and the cell viability
was determined. The blank and control groups were same as mentioned in Section 2.12.
2.14. In Vivo Toxicity and Safety Test
Due to the potent toxicity of ATO, the administration concentration at a safe level should be
determined at first. For 2 weeks, ATO with high (40 μg/mL), medium (20 μg/mL) and low concentration
(10 μg/mL) was administered through the tail vein respectively once a week at a dose volume of 0.2
mL per mouse. The mental state and death of nude mice were registered during the period.
The aim of the safety trial was to investigate whether the continuous intravenous injection of
RSANs would cause lesions on systemic, hematological, and major organs. Afterward, the healthy
nude mice were divided into the saline group, ATO group, SANs group, and RSANs group. The drugs
were administered once every 2 days at dose volume of 0.2 mL per mouse and repeated seven times.
The weight of the mice was recorded at 1, 3, 5, 7, 9, 11, 13 days after administration. Meanwhile, the
mental state and death of mice were observed during the process. 2 days after the last administration,
orbital blood was collected into the tubes, pre-mixed with heparin sodium, and white blood cells
(WBC), glutamate pyruvic transaminase (ALT), aspartate aminotransferase (AST) were analyzed. In
addition, after the mice were sacrificed by CO2 asphyxiation, the principal organs were excised. The
viscera coefficients were calculated after weighing. Furthermore, the tissues were fixed with paraffin
solution for immunohistochemical analysis (H & E) to examine its structure and morphology.
Visceral coefficient =weight of organ/body weight
2.15. In Vivo Anti-Tumor Studies
Male nude mice 6–8 weeks old with 7721 cells were used to investigate the anti-tumor effects
of our nanoparticles. First we established xenograft tumor model. For the establishment of tumor
model, 7721 cell suspension (2 × 107 cells /mL) in a volume of 0.2 mL was injected subcutaneously in
the armpit of the upper limb. In addition, then the formula width2 × length/2 was used to calculate
the tumor volume every other day. At tumor volume of 100–250 mm3, then mice were grouped
into four treatment groups (n = 5): (1) saline, (2) ATO, (3) SANs, and (4) RSANs. The drugs were
administered intravenously at a dose of 1.3 μg/g every two days and repeated seven times. The CG
was given normal saline for seven times. At the same time, the body weight and the tumor volume
were recorded to evaluate for tumor inhibition efficacy as well as systemic toxicity. Two days after the
last administration, the mice were sacrificed by CO2 asphyxiation, and the tumors were excised from
each animal. The tumors were rinsed with normal saline, dried, and photographed, and the average
tumor weight of each group was determined.
2.16. Statistics and Data Analysis
Data expression was shown as ± SD of the mean. Significant differences between SANs and
RSANs were analyzed by Tukey Kramer multiple comparison tests, using GraphPad Prism Software,
v.6.01 (GraphPad Software, Inc.). Results with p < 0.05 were considered significant and very significant
with p < 0.01.
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3. Results and Discussion
3.1. Characterization and Stability Test
The average size of RSANs was found to be 163.2 ± 4.4 nm (Figure 2A), which increased by about
15 nm as compared to SANs (147.9 ± 5.1 nm). The increment was consistent with the thickness of
RBCM [35]. The PDI of SANs and RSANs was 0.24 and 0.27, respectively (Figure 2B), which indicated
that NPs were well dispersed. In addition, the particle size of the nanoparticles was stable under
200 nm despite a slight increase in 15 days (Figure 2C) under the storage condition of 37 ◦C. The
PDI remained below 0.3 (Figure 2D). These results revealed that NPs were stable. The structure and
distribution were also uniform after 15 days. However, while the nanoparticles were stored under
condition of 4 ◦C, the particle size increased significantly within 4 days and the flocculation occurred
because of the obvious drug precipitation. It suggested that 37 ◦C may be a better storage condition.
Moreover, after incubating the nanoparticles with serum for three days, no significant precipitation
was observed, indicating that the nanoparticles can remain stable under serum conditions as well.
Figure 2. Particle size (A) and PDI (B) of SANs and RSANs. Changes of particle size (D) and PDI (C)
within 15 days. Data are shown as ± SD (n = 3) of mean (n = 3).
3.2. Morphological Observation
TEM showed that RSANs (Figure 3) were mostly spherical and uniformly distributed. RSANs
presented a complete core-shell structure, which demonstrated that the RBCM successfully wrapped
SANs. The particle size measured by TEM was about 50–100 nm, and it was smaller than the results
obtained by Zetasizer. The difference might be due to the elimination of the water film outside the
nanoparticles after the samples were dried.
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Figure 3. The TEM images of RSANs.
3.3. In Vitro Release Study
Analyzed by ICP-AES, the average EE and DL were 14.31% and 4.98%, respectively (Table S1). As
shown in Figure 4, the release of 3 groups was fast for 4 h. For the ATO group, the highest burst release
of 98.61% was observed within 2 h, and all ATO was released in 4 h. After 4 h, the release of the SANs
was slightly slow down with a cumulative release rate of 91% in 12 h, and the drug was completely
released at 36 h. The release of RSANs was further slowed down to 67% at 12 h. The drug was then
gradually released until the cumulative release rate of 95% was achieved at 84 h. Resultantly, RSANs
showed more significant sustained release than SANs. The result revealed that forming a physical
barrier around the nanoparticles by RBCM can significantly control the drug release.
 
Figure 4. In vitro release curve of ATO, SANs and RSANs at 37 ◦C for 84 h. Data are shown as ± SD of
the mean (n = 3).
3.4. Hemolysis Test
As RSANs are administered intravenously, the nanoparticles must not cause the rupture of RBCs.
As shown in Figure 5A,B, the positive CG (Tube 1) was completely red and transparent with no cell.
This confirmed that the RBCs were ruptured and causes hemolysis. For RSANs group, with the
increase in concentration, RBCs sank, and the supernatants become colorless and clear from tube 1
to tube 7 similar to the negative CG (Tube 2). Further observation showed that no erythrocyte was
aggregated under the inverted microscope. However, when the concentration increased gradually,
slight hemolysis and hemagglutination phenomena were observed (tube 8 to tube 12). Results of
hemolysis rate measurement were consistent with visual observation. The percentage of hemolysis
was below 0.5% at high concentration, while it was below 0.01% at low concentration. The hemolysis
test implied that RSANs were safe and suitable for the intravenous injection at final concentration of
ATO lower than 0.0375 mg/mL.
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Figure 5. In vitro hemolysis results of RSANs after incubation of 3 h (A) and 24 h (B). Tube 1 was
ultrapure water group, and tube 2 was the physiological saline group.
3.5. Macrophage Uptake Study
After the preparation of RSANs, it was necessary to confirm whether the biological activity of
RBCM retains. The character of immune escape is one of the essential biological characteristics. The
ability of RSANs for immune evasion was verified using confocal microscopy and flow cytometry by
investigating the uptake between SANs and RSANs on RAW 264.7 cells. As shown in Figure 6A, the
fluorescence intensity of RSANs groups observed by confocal microscopy was significantly weaker than
that of SANs group. Meanwhile, the average fluorescence intensity of SANs and RSANs determined
by flow cytometry were 4158.5 and 2045 respectively (p < 0.01), which was consistent with confocal
results. The study confirmed that encapsulation by RBCM could help the nanoparticles to avoid the
uptake of macrophages that can be related to special proteins such as CD47 [36,37]. It can be speculated
that RSANs can also be prevented from being ingested by macrophages in vivo, and thus avoid the
premature elimination of the drug.
 
Figure 6. Cellular uptake of SANs and RSANs on RAW 264.7 macrophages. (A) Confocal image 630×.
The SANs were labeled with 5(6)-Aminofluorescein (green), (B) Fluorescence intensity detection by
flow cytometry. (C) Quantitative analysis of the fluorescence intensity. Data are shown as ± SD of the
mean (n = 3). ** correspond to p < 0.01.
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3.6. In Vitro Cellular Uptake
To further confirm the in vitro cellular uptake and structure of RSANS, RBCM, SANs core and cell
nucleus of NB4 cells as well as 7721 cells were labeled with Dil, 5(6)-Aminofluorescein and Hoechst
33342, respectively. As shown in Figure 7A,D, the red, green, and blue fluorescence represent the
stained RBCM, SANs, and nuclei, respectively. After incubation of NB4 cells and 7721 cells with SANs
and RSANs, it was detected that both red and green fluorescence overlapped around the nuclei. This
indicated that both SANs and RSANs could be taken up by NB4 cells as well as 7721 cells. In addition,
it could be preliminarily speculated the integrity of the basic shell-core structure was also maintained
during the process. According to flow cytometry results, the average fluorescence intensity of SANs
and RSANs ingested by NB4 cells were 813 and 941 (Figure 7B,C), while those of 7721 cells were 5111
and 5211 (Figure 7E,F) respectively. Both confocal and flow cytometry results showed that the uptake
of RSANs was slightly increased without any significant difference. It can be predicted that the change
of the negative charge on the surface of the nanoparticles after being coated by RBCM may cause the
slight difference, which changed the repulsive force between membranes.
Figure 7. Cellular uptake of SANs and RSANs on NB4 cells and 7721 cells. (A,D) Confocal images 630×.
The nucleus of cells was labeled by Hoechst 33342 (blue), SANs were labeled by 5(6)-Aminofluorescein
(green) and RBCM were labeled by Dil (red). (B,E) Fluorescence intensity detection by flow cytometry.
(C,F) Quantitative analysis of the fluorescence intensity. Data are shown as ± SD of the mean (n = 3).
3.7. ATO Nanoparticles Cytotoxicity
In vitro cytotoxicity assays were performed to evaluate the safety of nanoparticles initially. As
shown in Figure 8A, the cell viability of SNs and RSNs were both higher than 95% at SA concentration
of 8–60 μg/mL. It indicated that SA and RBCM were not significantly toxic and had excellent
biocompatibility. Free ATO revealed potent cytotoxicity at different concentration; however, the
toxicity was reduced significantly after being encapsulated in nanoparticles (Figure 8B). It can be
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predicted that the nano-delivery system newly designed can remarkably improve drug safety during
medical treatment.
Figure 8. Cell survival of 293 cells after administration with different concentrations of (A) SNs and
RSNs, (B) ATO, SANs and RSANs for 24 h. Data are shown as ± SD of the mean (n = 3).
3.8. In Vitro Efficacy Study
Figure 9A,B showed that the inhibitory effects of free ATO, SANs, and RSANs on NB4 cells
and 7721cells were all dose-dependent. With the increase of ATO concentration, the inhibition was
significantly enhanced after 24 h. From Figure 9C,D, potent inhibition was observed at a lower
concentration of 1 μg/mL. NB4 cells and 7721 cells were almost completely inhibited at 60 h and 72 h,
respectively. At the same time point, the inhibitory intensity of the free ATO group, SANs group,
and RSANs group decreased. However, because of the closed system of culture plate and sustained
release nanoparticles, drugs in SANs and RSANs could be gradually released over time and eventually
reaching the same effect as the free group. According to the results, it can be speculated that RSANs
can avoid rapid elimination by the immune system in vivo with the inhibitory effect maintained.
Figure 9. The inhibition effects on NB4 and 7721 cells after administration with different formulations.
Cell survival of NB4 (A) and 7721 (B) cells after administration with different concentrations of ATO,
SANs and RSANs for 24 h. Cell survival of NB4 (C) and 7721 (D) cells after administration with
multiple groups at the ATO concentration of 1 μg/mL for 72 h. Data are shown as ± SD of the mean
(n = 3).
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3.9. In Vivo Toxicity and Safety Test
In acute toxicity test, some mice in the high concentration group died, and the surviving mice
were inferior to other groups in terms of mental vitality, drinking, and feeding. During continuous
administration, the average body weight of the mice in each group showed an increasing trend with
no abnormal change, as shown in Figure 10B,C. It indicated that all the agents have no significant
systemic toxicity. All hematological analysis results (Figure 10D–F) were within the normal range
except for a slight decrease in the number of WBC in the free ATO group. Analysis of the main organ
tissue sections after H & E staining showed that the SANs group and RSANs group were similar to the
saline group, while the ATO group developed certain lesions (Figure 10A). The specific manifestation
including a large number of cardiomyocytes was cytoplasmic loosely stained. Inflammatory infiltration
was observed around the local portal area of the liver. The white pulp of spleen part conglutinated
to each other with irregular shape and a small number of apoptotic bodies were seen. Moreover,
local interstitial congestion could be observed in the kidney. According to the above results, it can
be speculated that free ATO group can cause chronic toxicity if administered continuously in this
concentration as compared to SANs group and RSANs group. The transient blood concentration of the
nano-groups was reduced due to the sustained release, with a lower in vivo toxicity.
 
Figure 10. In vivo toxicity and safety evaluation. (A) H & E staining of primary organs under 100 μm.
(B) Weight changes of nude mice during the experiment. (C) Organ coefficients, (D) Number of white
blood cells, (E) ALT, and (F) AST of each group at the end of the experiment. Data are shown as ± SD
of the mean (n = 5).
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3.10. In Vivo Anti-Tumor Study
7221 tumor bearing nude mice were used to determine the anti-tumor efficacy of formulations.
Figure 11 shows the results of different anti-tumor studies. Figure 11A showed the change in tumor
volume during administration. In the saline group, the volume was gradually increased while the
change trends of ATO group, SANs group, and RSANs group were first increased and then decreased
(p < 0.01). The tumor mass and size at the end of the study were monitored as Figure 11C,D. According
to the results, it could be speculated that the free ATO was quickly cleared in the body, the amount of
drug reaching the tumor site was less than that of the other two groups, and that caused the lowest
tumor inhibition efficacy. Over the whole treatment period, SANs group and RSANs group can achieve
better tumor inhibition effects with the drug gradually released from the nanoparticles. At the same
time, because of the wrapping of RBCM, RSANs were less likely to be cleared by the immune system
than SANs, allowing more drugs to reach the tumor site. Figure 11B showed changes of body weight.
By the end of the study, body weight of the saline group increased significantly, while the other three
groups showed little variation, which was consistent with the results of the in vivo toxicity and safety
test. It was further supported that the safety and low toxicity of SANs and RSANs, and the DDS can
still improve efficacy of ATO.
 
Figure 11. In vivo anti-tumor efficacy of formulation in the 7721 tumor bearing nude mice study.
Changes of (A) tumor volume and (B) body weight during the period of treatment. (C) Average tumor
weight after treatment. (D) Photograph of tumors collected after treatment. Data are shown as ± SD of
the mean (n = 5). ** correspond to p < 0.01, * correspond to p < 0.05.
4. Conclusions
The objective of this project was to realize sustained release of ATO and ensure the safety and
efficacy of the DDS. SANs were prepared by coating ATO with SA, and then RSANs with a shell-core
bilayer structure was obtained by wrapping the RBCM on the surface of the SANs. The nanoparticles
were homogeneous with spherical structures and stable for 15 days with an average EE and DL of
14.31% and 4.98%, respectively. Compared to free ATO, the SANs and RSANs showed excellent
sustained release in vitro for 3 days. Generally, biological characteristics of RBCM could be used to
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avoid the recognition of macrophages. Even when ingested by NB4 cells and 7721 cells, RSANs still
could maintain its nuclear-shell structure. At the same time, in vitro safety test showed the safety of
carrier materials and without observable toxicity to 293 cells or hemolysis and aggregation of red
blood cells. Free drug can kill nearly half of cells at a low concentration, while RSANs can significantly
reduce the toxicity of ATO. After continuous administration of ATO formulations through IV tail
injection, the results revealed that the SANs and RSANs had no significant systemic, blood, and organ
toxicity. Moreover, the RSANs could maintain inhibition of NB4 cells and 7721 cells. After in vivo
administration, RSANs can avoid rapid clearance and exert their sustained release properties, thereby
enough drugs can be transported to the treatment site and achieve the effect. This may allow RSANs
greater advantages in the treatment of tumors. Therefore, it could be concluded that the Nano-drug
delivery system can decrease the toxicity of ATO with high safety and the potential for treating APL
as well as anti-hepatocarcinoma. Meanwhile, RSANs can prolong the duration of ATO in vivo, thus
reducing administration times and enhancing patient compliance. In consequence, the DDS can be
developed into a safe and sustained release delivery system for ATO.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/1/21/s1,
Table S1: Investigation of encapsulation efficiency and drug loading capacity.
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Abstract: Tuberculosis (TB) is a major cause of childhood death. Despite the startling statistics, it is
neglected globally as evidenced by treatment and clinical care schemes, mostly extrapolated from
studies in adults. The objective of this study was to formulate and evaluate a reconstitutable dry
suspension (RDS) containing isoniazid, a first-line anti-tubercular agent used in the treatment and
prevention of TB infection in both children and adults. The RDS formulation was prepared by direct
dispersion emulsification of an aqueous-lipid particulate interphase coupled with lyophilization
and dry milling. The RDS appeared as a cream-white free-flowing powder with a semi-crystalline
and microparticulate nature. Isoniazid release was characterized with an initial burst up to 5 min
followed by a cumulative release of 67.88% ± 1.88% (pH 1.2), 60.18% ± 3.33% (pH 6.8), and 49.36%
± 2.83% (pH 7.4) over 2 h. An extended release at pH 7.4 and 100% drug liberation was achieved
within 300 min. The generated release profile best fitted the zero order kinetics (R2 = 0.976). RDS was
re-dispersible and remained stable in the dried and reconstituted states over 4 months and 11 days
respectively, under common storage conditions.
Keywords: pediatric drug delivery; tuberculosis; reconstitutable dry suspension; isoniazid;
polymer-lipid; microparticulate; direct emulsification
1. Introduction
Tuberculosis (TB) remains a major global health problem present in every country in the world,
regardless of the availability of standard treatment guidelines [1,2]. It is the leading cause of death
from a single infectious agent, ranking above the Human Immunodeficiency Virus (HIV) with about
10 million new active infections and 1.5–2 million fatalities annually [1,3–5]. TB is an airborne, highly
contagious disease often spread by coughing and sneezing. It is caused by strains of bacteria known as
Mycobacterium tuberculosis (Mtb), which primarily infects the lungs (pulmonary TB) and, occasionally,
other body parts (extra-pulmonary TB) [1,5–7]. TB has been identified as a key cause of economic
devastation, revolving poverty and illness that has entrapped families, societies, and even entire
countries, with women, children, and HIV patients being the most vulnerable [2].
Tuberculosis is a major cause of childhood death. The World Health Organization (WHO) recently
estimated that 10%–11% of the global population infected with TB are children, with about 233,000
childhood deaths each year [1,3,6]. The TB mortality rate is 70% higher in children under the age of five
www.mdpi.com/journal/pharmaceuticsPharmaceutics 2020, 12, 286; doi:10.3390/pharmaceutics12030286
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than it is in adults in high burden areas [1,8]. Research indicates that children serve as reservoirs for
active TB infection later in life, evidenced by the fact that globally, about 67 million children under the
age of 15 have latent TB [1,9]. Latent TB infection is known as a state of persistent immune responses to
stimulation by Mtb antigens with no evidence of clinical manifestations associated with active infection
or symptoms of illness. Nevertheless, latent TB can develop into full-blown, active infection later [1].
Thus far, the greatest challenge to the successful treatment of TB in children is the significant
shortage of efficient pediatric pharmaceutical formulations [1,10–12]. Despite the alarming statistics
reported on the number of active TB cases in children, it is indeed shocking to note that to date,
childhood TB has been generally neglected worldwide, evidenced by treatment and clinical care
schemes mostly extrapolated from studies in adults [1,13–15]. Over the years, children have been
largely excluded from clinical trials resulting in weak evidence-based treatment of pediatric TB infection.
With the shortage of suitable child-friendly anti-TB pharmaceutical formulations, it is common global
practice to split adult fixed-dose combination (FDC) preparations: (i) into fractions; (ii) crushed to
be taken with food, milk, and other liquids; or (iii) extemporaneous compounding to allow for easy
use as needed per child. These practices can lead to dose inaccuracies, reduced active drug potencies,
impaired dosage stability, irregular bioavailability, and poor compliance [14–16]. Consequently, there
is an urgent need for innovative treatment strategies that can contribute towards combating the TB
epidemic in pediatric patients.
Isoniazid is the most widely used first-line anti-tubercular agent for the treatment and prevention
of TB infection in both children and adults. It is a drug of choice as it is bactericidal, easily administered,
inexpensive, and relatively non-toxic in children. Isoniazid is almost completely absorbed from the
gastrointestinal tract and penetrates all body fluid cavities, in which drug levels are similar to serum
levels [12,15]. Although subject to considerable hepatic metabolism (or first-pass effect) after oral
dosing, it reaches concentrations well above the minimum inhibitory levels of Mtb in most tissues and
TB lesions when given in standard doses [17]. Isoniazid is considered a class III drug according to the
Biopharmaceutics Classification System (BCS) [18], meaning that it is highly hydrophilic (aqueous
solubility = 125 mg/mL at 25 ◦C) [18,19] but not very permeable (log P = −0.64 at 25 ◦C) [19]. It is
weakly basic, crystalline in nature, and does not display polymorphism [20]. The aim of this study was,
therefore, to develop and characterize a microparticulate reconstitutable dry suspension containing
isoniazid as a model drug. To date, there is not much detailed in literature on the use of anti-tubercular
micro-suspensions for pediatric TB treatment or prophylaxis. Conventional dry suspensions are
powder mixtures that require the addition of water at the time of dispensing. They are often widely
acceptable, intended for oral administration, and usually choice alternatives when drug stability is a
major concern. Dry suspensions are easy to use by any age group (particularly children) and, therefore,
enhance patient compliance [13,21]. In this study, microparticulate dry suspensions as micro-structuring
remains an ideal way of manufacturing highly efficient, rate-modulated pharmaceutical formulations
that are beneficial to patients. Generally, microparticulate drug carriers are known to have high
stability with excellent drug loading capacities for hydrophobic and hydrophilic drug moieties,
enhanced bioavailability, and decreased toxicity [22]. The reconstitutable dry suspension (RDS) was
prepared by blending liquid and solid interphases of drug and excipient into a homogenous mix that
was lyophilized and pulverized to produce an isoniazid-loaded free-flowing powdery formulation.
Formulation evaluation involved zeta potential and polydispersity index analyses, particle sizing, drug
loading, dissolution testing, thermal behavior, structural transitions, surface morphology, crystallinity
determinations, cytotoxicity, hydro- and environmental- stability testing.
2. Materials and Methods
2.1. Materials
Polyethylene glycol, poly (vinyl alcohol) 87%–89% hydrolyzed, coconut oil, ethylcellulose, hydrochloric
acid, anhydrous sodium phosphate dibasic, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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bromide (MTT), Trypsin—EDTA, trypan blue, dimethylsulfoxide (DMSO), camptothecin, potassium
dihydrogen phosphate monobasic buffer salt, isoniazid, and phosphate buffered saline powder were
purchased from Sigma Chemical Company (St. Louis, MO, USA). D-fructose was obtained from Merck
Chemicals (Darmstadt, Germany). The human breast cancer (MCF-7) cell line was purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). Dulbecco’s Modified Eagle’s Medium
(DMEM) and fetal bovine serum (FBS) were procured from BD Biosciences (San Jose, CA, USA). All
other reagents utilized were of analytical grade and used as received from the supplier.
2.2. Formulation of the Reconstitutable Dry Suspension Employing a Direct Dispersion Emulsification Method
The RDS was prepared using a direct dispersion emulsification technique coupled with
lyophilization and dry milling. This involved emulsification of the aqueous phase, which contained
2%w/w polyethylene glycol, 9%w/w poly (vinyl alcohol), 4%w/w D-fructose, 10%w/w isoniazid dispersed
in water with the non-aqueous phase made up of 3%w/w ethylcellulose in coconut oil under constant
mechanical blending (Silverson Machines, Inc., East Longmeadow, MA, USA) at 6000 rpm over 5–10 min
until a monophasic emulsion was produced. With D-fructose as a lyoprotectant and sweetener, the
mono-phased emulsion was exposed to liquid nitrogen for 15 min until completely frozen. Thereafter,
the frozen sample was lyophilized (Benchtop Pro Freeze Dryer, VirTis, SP Scientific, Stone Ridge, NY,
USA) at a temperature of −60 ± 2 ◦C and pressure of 124 ± 2 mTorr over 96 h to produce a solid
lyophilisate that was then dry milled using a laboratory scale grinder (Kinematica GMBH, Eschbach,
Germany). The RDS was stored away in airtight, opaque containers until further testing.
2.3. Formulation Yield
The formulation yield was calculated by relating the total formulation weight (actual yield) to
the mass of the component excipients used in the preparation of the formulation (theoretical yield).
The constituting excipient plus the model drug and produced RDS formulation were weighed as
separate entities using a laboratory scale balance (Kern EG 620-3NM, Kern and Sohn, GmbH, Balingen,





2.4. Physicochemical Characterization of the Reconstitutable Dry Suspension
2.4.1. Particle Size, Polydispersity Index, and Zeta Potential
Measurement of particle size (PS) and polydispersity index (PDI) was based on the principle of
dynamic light scattering using the Nano series Zetasizer (Malvern Instruments Ltd, Malvern, UK). For
each quantification, RDS samples were re-dispersed in deionized water, appropriately diluted, and
sonicated (Table-type Supersonic Cleaner KQ118, Nanjing T-Bota Scietech Instruments and Equipment,
Co, Ltd., Nanjing, China) for 15 min at 37 ± 0.5 ◦C. All measurements were performed as three
independent replicates with 10 readings per sample at a measurement angle of 173◦ and temperature of
25 ◦C. Zeta potential (ZP) is an indicator of particle surface charge, which determines particle stability
in dispersions [23,24]. It was computed based on the Smoluchowski equation [25] using the Nano
series Zetasizer with RDS samples dispersed in deionized water and placed in disposable folded
capillary zeta cells maintained at 25 ◦C. For statistical relevance, samples were measured in triplicate
with 20 runs per measurement cycle.
2.4.2. Visualization of Surface Morphology
The surface microstructure of the RDS was observed under a JEOL Transmission Electron
Microscope (TEM) (JEM-2100 LaB6 200 kV Transmission Electron Microscope, JEOL, MA, USA). About
1 mg of the test sample was dispersed in ethanol and spotted on a carbon coated copper grid. Ethanol
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was allowed to evaporate under atmospheric conditions prior to sample loading into the TEM viewing
stage (JEOL JEM-2100 LaB6 200 kV Massachusetts, USA). The Gatan Digital Micrograph Software was
used to facilitate sample viewing.
2.4.3. Thermal Analysis
The thermal behavior of the drug loaded RDS and pure isoniazid (reference) was characterized
using a differential scanning calorimetry (DSC) machine equipped with a 50-position automatic
sampler (Q2000 Differential Scanning Calorimeter TA Instruments, New Castle, DE, USA). Separate
aluminum crucibles containing about 9 mg of each sample were analyzed under an inert nitrogen flow
of 25 mL/minute and heating rate of 10 ◦C.min−1 while an empty crucible subjected to the same testing
condition served as the reference. All measurements were performed in triplicate per sample under
three heating cycles at a temperature range of 0–220 ◦C.
2.4.4. Determination of Crystallinity
The crystalline nature of the RDS formulation and pure isoniazid were evaluated under ambient
conditions (25 ± 2 ◦C) using an X-ray diffractometer equipped with the X’Pert PRO data collector
software (PANalytical Inc. MA, USA). Each sample (about 3 mg) analysis was performed at a voltage
and current of 45 kV and 40 mA, respectively, and a 2θ range of 5 to 90◦ using a continuous scan mode
with a scan step size of 0.03.
2.4.5. Structural Elucidation
The RDS formulation and pure isoniazid chemical backbone structural transitions were determined
using the Fourier transform infrared (FTIR) spectrophotometric approach. The FTIR spectra of each
test sample was generated on a Perkin Elmer Spectrum 100 Series FTIR Spectrophotometer coupled
with Spectrum V 6.2.0 software (Beaconsfield, UK). Initially, blank background measurements were
taken, and then, about 5 mg of each test sample was placed on a clean holder situated on the test stage
of the machine for structural analysis that was recorded at a frequency range of 650–4000 cm−1, scan
time = 32 scans and resolution of 4 cm−1.
2.5. Drug Loading Efficiency
To determine the amount of isoniazid loaded in the RDS formulation, 10 mg sample was placed
in 100 mL phosphate buffered saline (pH 7.4) with continuous stirring over 4 h (Five-Position Hot
Plate/Stirrer, Model 51450 series, Cole-Parmer, IL, USA), to ensure complete dissolution and release of all
entrapped drug molecules. The resulting solution was then appropriately diluted with distilled water
and passed through a 0.45 μm nylon membrane Corning® syringe filter (Corning Incorporated, NY,
USA). The actual drug content was analyzed using Ultraviolet (UV) Spectrophotometry (PerkinElmer
Lambda 35, UV/Vis Spectrometer, Perkin Elmer, Singapore) at a maximum wavelength of absorption for
isoniazid, λmax = 262 nm. The percentage of isoniazid load in the RDS formulation was mathematically
computed with reference to the originally added amount (Equation (2)). Tests were conducted as three
replicate samples.
%Drug loading efficiency =
Actual drug amount (g)
Theoretical drug amount (g)
× 100 (2)
2.6. In Vitro Dissolution Studies
In vitro dissolution studies were performed on an RDS formulation sample size containing an
equivalent of 100 mg isoniazid. The study was carried out using the dissolution tester (Ewreka GmbH,
DT 820 series, Heusenstamm, Germany). The RDS formulation was contained in a gelatin capsule
(CapsCanada, Ontario, Canada), which was placed in a basket holder attached to the dissolution tester
stirring shaft (United States Pharmacopeia Apparatus 1). The basket was then immersed into separate
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dissolution jars containing 500 mL of either pH 7.4 or pH 6.8 or pH 1.2 pre-heated buffered solution
maintained at 37 ± 0.5 ◦C with continuous rotation at 100 rpm. Samples (5 mL) were removed at the
end of the 2-h time-point for quantification. Furthermore, at pH 7.4, drug loaded RDS formulation
underwent an extended release testing up to a point when 100% isoniazid liberation was observed.
Briefly, samples (5 mL) were removed at pre-determined time intervals and replaced with 5 mL
freshly prepared preheated, buffered solution (pH 7.4, 37 ± 0.5 ◦C). All experiments were performed
in triplicate under sink conditions and isolated samples were appropriately diluted, filtered using a
0.45 μm nylon membrane Corning® syringe filter (Corning Incorporated, NY, USA) and analyzed
spectrophotometrically (PerkinElmer Lambda 35, UV/Vis Spectrometer, Perkin Elmer, Singapore) at
λmax of 262, 263, and 267 nm for pH 7.4, 6.8, and 1.2 buffered solutions, respectively, to determine the
amount of isoniazid contained in each sample per time against buffer blanks. The actual quantity
of isoniazid released per unit time was calculated using the linear polynomial calibration equations
as follows: (a) pH 7.4: y = 39.38x; R2 = 0.98; (b) pH 6.8: y = 32.96x; R2 = 0.99, and (c) pH 1.2:
y = 45.77x; R2 = 0.98 where x and y, respectively, represent concentration (mg/mL) and absorbance.
Percentage cumulative drug release [26] was computed relative to the total amount of isoniazid present
in each medium at the end of the 2-h period. To get an indication of the release kinetics of the RDS
formulation, the pH 7.4 release profile was selected for further mathematical model fitting over an
extended period when 100% drug release was achieved. Resulting data were further analyzed using
the KientDS version 3.0 open source software, which aided the selection of the model of best fit, which
was based on mathematical computations, such as the zero, first, and second order kinetics, Higuchi,
Korsmeyer-Peppas, Michaelis-Menten and Weibull approaches [19,24,27].
2.7. Stability Evaluations
2.7.1. Short-Term Stability Testing under Different Environmental Conditions
The physicochemical stability of the RDS formulation (500.0 mg ± 2 mg per test) was monitored
under different storage conditions over four months. A set of samples were placed in an enclosed glass
holder that was transferred into the stability tester (Labcon PSIE RH 40 Chamber Standard Incubator,
Laboratory Marketing Services, Maraisburg, South Africa) fixed at 30 ◦C ± 2 ◦C and a relative humidity
of 65% ± 3% adapted from the WHO stability testing scheme for pharmaceutical products containing
well established drug substances [28]. Another sample group was stored in airtight, opaque glass
vials under standard room conditions (temperature: 25 ◦C ± 5 ◦C and humidity: 55% ± 5%). The last
sample set was stored in airtight, opaque glass vials and placed in the refrigerator (Sanya Labcool
Pharmaceutical Refrigerator, MPR-720R, Sanyo Electrical Biomedical Co. Ltd, CA, USA) at 4 ◦C ±
1 ◦C. Formulation stability was monitored at 0, 1, and 4 month intervals for changes in particle size,
polydispersity index, zeta potential, and drug content. Samples were also physically examined for any
changes in physical appearance or color changes. All tests were conducted in triplicate.
2.7.2. In Vitro Aqueous Stability Assessment
The stability of the RDS formulation in aqueous solution (mimicking the re-constitution process)
was evaluated. RDS samples (500 ± 2 mg) were placed in airtight, opaque containers and dispersed in
50 mL sterile deionized water. Hydrated samples were prepared in triplicate per test conditions. Test
conditions included placement under ambient conditions (25 ± 5 ◦C), as well as in the refrigerator
(4 ± 2 ◦C) for 11 days. Hydrated samples (2 mL) were collected from each test vessel for isoniazid
content quantification at 0, 1, 5, and 11 days using UVspectrophotometry, as described earlier. Samples
were manually agitated daily and before collection to ensure uniform re-dispersion. All tests were
carried out in triplicate.
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2.8. Preliminary Formulation Toxicity Assessment
The human breast adenocarcinoma (MCF-7) cell line was used for preliminary evaluation of the
RDS formulation biocompatibility. The sample was dissolved in double-distilled water to a final stock
concentration of 2 mg/mL, filter-sterilized through a 0.22 μm Cameo acetate membrane filter (Millipore
Co., Bedford, Massachusetts), and stored at 4 ◦C until used. The negative control was 1% DMSO while
100 μM camptothecin, a known chemotherapeutic agent, was used as the positive control. The MCF-7
cell line was routinely maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), at 5% carbon dioxide and 37 ◦C ± 0.1 ◦C. Cells
were seeded into 96-well plates at a final concentration of 15,000 cells/well. Test samples were added at
final well concentrations of 100, 50, 25 μg/ml, and incubated for 24 h. Thereafter, the spent medium was
replaced with 200 μL of 0.05 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(MTT) solution and incubated at 37 ◦C ± 0.1 ◦C for 3 h. The MTT was then aspirated from the cells
and replaced with 200 μL DMSO to dissolve the formazan crystals. The absorbance was read at a
maximum wavelength of 540 nm against DMSO as a blank using a microtiter plate reader (BioTek
Powerwave XS, Winooski, VT, USA). The absorbance readings obtained were used to compute the
number of viable cells present in the media. All results are presented as the mean reading ± standard
deviation, and the statistical significance of all experimental data was evaluated using the GraphPad
Prism 7 software (GraphPad, San Diego, CA, USA) using a two-way Analysis of Variance (ANOVA).
The number of viable cells in both test and control samples were determined using Equation (3), and
all tests were conducted in triplicate.
%Cell viability =
Number of viable test cells
Number of viable control cells
× 100 (3)
3. Results and Discussions
3.1. Formulation Synthesis and Yield
The isoniazid-loaded RDS formulation was developed using a combination of the direct dispersion
emulsification technique, lyophilization, and dry milling. A cream-white, free flowing isoniazid loaded
RDS powder with an average yield of 87.43% ± 0.13% was obtained.
3.2. Size, Polydispersity Index, and Zeta Potential Determination and Morphology
The RDS powder formulation showed an average particle size of 1.63 ± 0.20 μm, indicating
its intrinsic micro-structure. The PDI can be described as a ratio that provides information about
homogeneity of particle size distribution as it relates to a particular system serving as a useful reflection
of the quality of the particulate system/dispersion ranging from 0.0–1.0 with values ≤0.1 relating to
the highest quality of particulate dispersion, ≤0.3 as optimum, ≤0.5 as generally acceptable [24]. A
generally acceptable PDI value of 0.37 ± 0.04 was recorded for the RDS powder, indicating that the
particles were mostly homogenous and well dispersed within the formulation. The measured ZP was
−41.10 ± 5.57 mV, showing a stable system, where a ZP value of ±30 mV is considered a stable and
satisfactory formulation [24,29]. Representative graphs based on an independent measurement of
the zeta potential and particle size distribution are shown in Figure 1a,b. Researchers have shown
that TEM imaging is an effective and powerful tool for characterizing the morphology of nano- and
micro-structured biomaterials and drug carriers as it uses more powerful beams to produce higher
resolution images with more details and information [30,31]. The TEM micrographs showed minimally
aggregated, dispersed RDS particles that appeared as darker areas relative to the background, with
rounded outer morphologies (Figure 1c,d).
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Figure 1. Representative graphs displaying: (a) particle size distribution, (b) zeta potential distribution,
as well as TEM micrographs showing different surface topographies and characteristics of the
reconstitutable dry suspension (RDS) particles at different scales: (c) 1μm and (d) 5 μm, respectively.
3.3. Thermal Behavior
Salient changes in the thermal behavior of isoniazid relative to that of the RDS formulation were
studied using conventional DSC methods. The recorded melting peak of pure, unformulated isoniazid
was 171.7 ◦C, which compared well to literature [32]. The melting peak of isoniazid (Figure 2a) was
characterized by its sharp and defined geometry confirming its purity and crystalline nature. The
RDS thermogram was typified by the presence of multiple distinct sharp or broad peaks showing its
physicochemically stable and multi-component state. The RDS formulation showed an intermittent
appearance of sharp and blunt peaks representing its semi-crystalline nature (Figure 2b,c). The isoniazid
melting peak identified on the RDS formulation thermogram (171.1 ◦C) was similar to that of the pure
drug (171.7 ◦C), showing its stability within the excipient matrix. However, the formulated isoniazid
peak presented as a broad band, which can be related to physical transitioning from crystalline into
amorphous structures attributable to solvation and encapsulation of drug molecules into the processed
polymeric carrier. A significant change in heat flow from −36.4 mW (unformulated isoniazid) to
−3.7 mW (isoniazid in RDS) (Figure 2b,c) was seen, further supporting the likely drug encapsulation
in the amorphous state, coupled with stable molecular dispersions within the polymeric chains [24].
Overall, the thermograms (Figure 2a–c) demonstrate the absence of any destructive/irreversible
physicochemical interactions between isoniazid and the excipients during the RDS preparation process.
200
Pharmaceutics 2020, 12, 286
Figure 2. Differential scanning calorimetry (DSC) thermograms of (a) unformulated isoniazid, (b)
RDS formulation, and (c) an expanded segment of the RDS thermograms showing the transitions that
occurred with formulated isoniazid.
3.4. X-ray Diffractometry
The changes in matrix crystallinity between pure isoniazid and the RDS formulation was further
confirmed using X-ray diffraction analysis (XRD) with recorded diffractograms presented in Figure 3a,b.
Diffractograms recorded for pure isoniazid showed high intensity, well-defined sharp peaks between
9.3θ and 32.3θ, with intensities as high as 39,885.7 validating the crystalline nature of isoniazid
(Figure 3a). This trend differs from that observed for the RDS formulation, which presents broader, not
so well-defined peaks between 13.9θ and 28.1θ at a maximum intensity of 11,142.9, which is much
lower relative to the isoniazid diffractogram. Furthermore, low intensity (less than 4288.1) plateau-like,
broad-banded sections were also identified between 5.3θ—14.6θ and 28.5θ—90.1θ, further confirming
that the RDS formulation consists of more than one component, characterized with intermittent, mostly
amorphous and minimal crystalline domains, i.e., a semi-crystalline nature (Figure 3b). These findings
agree with the outcomes of the DSC analysis.
Figure 3. X-ray diffractograms of (a) unformulated isoniazid and (b) isoniazid loaded RDS formulation.
3.5. Structural Analysis
FTIR spectrum depicting characteristic vibrational frequencies of isoniazid in its unformulated
state and encapsulated within the RDS formulation were compared (Figure 4). The vibrational band
assignments for formulated and unformulated isoniazid were executed based on their positions,
nature, magnitudes, and intensities relative to each characteristic functional group. The key bands
plus wavenumbers identified and compared for both the RDS formulation and isoniazid in its pure
state are presented in Table 1. The vibrational frequencies of key functional groups as it relates to the
chemical backbone structure of isoniazid compares well for both pure drug and RDS formulation,
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with characteristic peaks presenting with varying intensities. The isoniazid loaded RDS formulation
appeared overly dominant in most regions with some of its peaks suppressing those of pure isoniazid.
This suggests physical solid–liquid/solid–solid dispersion and significant drug encapsulation. The
O–H stretch recorded at 3676 cm−1 for the RDS formulation further supports the physically dispersed
state in the water/oil medium, followed by snap-freezing and lyophilization.
Figure 4. The Fourier transform infrared (FTIR) spectrum of the unformulated isoniazid and RDS
formulation, showing different characteristic vibrational bands.
Table 1. FTIR vibrational frequencies representing formulated and unformulated isoniazid key
functional groups.
Functional Groups and Remarks
Vibrational Frequencies (cm−1)
Unformulated Isoniazid Isoniazid Loaded RDS Formulation
C–C–C–C and C–N–C–C torsion 653 665
NH2 rock 677 677
C–C–C out of plane bending 746 757
C–C–H out of plane bending 850 and 1022 850 and 1023
C–N–C and C–C–C in plane bending 1063 1062
Aromatic C–N stretching 1344 1330
C–C–H in plane bending 1210 1212
O=C-N in plane bending 1330 1333
C–N–H in plane bending 1411 1408
C–C stretching 1477 1471
C=O stretching 1558 1552
NH2 scissoring 1632 1635
Aromatic C–H stretching 3052 3054
N–H stretching 3307 3308
O–H stretching - 3676
3.6. Drug Content
The percentage content of isoniazid encapsulated within the RDS formulation matrix was
computed relative to the theoretical drug content, totaling 94.12% ± 2.10%. This indicates that there
was minimal drug loss during the RDS manufacturing and processing phases.
3.7. Drug Release Behavior
To understand the in vitro drug release behavior and kinetics, dissolution studies were carried
out on the RDS formulation containing an equivalence of 100 mg isoniazid in pH 7.4, 6.8, and 1.2
buffered solution over two hours under biorelevant conditions. Percentage cumulative drug release
(%CDR) was calculated as the total amount of isoniazid liberated from the RDS formulation matrix,
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with an increase or decrease in %CDR representing a respective rise or decline in the release rates.
%CDR varied for each dissolution media (pH 1.2 = 67.88% ± 1.88%, pH 6.8 = 60.18% ± 3.33%, and
pH 7.4 = 49.36% ± 2.83%). Isoniazid release decreased as media pH increased. In other words, a
reduction in the pH of the aqueous micro-environment seemed to impact the processes of formulation
wetting, pore formation and closure, water penetration, phase transitioning, drug-excipient dissolution
and degradation, changes in drug-excipient physical interaction and solubility process, and eventual
diffusion of drug molecules coupled with gradual matrix geometry transitions (erosion or swelling) [33].
The RDS formulation demonstrated the potential to stabilize and release the isoniazid molecules in
different dissolution media with significant differences in the percentage of drug released under these
different conditions.
In addition, isoniazid release at pH 7.4 was selected for further mathematical model fitting to
understand the RDS formulation release kinetics over a period when 100% drug liberation was achieved
(Figure 5). In vitro isoniazid release from the RDS formulation at pH 7.4 was characterized with an
initial burst at 5 min (7.51 ± 0.72 %), followed by a relatively consistent increase in drug release over
time, until complete release (100%) was recorded at approximately 300 min.
Figure 5. Graphical profile showing 100% isoniazid release from the RDS formulation over time.
The generated profile (Figure 5) was further analyzed using mathematical kinetic models
employing the KinetDS, version 3.0 open source freeware. Release profile analysis and model of best fit
selection was based on a combination of robust validation quantities, namely the correlation coefficient
(R2) closest to one and lowest Akaike Information Criterion (AIC) numerical value (Table 2) [31]. On
this basis, the zero order kinetic model provided the best fit parameters (R2 = 0.976 and AIC = 74.080)
for the isoniazid release data depicted in Figure 5. This indicates that isoniazid release from the RDS
formulation is consistent over time, irrespective of the initial drug concentration. In principle, zero order
drug release mechanism is beneficial for achieving continuous drug plasma and biological fluid levels,
reducing dosing frequency, and improving patient compliance, aiding desired pharmacotherapeutic
efficacy [34].
Table 2. Representative mathematical models and their respective fit parameters.
Mathematical Models R2 AIC
Zero order 0.976 74.080
First order 0.159 176.881
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3.8. Short-Term Formulation Stability Assessment
3.8.1. Stability Evaluation under Varying Storage Conditions
Evaluation of formulation stability was performed in triplicate per sample under multiple storage
conditions: Stability tester—30 ◦C ± 2 ◦C and 65% ± 3%; Room—25 ◦C ± 5 ◦C and 55% ± 5%; and
Refrigerator—4 ◦C ± 1 ◦C; over four months employing particle size, polydispersity index, zeta
potential, and drug content as indicators of stability. Results showed minimal numerical differences
in indicators measured, indicating that the isoniazid loaded RDS formulation can be described as
stable under the prescribed environmental storage conditions (Table 3). A slight alteration in physical
appearance relating to a color change from white to cream-white was observed at four months, under
accelerated storage in the stability chamber (30 ◦C ± 2 ◦C; 65% ± 3%) and room conditions (25 ◦C ± 5
◦C; 55% ± 5%). Despite the fact that stability indicators remain closely related, the slight color change
is undesirable, considering patient acceptance, making these environments unsuitable for the storage
of the RDS formulation. Therefore, the most ideal storage setting for the RDS formulation is, thus, at
4 ± 1 ◦C as stability indicators are comparable with no color change observed (Table 3).







PDI a ZP b (mV) PS c (μm) DC d (%) Color
0 0.37 −41.10 1.63 94.12 No change
1 0.40 −42.59 1.58 94.07 No change
4 0.39 −43.60 1.82 93.76 Slight change
Room
0 0.37 −41.10 1.63 94.12 No change
1 0.44 −42.71 1.69 93.95 No change
4 0.46 −40.51 1.97 91.05 Slight change
Refrigerator
0 0.37 −41.10 1.63 94.12 No change
1 0.39 −41.65 1.61 93.95 No change
4 0.38 −40.91 1.70 94.02 No change
a Particle Size (standard deviation ≤ 0.13 μm in all cases), b Polydispersity Index (standard deviation ≤ 0.03 in all
cases), c Zeta Potential (standard deviation ≤ 1.03 mV in all cases), d Drug Content (standard deviation ≤ 0.99% in
all cases).
3.8.2. Formulation Stability in an Aqueous Environment
The stability of the drug loaded RDS formulation in an aqueous medium was investigated under
select storage conditions (room and refrigeration) over 11 days, mimicking storage duration for
commonly reconstituted antibiotic solutions/suspensions. Percentage drug content was chosen as the
hydrostability indicator, and overall, there were insignificant changes in its numerical values under
room or refrigerated storage conditions, with no visible color changes (Table 4). Summarily, the RDS
formulation is stable in the aqueous medium over 11 days, either refrigerated or stored under ambient
conditions, suggesting that the RDS formulation is a potentially useful preparation for re-constitution
purposes, especially in pediatrics.
Table 4. Hydrostability indicators at different time-points, under ambient and refrigerated conditions.
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3.9. Cell Viability Assessment
Preliminary assessment of the effects of the RDS formulation on viability was performed on
MCF-7 cell lines. Tests were conducted over 24 h using different concentrations of the RDS ranging
from 0 μg/mL (negative control) to 100 μg/mL. This cell line is routinely used as a prototype for
assessing the biocompatibility of drugs, delivery systems, and biologicals that are non-specific for
treating carcinomas [35–37]. Graphical representations of the impact of different test formulation
concentrations on cell viability relative to camptothecin (positive control) and the negative control
are presented in Figure 6. The RDS lowest concentration (25 μg/mL) caused significant MCF-7 cell
proliferation (p < 0.0500: p = 0.0001). The increased viability may signify that the RDS formulation
supported cell growth at a low concentration (25 μg/mL) and can be considered an indication of
biocompatibility. This may be attributed to the drug or excipient concentration or a combination of
both. In contrast, the 50 and 100 μg/mL reduced cell viability, although not significantly (p > 0.0500:
50 μg/mL—p = 0.0056; 100 μg/mL—p = 0.0001). Nevertheless, higher concentrations of the RDS (50
and 100 μg/mL) did not reduce cell viability as much as the camptothecin that decreased it to 48.93% ±
3.99%. In general, the RDS was well-tolerated by the MCF-7 cells at all test concentrations. Cellular
responses following exposure to the formulation can be described as biphasic and dose-dependent,
a phenomenon associated with hormesis (a two-phased adaptive response of cells and organisms
to increasing or decreasing amounts of external stress, e.g., drug, chemical substances, and disease
state) [38,39]. It is not unusual for cells to exhibit hormetic effects as they are biological systems known
to be dynamic and constantly evolving. These initial findings form a baseline for future work on
understanding the biocompatibility of the RDS formulation and its components (active drug and
excipients) in vitro and in vivo.
 
Figure 6. Graphical illustration of the percentage cell viability 24-h post-exposure to the RDS formulation
in the human breast cancer (MCF-7) cell lines as a prototype. Statistical difference between two data
sets was considered significant when p < 0.05.
4. Conclusions and Future Work
In this study, isoniazid loaded reconstitutable dry suspension was prepared using the direct
dispersion emulsification technique, coupled with lyophilization and dry milling. The direct dispersion
technique produced a relatively high yield (87.43% ± 0.13%) of RDS particles with good drug
loading capabilities (94.12% ± 2.10%). The RDS formulation showed no significant evidence of
toxicity supported by outcomes from viability studies in the MCF-7 cells. The formulation was
physicochemically stable, mostly amorphous, with marginal intermittent crystalline domains, and had
205
Pharmaceutics 2020, 12, 286
no irreversible alterations in its backbone chemical structure. It demonstrated the ability to regulate
isoniazid release in a controlled, zero order manner, and was environmentally stable under common
storage conditions, either as a dry powder or in the hydrated form. The findings from this work may
contribute towards improving flexible pediatric dosing for tuberculosis drug treatment, considering
the current global shortage of such preparations, especially for the first-line anti-tubercular drugs.
To establish a course for further investigations, we identified the need to extend biocompatibility
testing for the RDS formulation and its components to normal cells and tissue isolates from animal
models (e.g., mice, rabbit, or pigs) employing cytotoxicity assays and histopathological techniques,
respectively. Further preclinical evaluation of pharmacokinetics, efficacy, and eventual optimization of
isoniazid dosing and absorption from the RDS formulation, in animal models similar to humans, such
as pigs, are important next steps. Considering the hydrophilic/hydrophobic and particulate nature of
the RDS, we anticipate that it can find extensive use as an effective carrier for other anti-tubercular
drugs (e.g., pyrazinamide, rifampicin) suitable for pediatrics irrespective of their solubilities and
molecular weights. For implementation purposes, a range of these bioactives would need to be tested
in vitro/in vivo and optimized to ensure desirable drug loading, controlled release, and absorption for
the intended pharmacotherapeutic application. Overall, the RDS formulation reported herein has the
potential for improving tuberculosis treatment within the pediatric population.
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